

ALBERTO BRIGANTI

CURRICULUM VITAE

Milan, 25/11/2023

Alberto Briganti

1. General information

Current Position

- Full Professor of Urology, Faculty of Medicine, Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, since June 2018
- Full staff Urologist, Department of Urology, IRCCS San Raffaele Hospital, Milan, since April 2009
- Coordinator, Prostate Cancer Disease Unit, IRCCS San Raffaele Hospital, since 2021
- Group Leader, Prostate Cancer Research Programme, IRCCS San Raffaele Hospital, since May 2014
- Director, Robotic Surgical Programme, Department of Urology, IRCCS San Raffaele Hospital, since September 2017
- Deputy Director, Urological Research Institute (URI), IRCCS San Raffaele Hospital, since May 2014

Education

- High School completed in July 1996 at the Liceo Classico Giovanni Berchet (Milan, Italy)
- Medical School completed with honours (110/110 cum laude) in July 2002 at the Vita-Salute San Raffaele University (Milan, Italy)
- Residency in Urology completed with honours (70/70 cum laude) in November 2007 at the Vita-Salute San Raffaele University (Milan, Italy)
- PhD in Clinical and Experimental Biotechnology in Urology at the Magna Graecia University (Catanzaro, Italy)

Clinical activity

Scientific Activity

- Full staff Urologist at IRCCS San Raffaele Hospital since April 2009
- Editor in Chief, European Urology (since 2023)
- Editor in Chief, European Urology Oncology (2017-2023)
- Member, Scientific Congress Office (SCO), European Association of Urology (EAU), since 2011.
- Member, Faculty of the European School of Urology (ESU), since 2011.
- Member of the European Association of Urology (EAU) Board since 2023

Awards

- Matula Italian Award, for the best scientific curriculum of a young urologist (<40 years), Italian Association of Urology (SIU), October 2015.
- European Association of Urology (EAU) Crystal Matula Award, for the best scientific curriculum of a young European urologist (<40 years), European Association of Urology, March 2016.

List of internationally indexed publications

- International Indexed Publications: 1.363 (Pubmed)
- Total Number of Citations: 39.819 (Scopus)
- H-Index: 95 (Scopus)

Current Address

Department of Urology
Vita-Salute San Raffaele University
IRCCS San Raffaele Hospital
Via Olgettina,60
20132 Milano, Italy
Tel. +39 02 26436923
Fax +39 02 26437298
e-mail: briganti.alberto@hsr.it

2. Academic Career

- Associate Professor of Urology at the Vita Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, May 2015 – May 2018.
- Full Professor of Urology at the Vita-Salute San Raffaele University, IRCCS San Raffaele Hospital, Milan, since June 2018.

3. Teaching Activities

- Director, Teaching Course on “Health Outcome Research in Urology”, MD Program, Vita-Salute San Raffaele University, Milan, (2010-2013).
- Director, Teaching Course on “Prostate Diseases”, MD Program, Vita-Salute San Raffaele University, Milan, since 2014.
- Teaching activity, Faculty of Medicine, Vita-Salute San Raffaele University since October 2010
- Secretary, Residency Program in Urology, Department of Urology, Vita-Salute San Raffaele University, since 2019
- Teaching activity, Residency Program in Urology, Vita-Salute San Raffaele University since October 2014
- Course Coordinator, Nursing School, Clinical Nursing in Specialized Surgery, Vita-Salute San Raffaele University, Milan, since October 2014.
- Co-director of the Postgraduate course “Erectile Dysfunction - A One-Year-Update” held during the 8th Meeting of the European Society for Sexual Medicine (ESSM; 5th-7th, December 2005, Copenhagen, Denmark).
- Lecturer during the European School of Urology (ESU) course held in Krasnodar, Russia (September 30th, 2010): “Nomogram and prostate cancer: an update” and “Novel imaging in prostate cancer: what to expect”.
- Lecturer during the Multidisciplinary teaching course on prostate cancer, European Society for Radiotherapy and Oncology (ESTRO) School (February 6th – 10th 2011, Lisbon, Portugal).
- Director of the ABC Master course entitled “Cancer and sexuality” during the 14th Meeting of the European Society for Sexual Medicine (December 1st-4th, 2011, Milan, Italy).
- Co-Director of “Multidisciplinary Teaching Course on Prostate Cancer”, European Society for Radiotherapy and Oncology (ESTRO) School 2012-2015.
- Faculty Member, Global Congress on Prostate Cancer 2012.

- Faculty Member, 3rd ESO ESTRO Masterclass in Radiation Oncology (November 3rd-8th, 2012, Milan, Italy).
- Lecturer during the European School of Urology (ESU) course “What’s new in prostate cancer and female urology”): “Tips and tricks for minimal invasive radical prostatectomy” and “Treatment of locally advanced prostate cancer, role of the urologist” (September 28th, 2012, Yerevan, Armenia).
- Tutor of Urocampus training project, Italian Society of Urology (SIU), 2012,2013 and 2015, Rome, Italy.
- Tutor of integrated Course of Surgery and Surgical Specialties, Faculty of Medicine and Surgery, Vita-Salute San Raffaele University, Milan (2013-2014).
- Lecturer during the European School of Oncology e-Onco-review ESO: “Robotic Surgery in Prostate cancer” (April 3rd 2012, Milan, Italy).
- Lecturer during European School of Oncology e-Onco-review ESO: “Future perspectives in Prostate cancer” (November 21st 2013, Milan, Italy).
- Faculty member e lecturer of “Lights and Shadows in the Management of Prostate Cancer” course, Euro-Arab School of Oncology (EASO), (October 25th -26th 2013, Marrakech, Morocco).
- Lecturer during European School of Urology (ESU) “Update on localized prostate cancer, “Surgery or minimally invasive radical prostatectomy” and “Pre- and post-operative erectile dysfunction: The role of penile rehabilitation” course (November 1st 2013, Antalya, Turkey).
- Teaching activity, Nursing School, Vita-Salute San Raffaele University since October 2010
- Tutorship in Residency Program in Urology, Vita-Salute San Raffaele University, since 2011.
- Co-relator of MD degree thesis: “Critical assessment of the role of post-operative radiation therapy in cancer control and functional outcome sin patients treated with radical prostatectomy for prostate cancer”, Academic Year 2011-2012, July 2012, Author: Paolo Dell’Oglio.
- Co-relator of MD degree thesis: “Surgical treatment of high-risk prostate cancer: patient stratification, identification of the best candidate, and predictors of long term survival”, Academic Year 2010-2011, July 2011, Author: Niccolò Maria Passoni.
- Co-relator of Degree Thesis: “Trends and optimal management of node positive prostate cancer treated with anatomically extended pelvic lymph node dissection in the PSA era”, Academic Year 2012-2013, October 2013, Author: Damiano Vizziello.
- Co-relator of Postgraduate Thesis in Urology: “The role of adjuvant and salvage radiotherapy in prostate cancer patients treated with radical prostatectomy: cancer control and functional outcome analysis”, Academic Year 2010-2011, September 2012, Author: Firas Abdollah.
- Co-relator of Postgraduate Thesis in Urology: “Oncological outcome of patients with positive nodes and peri-operative outcomes of an extended pelvic lymphadenectomy with robotic assisted approach. Results from a a single tertiary center”. Academic Year 2012-2013, July 2014, Author: Marco Bianchi.
- Co-relator of Postgraduate Thesis in Urology: “Three incisions vs one incision: who wins at 5 years? Comparisons of outcomes of miniarc and monarc slings in a single center surgical series”, Academic Year 2012-2013, July 2014, Author: Manuela Tutolo.
- Co-relator of Postgraduate Thesis in Urology: “Development of the first model of radical prostatectomy in mouse: A feasibility study with biochemical validation”. Academic Year 2013-2014, July 2015, Author: Ettore Di Trapani.
- Co-relator of MD degree thesis: “The procariotic neighbours of the prostate cells: how they change with the disease”, Academic Year 2014-2015, July 2015, Author: Walter Cazzaniga.

- Co-relator of MD degree thesis: “Antisense transcription at the TRPM2 locus as a novel therapeutic target in bladder cancer”, Academic Year 2014-2015, July 2015, Author: Stefano Luzzago.
- Co-relator of MD degree thesis: “GnRH receptor blockade improves the outcomes of bladder toxicity in a rat model of pelvic irradiation”, Academic Year 2015-2016, October 2016, Author: Giuseppe Fallara.
- President, Evaluating Committee of degree thesis, Nursing School, Vita-Salute University San Raffaele, Academic Year 2014-2015, November 2015.
- President, Evaluating Committee of degree thesis, Nursing School, Vita-Salute University San Raffaele, Academic Year 2015-2016, November 2016.
- Lecturer during the 23rd National Meeting of Italian Society of Uro-Oncology (SIUrO) in the course “Predictive Models in Prostate Cancer”, “Introduction and Methodological Aspects” (June 8th-10th 2013, Florence, Italy).
- Lecturer during the fourth Course on Prostate Cancer, Spanish Society of Radiation Therapy, Spanish School of Radiation Oncology (SEOR-EEOR), “Active surveillance for low risk Prostate Cancer”, “Focal treatment with cryotherapy and HIFU”, “Role of surgery for Intermediate/High risk prostate cancer” (November 12nd 2014, Madrid, Spain).
- Lecturer during the Classroom of the Italian Society of Urology on Benign Prostatic Hypertrophy (BPH), “Update: The best of the literature of the last year sull’Iperplasia Benign Prostate” and “LUTS and Sexual Dysfunctions: pathophysiology and treatment of common bases” (March 7th, 2014, Rome, Italy).
- Lecturer during the Multidisciplinary Teaching Course on Prostate Cancer, “Locally advanced- high risk prostate cancer: the role of surgery”, “The role of surgery for N1 disease”, “Non-systemic treatment of metastatic prostate cancer” (February 23rd-27th, 2014, Amsterdam, The Netherlands).
- Lecturer during the Multidisciplinary Teaching Course on Prostate Cancer, “Surgical staging: limited versus extended lymph node dissection”, “Locally advanced- high risk prostate cancer: the role of surgery”, “Erectile dysfunction: frequency and different treatment modalities”, “Treatment of therapy related complications” (March 25th -29th, 2012, Lyon, France).
- Lecturer during the Multidisciplinary Teaching Course on Prostate Cancer, “Locally advanced- high risk prostate cancer: the role of surgery”, “Surgical treatment of localized prostate cancer: the role of lymph node dissection”, Treatment of patients with N1 disease. Surgical perspectives”, “Non systemic treatment of metastatic prostate cancer” (February 2nd-6th, 2013, Madrid, Spain).
- Lecturer during the 13th European Urology Residents Education Programme (EUREP), in the Module 2 on “Prostate Cancer and BPH” with the following lectures: “Castration resistant prostate Cancer and new agents” and “Clinical cases discussion” (4th-9th September 2015, Prague).
- Lecturer during the 14th European Urology Residents Education Programme (EUREP), in the Module 2 on “Prostate Cancer and BPH” with the following lectures: “Castration resistant prostate Cancer and new agents” and “Clinical cases discussion” (2nd-7th September 2016, Prague).
- Lecturer during the 15th European Urology Residents Education Programme (EUREP), in the Module 2 on “Prostate Cancer and BPH” with the following lectures: “Castration resistant prostate Cancer and new agents” and “Clinical cases discussion” (1st-6th September 2017, Prague).
- Lecturer during the 15th European Urology Residents Education Programme (EUREP), in the Module 2 on “Prostate Cancer and male voiding LUTS” with the following lecture: “Treatment for localised disease: Active surveillance, surgical treatment, radiation, focal therapy” (31st August - 5th September 2018, Prague).

- Lecturer during the 15th European Urology Residents Education Programme (EUREP), in the Module 2 on “Prostate Cancer and male voiding LUTS” with the following lecture: “Treatment for localised disease: Active surveillance, surgical treatment, radiation, focal therapy” (6th-11th September 2019, Prague).
- Lecturer during the Teaching Course on Prostate Cancer with a lecture entitled “Pelvic lymph node dissection: open or robotic?” during the 88th annual Meeting of the Italian Association of Urology (October 10th -13th 2015, Riccione, Italy).
- Chair and Lecturer during the 4th Global Congress on Prostate Cancer in the Workshop “Advanced course on robotic surgery in high risk and locally advanced prostate cancer”: (June 29th-July 1st, Vienna, Austria).
- Member of the Teaching Committee of the post-degree course “Robotic Surgery”, October 2015 – November 2016, San Raffaele Hospital, Milan, Italy
- Co-relator of Postgraduate Thesis in Urology: “Long-term efficacy and toxicity of postoperative radiation therapy in prostate cancer patients: Results from a large multi-institutional experience”. Academic Year 2015-2016, July 2017, Author: Giorgio Gandaglia.
- Co-relator of Postgraduate Thesis in Urology: “The role of salvage lymph node dissection for prostate cancer patients affected by nodal recurrence after radical prostatectomy: Results from a large multi-institutional experience”. Academic Year 2015-2016, July 2017, Author: Nicola Fossati.
- Co-relator of Postgraduate Thesis in Urology: “Comparison of robot-assisted and open partial nephrectomy: an observational, prospective study”. Academic Year 2015-2016, July 2017, Author: Alessandro Larcher.
- Co-relator of MD degree thesis: “Uromodulin genotype rs4293393 as a novel biomarker of renal cancer aggressiveness”, Academic Year 2016-2017, July 2017, Author: Francesco Ripa.
- Co-relator of MD degree thesis: “Development of a novel metabolomic signature in EPS-urine for early diagnosis of prostate cancer: first results of a prospective, single-center study”, Academic Year 2015-2017, July 2017, Author: Luigi Nocera.
- Co-relator of MD degree thesis: “Single nucleotide polymorphisms and prostate cancer: development and validation of a novel genetic risk score for individualized screening and diagnostic programmes”, Academic Year 2016-2017, July 2017, Author: Roy El Koussa
- Lecturer during the 1st Updates in onco-urology course (UDOU) with the following lectures: “Locally advanced prostate cancer- Surgeon point of view: how to do it?”, “Multimodal treatment in prostate cancer: for who and how?” and “Clinical cases discussion” (15st-17th June, 2017, Paris).
- Lecturer during the 32nd Meeting of the European Association of Urology (EAU) in the European School of Urology (ESU) course “Oligometastatic prostate cancer” with the lecture entitled “Surgery for recurrent nodal metastasis with updates on molecular/PET imaging” (24th-28th March, 2017, London, UK).
- Co-relator of MD degree thesis: “Identification of a novel micro-RNA signature associated with renal clear cell carcinoma: The essential role of tissue micro-environment”, Academic Year 2016-2017, July 2017, Author: Domenico Fichera
- Lecturer during the first EAU Update on Prostate Cancer Meeting during in the Case discussion session: “Management of clinically node positive prostate cancer patients” (15th- 16th September, 2017, Vienna, Austria)
- Member of the International Jury PhD thesis degree: “Molecular and clinical response of renal cell carcinoma to intermittent hypoxia”, Author Antoni Villaseca, 22nd November 2017, Barcellona, Spagna

- Lecturer during the 33th Meeting of the European Association of Urology (EAU) - European School of Urology (ESU) "Oligometastatic prostate cancer" with a presentation titled: "Surgery for recurrent nodal metastasis with updates on molecular/PET imaging" (16th-20th March, 2018, Copenhagen, Denmark).
- Co-relator of Postgraduate Thesis in Urology "Optimizing the role of multiparametric magnetic resonance imaging in prostate cancer diagnostic pathway. A patient-tailored approach. Academic Year 2016-2017, July 2018, Author: Paolo Dell'Oglio.
- Co-relator of MD degree thesis: "Exploiting iron modulation to induce ferroptosis and to increase the efficacy of anti-androgen therapy in prostate cancer" Academic Year 2017-2018, July 2018, Author: Barletta Francesco Maria.
- Co-relator of MD degree thesis: "Pre-operative Pembrolizumab before radical cystectomy for muscle invasive urothelial bladder carcinoma: interim clinical and biomarker findings from the phase II PURE-01 study" Academic Year 2017-2018, July 2018, Author: Simone Luca Antonio Scuderi.
- Co-relator of MD degree thesis: "Methylation pattern of primary and lymph-node metastases in prostate cancer. A detailed analysis of multiple cancer foci" Academic Year 2017-2018, July 2018, Author: Grillo Luca.
- Lecturer during the 2nd EAU Update on Prostate Cancer Meeting "Treatment of oligometastatic disease" (14th-15th September, 2018, Milan, Italy).
- Lecturer during the 34th Meeting of the European Association of Urology (EAU) - European School of Urology (ESU) - "Oligometastatic prostate cancer" with a presentation entitled: "Surgery for recurrent nodal metastasis with updates on molecular/PET imaging" (15th-18th March, 2019, Barcelona, Spain).
- Co-relator of MD degree thesis: "Towards a non-invasive identification of tumor response to neoadjuvant pembrolizumab in muscle-invasive bladder cancer (MIBC): translational imaging findings from the PURE-01 STUDY". Academic Year 2018-2019, July 2019, Author: Donato Cannoletta.
- Co-relator of MD degree thesis: "Development and validation of a novel EPS-metabolomic signature for the diagnosis of clinically significant prostate cancer". Academic Year 2018-2019, July 2019, Author: Aldo Rizzo.
- Co-relator of MD degree thesis: "Targeting metabolic vulnerabilities in metastatic prostate cancer to bone" Academic Year 2018-2019, July 2019, Author: Daniele Robesti.
- Lecturer during the 3rd EAU Update on Prostate Cancer Meeting - "Active surveillance: Patient selection and follow-up" (11th-12th October 2019, Vienna, Austria).
- Scientific Coordinator of the Masterclass "Update sul trattamento del carcinoma prostatico localmente avanzato e metastatico" during the 92th Annual Meeting of the Italian Society of Urology (12th -15th October 2019, Venice, Italy).
- Co-relator of Postgraduate Thesis in Urology: "Focal Therapy for clinically localized prostate cancer: oncological outcomes, trend analyses and follow-up strategies in a large, multi-institutional contemporary series". Academic Year 2018-2019, Author: Armando Stabile.
- Co-relator of MD degree thesis: "Exploiting iron administration to inhibit prostate cancer growth and ameliorate anti-androgen therapy: pre-clinical studies". Academic Year 2019-2020, June 2020, Author: Raffaele La Mura.
- Co-relator of MD degree thesis: "Pembrolizumab and nab-paclitaxel as salvage therapy for platinum treated, locally-advanced or metastatic urothelial carcinoma of the bladder: results of the peanut study". Academic Year 2019-2020, June 2020, Author: Filippo Scalvi

- Co-relator of MD degree thesis: "Epigenetic changes in primary prostate cancer and matched lymph node metastases. Implication of altered DNA methylation patterns in nodal dissemination from prostate cancer". Academic Year 2019-2020, June 2020, Author: Zito Elio
- Co-relator of MD degree thesis: "Chromosomal instability as a driver of metastasis in prostate cancer through non-canonical NF-Kb signalling". Academic Year 2019-2020, July 2020, Author: Antony Pellegrino.
- Lecturer during the Virtual EAU Update on Prostate Cancer Meeting - "Update on the treatment of recurrent disease" (PCa20 Virtual meeting 17th October 2020).
- Co-relator of MD degree thesis: "Metabolomic profiling of eps-urine derived-extracellular vesicles in prostate cancer: a preliminary exploratory mass-spectrometry analysis". Academic Year 2020-2021, July 2021, Autthor: Lucilla Violetta Sciacqua.
- Co-relator of Postgraduate Thesis in Urology: "Enhanced recovery after surgery (ERAS) on radical Cystectomy: the unmet need of a tailored patient-based approach". Academic Year 2018-2019, November 2021. Author: Emanuele Zaffuto.
- Co-relator of Postgraduate Thesis in Urology: "Assessing in-Hospital Morbidity after urethroplasty using the European association of Urology quality criteria for standardized reporting". Academic Year 2018-2019, November 2021. Author: Marco Bandini.
- Co-relator of MD degree thesis: "Exploiting the role of PSMA and bombesin pet/mri for the diagnostic and therapeutic management of patients with prostate cancer recurrence after primary treatment. initial results of a prospective single center trial" Academic Year 2020-2021, July 2022, Author: Sabrina Comana
- Co-relator of MD degree thesis: "The role of PSMA- and Bombesin PET/MRI and peripheral immunological profile in the assessment of high-risk prostate cancer patients undergoing radical prostatectomy". A prospective study Academic Year 2020-2021, July 2022, Author: Enrico Camisassa
- Co-relator of MD degree thesis: "The role of pre-surgical multiparametric megnetic resonance imaging features in predictong continence after radical cystectomy with orthotopic bladder reconstruction: preliminary findings from PURE-01 Trial" Academic Year 2020-2021, July 2022, Author: Martina Cristodoro
- Co-relator of MD degree thesis: "US Mirror trial: Micro-ultrasound vs multiparametric magnetic resonance imaging targeted biopsy for prostate cancer diagnosis. Academic Year 2021-2022, July 2022, Author: Bravin Sara
- Co-relator of MD degree thesis: "PSMA radio-guided surgery to detect nodal metastases in primary prostaee cancer patients undergoing robot assisted radical prostatectomy and extended pelvic lymph node dissection: a prospectove, phase II study". Academic Year 2021-2022, July 2022, Author: Leonardo Quarta
- Co-relator of Postgraduate Thesis in Urology: "Oncologic Surveillance After Radical Nephroureterectomy For High-Risk Upper Tract Urothelial Carcinoma". Academic year 2019-2020, Author Carlo Andrea Bravi.
- Co-relator of Postgraduate Thesis in Urology: "Risk stratification of patients candidate to radical prostatectomy based on clinical and multi-parametric magnetic resonance imaging parameters: development and external validation of novel risk groups". Academic year 2019-2020, Author Alberto Martini.
- Co-relator of Postgraduate Thesis in Urology: "The surgical learning curve for prostate cancer control after robot-assisted radical prostatectomy." Academic year 2019-2020, Author Elio Mazzone

- Lecturer during the 37th meeting of the European Association of Urology (EAU), ESU Course 10, Thematic session Oligometastatic prostate cancer. Lecture entitled: “Surgery for recurrent nodal metastasis with updates on molecular/PET imaging” (2nd July 2022, Amsterdam, The Netherlands).

4. Visiting Professorships

- Visiting Professor at the Departement of Radiotherapy, Institute Goustave Roussy (IGR), Villejuif, France (April 13rd 2012).
- Visiting Professor at the Department of Urology, Mayo Clinic, Rochester, MN, USA, (September 26th-28th, 2013).
- Visiting Professor at the Department of Urology, Napoli, Italy (27th March, 2018)
- Visiting Professor at the Department of Urology, Tubingen, Germany (2nd May, 2018)
- Visiting Professor at the Department of Urology, Koln, Germany (11th October, 2018)
- Visiting Professor at the Department of Urology, Mainz, Germany (13th-14th June, 2019)
- Visiting Professor at the Department of Urology, University of Illinois, Chicago, US (28th April, 2023)
- Visiting Professor at the Department of Urology, Mount Sinai, Ichan School of Medicine, New York, US (3rd-4th October, 2023)

5. Research activity

FELLOWSHIPS

- Fellowship at the Institute for Sexual Medicine Boston University, Boston, MA, USA, (August-September 2002).
- Fellowship in Uro-Oncology at the “Health Outcome Research Unit” – University of Montreal, Montreal, Quebec, Canada (September 2005-March 2006).
- Fellow of the European Board of Urology (since July 2007).
- Fellow of the “European School of Andrological Surgery” (2004-2005), Italian Society of Andrology.
- European Association of Urology Masterclass in Uro-Oncology, European School of Urology and Weill Medical College of Cornell University, Salzburg, Austria (July 2008).
- Fellowship in Robotic Surgery, ERUS robotic curriculum, Olv Vattikuti Robotic Surgery Institute (ORSI), Alst, Belgium (June-September 2013)

MEMBERSHIP IN SCIENTIFIC SOCIETIES AND GROUPS

- Società Italiana di Urologia (SIU)
- European Association of Urology (EAU)
- Endourological Society

- Urological Research Society (URS)
- The Association of Academic European Urologists (AAEU)
- Genito-Urinary group of the European Organization for Research and Treatment of Cancer (EORTC)
- American Association of Genito-Urinary Surgeons (AAGUS)
- American Society of Clinical Oncology (ASCO), Genitourinary Cancer Guideline Advisory Group (GAG)

REVIEWER OF THE FOLLOWING JOURNALS

- Lancet
- Lancet Oncology
- Nature Medicine
- Journal of Clinical Oncology
- Cancer
- European Urology
- European Journal of Cancer
- Clinical Cancer Research
- The Journal of Urology
- British Journal of Urology International
- Nature Clinical Practice in Urology
- International Journal of Clinical Practice
- World Journal of Urology
- The Journal of Sexual Medicine
- International Journal of Urology
- Neurourology and Urodynamics
- Prostate Cancer and Prostatic Disease
- Radiotherapy and Oncology
- International Journal of Radiation Oncology, Biology, Physics
- Archives of Medical Science
- Canadian Journal of Surgery
- Journal of Cancer Research and Clinical Oncology
- PLOS One
- Molecular Cancer Therapeutics
- European Journal of Nuclear Medicine and Molecular Imaging
- Journal of Clinical Epidemiology
- Supportive Care in Cancer
- OncoTargets and Therapy
- Clinical Genitourinary Cancer
- Acta Oncologica

OFFICIAL POSITIONS IN SCIENTIFIC JOURNALS

- Editor in Chief, European Urology (since 2023)
- Editor in Chief, European Urology Oncology (2017 -2022)
- Co-Editor, European Urology Focus (2015-2017)
- Member, Editorial Board, World Journal of Urology

- Member, International Editorial Committee, Urologic Oncology section, Archivos Espanoles de Urologia
- Member, Editorial Board, Minerva Urologica e Nefrologica

PARTICIPATIONS IN PROSPECTIVE MULTI-INSTITUTIONAL CLINICAL STUDIES

PRINCIPAL INVESTIGATOR

- National Coordinator and Principal Investigator for Italy of the EORTC study 30072 SORCE trial: “A Phase III Randomised Double-blind Study Comparing Sorafenib With Placebo In Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse”.
- National Coordinator and Principal Investigator for Italy of the EORTC 22043-30041 study “Post-operative external radiotherapy combined with concomitant and adjuvant hormonal treatment vs post-operative external radiotherapy alone in pathological stage pT3a-b R0-1 N0 M0/pT2 R1 N0 M0, Gleason score 5-10, prostatic carcinoma. A phase III study”.
- Principal Investigator for Italy of the study CV-9104-004 (CureVac GmbH): a Randomised, double-blind, placebo-controlled phase I/II trial of RActive®-derived cancer vaccine (CV9104) for asymptomatic or minimally symptomatic patients with metastatic, castrate-refractory prostate cancer.
- Principal Investigator for Italy of the study MIP-1404-201 (Molecular Insight Pharmaceuticals): A Phase 2 Assessment of the Diagnostic Accuracy of 99mTc-MIP-1404 Imaging in Men with High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology.
- Principal Investigator for Italy of the study PRECISION trial: A randomised controlled trial of magnetic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without biopsy
- Principal Investigator for Italy of the study “A Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy (PROTEUS)”
- Member of the Team “Prostate Cancer Outcomes: Global Initiative to Compare & Reduce Variation (PCO-CRV protocol) - Movember Foundation, 2016-2018
- Principal Investigator of the study “Discovery and prospective validation of a novel expressed prostatic secretions (EPS) urine metabolomic signature for the diagnosis of clinically significant prostate cancer”
- Principal Investigator of the study “Prostate Cancer Diagnosis and Treatment Enhancement Through the Power of Big Data in Europe -PIONEER”
- Principal Investigator of the study “Creating a Platform to Audit Adherence to Urological Guideline Recommendations in European Countries – A Pilot Study for an Implementation Science Program – IMAGINE”
- Principal Investigator of the study Optimizing the number of Systematic COres during a MRI Target biopsy - SCOT trial
- Principal Investigator of the study Molecular Test To sElect biopsy candidates after a negative multiparametRic MRI – MATTER study”
- Principal Investigator for Italy of the study “A Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer (CREST)

STUDY INVESTIGATOR

- Eli Lilly. Tadalafil for radical prostatectomy patients
- Pfizer. Sildenafil vs apomorphine comparative study
- Bayer. Vardenafil in patients with ED and depression (DRIVER)
- Advanced Bionics Corporation. Erection Pacemaker in RRP patients
- GSK. Vardenafil for patients with SCI
- Bioxell. Vitamin 3 analogue for BPH
- GSK. Vardenafil long term reliability
- GSK Vardenafil vs tadalafil comparative study
- Pfizer. UK390 for premature ejaculation phase II b (open-label)
- Pfizer. UK390 for premature ejaculation phase II b (placebo-controlled)
- Bayer. Vardenafil vs Tadalafil - LUTETIA
- Schwarz Pharma. Fesoterodine for overactive bladder (phase 3)
- Schwarz Pharma. Fesoterodine extension study open label
- Gen-Probe. PCA3 Cystoprostatectomy study
- Prosper. Medivation. Enzalutamide in castration-resistant non-metastatic Prostate Cancer
- Prolaris. Risk genomic classifier in high risk prostate cancer.
- A randomized controlled trial of magnetic resonance imaging-targeted biopsy compared to standard trans-rectal ultrasound guided biopsy for the diagnosis of prostate cancer in men without prior biopsy (PRECISION)
- A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Prostate-Specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Positive Hormone-Sensitive Prostate Cancer Participants (PRIMORDIUM)
- Prostate Imaging Using MRI +/- Contrast Enhancement (PRIME)
- Bayer 21492: A randomized, double-blind, placebo-controlled Phase 3 study of darolutamide plus androgen deprivation therapy (ADT) compared to placebo plus ADT in patients with high-risk biochemical recurrence (BCR) of prostate cancer”

6. Grants and Awards

AWARDS

- European Society for Sexual Medicine (ESSM) Award 2003 for the best presentation of the Meeting on Male Sexual Dysfunction (Clinical Science): “Five years follow-up of plaque incision and vein grafting for Peyronie’s disease”. Awarded during the European Society for Sexual Medicine meeting in Istanbul, 2003.
- In February 2008 he was elected as “Reviewer of the Month” by the peer reviewed indexed journal “European Urology”.
- Best poster presentation of the session at the 21st Meeting of the European Association of Urology (EAU) (April 5th-8th 2006, Paris, France). Title: “A critical appraisal of the ability of body mass index (BMI) to predict high grade prostate cancer (PCa)”.
- Best poster presentation of the session at the 24th Meeting of the European Association of Urology (March 17th-21th, 2009, Stockholm, Sweden). Title: “Adjuvant radiotherapy has a positive impact on cancer-specific survival of lymph node positive prostate cancer patients. Results of a matched analysis of a two-institution series with 703 lymph node positive patients”.
- Best poster presentation of the session at the 24th Meeting of the European Association of Urology (March 17th-21th, 2009, Stockholm, Sweden). Title: “Which is the optimal timing of erectile function assessment after bilateral nerve sparing radical prostatectomy? Results from a prospective analysis”.
- Best poster presentation of the session at the 24th Meeting of the European Association of Urology (March 17th-21th, 2009, Stockholm, Sweden). Title: “Pelvic lymph node dissection should be omitted in low risk prostate cancer patients. Results of a matched analysis”.
- Best poster presentation of the session at the 24th Meeting of the European Association of Urology (March 17th-21th, 2009, Stockholm, Sweden). Title: “A novel nomogram predicting a positive [11c] choline positron emission tomography/computed tomography (PET/TC) scan in patients with biochemical recurrence after radical prostatectomy”.
- Best poster presentation of the session at the 26th Meeting of the European Association of Urology (EAU) (March 18th-22nd, 2011, Vienna, Austria) Title: “Adjuvant radiotherapy leads to superior recurrence free survival compared to early salvage radiotherapy in patients with locally advanced prostate cancer: Results from a matched-controlled multi-institutional analysis”.
- Best poster presentation of the session at the 26th Meeting of the European Association of Urology (EAU) (March 18th-22nd, 2011, Vienna, Austria) Title: “Development and internal validation of nomograms predicting prostate cancer specific survival in patients with high risk disease. Results of a multi-institutional analysis”.
- Best poster presentation of the session at the Annual Meeting of the American Urological Association (May 29th- June 3rd, 2010, San Francisco, CA, USA). Title: “Predicting favourable pathological outcome in patients with clinical high risk prostate cancer. a novel nomogram based on a multi-institutional analysis”.
- Best poster presentation of the session at the Annual Meeting of the American Urological Association (May 14th-19th, 2011, Washington DC, CA, USA). Title: “Adjuvant radiotherapy leads to

superior biochemical recurrence free survival compared to early salvage radiotherapy in patients with locally advanced prostate cancer: results of a matched-controlled multi-institutional analysis”.

- Best poster presentation of the session at the Annual Meeting of the American Urological Association (May 14th-19th, 2011, Washington DC, CA, USA). Title: “Does biochemical progression after radical prostatectomy and adjuvant radiotherapy for locally advanced prostate cancer invariably impact cancer-specific mortality?”
- In March 2011, he obtained the ESUI Vision Award 2011 for the abstract entitled: “The value of Computed Tomography in predicting prostate cancer lymph node invasion is negligible even in contemporary patients with very high risk of nodal metastases” presented during the 26th Meeting of the European Association of Urology (March 18th-22th, 2011, Vienna, Austria).
- Abstract prize among the best annual contributions, Annual Congress of the American Urological Association (AUA) (May 16th-21st, 2014, Orlando, FL, USA), with a project entitled: “The impact of time to biochemical recurrence on cancer specific mortality in patients with high risk prostate cancer treated with radical prostatectomy: a competing risks regression analysis”.
- 2015 Matula Italian Award, for the best scientific curriculum of a young urologist (<40 years), Italian Association of Urology, October 2015.
- 2016 European Association of Urology (EAU) Crystal Matula Award, for the best scientific curriculum of a young European urologist (<40 years), European Association of Urology, March 2016.

GRANTS

- In 2009 he obtained the Italian Ministry of Health grant for young researchers in the field of prostate cancer with a project entitled: “Assessment of individual genetic profile in young individuals with and without family history of prostate cancer: implications for individualized prostate cancer screening programs” (GR-2009-10608159),
- In 2011 he obtained the ESSM (European Society for Sexual Medicine) grant for medical research with a project entitled: “Potential neuroprotective effects of a cannabinoid 2 receptor agonist in a rat model of cavernous nerve crush injury”
- Research grant, Sandoz Biopharmaceuticals, with a project entitled: Mechanisms of resistance to anti-androgen therapies in prostate cancer, 2015.
- Research grant, Sandoz Biopharmaceuticals, with a project entitled: Role of macrophages in shaping disease progression in node-positive prostate cancer, 2016.
- Team member, Prostate Cancer Outcomes: Global Initiative to Compare & Reduce Variation (PCO-CRV protocol) - Movember Foundation, 2016-2018
- In 2018 he obtained the the Italian Ministry of Health grant – Ricerca finalizzata – “Development of a Novel Signature Integrating Clinical, Imaging And Epigenetic Information to Tailor Pelvic Nodal Treatment in Prostate Cancer”
- Responsible, Work Package 2, PIONEER, the European Network of Excellence for Big Data in Prostate Cancer, Innovative Medicine Initiative (IMI) funded project
- Lead, Clinical Prostate Cancer group, OPTIMA, Tackling cancer through Real World data and Artificial Intelligence, Innovative Medicine Initiative (IMI) funded project

7. National and international meetings

PARTICIPATIONS AS INVITED SPEAKER

- Lecturer for the “Point and Counterpoint session” entitled “PDE5 inhibitors in Patients with PrematureEjaculation but not ED?” during the 9th Meeting of the European Society for Sexual Medicine (December 3th-6th, 2006, Vienna, Austria).
- Lecturer during the 9th Congress of the European Federation of Sexuology: “Current Perspectives in Sexual Dysfunction: New Choices for the Couple” (Satellite Symposium Pfizer; April 13th-17th, 2008, Rome, Italy).
- Lecturer during the 23rd Meeting of the European Association of Urology “PDE5 inhibitors, erectile dysfunction and prostate disease”: “Erectile dysfunction, vascular disease and PDE5 inhibitors”, (Satellite Symposium Lilly; March 26th-29th, 2008, Milan, Italy).
- Lecturer during the European School of Oncology (ESO) Inside Track Conference “Predictive modeling in prostate cancer”: “Predictive models in andrology” (April 17th-19th, 2008, Venice, Italy).
- Lecturer during the 4th edition of the Experts on Sexual Medicine Meeting (REMS): “Prostate Cancer and Erectile dysfunction”: “Penile rehabilitation: clinical evidence and performance protocol” (December 18th, 2008, Madrid, Spain).
- Lecturer during the European Regional Medical Conference “The ED puzzle: filling the gaps with the right pieces”: “Penile Rehabilitation: Improving Patient Outcome In Silence” (October 3rd-4th, 2008, Copenhagen, Denmark).
- Lecturer during the Autumn Meeting of the Genito-Urinary group of the European Organization for Research and Treatment of Cancer: “Novel aspects in the treatment of prostate cancer” (October 9th-11th, 2008, Palermo, Italy).
- Lecturer during the 24th Meeting of the European Association of Urology “BPH/LUTS: Role of inflammation and clinical consequences”: “Why does BPH develop?”, (Satellite Symposium Pierre Fabre; March 17th-21st, 2009, Stockholm, Sweden).
- Lecturer during the Autumn Meeting of the Genito-Urinary group of the European Organization for Research and Treatment of Cancer: “Pelvic lymph node dissection in prostate cancer: Pro and cons” (October 15th-18th, 2009, London, UK).
- Master lecture entitled “How to apply outcome research models to sexual medicine?” during the 12th Meeting of the European Society for Sexual Medicine (November 15th -18th, 2009, Lyon, France).
- Lecturer during the 2nd European Multidisciplinary Meeting on Urological Cancers (EMUC): “State-of-the-art-lecture: Post prostatectomy erectile dysfunction” (November 27th-29th, 2009, Barcelona, Spain).
- Lecturer during the Plenary Session 1 at the British Association of Urological Surgeons (BAUS) Annual Meeting: “Lymph node dissection in prostate cancer – Curative treatment or staging tool?” (June 21th -24th, 2010, Manchester, UK).
- Lecturer in the debate “Pelvic lymphadenectomy for prostate cancer: No vs limited vs extended: why extended?” during the 1st Innovation in Urology Meeting (September 17th -19th, 2010, Milan, Italy).
- Lecturer during the EORTC Genito-Urinary group Symposium: “Multidisciplinary case discussion on the management of lymph node disease in Prostate Cancer” (March 25th-27th, 2010, Brussels, Belgium).

- Lecturer during the 4th Leading Lights in Urology Meeting: “Controversies in the management of organ confined prostate cancer: PCA3?” (April 7th-9th 2011, Baveno, Italy).
- Lecturer during the during the 4th Leading Lights in Urology Meeting: “Risk assessment of bone metastases in newly diagnosed prostate cancer” (Satellite Symposium Amgen, April 7th-9th, 2011, Baveno, Italy).
- Lecturer in Joint Session of the European Association of Urology (EAU) and the Iranian Urological Association (IUA): “Sexual dysfunction after radical treatment for prostate cancer”, during the 26th Meeting of the European Association of Urology (March 18th-22nd, 2011, Vienna, Austria).
- Lecturer during the 2nd Innovation in Urology Meeting “Role of surgery in high risk prostate cancer” (October 1st-2nd, 2011, Milan, Italy).
- Lecturer during the 11th Annual Meeting of the Belgian Association of Urology: “Use of prostate cancer nomograms in patient tailored approach – The Belgian PCa nomogram project, final outcomes” (Sponsored lecture by Ipsen, December 9th-10th 2011, Ghent, Belgium).
- Lecturer during the 27th Meeting of the European Association of Urology: “Case-based update on the optimal management of bone metastases from prostate cancer”, sponsored by Amgen (February 24th-28th, 2012, Paris, France).
- Lecturer during the Meeting “Urology in 2012: What’s in and What’s new”: “Unmet needs in prostate cancer diagnosis and treatment” (October 11th, 2012, Pisa, Italy).
- Lecturer during the Global Congress on Prostate Cancer: “Lymph node dissection: when is it indicated?” and “Choline PET scan in the detection of early recurrence” (June 28th-30th, Brussels, Belgium).
- Lecturer during the 4th European Multidisciplinary Meeting on Urological Cancers (EMUC): “What does the future hold in prostate cancer? - The future of surgery (November 16th-18th, 2012, Barcelona, Spain).
- Lecturer during the 10th Meeting of the EAU Section of Oncological Urology (ESOU), “The role of salvage lymph node dissection in prostate cancer” (January 18th -20th, Rome, Italy).
- Lecturer, Souvenir Session on Prostate Cancer, 28th Meeting of European Association of Urology (EAU) (March 15th-19th 2013, Milan, Italy).
- Lecturer during the joint session of the European Association of Urology (EAU)-Iranian Urological Association (IUA), “How to manage high risk prostate cancer” during the 28th Meeting of the European Association of Urology (March 15th-19th 2013, Milan, Italy).
- Lecturer during the 2nd Global Congress on Prostate Cancer, “Non-systemic relapse after local treatment: facts and fiction” (June 12th-14th, 2013, Marseilles, France).
- Lecturer during the 2nd Global Congress on Prostate Cancer, “Focal therapy: still utopia?” (June 12th -14th 2013, Marseilles, France).
- Lecturer during the Annual Meeting of the American Urological Association (AUA), Subspecialty Society & International Meetings – Italian Society of Urology: “Should an Extended PLND be Performed During RP” (May 4th -8th, 2013, San Diego, USA).
- Lecturer during the 3rd Meeting of the European Association of Urology (EAU) Section of Urological Imaging (ESUI): “Imaging guided therapy in prostate cancer will become a standard in prostate cancer management: CON” (November 13th, Lisbon, Portugal).
- Lecturer during the 11th Meeting of the European Association of Urology (EAU) Section of Oncological Urology (ESOU): “Local treatment of oligo-metastatic prostate cancer: Lymphadenectomy” (January 17th-19th, 2014, Prague, Czech Republic).

- Lecturer and Faculty, Current trends in the management of advanced prostate cancer: “Multimodal treatment in high risk prostate cancer” (June 20th, 2014, Tbilisi, Georgia).
- Lecturer and Faculty during the European School of Oncology (ESO) conference on Active surveillance for low risk prostate cancer: “Pitfalls and criticism of active surveillance” (February 21st-22nd, 2014, Amsterdam, Holland).
- Lecturer during the 33rd Meeting of the European Society for Radiotherapy and Oncology (ESTRO): “Should oligometastatic prostate cancer be treated systemically? The urologist point of view” (April 4th-8th, 2014, Vienna, Austria).
- Lecturer during the 29th Meeting of the European Association of Urology “Prostate cancer: a state of the heart”, “A patient-centred approach to making treatment decisions” (Satellite Symposium Ferring, April 11th-15th, 2014, Stockholm, Sweden).
- Lecturer during the 29th Meeting of the European Association of Urology (EAU) “Souvenir session – prostate cancer, localized disease” (April 11th-15th, 2014, Stockholm, Sweden).
- Lecturer during the Joint Session European Association of Urology (EAU)-Korean Urological Association (KUA): “Adjuvant and salvage radiotherapy for locally advanced prostate cancer” during the 29th Meeting of the European Association of Urology (April 11th-15th, 2014, Stockholm, Sweden).
- Lecturer during the Joint Session European Association of Urology (EAU)-European Society of Nuclear Medicine (EANM): “Unmet needs in prostate cancer recurrence imaging: urological perspective”, during the 29th Meeting of the European Association of Urology (April 11th-15th, 2014, Stockholm, Sweden).
- Lecturer and Faculty, “Multimodal treatment of high risk prostate cancer”, “Role of extended lymph node dissection in high risk prostate cancer: where?, when?, how?” (November 6th, 2014, Bucharest, Romania).
- Lecturer during the 5th European Multidisciplinary Meeting on Urological Cancers (EMUC): “Salvage surgery for positive nodes in prostate cancer: novel concept in selected patients”, “Clinical Case discussion”, “Take home messages: surgery” (November 15th-17th, 2013, Marseilles, France).
- Lecturer during the International Symposium on Prostate, Androgens and Men’s Sexual Health (ESSM-ISSM) “Curative treatment for prostate cancer: what is best for survival?” (June 21st-23rd, 2013, Berlin, Germany).
- Lecturer during the 22nd Panhellenic Urological Congress: “Local treatment of oligo-metastatic prostate cancer: Lymphadenectomy”, (October 16th-19th, 2014, Crete).
- Lecturer and Faculty of the Fifth Symposium on Hormonal Treatment of Prostate Cancer (STOP 5) “The role of surgery in intermediate risk prostate cancer”, Castration resistant prostate cancer: Clinical case discussions, Oligometastatic disease/ metastases at diagnosis (workshop), Debate on the management of positive lymph nodes (October 17th-19th, 2014, Prague, Czech Republic).
- Lecturer during the 6th European Multidisciplinary Meeting on Urological Cancers (EMUC): “Take home messages: surgery” (November 13th-16th, 2014, Lisbon, Portugal).
- Lecturer during the Annual Meeting of the Urological Research Society: “Impact of adjuvant radiotherapy on survival of patients with node positive prostate cancer” (September 18th-20th, 2014, Monaco, Germany).
- Lecturer during the 12th Meeting of the European Association of Urology (EAU) Section of Oncological Urology (ESOU): “Debate: The role of choline/PSMA – PET/CT in relapsing prostate cancer following local treatment: Pro” (January 16th-18th, 2015, Monaco, Germany).

- Lecturer during the Meeting “Recent advances in the treatment of prostate cancer– focus on lymph node positive disease and metastatic castration resistant prostate cancer”, “Treatment strategies for N1/M0 disease” (January 20th, 2015, Aarhus, Denmark).
- Lecturer during the 3rd Global Congress on Prostate Cancer, session “Surgery or radiotherapy for prostate cancer: are we comparing apples with oranges?”, “What are we talking about?” (February 5th-7th 2015, Rome, Italy).
- Lecturer during the 3rd Global Congress on Prostate Cancer, session “Targeting the AR signalling pathway: Redefining clinical practice in mCRPC?” sponsored symposium, Astellas (February 5th-7th 2015, Rome, Italy).
- Lecturer during the 3rd Global Congress on Prostate Cancer, session “Expert opinions in mCRPC treatment: what’s their recommendation?” sponsored symposium, Janssen (February 5th-7th 2015, Rome, Italy).
- Lecturer at the European Section of Urological Imaging (ESUI) meeting during during the 30th Meeting of the European Association of Urology (EAU), “Critical assessmen of PET/CT in the staging of prostate cancer recurrence (March 20th-24th, 2015, Madrid, Spain).
- Discussant, Late Breaking News session, A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of Enzalutamide vs. Bicalutamide in Metastatic Castrate Resistant Prostate Cancer: TERRAIN Trial during during the 30th Meeting of the European Association of Urology (EAU) (March 20th-24th, 2015, Madrid, Spain).
- Lecturer during the 30th Meeting of the European Association of Urology (EAU) “Souvenir session – prostate cancer, localized and disease” (March 20th-24th, 2015, Madrid, Spain).
- Lecturer during the 1st Prostate Cancer Summit, session “Treatment of metastatic disease” with a lecture entitled: “The role of surgery in the management of prostate cancer recurrence” (August 27th-29th, 2015, Hamburg, Germany).
- Lecturer during the 15th Congress of the Russian Association of Urology session “Uro-Oncology” with a lecture entitled “Management of Localized Kidney Cancer” (September 18th-20th, 2015, Sain Petersburg, Russia).
- Lecturer during the Meeting “Prostate Cancer: Hot Topics” with a lecture entitled “Treatment options for high risk prostate cancer” (September 23rd,2015, Padua, Italy).
- Lecturer during the 1st Urology Robotic Oncology Paris (UROP) Meeting, Astellas sponsored symposium “mCRPC: Treatment decisions in a new therapeutic landscape” with a lecture entitled “Treating patients whose cancer has advanced after ADT in a new landscape” (October 8th-9th, 2015, Paris, France)
- Lecturer during the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC): “Take home messages: surgery” (November 12nd-15th, 2015, Barcelona, Spain).
- Lecturer during the European School of Oncology (ESO) Conference “Personalized approach to prostate cancer management” with a lecture entitled “What do we need in surgery” (November 12nd, 2015, Barcelona, Spain).
- Lecturer during the Meeting “Tribute to Uro-Oncology” with a lecture entitled “Metastases directed therapy in prostate cancer: a surgeon’s view” (November 20th-21st, 2015, Leuven, Belgium).
- Lecturer during the 14th Meeting of the Academic European Urologists (AAEU) with a lecture entitled: “Assessing the optimal timing for early salvage radiation therapy in patients with PSA rise after radical prostatectomy” (December 3rd-6th, 2015, London, UK).
- Lecturer during the 2016 Genitourinary Cancer Symposium of the American Society of Clinical Oncology (GU ASCO) with a lecture entitled: “Incidence and Distribution of Lymph Node Metastases

in Localized Prostate Cancer: Role of Imaging and Surgery” (January 7th-9th, 2016, San Francisco, USA).

- Lecturer the “4th Techno Urology Meeting” with a lecture entitled “Screening for prostate cancer: Who does benefit? How to do it?” (January 27th-29th, 2016, Orbassano, Turin, Italy).
- Lecturer during the Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA) with a lecture entitled: “Optimal Managements for biochemical recurrence: European approach” during the 31st Meeting of the European Association of Urology” (EAU- 11th-15th March, 2016, Munich, Germany).
- Lecturer during the 17th Annual Meeting of the Society of Urologic Oncology (SUO) at the American Urological Association (AUA), “Evolving the role of Image-Guided treatment for pelvic nodal relapse after definitive local therapy” (May 7th, 2016, San Diego, USA).
- Panelist during the 17th Annual Meeting of the Society of Urologic Oncology (SUO) at the American Urological Association (AUA), “Case-based discussion of high risk/advanced disease” (May 7th, 2016, San Diego, USA).
- Provoker during the Annual Meeting of the American Urological Association (AUA), Subspecialty Society & International Meetings – Italian Society of Urology: “Prostate cancer biology, staging and grading” (May 9th, 2016, San Diego, USA).
- Lecturer during the 4th Global Congress on Prostate Cancer: “A provocative discussion on the best discovery over the the last 5 year - Surgery” and “Local disease control in clinical N+ patients” (June 29th-July 1st, Vienna, Austria).
- Lecturer during the European Association of Urology (EAU)- Chinese Urological Association (CUA) Workshop with a lecture entitled “Assessment of Guidelines Implementation and Education (IMAGINE)” (August 25th- 26th, 2016, Guangzhou, China).
- Lecturer during the 13th Meeting if the EAU Robotic Urology Section (ERUS) “One-stage pelvic and retroperitoenal primary or salvage lymph node dissection in prostate cancer” (June 14th- 16th, 2016, Milan, Italy).
- Lecturer during 2nd Urology Robotic Oncology Paris (URO) Meeting: “Is there any further indication of active treatment for low-risk, localized prostate cancer patients? and “Exploring decision-making with new generation hormonal therapies in mCRPC patients progressing on ADT” - Astellas Symposium (October 13th-14th, 2016, Paris, France)
- Lecturer during the Meeting entitled “Lymphadeectomy in Urological surgery – Technique and Template. Myths and facts” with two lectures “How high is enough?: Limited vs Extended vs Super-extended lymph node dissection in prostate cancer” and “Oncological meanings of a positive node during radical prostatectomy” (November 4th 2016, Bergamo, Italy)
- Lecturer during the “Urologie and Andrologie” annual meeting in the International Lectures session with two lectures entitled “Role of lymphadenectomy for prostate cancer” and “How to make successfully academic career in urology (November 5th 2016, Linz, Austria)
- Lecturer as guest speaker during the Martini-Klinik Autumn Seminar “The role of metastasis-directed therapy in the era of systemic treatments in prostate cancer (November 18th, Hamburg, Germany)
- Lecturer during the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC): “Take-home messages – Urologist” (November 24th-27th, 2016, Milan, Italy).
- Panelist during the Uroforum 2016 “Debate – Management of high risk localized and locally advanced prostate cancer” (December 1st- 2nd, Barcelona, Spain)
- Lecturer during Movember Uro-Webinar “Debate on screening for prostate cancer: USPSTF recommendations against PSA testing – a good thing?”, (November 22nd, 2016)

- Lecturer during the Joint session of the EAU Section of Urological Imaging (ESUI) and the European Association of Nuclear Medicine (EANM): “The more you look, the more you find: clinical consequences of new imaging technologies in prostate cancer” (November 24th, 2016, Milan, Italy).
- Lecturer during the 14th Meeting of the EAU Section of Oncological Urology (ESOU), “Targeted MRI prostate biopsy: Relevant drawbacks” (January 20th -22nd 2017, Prague, Czech Republic).
- Lecturer during the “5th Techno Urology Meeting” with a lecture entitled “Radical prostatectomy in oligometastatic patients: biological rationale and clinical impact” (January 25th-27th, 2017, Orbassano, Turin, Italy).
- Lecturer during 9th Uro-Oncology Symposium “Controversies in Uro-Oncology” with a lecture entitled “Adjuvant and salvage radiation therapy in prostate cancer (January 27th 2017, Zurich, Switzerland)
- Lecturer during the ESUT-Expert Meeting "Management of locally confined prostate cancer" with a lecture entitled “Staging of prostate cancer with MRI: a real benefit or waste of money?” (February 4th 2017, Davos, Switzerland).
- Lecturer during the annual meeting of the European Society of Radiology with a lecture entitled “Prostate biopsy strategy” (March 1st-5th 2017, Vienna, Austria)
- Lecturer during the 32nd Meeting of the European Association of Urology (EAU) in the Joint Session of the European Association of Urology (EAU) and the Confederación Americana de Urología (CAU) with a lecture entitled “High risk localised prostate cancer, radical prostatectomy versus radiotherapy” (24th-28th March, 2017, London, UK).
- Lecturer during the 32nd Meeting of the European Association of Urology (EAU) in the Joint Session of the European Association of Urology (EAU) and the Japanese Urological Association (JUA) with a lecture entitled “Extending the use of androgen receptor targeted drugs in men with nmCRPC: No” (24th-28th March, 2017, London, UK).
- Lecturer during the 32nd Meeting of the European Association of Urology (EAU) in the Meeting of the Young Academic Urologists (YAU) with a lecture entitled “Establishing a professional career at a European level: Motivational talk by Crystal Matula Award Winner” (24th-28th March, 2017, London, UK).
- Lecturer during the 32nd Meeting of the European Association of Urology (EAU) in the Meeting of Meeting of the EAU Section of Urological Imaging (ESUI) in cooperation with the EAU Section of Urological Research (ESUR) and the European Society of Nuclear Medicine (EANM) with a lecture entitled: “Controversies - Focal therapy and the concept of the index lesion: Nonsense” (24th-28th March, 2017, London, UK).
- Lecturer during the annual meeting of the American Society of Clinical Oncology (ASCO) in the Education session: Disparities in Screening and Treatment of Prostate Cancer for the Older Patient with a lecture entitled: “Does Prostate Cancer Presentation and Biologic Characteristics Differ in Older Patients?” (June 2nd-6th, 2017, Chicago, US)
- Lecturer during the first EAU Update on Prostate Cancer Meeting with a lecture entitled: “Salvage local treatment for recurrent disease” (September 15th- 16th, 2017, Vienna, Austria)
- Lecturer during the 14th Meeting of the EAU Robotic Urology Section (ERUS) with a lecture entitled “How to find lymph nodes suspicious on preoperative PSMA PET Scan: How to do it” (September 25th- 27th, 2017, Bruges, Belgium).
- Lecturer during the 2018 Genitourinary Cancer Symposium of the American Society of Clinical Oncology (GU ASCO) with a lecture entitled: “Adjuvant radiotherapy and Chemotherapy in node positive prostate cancer” (8th-10th February, 2018, San Francisco, USA)

- Lecturer during the 2nd EAU Update on Prostate Cancer Meeting with a lecture entitled: “Salvage treatment for recurrent disease” (14th-15th September, Milan, Italy)
- Lecturer during the 33th Meeting of the European Association of Urology (EAU) in the 5th ESO Prostate Cancer Observatory with a lecture entitled: “The urologist’s perspective on surgery” (16th-20th March, 2018, Copenhagen, Denmark)
- Lecturer during the 33th Meeting of the European Association of Urology (EAU) - Young Academic Urologists (YAU) with a presentation entitled: “PROTECT trial and sexual outcomes: Lights and shadows” (16th-20th March, 2018, Copenhagen, Denmark)
- Lecturer during the 55th Urology Course of Fundacio Puigvert with lectures entitled: “Active surveillance vs focal treatment. Does the vascular-targeted photodynamic therapy trial make a difference?” and “Lymphadenectomy in prostate cancer: when, how, for what?” (17th-19th September, 2018, Barcelona, Spain)
- Lecturer during the multidisciplinary case discussion “Controversies and contradictions in staging of prostate cancer” 10th European Multidisciplinary Meeting on Urological Cancers (EMUC) (8th-11th November, 2018, Amsterdam, The Netherlands)
- Lecturer during 10th European Multidisciplinary Meeting on Urological Cancers (EMUC) with a presentation entitled: “Everything in prostate cancer pathology you were afraid to ask” (8th-11th November, 2018, Amsterdam, The Netherlands)
- Lecturer during the 16th Meeting of the EAU Section of Urology Oncology (ESOU) with a lecture entitled “Reliability of PET/CT in the primary staging of prostate cancer” (18th-20th January, 2019, Prague, Czech Republic)
- Lecturer during the 2019 Genitourinary Cancer Symposium of the American Society of Clinical Oncology (GU ASCO) with a lecture entitled: “Intensification Versus Deintensification in High-Risk Prostate Cancer: Surgery” (14th-16th February, 2019, San Francisco, USA)
- Lecturer during the 6th Multidisciplinary Meeting on Prostate Cancer with lectures entitled “Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in 2018” and “A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies” (21st-22nd February, 2019, Bilbao, Spain)
- Lecturer during the 34th Meeting of the European Association of Urology (EAU) - Joint Session EAU - Urological Society of Australia and New Zealand (USANZ) with a lecture entitled: “Prostate biopsy: is multiparametric MRI the decision maker?” (15th-19th March, 2019, Barcelona, Spain)
- Discussant of the study: “The role of (fast) bi-parametric MRI versus multi-parametric MRI and TRUS-biopsy for detecting clinically significant prostate cancer in biopsy naïve men with elevated PSA in Plenary Session 3” during the 34th Meeting of the European Association of Urology (EAU) (15th-19th March, 2019, Barcelona, Spain)
- Lecturer during the 34th Meeting of the European Association of Urology (EAU) - Souvenir session (Plenary session 7) with a presentation entitled: “Prostate cancer: localized and advanced disease” (15th-19th March, 2019, Barcelona, Spain).
- Lecturer during the course Fundacio Puigvert sul Advanced Prostate Cancer Treatment with lectures entitled “Therapeutic Options after pelvic and extra-pelvic nodal recurrence” and “How to perform lymphadenectomy in locally advanced case? Technique and management of complications” (28th March, 2019, Barcelona, Spain).

- Lecturer during the Annual Meeting of the American Urological Association (AUA) – Italian Society of Urology (SIU) Session “What’s new in local staging - LAD Nomograms” (12th-16th May 2019, Boston, USA).
- Lecturer during the 92th Annual Meeting of the Italian Society of Urology (SIU) in the session named: Carcinoma prostatico avanzato: i benefici di un trattamento precoce in pratica clinica con la relazione - “Novità Sulle Terapie Ormonali Di Nuova Generazione Del Trattamento Del Carcinoma Prostatico Avanzato” sponsored symposium, Astellas, (12th-15th October 2019, Venice, Italy).
- Lecturer during the 92th Annual Meeting of the Italian Society of Urology (SIU) - session AUA - SIU Symposium - “therapeutic advances in immuno-oncology” (12th-15th October 2019, Venice, Italy)
- Lecturer during the 11th European Multidisciplinary Meeting on Urological Cancers (EMUC) – Plenary session “Pathology in active surveillance: Update and controversies” (14th-17th November 2020, Vienna, Austria).
- Lecturer during the 11th European Multidisciplinary Meeting on Urological Cancers (EMUC) – Plenary session “Take home messages” (14th-17th November 2020, Vienna, Austria).
- Lecturer during the USANZ meeting 2020 - Plenary Session 2 with a lecture entitled: “Impact of node burden on long term outcome for localised prostate cancer” (USANZ virtual meeting 7th-10th March, 2020)
- Lecturer during the USANZ meeting 2020 - EAU Session - seated panel with a lecture entitled: “Salvage RP for radiation-recurrent CaP” (USANZ virtual meeting 7th-10th March, 2020)
- Lecturer during the USANZ meeting 2020 – Oncology and Robotics with a lecture entitled: “High risk CaP - robotic assisted radical prostatectomy” (USANZ virtual meeting 7th-10th March, 2020)
- Lecturer during the USANZ meeting 2020 – Oncology, Andrology - with a lecture entitled: “Optimising erectile recovery after Radical Prostatectomy” (USANZ virtual meeting 7th-10th March, 2020)
- Lecturer during the 35th Virtual Meeting of the European Association of Urology (EAU) - thematic session “Five things I wish I would have known earlier in my career: Lessons from the mentors – Prostate Cancer” (EAU20V online 17th-21st July, 2020).
- EAU Guest Lecture during the British Association of Urological Surgeons (BAUS) virtual meeting with a presentation entitled “Current Management of Prostate Cancer Recurrence after Radical Prostatectomy” (June 21st-23rd 2021, BAUS virtual).
- Lecturer during the 36th Virtual Meeting of the European Association of Urology (EAU) - Thematic session “Best of EAU21 abstracts on Prostate Cancer” (EAU21V online 8th-12th July, 2021).
- Lecturer during the 36th Virtual Meeting of the European Association of Urology (EAU) - Plenary session 5 “Treatment for metastatic hormone-sensitive prostate cancer” with a lecture entitled: “Local treatment: Surgery (primary +/- lymph nodes)” (EAU21V online 8th-12th July, 2021).
- Lecturer during the 36th Virtual Meeting of the European Association of Urology (EAU) - Joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC), Session cN1 patients. Lecture entitled: Surgical treatment (EAU21V online 8th-12th July, 2021).
- Lecturer during the 36th Virtual Meeting of the European Association of Urology (EAU) - Thematic session Controversies in onco-urology with a lecture entitled “Should we perform PSMA PET/TC in the initial staging of prostate cancer?” (EAU21V online 8th-12th July, 2021).
- Lecturer during the Annual Meeting of the American Urological Association (AUA) – European Association of Urology (EAU) Lecture. Lecture entitled: “Clinically Relevant Questions in the Management of Locally Advanced and Oligometastatic Prostate Cancer.” (AUA virtual meeting 11th September, 2021)

- Lecturer during the Virtual EAU Update on Prostate Cancer Meeting (PCa21)- Debate on “Clinically node-positive PCa” and “Oligometastatic recurrence after local treatment”. (PCa20 Virtual meeting 16th October 2021).
- Lecturer during the 18th Meeting of the EAU Robotic Urology Section (ERUS) in conjunction with the 13th meeting of the German society of Robotic Urology (DRUS) - Scientific session: The Newsroom. Lecture entitled: “High risk PCa: Neoadjuvant ADT plus surgery as a viable multimodal treatment option” (11th-13th November 2021, Dusseldorf, Germany)
- Lecturer during the multi-disciplinary case discussions from local to systemic disease, Oligo recurrent disease at the 13th European Multidisciplinary Meeting on Urological Cancers (EMUC) - (25th-28th November 2021, Athens, Greece)
- Lecturer during the meeting USANZ 2022 - Session “Combined USANZ & ANZUNS workshop”. Lecture entitled: “What the modern uro-oncologist needs to know about drugs used in the management of advanced disease” (25th-28th June 2022, Broadbeach, Australia).
- Lecturer during the meeting USANZ 2022 – Session “Diversity in Urology Panel Discussion”. Lecture entitled: “Is pelvic lymphnode dissection still important in the era of PSMA PET?” (25th-28th June 2022, Broadbeach, Australia).
- Lecturer during the meeting USANZ 2022 – “Plenary session 1”. Lecture entitled: “Salvage radical prostatectomy for radiation recurrent prostate cancer” (25th-28th June 2022, Broadbeach, Australia).
- Lecturer during the 37th Meeting of the European Association of Urology (EAU), thematic session Controversies in onco-urology “How should PET-detected oligorecurrent prostate cancer best be treated?”. Lecture entitled: “Metastasis-directed therapy” (1st-4th July, Amsterdam, The Netherlands).
- Lecturer during the 37th Meeting of the European Association of Urology (EAU), Joint session of the EAU and the Advanced Prostate Cancer Consensus (APCCC). Lecture entitled: “How to optimally manage such situations: How to confirm metastases seen in PSMA PET and how to treat?” (1st- 4th July, Amsterdam, The Netherlands).
- Lecturer during the 37th Meeting of the European Association of Urology (EAU). Lecture entitled: “Best EAU22 abstracts selected by the Scientific Committee on Prostate cancer” (1st- 4th July, Amsterdam, The Netherlands).
- EAU-Lecture during the Kongress der Deutschen Gesellschaft für Urologie (DGU) with a presentation entitled: “Role of imaging for clinical diagnosis and staging” (September 21st- 24th 2022, Hamburg, Germany).

MODERATIONS AT NATIONAL AND INTERNATIONAL UROLOGICAL MEETINGS

- Poster session 42: Sexual dysfunction and the treatment of pelvic malignancy during the 22nd Annual Meeting of the European Association of Urology. (March 21st-24th, 2007, Berlin, Germany).
- Poster Session 56: Radical prostatectomy: Age, comorbidities and complications during the 23th Meeting of the European Association of Urology (March 26th-29th, 2008, Milan, Italy).
- Poster Session 55 Prostate cancer: Diagnosis and staging during the 24th Meeting of the European Association of Urology (March 17th-21th, 2009, Stockholm, Sweden).
- Podium session P-6: Erectile Dysfunction following RadicalProstatectomy during the 9th Meeting of the European Society for Sexual Medicine (ESSM; December 3rd-6th, 2006, Vienna, Austria).
- Podium session P-04: Erectile dysfunction during the 10th Meeting of the European Society for Sexual Medicine (ESSM; November 25th-28th, 2007, Lisbon, Portugal).

- Highlight Session during the annual 11th Meeting of the European Society for Sexual Medicine (ESSM; December 7th-11th, 2008, Brussels, Belgium).
- Poster Session: Andrology during the 82th annual Meeting of the Italian Society of Urology (October 4th-7th, 2009, Rimini, Italy).
- Session Papers A: Prostate cancer treatment during the British Association of Urological Surgeons (BAUS) Annual Meeting (June 21th-24th, 2010, Manchester, UK).
- Session entitled: "Re-definition of the oncological risk" during the 83th annual Meeting of the Italian Society of Urology (October 17th-20th, 2010, Milan, Italy).
- Highlight session during the 83th annual Meeting of the Italian Society of Urology (October 17th-20th, 2010, Milan, Italy).
- Highlight session during the 84th annual Meeting of the Italian Society of Urology (October 23rd-26th 2011, Rome, Italy).
- Poster session 11: "How to improve prostate cancer detection" during the 26th Meeting of the European Association of Urology (March 18th-22th, 2011, Vienna, Austria).
- Session "Lymphadenectomy in uro-oncology", during the 85th annual meeting of the Italian Society of Urology (October 21st-24th 2012, Venice, Italy).
- Highlight session during the 85th annual Meeting of the Italian Society of Urology (October 21st-24th 2012, Venice, Italy).
- Poster session (P216-P227): "Prostate Cancer: Surgical Therapy" during the 85th Meeting of the Italian Society of Urology (October 21st-24th, 2012, Venice, Italy).
- Poster session (P248-P263): "Andrology" during the 85th Meeting of the Italian Society of Urology (October 21st-24th, 2012, Venice, Italy).
- Session "Modern imaging in prostate cancer: the light at the end of the tunnel?" during the 2nd Global Congress on Prostate Cancer (June 12th-14th, 2013, Marseilles, France).
- Session "AFU Corner", during the 86th annual Meeting of the Italian Society of Urology (October 5th-8th 2013, Milan, Italy).
- Moderator during live surgery session at the "2nd Techno Urology Congress: improving minimally invasive surgery" (January 30th-31st, 2014, Orbassano, Turin, Italy).
- Workshop Radiotherapy and/or salvage hormonotherapy after failure of surgery in High risk Prostate Cancer during the 23rd Meeting of the Italian Society of Uro-Oncology (SIUrO) (June 8th-10th, 2013, Florence, Italy).
- Session "Node positive/oligometastatic prostate cancer" during the 5th Meeting: "Embracing Excellence in Prostate, Bladder and Kidney Cancer" (EMUC): "Take home messages: surgery" (November 15th-17th, 2013, Marseilles, France).
- Sessions "Quality assessment in uro-oncology" during the 6th meeting: "Embracing Excellence in Prostate, Bladder and Kidney Cancer" (EMUC) and "Take home messages: surgery" (November 13th-16th, 2014, Lisbon, Portugal).
- Session "Screening and diagnosis of prostate cancer" during the "Oncoforum Summary Meeting" (November 28th-29th 2014, Paris, France).
- Session "Localized prostate cancer- part 2" during the "Oncoforum Summary Meeting" (November 29th-30th 2014, Prague, Czech Republic).
- Session "Optimal management of relapsing/oligometastatic disease" during the 3rd Global Congress on Prostate Cancer (February 5th-7th, 2015, Rome, Italy).
- Chair of the Thematic Session: "Imaging in Prostate Cancer" during the 30th Meeting of the European Association of Urology (EAU) (March 20th-24th, 2015, Madrid, Spain).

- Chairman during the 3rd Global Congress on Prostate Cancer, session “Targeting the AR signalling pathway: Redefining clinical practice in mCRPC?” sponsored symposium, Astellas (February 5th-7th 2015, Rome, Italy).
- Session “Urothelial Carcinoma and Live Surgery” during the 1st Urology Robotic Oncology Paris (UROP) Meeting (October 8th-9th, 2015, Paris, France)
- Session “What’s new in prostate cancer” 88th annual Meeting of the Italian Society of Urology (October 10th-13th 2015, Riccione, Italy).
- Chairman during 88th annual Meeting of the Italian Society of Urology, session “Role of enzalutamide in the treatment of patient with mCRPC prior to chemotherapy” sponsored symposium, Astellas (October 10th-13th 2015, Riccione, Italy).
- Co-Chairman during the 4th Meeting of the EAU Section of Urological Imaging (ESUI) of the session “Molecular imaging in Urology: Joint sessions of the EAU Section of Urological Imaging (ESUI) and the European Association of Nuclear Medicine (EANM)” (November 12nd, 2015, Barcelona, Spain).
- Co-chairman during the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC): “Prostate cancer in the young patient” (November 12nd-15th, 2015, Barcelona, Spain).
- Co-chairman during the 3rd Conference on Active Surveillance for Low Risk Prostate Cancer, European School of Oncology (ESO) of the session “Current selection of men for active surveillance” (February 12th-13th 2016, Milan, Italy).
- Co-Chairman during the Joint Session of the European Association of Urology (EAU) and the Korean Urological Association (KUA) of the session “Prostate cancer: Biochemical recurrence after radical prostatectomy” during the 31st Meeting of the European Association of Urology (EAU- 11th-15th March, 2016, Munich, Germany)
- Session “Live Surgery” during the 2nd Urology Robotic Oncology Paris (UROP) Meeting (October 13th-14th, 2016, Paris, France)
- Chairman of the session: “Lecture: The role of micro-environment in GU cancers” during the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC -November 24th-27th, 2016, Milan, Italy).
- Co-chairman of the session: “Announcement of the 3 best unmoderated posters” during the 8th European Multidisciplinary Meeting on Urological Cancers (EMUC - November 24th-27th, 2016, Milan, Italy).
- Co-chairman during the Joint session of the EAU Section of Urological Imaging (ESUI) and the European Association of Nuclear Medicine (EANM) of the session entitled: “Molecular imaging in Urology” (November 24th, 2016, Milan, Italy).
- Co-chairman of the EMUC symposium on Genito-Urinary Pathology and Molecular Diagnostics (ESUP) entitled “From the latest novelties to guidelines and protocols” (November 24th, 2016, Milan, Italy).
- Co-chairman of the session: “Treatment of metastatic prostate cancer” during the annual meeting of the Italian Association of Urology (October 15th-18th 2016, Venice, Italy)
- Co-chairman of the plenary session 5 during the 32nd Meeting of the European Association of Urology (EAU) (24th-28th March, 2017, London, UK)
- Co-chairman of the Podium Session: “Prostate Cancer: Localized: Surgical Therapy I” during the annual meeting of the American Urological Association (AUA – May 12-16th, Boston, US).
- Co-chairman of the session Prostate cancer- Tailoring the therapy during the “5th Techno Urology Meeting” (January 25th-27th, 2017, Orbassano, Turin, Italy).

- Co-chairman of the session Diagnosis of prostate cancer – solutions for fusion biopsy during the ESUT-Expert Meeting "Management of locally confined prostate cancer" (February 4th, 2017, Davos, Switzerland).
- Co-chairman of the session "Future perspectives in prostate cancer management" during the first EAU Update on Prostate Cancer Meeting (September 15th- 16th, Vienna, Austria)
- Co-chairman of the Thematic session 06 "Semi-live session: Oncological surgery under scrutiny" during the 33th Meeting of the European Association of Urology (EAU) (16th-20th March, 2018, Copenhagen, Denmark).
- CoPlenary session 3 "PET/CT detected oligometastatic prostate cancer" during the 33th Meeting of the European Association of Urology (EAU) – (16th-20th March, 2018, Copenhagen, Denmark)
- Co-Chairman of the session MP05: Prostate cancer localized. Surgical therapy I, during the Annual meeting of the American Urological Association (AUA) (18th-21st May, 2018, San Francisco, USA).
- Co- Chairman of the Plenary Session 5 during the 34th Meeting of the European Association of Urology (EAU) (15th-19th March, 2019, Barcelona, Spain).
- Co-Chairman of the Session "Medicina di precisione nel tumore della prostata" during the 92th Annual Meeting of the Italian Society of Urology (12th-15th October 2019, Venice, Italy).
- Co-chairman of the planary session: "Oral presentation of the 6 best abstracts" during the 11th European Multidisciplinary Meeting on Urological Cancers (EMUC – 14th-17th November 2020, Vienna, Austria).
- Chair of the Session Game Changing 1, during the 35th Virtual Meeting of the European Association of Urology (EAU) (EAU20V online 17th-21st July, 2020).
- Chair of the Thematic Session "Radioligand therapy in metastatic castration-resistant prostate cancer, during the 35th Virtual Meeting of the European Association of Urology (EAU) (EAU20V online 17th-21st July, 2020).
- Chair of the thematic Session "Prostate Cancer: Challenge the Expert – Controversies in Prostate Cancer", during the British Association of Urological Surgeons (BAUS) virtual meeting (Birmingham, November 9th-11th 2020 BAUS virtual).
- Chair of the ePoster Session "Prostate Cancer 1 - Optimising Diagnostics", during the British Association of Urological Surgeons (BAUS) virtual meeting (Birmingham, November 9th-11th 2020 BAUS virtual).
- Chair of the Plenary Session 5 "Treatment for metastatic hormone-sensitive prostate cancer" during the 36th Virtual Meeting of the European Association of Urology (EAU) (EAU21V online 8th-12th July, 2021).
- Chair of the Plenary session "Game changing session 5" during the 36th Virtual Meeting of the European Association of Urology (EAU) (EAU21V online 8th-12th July, 2021).
- Co-Chairman during the Virtual EAU Update on Prostate Cancer Meeting (PCa21) - Session "Update on the role of genetic in clinical management of prostate cancer" (PCa20 Virtual meeting 16th October 2021).
- Co-chairman of the planary session: "Oligometastatic disease in genito-urinary cancers" during the 12th Virtual European Multidisciplinary Meeting on Urological Cancers (EMUC Virtual- November 13th-14th, 2020).
- Moderator of the Live surgery I: The way I do nerve sparing radical prostatectomy during the 18th Meeting of the EAU Robotic Urology Section (ERUS) in conjunction with the 13th meeting of the German society of Robotc Urology (DRUS) (11th-13th November 2021, Dusseldorf, Germany).

- Chair of the session PD33: “Kidney Cancer: Localized: Surgical Therapy II” during the Annual meeting of the American Urological Association (AUA) (13th-16th May 2022, New Orleans, USA)
- Chair of the thematic session “Game changing session 3” during the 37th Meeting of the European Association of Urology (EAU) (1st- 4th July 2022, Amsterdam, The Netherlands).
- Chair of the thematic session “PCa high-risk local treatment” during the 37th Meeting of the European Association of Urology (EAU) (1st- 4th July 2022, Amsterdam, The Netherlands).

PARTICIPATIONS AS INVITED SURGEON AT LIVE SURGERY EVENTS

- First operator of a live surgery case “Radical cystectomy, extended pelvic lymph node dissection and ileal conduit” during the first SIU live Meeting (April 27th- 28th, 2017, Rome, Italy).
- First operator of a live surgery case “Robotic assisted radical prostatectomy and extended pelvic lymph node dissection” during the 14th Meeting of the EAU Robotic Urology Section (ERUS - September 25th- 27th, 2017, Brugges, Belgium).
- First operator of a live surgery case “Robotic assisted radical prostatectomy and extended pelvic lymph node dissection” during the 55th Urology Course of Fundacio Puigvert (17th-19th September, 2018, Barcelona, Spain)
- First operator of a live surgery case “Robotic assisted radical prostatectomy and extended pelvic lymph node dissection” during the 34th Meeting of the European Association of Urology EAU (15th- 19th March, 2019, Barcelona, Spagna)
- First operator of a live surgery case “Robotic radical cystectomy with intracorporeal neobladder” during the meeting Challenges in Laparoscopy & Robotics (3rd-5th July 2019, Barcelona, Spain).
- First operator of a live surgery case “Robotic Radical Prostatectomy - Tc-PSMA radioguided LND” during the meeting Challenges in Laparoscopy & Robotics (15th-17th June 2022, Baveno, Italy)

8. Organizational and managerial activities

OFFICIAL POSITIONS IN SCIENTIFIC SOCIETIES AND GROUPS

- Member, Italian Study Group for the Study of Female Sexual Dysfunctions, Italian Society of Andrology (SIA), 2006).
- Member, Clinical Sub-Committee, “Meetings of the European Society for Sexual Medicine (ESSM)”, 2006-2008.
- Member, “Sexual Rehabilitation After Treatment For Prostate Cancer” Committee of the “Third International Consultation on Sexual Dysfunctions”, International Consultation on Urological Diseases (ICUD), Paris, 2009.
- Member, Scientific Committee, M.I.R.R.O.R. (Multicenter Italian report on radical prostatectomy: Outcome and Research) of the L.U.N.A. (Leading Urological No profit Advanced Research) foundation of the Italian Society of Urology, since 2010.
- Coordinator, Prostate Cancer follow-up after treatment, Regional Guidelines, Lombardia, Italy, since 2011.
- Member, Scientific Committee, Italian Society of Urology, 2010-2016.
- Member, Scientific Congress Office (SCO), European Association of Urology (EAU), since 2011.
- Member, Faculty of the European School of Urology (ESU), since 2011.
- Member, Young Academic Urologists Group (YAUG), European Association of Urology, since 2011.
- Member, Scientific Committee of the 17th ECCO-38th ESMO- 32nd ESTRO European Cancer Congress, 2013.
- Member, International Clinical Cancer Research Committee (CIR2C) for Grants, National Institute of Cancer (INCA), France, 2013-2015.
- Member, Expert Review Panel for National Grants, Cancer Research UK, October 2012.
- International Reviewer, National Grants, Swiss National Science Foundation, 2012 and 2017.
- International Reviewer, German Research Foundation (DFG), 2014-2015.
- International Reviewer, Research Foundation Flanders (FWO), 2015.
- International Reviewer, Clinical Cancer Research Committee (CIR2C) for Grants, National Institute of Cancer (INCA), 2017.
- Chairman, Steering Committee of the EMPaCT group (European Multicenter Prostate Cancer Clinical and Translational Research Group), since 2012.
- Member, Scientific Committee, EMUC (European Multidisciplinary Meeting on Urological Cancer), since 2013.
- Member, Committee on “Minimally Invasive Lymphadenectomy in Minimally Invasive Surgery in Urology (MISU)”, International Consultation on Urological Diseases – European Association of Urology (ICUD-EAU), 2013-2014.
- Member, Prostate Cancer Committee on Cytotoxic chemotherapy and targeted agents, International Consultation on Urological Diseases – European Association of Urology (ICUD-EAU), 2013-2014.
- Member, International Consortium for Health Outcomes Measurement (ICHOM), Group on Standard Set for Localized Prostate Cancer, 2015.
- Member, board of the European Association of Urology (EAU) Section of Uro-pathology (ESUP).
- Associate Member, European Association of Urology (EAU) Section of Urological Imaging (ESUI).
- Ex-officio Member, European Association of Urology (EAU) Section of Oncological Urology (ESOU).
- Faculty member, European Urology Residents Education Programme (EUREP), 2014-18.

- Member, Scientific Committee, Global Congress on Prostate Cancer, 2015.
- Member, Pasadena Consensus Panel on Robotic Assisted Radical Prostatectomy, 2015.
- Member, Impact Assessment of Guidelines Implementation and Education (IMAGINE) group, European Association of Urology (EAU) guidelines, since 2015.
- Member, European Association of Urology (EAU) Guideline Office Board, 2015-2022
- Member, The American Association of Genitourinary Surgeons (AAGUS), since 2018.
- Member, Scientific Committee, European Association of Urology (EAU) update on prostate cancer Meeting, September, since 2017.
- Member, European School of Oncology (ESO) core faculty, Surgical Oncology – Section of Genitourinary cancer
- Member, Advanced Prostate Cancer Consensus Conference (APCCC) since 2019
- Member, Scientific Committee, UroOnco Meeting, since 2021.

OFFICIAL POSITIONS IN INTERNATIONAL ADVISORY BOARDS AND TRIAL COMMITTEES

- Member, European Advisory Board, 4kscore Test (OPKO Health Europe).
- Member, European Advisory Board, SelectMDx Test (MDxHealth).
- Member, European Advisory Board, miR Scientific, LLC ("miR")
- Member, European Advisory Board, Sthockholm 3
- Member, Independent Data Monitoring Committee (IDMC), ARN-509 M1 study (protocol: 56021927PCR3002 aka TITAN) in hormone sensitive prostate cancer, Janssen research/JnJ, since 2015
- Member, PACE trial (International Randomised study to compare laparoscopic prostatectomy vs Stereotactic body radiotherapy and conventionally fractionated radiotherapy vs SBRT for early stage organ-confined prostate cancer), Independent Steering Committee, since 2015.
- Member, Prostate Cancer Radiological Estimation of Change in Sequential Evaluation (PRECISE) task force, European School of Oncology (ESO), 2016.
- Member, Prostate Cancer Radiological Estimation of Change in Sequential Evaluation II (PRECISE II) task force, 2023.
- Member, Steering Committee, CORE (Conventional care Or Radioablation for Extracranial Oligometastases), trial, 2017
- Member, Scientific Committee PROTEUS trial: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) vs ADT plus PBO in patients with localized high-risk or locally advanced prostate cancer (PC) who are candidates for radical prostatectomy (RP), 2019
- Faculty Member, Comprehensive PSMA reporting (COPRA), 2023-24
- Member, Scientific Committee DAROL study, 2019

ADVISORY BOARDS AND CONSULTATION SERVICES

- Advisory board - Astrazeneca
- Advisory Board - Bayer HealthCare Pharmaceuticals
- Advisory Board / Focus Group Agreement - Janssen-Cilag

- Advosry Board – Astellas
- Advisory Board - Hauora

9. List of internationally indexed publications

- **INTERNATIONAL INDEXED PUBLICATIONS: 1,363 (Pubmed)**
- **TOTAL NUMBER OF CITATIONS: 39,760 (Scopus)**
- **H-INDEX: 95 (Scopus)**
- **INTERNATIONAL BOOK CHAPTERS: 7**

1. Scheipner L, Incesu RB, Morra S, Baudo A, Assad A, Jannello LMI, Siech C, de Angelis M, Tian Z, Saad F, Shariat SF, **Briganti A**, Chun FKH, Tilki D, Longo N, Carmignani L, De Cobelli O, Pichler M, Ahyai S, Karakiewicz PI. Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients. *Clin Genitourin Cancer*. 2023 Oct 30:S1558-7673(23)00227-6. doi: 10.1016/j.clgc.2023.10.007. Epub ahead of print. PMID: 37981546.
2. Myers AA, **Briganti A**, Leibovich B, Lerner SP, Moschini M, Rouprêt M, Shariat SF, Spiess PE, Stenzl A, Taneja SS, Touijer KA, Kamat AM. Contemporary Role of Lymph Node Dissection in Genitourinary Cancers: Where Are We in 2023? *Eur Urol Oncol*. 2023 Nov 16:S2588-9311(23)00245-6. doi: 10.1016/j.euo.2023.10.028. Epub ahead of print. PMID: 37980250.
3. Montorsi F, Rosiello G, Gandaglia G, Salonia A, **Briganti A**. Re: David D'Andrea, Francesco Soria, Rodolfo Hurle, et al. En Bloc Versus Conventional Resection of Primary Bladder Tumor (eBLOC): A Prospective, Multicenter, Open-label, Phase 3 Randomized Controlled Trial. *Eur Urol Oncol*. In press. <https://doi.org/10.1016/j.euo.2023.07.010>. *Eur Urol Oncol*. 2023 Nov 9:S2588-9311(23)00237-7. doi: 10.1016/j.euo.2023.10.020. Epub ahead of print. PMID: 37951819.
4. Miszczyk M, Rajwa P, Yanagisawa T, Nowicka Z, Shim SR, Laukhtina E, Kawada T, von Deimling M, Pradere B, Rivas JG, Gandaglia G, van den Bergh RCN, Goldner G, Supiot S, Zilli T, Trinh QD, Nguyen PL, **Briganti A**, Ost P, Ploussard G, Shariat SF. The Efficacy and Safety of Metastasis-directed Therapy in Patients with Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies. *Eur Urol*. 2023 Nov 7:S0302-2838(23)03209-8. doi: 10.1016/j.eururo.2023.10.012. Epub ahead of print. PMID: 37945451.
5. Ghezzi S, Mapelli P, Samanes Gajate AM, Palmisano A, Cucchiara V, Brembilla G, Bezzi C, Suardi N, Scifo P, **Briganti A**, De Cobelli F, Chiti A, Esposito A, Picchio M. Diagnostic accuracy of fully hybrid [⁶⁸Ga]Ga-PSMA-11 PET/MRI and [⁶⁸Ga]Ga-RM2 PET/MRI in patients with biochemically recurrent prostate cancer: a prospective single-center phase II clinical trial. *Eur J Nucl Med Mol Imaging*. 2023 Oct 28. doi: 10.1007/s00259-023-06483-y. Epub ahead of print. PMID: 37897615.
6. Scheipner L, Barletta F, Garcia CC, Incesu RB, Morra S, Baudo A, Assad A, Tian Z, Saad F, Shariat SF, **Briganti A**, Chun FKH, Tilki D, Longo N, Carmignani L, Pichler M, Ahyai S, Karakiewicz PI. ASO Visual Abstract: Prognostic Significance of Pathological Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era. *Ann Surg Oncol*. 2023 Oct 27. doi: 10.1245/s10434-023-14476-2. Epub ahead of print. PMID: 37891455.
7. Scheipner L, Incesu RB, Morra S, Baudo A, Assad A, Jannello LMI, Siech C, de Angelis M, Barletta F, Tian Z, Saad F, Shariat SF, **Briganti A**, Chun FKH, Tilki D, Longo N, Carmignani L, De Cobelli O, Ahyai S,

- Karakiewicz PI. Characteristics of incidental prostate cancer in the United States. *Prostate Cancer Prostatic Dis.* 2023 Oct 23. doi: 10.1038/s41391-023-00742-7. Epub ahead of print. PMID: 37872250.
8. Pellegrino F, Stabile A, Sorce G, Quarta L, Robesti D, Cannoletta D, Cirulli G, Barletta F, Scuderi S, Mazzone E, de Angelis M, Brembilla G, De Cobelli F, Salonia A, Montorsi F, **Briganti A**, Gandaglia G. Added Value of Prostate-specific Antigen Density in Selecting Prostate Biopsy Candidates Among Men with Elevated Prostate-specific Antigen and PI-RADS ≥ 3 Lesions on Multiparametric Magnetic Resonance Imaging of the Prostate: A Systematic Assessment by PI-RADS Score. *Eur Urol Focus.* 2023 Oct 19;S2405-4569(23)00223-7. doi: 10.1016/j.euf.2023.10.006. Epub ahead of print. PMID: 37865591.
 9. Rajwa P, Robesti D, Chaloupka M, Zattoni F, Giesen A, Huebner NA, Krzywon A, Miszczyk M, Moll M, Stando R, Cisero E, Semko S, Checcucci E, Devos G, Apfelbeck M, Gatti C, Marra G, van den Bergh RCN, Goldner G, Rasul S, Ceci F, Dal Moro F, Porpiglia F, Gontero P, Bjartell A, Stief C, Heidenreich A, Joniau S, **Briganti A**, Shariat SF, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Outcomes of Cytoreductive Radical Prostatectomy for Oligometastatic Prostate Cancer on Prostate-specific Membrane Antigen Positron Emission Tomography: Results of a Multicenter European Study. *Eur Urol Oncol.* 2023 Oct 14;S2588-9311(23)00197-9. doi: 10.1016/j.euo.2023.09.006. Epub ahead of print. PMID: 37845121.
 10. Courboin E, Mathieu R, Panetta V, Mjaess G, Diamand R, Verhoest G, Roumiguié M, Bajet AS, Soria F, Lonati C, Simeone C, Simone G, Anceschi U, Umari P, Sridhar A, Kelly J, Mertens LS, Sanchez-Salas R, Colomer A, Cerruto MA, Antonelli A, Krajewski W, Quackels T, Peltier A, Montorsi F, **Briganti A**, Teoh JYC, Pradere B, Moschini M, Roumeguère T, Albinini S; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. Comparing Robotic-Assisted to Open Radical Cystectomy in the Management of Non- Muscle-Invasive Bladder Cancer: A Propensity Score Matched-Pair Analysis. *Cancers (Basel).* 2023 Sep 26;15(19):4732. doi: 10.3390/cancers15194732. PMID: 37835425; PMCID: PMC10571883
 11. Gandaglia G, Barletta F, **Briganti A**, Montorsi F. Re: Laura Bukavina, Amy N. Luckenbaugh, Michael S. Hofman, et al. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. *Eur Urol* 2022;83:521-33. *Eur Urol.* 2023 Oct 11;S0302-2838(23)03140-8. doi: 10.1016/j.eururo.2023.09.015. Epub ahead of print. PMID: 37833180.
 12. Scheipner L, Barletta F, Cano Garcia C, Incesu RB, Morra S, Baudo A, Assad A, Tian Z, Saad F, Shariat SF, **Briganti A**, Chun FKH, Tilki D, Longo N, Carmignani L, Pichler M, Ahyai S, Karakiewicz PI. Prognostic Significance of Pathologic Lymph Node Invasion in Metastatic Renal Cell Carcinoma in the Immunotherapy Era. *Ann Surg Oncol.* 2023 Dec;30(13):8780-8785. doi: 10.1245/s10434-023-14367-6. Epub 2023 Oct 10. PMID: 37815682; PMCID: PMC10625944
 13. Necchi A, Basile G, Gibb EA, Raggi D, Calareso G, de Padua TC, Patanè D, Crupi E, Mercinelli C, Cigliola A, Tateo V, Giannatempo P, Moschini M, **Briganti A**, Montorsi F, Messina A, Ross JS, Pavlick D, De Cobelli F, Brembilla G. Vesical Imaging-Reporting and Data System use predicting the outcome of neoadjuvant pembrolizumab in muscle-invasive bladder cancer. *BJU Int.* 2023 Oct 6. doi: 10.1111/bju.16191. Epub ahead of print. PMID: 37803523.
 14. Garcia CC, Tappero S, Piccinelli ML, Barletta F, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Saad F, Shariat SF, Carmignani L, Ahyai S, Longo N, Tilki D, **Briganti A**, De Cobelli O, Terrone C, Banek S, Kluth L, Chun FKH, Karakiewicz PI. Regional differences in metastatic urothelial carcinoma of the urinary bladder patients across the United States SEER registries. *Can Urol Assoc J.* 2023 Aug 29. doi: 10.5489/cuaj.8442. Epub ahead of print. PMID:37787591.
 15. Gandaglia G, Leni R, Plagakis S, Stabile A, Montorsi F, **Briganti A**. Active surveillance should not be routinely considered in ISUP grade group 2 prostate cancer. *BMC Urol.* 2023 Sep 30;23(1):153. doi: 10.1186/s12894-023-01315-5. PMID: 3777767; PMCID: PMC10542696.
 16. Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Parodi S, Dell'Oglio P, **Briganti A**, de Cobelli O, Chun FKH, Graefen M, Longo N, Ahyai S, Carmignani L, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Survival of patients with clear cell renal carcinoma according to number and location of organ-specific metastatic sites. *Urol Oncol.*

- 2023 Sep 28:S1078-1439(23)00288-0. doi:10.1016/j.urolonc.2023.08.014. Epub ahead of print. PMID: 37775340.
17. Mapelli P, Ghezzi S, Pini C, Samanes Gajate AM, Spataro A, Bezzi C, Landoni C, Scifo P, **Briganti A**, Chiti A, Picchio M. Predictors of PSMA PET Positivity: Analysis in a Selected Cohort of Biochemical Recurrence Prostate Cancer Patients after Radical Prostatectomy. *Cancers (Basel)*. 2023 Sep 15;15(18):4589. doi: 10.3390/cancers15184589. PMID: 37760557; PMCID: PMC10526235.
 18. Morra S, Incesu RB, Scheipner L, Baudo A, Jannello LMI, de Angelis M, Siech C, Goyal JA, Tian Z, Saad F, Califano G, la Rocca R, Capece M, Shariat SF, Ahyai S, Carmignani L, de Cobelli O, Musi G, Tilki D, **Briganti A**, Chun FKH, Longo N, Karakiewicz PI. Demographics, Clinical Characteristics and Survival Outcomes of Primary Urinary Tract Malignant Melanoma Patients: A Population-Based Analysis. *Cancers (Basel)*. 2023 Sep 10;15(18):4498. doi: 10.3390/cancers15184498. PMID: 37760467; PMCID: PMC10527544.
 19. Zattoni F, Pereira LJP, Marra G, Valerio M, Olivier J, Puche-Sanz I, Rajwa P, Maggi M, Campi R, Amparore D, De Cillis S, Junlong Z, Guo H, La Bombarda G, Fuschi A, Veccia A, Ditunno F, Marquis A, Barletta F, Leni R, Serni S, Kasivisvanathan V, Antonelli A, Dal Moro F, Rivas JG, van den Bergh RCN, **Briganti A**, Gandaglia G, Novara G. The impact of a second MRI and re-biopsy in patients with initial negative mpMRI-targeted and systematic biopsy for PIRADS ≥ 3 lesions. *World J Urol*. 2023 Nov;41(11):3357-3366. doi: 10.1007/s00345-023-04578-7. Epub 2023 Sep 27. PMID: 37755520; PMCID: PMC10632220.
 20. Scheipner L, Tappero S, Piccinelli ML, Barletta F, Garcia CC, Incesu RB, Morra S, Baudo A, Tian Z, Saad F, Shariat SF, Terrone C, De Cobelli O, **Briganti A**, Chun FKH, Tilki D, Longo N, Carmignani L, Pichler M, Hutterer G, Ahyai S, Karakiewicz PI. Regional differences in clear cell metastatic renal cell carcinoma patients across the USA. *World J Urol*. 2023 Nov;41(11):2991-3000. doi: 10.1007/s00345-023-04589-4. Epub 2023 Sep 27. PMID: 37755519; PMCID: PMC10632241.
 21. Montorsi F, Moschini M, Gandaglia G, **Briganti A**. Re: Jakob Klemm, Michael Rink, Markus von Deimling, et al. Time-to-complication Patterns After Radical Cystectomy: A Secondary Analysis of a 30-day Morbidity Assessment Using the European Association of Urology Quality Criteria for Standardized Reporting. *Eur Urol Focus*. In press. <https://doi.org/10.1016/j.euf.2023.06.005>. *Eur Urol Focus*. 2023 Sep 23:S2405-4569(23)00206-7. doi: 10.1016/j.euf.2023.09.008. Epub ahead of print. PMID: 37748951.
 22. Cano Garcia C, Tappero S, Piccinelli ML, Barletta F, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Hoeh B, Chierigo F, Sorce G, Saad F, Shariat SF, Carmignani L, Ahyai S, Longo N, Tilki D, **Briganti A**, De Cobelli O, Dell'Oglio P, Mandel P, Terrone C, Chun FKH, Karakiewicz PI. ASO Visual Abstract: In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urological Cancer Surgery. *Ann Surg Oncol*. 2023 Dec;30(13):8789-8790. doi: 10.1245/s10434-023-14315-4. PMID: 37743458.
 23. Oprea-Lager DE, MacLennan S, Bjartell A, **Briganti A**, Burger IA, de Jong I, De Santis M, Eberlein U, Emmett L, Fizazi K, Gillissen S, Herrmann K, Heskamp S, Iagaru A, Jereczek-Fossa BA, Kunikowska J, Lam M, Nanni C, O'Sullivan JM, Panebianco V, Sala E, Sathekge M, Sosnowski R, Tilki D, Tombal B, Treglia G, Tunariu N, Walz J, Yakar D, Dierckx R, Sartor O, Fanti S. European Association of Nuclear Medicine Focus 5: Consensus on Molecular Imaging and Theranostics in Prostate Cancer. *Eur Urol*. 2023 Sep 22:S0302-2838(23)03092-0. doi: 10.1016/j.eururo.2023.09.003. Epub ahead of print. PMID: 37743194.
 24. Scuderi S, Pellegrino F, Tin A, Beech BB, Gandaglia G, Stabile A, Eastham JA, Montorsi F, **Briganti A**, Vickers AJ. The Highest Grade Group Does Not Drive the Risk of Recurrence when Systematic and Multiparametric Magnetic Resonance Imaging (MRI)-targeted Biopsies are Discordant: Preliminary Findings Using Radical Prostatectomy Pathology as a Surrogate for MRI-targeted Biopsy Grade. *Eur Urol Focus*. 2023 Sep 20:S2405-4569(23)00188-8. doi: 10.1016/j.euf.2023.07.011. Epub ahead of print. PMID: 37739916.
 25. Cano Garcia C, Tappero S, Piccinelli ML, Barletta F, Incesu RB, Morra S, Scheipner L, Baudo A, Tian Z, Hoeh B, Chierigo F, Sorce G, Saad F, Shariat SF, Carmignani L, Ahyai S, Longo N, Tilki D, **Briganti A**, De Cobelli O, Dell'Oglio P, Mandel P, Terrone C, Chun FKH, Karakiewicz PI. In-Hospital Venous Thromboembolism and Pulmonary Embolism After Major Urologic Cancer Surgery. *Ann Surg Oncol*.

- 2023 Dec;30(13):8770-8779. doi: 10.1245/s10434-023-14246-0. Epub 2023 Sep 18. PMID: 37721691; PMCID: PMC10625997.
26. Schostak M, Bradbury A, **Briganti A**, Gonzalez D, Gomella L, Mateo J, Penault- Llorca F, Stenzinger A, Wyatt AW, Bjartell A. Practical Guidance on Establishing a Molecular Testing Pathway for Alterations in Homologous Recombination Repair Genes in Clinical Practice for Patients with Metastatic Prostate Cancer. *Eur Urol Oncol*. 2023 Sep 13:S2588-9311(23)00166-9. doi: 10.1016/j.euo.2023.08.004. Epub ahead of print. PMID: 37714762.
 27. Ninatti G, Pini C, Gelardi F, Ghezzi S, Mapelli P, Picchio M, Antunovic L, **Briganti A**, Montorsi F, Landoni C, Sollini M, Chiti A. The potential role of osteoporosis in unspecific [¹⁸F]PSMA-1007 bone uptake. *Eur J Nucl Med Mol Imaging*. 2023 Sep 12. doi: 10.1007/s00259-023-06424-9. Epub ahead of print. PMID: 37698646.
 28. Tappero S, Piccinelli ML, Incesu RB, Cano Garcia C, Barletta F, Morra S, Scheipner L, Baudo A, Tian Z, Parodi S, Dell'Oglio P, de Cobelli O, Graefen M, Chun FKH, **Briganti A**, Longo N, Ahyai S, Carmignani L, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Overall Survival of Metastatic Prostate Cancer Patients According to Location of Visceral Metastatic Sites. *Clin Genitourin Cancer*. 2023 Aug 11:S1558-7673(23)00187-8. doi: 10.1016/j.clgc.2023.08.004. Epub ahead of print. PMID: 37690970.
 29. Mazzone E, Gandaglia G, Robesti D, Rajwa P, Gomez Rivas J, Ibáñez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler WP, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Moreno Sierra J, Porpiglia F, Picchio M, Chiti A, van den Bergh R, Shariat SF, Montorsi F, **Briganti A**. Which Patients with Prostate Cancer and Lymph Node Uptake at Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography/Computerized Tomography Scan Are at a Higher Risk of Prostate-specific Antigen Persistence After Radical Prostatectomy? Identifying Indicators of Systemic Disease by Integrating Clinical, Magnetic Resonance Imaging, and Functional Imaging Parameters. *Eur Urol Oncol*. 2023 Sep 7:S2588-9311(23)00173-6. doi: 10.1016/j.euo.2023.08.010. Epub ahead of print. PMID: 37689506.
 30. Montorsi F, Gandaglia G, Salonia A, **Briganti A**. Early Detection of Prostate Cancer: AUA/SUO Guideline. *Letter. J Urol*. 2023 Nov;210(5):731-732. doi: 10.1097/JU.0000000000003683. Epub 2023 Sep 6. PMID: 37671725.
 31. Morra S, Piccinelli ML, Cano Garcia C, Tappero S, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, Saad F, Mirone V, Califano G, Colla' Ruvolo C, Shariat SF, de Cobelli O, Musi G, Chun FKH, Terrone C, **Briganti A**, Tilki D, Ahyai S, Carmignani L, Longo N, Karakiewicz PI. Differences in future life expectancy of testicular germ-cell tumor patients vs. age-matched male population-based controls. *Int Urol Nephrol*. 2023 Dec;55(12):3119-3128. doi: 10.1007/s11255-023-03763-2. Epub 2023 Aug 28. PMID: 37640983.
 32. Uleri A, Baboudjian M, Tedde A, Gallioli A, Long-Depaquit T, Palou J, Basile G, Gaya JM, Lughezzani G, Rajwa P, Pradere B, Roupert M, **Briganti A**, Ploussard G, Breda A. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy in Clinically Significant Prostate Cancer Detection Rate? A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2023 Aug 25:S2588-9311(23)00164-5. doi: 10.1016/j.euo.2023.08.001. Epub ahead of print. PMID: 37634971.
 33. Ghezzi S, Neri I, Mapelli P, Savi A, Samanes Gajate AM, Brembilla G, Bezzi C, Maghini B, Villa T, **Briganti A**, Montorsi F, De Cobelli F, Freschi M, Chiti A, Picchio M, Scifo P. [⁶⁸Ga]Ga-PSMA and [⁶⁸Ga]Ga-RM2 PET/MRI vs. Histopathological Images in Prostate Cancer: A New Workflow for Spatial Co-Registration. *Bioengineering (Basel)*. 2023 Aug 11;10(8):953. doi: 10.3390/bioengineering10080953. PMID: 37627838; PMCID: PMC10451901.
 34. Capogrosso P, Dehò F, Salonia A, **Briganti A**, Montorsi F. Re: Jean-Nicolas Cornu, Paul Zantek, Glyn Burt, et al. Minimally Invasive Treatments for Benign Prostatic Obstruction: A Systematic Review and Network Meta-analysis. *Eur Urol* 2023;83:534-47. *Eur Urol*. 2023 Dec;84(6):e146. doi: 10.1016/j.eururo.2023.07.018. Epub 2023 Aug 19. PMID: 37599159.
 35. Candela L, Ventimiglia E, Solano C, Chicaud M, Kutchukian S, Panthier F, Corrales M, Villa L, **Briganti A**, Montorsi F, Salonia A, Doizi S, Traxer O. Endoscopic Conservative Treatment of Upper Urinary Tract

- Urothelial Carcinoma with a Thulium Laser: A Systematic Review. *J Clin Med*. 2023 Jul 26;12(15):4907. doi: 10.3390/jcm12154907. PMID: 37568309; PMCID: PMC10419594.
36. Incesu RB, Barletta F, Tappero S, Morra S, Garcia CC, Scheipner L, Piccinelli ML, Tian Z, Saad F, Shariat SF, de Cobelli O, Ahyai S, Chun FKH, Longo N, Terrone C, **Briganti A**, Tilki D, Graefen M, Karakiewicz PI. Conditional survival of stage III non-seminoma testis cancer patients. *Urol Oncol*. 2023 Oct;41(10):435.e11-435.e18. doi: 10.1016/j.urolonc.2023.06.005. Epub 2023 Aug 7. PMID: 37558516.
 37. Barletta F, Ceci F, van den Bergh RCN, Rajwa P, Montorsi F, **Briganti A**, Gandaglia G; EAU-YAU Prostate Cancer Working Party. The role of nuclear medicine tracers for prostate cancer surgery: from preoperative to intraoperative setting. *Curr Opin Urol*. 2023 Nov 1;33(6):502-509. doi: 10.1097/MOU.0000000000001118. Epub 2023 Aug 2. PMID: 37530704.
 38. Panunzio A, Tappero S, Piccinelli M, Cano Garcia C, Barletta F, Incesu RB, Law KW, Tian Z, Tafuri A, Saad F, Shariat SF, Tilki D, **Briganti A**, Chun FK, DE Cobelli O, Terrone C, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Regional differences in stage distribution and rates of treatment for adrenocortical carcinoma across United States SEER registries. *Minerva Urol Nephrol*. 2023 Aug;75(4):443-451. doi: 10.23736/S2724-6051.23.05342-9. PMID: 37530661.
 39. Villa L, Weinhold P, Zaffuto E, Castiglione F, Pozzi E, Ventimiglia E, Buono R, **Briganti A**, Montorsi F, Salonia A, Hedlund P. The Rho-kinase inhibitor Y27632 promotes ureteral relaxation in an in vivo rat model for partial ureteral obstruction. *World J Urol*. 2023 Sep;41(9):2541-2547. doi: 10.1007/s00345-023-04528-3. Epub 2023 Aug 1. PMID: 37528287.
 40. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Shariat SF, Antonelli A, Guano G, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. Racial/ethnic disparities in the distribution and effect of type and number of high-risk criteria on mortality in prostate cancer patients treated with radiotherapy. *Arab J Urol*. 2022 Nov 21;21(3):135-141. doi: 10.1080/2090598X.2022.2148867. PMID: 37521449; PMCID: PMC10373609.
 41. Casirati A, Da Prat V, Bettiga A, Aretano L, Trevisani F, Cereda E, **Briganti A**, Colombo E, Preziati G, De Simeis F, Salonia A, Montorsi F, Caccialanza R, Naspro R. Immunonutrition in Radical Cystectomy: State of the Art and Perspectives. *Cancers (Basel)*. 2023 Jul 24;15(14):3747. doi: 10.3390/cancers15143747. PMID: 37509408; PMCID: PMC10378592.
 42. Scheipner L, Cano Garcia C, Barletta F, Incesu RB, Morra S, Baudo A, Assad A, Tian Z, Saad F, Shariat SF, Chun FKH, **Briganti A**, Tilki D, Longo N, Carmignani L, Leitsmann M, Ahyai S, Karakiewicz PI. Regional differences in penile cancer patient characteristics and treatment rates across the United States. *Cancer Epidemiol*. 2023 Oct;86:102424. doi: 10.1016/j.canep.2023.102424. Epub 2023 Jul 26. PMID: 37506474.
 43. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Graefen M, Shariat SF, Guano G, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. The association of the type and number of D'Amico high-risk criteria with rates of pathologically non-organ-confined prostate cancer. *Cent European J Urol*. 2023;76(2):104-108. doi: 10.5173/ceju.2023.030. Epub 2023 Apr 30. PMID: 37483849; PMCID: PMC10357822.
 44. Hugar LA, Peak TC, Naqvi M, Kim Y, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, **Briganti A**, Salvioni R, Chakiryan NH, Montorsi F, Necchi A, Spiess PE. Predicting Limited Survival Following Inguinal Lymph Node Dissection in Penile Cancer: Should We Revisit the Goals of Care? *Urology*. 2023 Oct;180:176-181. doi: 10.1016/j.urology.2023.07.006. Epub 2023 Jul 17. PMID: 37467807.
 45. Gandaglia G, Barletta F, **Briganti A**, Montorsi F. Re: Ragheed Saoud, Varat Woranisarakul, Gladell P. Paner, et al. Physician Perception of Grade Group 1 Prostate Cancer. *Eur Urol Focus*. In press. <https://doi.org/10.1016/j.euf.2023.04.002>. *Eur Urol Focus*. 2023 Jul 14:S2405-4569(23)00151-7. doi: 10.1016/j.euf.2023.06.011. Epub ahead of print. PMID: 37455217.
 46. Tappero S, Chierigo F, Parodi S, Bandini M, Moschini M, Cucchiara V, Chessa F, Di Maida F, Mari A, Manfredi M, Mantica G, Cerruto MA, Fiori C, Schiavina R, **Briganti A**, Suardi N, Brunocilla E, Antonelli A, Porpiglia F, Minervini A, Montorsi F, Terrone C. Radical cystectomy in bladder cancer patients

- previously treated for prostate cancer: Insights from a large European multicentric series. *Surg Oncol.* 2023 Oct;50:101973. doi: 10.1016/j.suronc.2023.101973. Epub 2023 Jul 11. PMID: 37454433.
47. Montorsi F, Stabile A, Gandaglia G, **Briganti A**. Long-term Outcomes Following Active Surveillance of Low-grade Prostate Cancer: A Population-based Study Using a Landmark Approach. *Letter. J Urol.* 2023 Sep;210(3):410. doi: 10.1097/JU.0000000000003614. Epub 2023 Jul 14. PMID: 37449312.
 48. Capogrosso P, Ventimiglia E, Fallara G, Schifano N, Costa A, Candela L, Pellegrino F, Colandrea G, Cignoli D, De Angelis M, Belladelli F, Longoni M, Avesani G, Lanzaro F, Scattoni V, Dehò F, Salonia A, **Briganti A**, Montorsi F. Reply to: Antonio Andrea Grosso, Agostino Tuccio, Matteo Salvi, Daniele Paganelli, Andrea Minervini, and Fabrizio Di Maida's Letter to the Editor re: Paolo Capogrosso, Eugenio Ventimiglia, Giuseppe Fallara, et al. Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve. *Eur Urol Focus.* In press. <https://doi.org/10.1016/j.euf.2023.03.018>. *Eur Urol Focus.* 2023 Jul 11:S2405-4569(23)00148-7. doi: 10.1016/j.euf.2023.06.008. Epub ahead of print. PMID: 37442724.
 49. Piccinelli ML, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Ahyai S, Longo N, Tilki D, **Briganti A**, Chun FKH, Terrone C, de Cobelli O, Musi G, Karakiewicz PI. Assessment of the VENUSS and GRANT Models for Individual Prediction of Cancer-specific Survival in Surgically Treated Nonmetastatic Papillary Renal Cell Carcinoma. *Eur Urol Open Sci.* 2023 Jun 13;53:109-115. doi: 10.1016/j.euro.2023.05.005. PMID: 37441347; PMCID: PMC10334233.
 50. Sood A, Kishan AU, Evans CP, Feng FY, Morgan TM, Murphy DG, Padhani AR, Pinto P, Van der Poel HG, Tilki D, **Briganti A**, Abdollah F. The Impact of Positron Emission Tomography Imaging and Tumor Molecular Profiling on Risk Stratification, Treatment Choice, and Oncological Outcomes of Patients with Primary or Relapsed Prostate Cancer: An International Collaborative Review of the Existing Literature. *Eur Urol Oncol.* 2023 Jul 7:S2588-9311(23)00114-1. doi: 10.1016/j.euo.2023.06.002. Epub ahead of print. PMID: 37423774.
 51. Gandaglia G, Pellegrino F, Golozar A, De Meulder B, Abbott T, Achtman A, Imran Omar M, Alshammari T, Areia C, Asimwe A, Beyer K, Bjartell A, Campi R, Cornford P, Falconer T, Feng Q, Gong M, Herrera R, Hughes N, Hulsen T, Kinnaird A, Lai LYH, Maresca G, Mottet N, Oja M, Prinsen P, Reich C, Remmers S, Roobol MJ, Sakalis V, Seager S, Smith EJ, Snijder R, Steinbeisser C, Thurin NH, Hijazy A, van Bochove K, Van den Bergh RCN, Van Hemelrijck M, Willemsse PP, Williams AE, Zounemat Kermani N, Evans-Axelsson S, **Briganti A**, N'Dow J; PIONEER Consortium. Clinical Characterization of Patients Diagnosed with Prostate Cancer and Undergoing Conservative Management: A PIONEER Analysis Based on Big Data. *Eur Urol.* 2023 Jul 4:S0302-2838(23)02944-5. doi: 10.1016/j.eururo.2023.06.012. Epub ahead of print. PMID: 37414703.
 52. Barletta F, Tappero S, Morra S, Incesu RB, Cano Garcia C, Piccinelli ML, Scheipner L, Baudo A, Tian Z, Gandaglia G, Stabile A, Mazzone E, Terrone C, Longo N, Tilki D, Chun FKH, de Cobelli O, Ahyai S, Carmignani L, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion. *Clin Genitourin Cancer.* 2023 May 18:S1558-7673(23)00122-2. doi: 10.1016/j.clgc.2023.05.010. Epub ahead of print. PMID: 37365054.
 53. Cano Garcia C, Flammia RS, Piccinelli M, Panunzio A, Tappero S, Barletta F, Incesu RB, Law KW, Morra S, Tian Z, Saad F, Kapoor A, Shariat SF, Longo N, Tilki D, **Briganti A**, Terrone C, Antonelli A, De Cobelli O, Hoeh B, Kluth LA, Chun FKH, Karakiewicz PI. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy. *Clin Genitourin Cancer.* 2023 Jun 12:S1558-7673(23)00142-8. doi: 10.1016/j.clgc.2023.06.003. Epub ahead of print. PMID: 37344282.
 54. Pellegrino A, Gandaglia G, de Angelis M, Fallara G, Mazzone E, Stabile A, Pellegrino F, Robesti D, Leni R, Scuderi S, Cucchiara V, Cirulli GO, Barletta F, Montorsi F, **Briganti A**. Oncological and perioperative outcomes of surgery with or without metastasis-directed therapy as part of a multimodal treatment in men with de-novo oligometastatic prostate cancer. *World J Urol.* 2023 Aug;41(8):2069-2076. doi: 10.1007/s00345-023-04460-6. Epub 2023 Jun 16. PMID: 37326656.

55. Gandaglia G, Barletta F, Robesti D, Scuderi S, Rajwa P, Gomez Rivas J, Ibanez L, Soeterik TFW, Bianchi L, Afferi L, Kesch C, Darr C, Guo H, Zhuang J, Zattoni F, Fendler W, Marra G, Stabile A, Amparore D, Huebner NA, Giesen A, Joniau S, Schiavina R, Brunocilla E, Mattei A, Dal Moro F, Sierra JM, Porpiglia F, Picchio M, van den Bergh R, Shariat SF, Montorsi F, **Briganti A**. Identification of the Optimal Candidates for Nodal Staging with Extended Pelvic Lymph Node Dissection Among Prostate Cancer Patients Who Underwent Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. External Validation of the Memorial Sloan Kettering Cancer Center and Briganti Nomograms and Development of a Novel Tool. *Eur Urol Oncol*. 2023 Jun 1:S2588-9311(23)00086-X. doi: 10.1016/j.euo.2023.05.003. Epub ahead of print PMID: 37270378.
56. Stabile A, Gandaglia G, Dehò F, **Briganti A**, Montorsi F. Re: Caroline M. Moore, Lauren E. King, John Withington, et al. Best Current Practice and Research Priorities in Active Surveillance for Prostate Cancer-A Report of a Movember International Consensus Meeting. *Eur Urol Oncol*. 2023 Oct;6(5):540. doi: 10.1016/j.euo.2023.04.008. Epub 2023 May 30. PMID: 37263905.
57. Gelardi F, **Briganti A**, Pini C, Ninatti G, Gandaglia G, Montorsi F, Chiti A. European guidelines update on PSMA PET/CT for prostate cancer staging-snap back to reality. *Eur J Nucl Med Mol Imaging*. 2023 Jul;50(9):2572-2575. doi: 10.1007/s00259-023-06287-0. PMID: 37261474.
58. Piccinelli ML, Panunzio A, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Tilki D, **Briganti A**, Chun FK, Terrone C, Antonelli A, DE Cobelli O, Musi G, Karakiewicz PI. Cancer-specific mortality free survival rates in non-metastatic non-clear cell renal carcinoma patients at intermediate/high risk of recurrence. *Minerva Urol Nephrol*. 2023 Jun;75(3):319-328. doi: 10.23736/S2724-6051.23.05151-0. PMID: 37221827.
59. Bamias A, Stenzl A, Brown SL, Albiges L, Babjuk M, Birtle A, **Briganti A**, Burger M, Choudhury A, Colecchia M, De Santis M, Fanti S, Fonteyne V, Gallucci M, Rivas JG, Huddart R, Junker K, Kroeze S, Lorient Y, Merseburger A, Montironi R, Necchi A, Oing C, Oldenburg J, Ost P, Pinkawa M, Ribal MJ, Rouprêt M, Thoeny H, Zilli T, Hoskin P. Definition and Diagnosis of Oligometastatic Bladder Cancer: A Delphi Consensus Study Endorsed by the European Association of Urology, European Society for Radiotherapy and Oncology, and European Society of Medical Oncology Genitourinary Faculty. *Eur Urol*. 2023 Oct;84(4):381-389. doi: 10.1016/j.eururo.2023.05.005. Epub 2023 May 20. PMID: 37217391.
60. Pellegrino F, Sjoberg DD, Tin AL, Benfante NE, **Briganti A**, Montorsi F, Scardino PT, Eastham JA, Vickers AJ, Lilja H, Laudone VP. Predictive value of kallikrein forms and β -microseminoprotein in blood from patients with evidence of detectable levels of PSA after radical prostatectomy. *World J Urol*. 2023 Jun;41(6):1489-1495. doi: 10.1007/s00345-023-04420-0. Epub 2023 May 20. PMID: 37209144; PMCID: PMC10547122.
61. Pellegrino F, Mazzone E, Stabile A, Beauval JB, Marra G, Campi R, Afferi L, Zhuang J, Sorce G, Rosiello G, Barletta F, Scuderi S, Guo H, Gontero P, Minervini A, Ploussard G, Montorsi F, **Briganti A**, Gandaglia G. Impact of the time elapsed between prostate biopsy and surgery on the accuracy of nomograms predicting lymph node invasion in patients with clinically localized prostate cancer. *Urol Oncol*. 2023 Sep;41(9):387.e17-387.e25. doi: 10.1016/j.urolonc.2023.04.019. Epub 2023 May 16. PMID: 37198026.
62. Gandaglia G, **Briganti A**, Chiti A, Cozzarini C, Montorsi F. Re: Prostate- specific Membrane Antigen Positron Emission Tomography/Computed Tomography-based Lymph Node Atlas for Salvage Radiotherapy in Patients with Recurrent Prostate Cancer: A Validation of the New NRG Oncology 2020 Guideline. *Eur Urol Oncol*. 2023 May 12:S2588-9311(23)00077-9. doi: 10.1016/j.euo.2023.04.001. Epub ahead of print. PMID: 37183078.
63. Scuderi S, Tin A, Gandaglia G, Stabile A, Montorsi F, **Briganti A**, Vickers AJ. Implementation of 4Kscore as a Secondary Test Before Prostate Biopsy: Impact on US Population Trends for Prostate Cancer. *Eur Urol Open Sci*. 2023 Apr 29;52:1-3. doi: 10.1016/j.euros.2023.03.011. PMID: 37182119; PMCID: PMC10172694.
64. Rosiello G, Scilipoti P, Larcher A, Fallara G, Colandrea G, Basile G, Re C, Tian Z, Karakiewicz PI, Mottrie A, Trevisani F, Marandino L, Raggi D, Necchi A, Bertini R, Salonia A, **Briganti A**, Montorsi F, Capitanio U. Neglected lymph nodal metastases in patients with renal cancer: when to extend the anatomical

- template of lymph node dissection during nephrectomy. *World J Urol.* 2023 Jun;41(6):1573-1579. doi: 10.1007/s00345-023-04413-z. Epub 2023 May 6. PMID: 37148324.
65. Brembilla G, Lavalle S, Parry T, Cosenza M, Russo T, Mazzone E, Pellegrino F, Stabile A, Gandaglia G, **Briganti A**, Montorsi F, Esposito A, De Cobelli F. Impact of prostate imaging quality (PI-QUAL) score on the detection of clinically significant prostate cancer at biopsy. *Eur J Radiol.* 2023 Jul;164:110849. doi: 10.1016/j.ejrad.2023.110849. Epub 2023 Apr 28. PMID: 37141845.
 66. Sholkapper TN, Ballon J, Sayegh AS, La Riva A, Perez LC, Huang S, Eppler M, Nelson G, Marchegiani G, Hinchliffe R, Gordini L, Furrer M, Brenner MJ, Dell-Kuster S, Biyani CS, Francis N, Kaafarani HMA, Siepe M, Winter D, Sosa JA, Bandello F, Siemens R, Walz J, **Briganti A**, Gratzke C, Abreu AL, Desai MM, Sotelo R, Agha R, Lillemoe KD, Wexner S, Collins GS, Gill I, Cacciamani GE. Bibliometric analysis of academic journal recommendations and requirements for surgical and anesthesiologic adverse events reporting. *Int J Surg.* 2023 May 1;109(5):1489-1496. doi: 10.1097/JS9.0000000000000323. PMID: 37132189; PMCID: PMC10389352.
 67. Tappero S, Dell'Oglio P, Cerruto MA, Sanchez Salas R, Buisan Rueda O, Simone G, Hendricksen K, Soria F, Umari P, Antonelli A, **Briganti A**, Montorsi F, de Cobelli O, Terrone C, Galfano A, Moschini M, Di Trapani E; European Association of Urology-Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group. Ileal Conduit Versus Orthotopic Neobladder Urinary Diversion in Robot-assisted Radical Cystectomy: Results from a Multi-institutional Series. *Eur Urol Open Sci.* 2023 Feb 18;50:47-56. doi: 10.1016/j.euros.2023.01.009. PMID: 37101775; PMCID: PMC10123439.
 68. Capogrosso P, Ventimiglia E, Fallara G, Schifano N, Costa A, Candela L, Pellegrino F, Colandrea G, Cignoli D, De Angelis M, Belladelli F, Longoni M, Avesani G, Lanzaro F, Scattoni V, Dehò F, Salonia A, **Briganti A**, Montorsi F. Holmium Laser Enucleation of the Prostate Is Associated with Complications and Sequelae Even in the Hands of an Experienced Surgeon Following Completion of the Learning Curve. *Eur Urol Focus.* 2023 Apr 15:S2405-4569(23)00084-6. doi: 10.1016/j.euf.2023.03.018. Epub ahead of print. PMID: 37069007.
 69. Tutolo M, **Briganti A**, Salonia A, Montorsi F. Role of Antimuscarinics Combined With Alpha-blockers in the Management of Urinary Storage Symptoms in Patients With Benign Prostatic Hyperplasia: An Updated Systematic Review and Meta-analysis. *Letter. J Urol.* 2023 Jul;210(1):33-34. doi: 10.1097/JU.00000000000003484. Epub 2023 Apr 13. PMID: 37053542.
 70. Martini A, Wever L, Soeterik TFW, Rakauskas A, Fankhauser CD, Grogg JB, Checcucci E, Amparore D, Haiquel L, Rodriguez-Sanchez L, Ploussard G, Qiang P, Affentranger A, Marquis A, Marra G, Ettala O, Zattoni F, Falagarino UG, De Angelis M, Kesch C, Apfelbeck M, Al-Hammouri T, Kretschmer A, Kasivisvanathan V, Preisser F, Lefebvre E, Olivier J, Radtke JP, **Briganti A**, Montorsi F, Carrieri G, Moro FD, Boström P, Jambor I, Gontero P, Chiu PK, John H, Macek P, Porpiglia F, Hermanns T, van den Bergh RCN, van Basten JA, Gandaglia G, Valerio M. Reply by Authors. *J Urol.* 2023 Jul;210(1):127. doi: 10.1097/JU.00000000000003442.02. Epub 2023 Apr 13. PMID: 37052482.
 71. Martini A, Wever L, Soeterik TFW, Rakauskas A, Fankhauser CD, Grogg JB, Checcucci E, Amparore D, Haiquel L, Rodriguez-Sanchez L, Ploussard G, Qiang P, Affentranger A, Marquis A, Marra G, Ettala O, Zattoni F, Falagarino UG, De Angelis M, Kesch C, Apfelbeck M, Al-Hammouri T, Kretschmer A, Kasivisvanathan V, Preisser F, Lefebvre E, Olivier J, Radtke JP, **Briganti A**, Montorsi F, Carrieri G, Moro FD, Boström P, Jambor I, Gontero P, Chiu PK, John H, Macek P, Porpiglia F, Hermanns T, van den Bergh RCN, van Basten JA, Gandaglia G, Valerio M. Unilateral Pelvic Lymph Node Dissection in Prostate Cancer Patients Diagnosed in the Era of Magnetic Resonance Imaging-targeted Biopsy: A Study That Challenges the Dogma. *J Urol.* 2023 Jul;210(1):117-127. doi: 10.1097/JU.00000000000003442. Epub 2023 Apr 13. PMID: 37052480.
 72. Piccinelli ML, Morra S, Tappero S, Cano Garcia C, Barletta F, Incesu RB, Scheipner L, Baudo A, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Carmignani L, Ahyai S, Tilki D, **Briganti A**, Chun FKH, Terrone C, Longo N, de Cobelli O, Musi G, Karakiewicz PI. Critical Appraisal of Leibovich 2018 and GRANT Models for Prediction of Cancer-Specific Survival in Non-Metastatic Chromophobe Renal Cell Carcinoma. *Cancers (Basel).* 2023 Apr 5;15(7):2155. doi: 10.3390/cancers15072155. PMID: 37046815; PMCID: PMC10093654.
 73. Bianchi L, Ceci F, Balestrazzi E, Costa F, Droghetti M, Piazza P, Pissavini A, Presutti M, Farolfi A, Mei R, Castellucci P, Gandaglia G, Larcher A, Robesti D, Mottrie A, **Briganti A**, Morganti AG, Fanti S,

- Montorsi F, Schiavina R, Brunocilla E. PSMA-PET Guided Treatment in Prostate Cancer Patients with Oligorecurrent Progression after Previous Salvage Treatment. *Cancers (Basel)*. 2023 Mar 29;15(7):2027. doi: 10.3390/cancers15072027. PMID: 37046687; PMCID: PMC10093227.
74. Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, **Briganti A**, De Cobelli O, Chun FKH, Tilki D, Terrone C, Saad F, Shariat SF, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. African American vs Caucasian race/ethnicity in adrenocortical carcinoma patients. *Endocr Relat Cancer*. 2023 Jun 2;30(7):e220249. doi: 10.1530/ERC-22-0249. PMID:37043366.
75. Pellegrino F, Tin AL, Sjoberg DD, Benfante NE, Weber RC, Porwal SP, **Briganti A**, Montorsi F, Eastham JA, Laudone VP, Vickers AJ. The effect of the da Vinci[®] Vessel Sealer on robot-assisted laparoscopic prostatectomy complications. *J Robot Surg*. 2023 Aug;17(4):1763-1768. doi: 10.1007/s11701-023-01595-x. Epub 2023 Apr 12. PMID: 37043122.
76. Moschini M, Necchi A, **Briganti A**, Montorsi F. Repeat Transurethral Resection of Muscle-invasive Bladder Cancer Prior to Radical Cystectomy Is Prognostic but Not Therapeutic. Letter. *J Urol*. 2023 Jun;209(6):1107. doi: 10.1097/JU.0000000000003455. Epub 2023 Apr 10. PMID: 37035866.
77. Montorsi F, Moschini M, **Briganti A**. Re: Wei Shan Tan, Gary Steinberg, J. Alfred Witjes, et al. Intermediate-risk Non-muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. *Eur Urol Oncol* 2022;5:505-16. *Eur Urol Oncol*. 2023 Jun;6(3):354. doi: 10.1016/j.euo.2023.03.007. Epub 2023 Apr 6. PMID: 37031078.
78. Piccinelli ML, Barletta F, Tappero S, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Luzzago S, Mistretta FA, Ferro M, Saad F, Shariat SF, Ahyai S, Longo N, Tilki D, Chun FKH, Terrone C, **Briganti A**, de Cobelli O, Musi G, Karakiewicz PI. Development and External Validation of a Novel Nomogram Predicting Cancer-specific Mortality-free Survival in Surgically Treated Papillary Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2023 Apr 4:S2405-4569(23)00082-2. doi: 10.1016/j.euf.2023.03.014. Epub ahead of print. PMID: 37024421.
79. Tutolo M, **Briganti A**, Salonia A, Montorsi F. Re: Roselyne Choinière, Philippe D. Violette, Mélanie Morin, et al. Evaluation of Benefits and Harms of Surgical Treatments for Post-radical Prostatectomy Urinary Incontinence: A Systematic Review and Meta-analysis. *Eur Urol Focus* 2022;8:1042-52. *Eur Urol Focus*. 2023 Apr 1:S2405-4569(23)00075-5. doi: 10.1016/j.euf.2023.03.007. Epub ahead of print. PMID: 37012087.
80. Leni R, Gandaglia G, Stabile A, Mazzone E, Pellegrino F, Scuderi S, Robesti D, Barletta F, Cirulli GO, Cucchiara V, Zaffuto E, Dehò F, Montorsi F, **Briganti A**. Is Active Surveillance an Option for the Management of Men with Low-grade Prostate Cancer and a Positive Family History? Results from a Large, Single- institution Series. *Eur Urol Oncol*. 2023 Oct;6(5):493-500. doi: 10.1016/j.euo.2023.02.014. Epub 2023 Mar 31. PMID: 37005213.
81. Gillissen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney CJ, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, **Briganti A**, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higano C, Hofman MS, Horvath LG, Hussain M, Jereczek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khamli RB, Klotz L, Kramer G, Leibowitz R, Logothetis C, Mahal B, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro CJ, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of patients with advanced prostate cancer-metastatic and/or castration-resistant prostate cancer: Report of the Advanced Prostate Cancer Consensus Conference (APCCC) 2022. *Eur J Cancer*. 2023 May;185:178-215. doi: 10.1016/j.ejca.2023.02.018. Epub 2023 Mar 3. PMID: 37003085.

82. Cano Garcia C, Panunzio A, Tappero S, Piccinelli ML, Barletta F, Incesu RB, Law KW, Scheipner L, Tian Z, Saad F, Shariat SF, Tilki D, **Briganti A**, De Cobelli O, Terrone C, Antonelli A, Banek S, Kluth LA, Chun FKH, Karakiewicz PI. Survival of Testicular Pure Embryonal Carcinoma vs. Mixed Germ Cell Tumor Patients across All Stages. *Medicina (Kaunas)*. 2023 Feb 24;59(3):451. doi: 10.3390/medicina59030451. PMID: 36984452; PMCID: PMC10056449.
83. Moschini M, Salonia A, **Briganti A**, Montorsi F. Re: Clinical Efficacy of Neoadjuvant Intravesical Mitomycin-C Therapy Immediately Before Transurethral Resection of Bladder Tumor in Patients with Nonmuscle-invasive Bladder Cancer: Preliminary Results of a Prospective, Randomized Phase II Study. *Eur Urol*. 2023 Oct;84(4):439-440. doi: 10.1016/j.eururo.2023.03.010. Epub 2023 Mar 25. PMID: 36967362.
84. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Regional differences in total hospital costs for radical cystectomy in the United States. *Surg Oncol*. 2023 Jun;48:101924. doi: 10.1016/j.suronc.2023.101924. Epub 2023 Mar 9. PMID: 36948042.
85. Basile G, de Angelis M, Leni R, Re C, Longoni M, Mari A, Soria F, Pradere B, Del Giudice F, Laukhtina E, D'Andrea D, Mori K, Krajewski W, Albisinni S, Gallioli A, Breda A, Esperto F, **Briganti A**, Montorsi F, Moschini M, Carando R; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Implications for diagnosis and treatment strategies in non-muscle invasive bladder cancer with variant histology: a systematic review. *Minerva Urol Nephrol*. 2023 Jun;75(3):278-288. doi: 10.23736/S2724-6051.23.05091-7. Epub 2023 Mar 22. PMID: 36946716.
86. Stabile A, Sorce G, Barletta F, Brembilla G, Mazzone E, Pellegrino F, Cannoletta D, Cirulli GO, Gandaglia G, De Cobelli F, Montorsi F, **Briganti A**. Impact of prostate MRI central review over the diagnostic performance of MRI-targeted biopsy: should we routinely ask for an expert second opinion? *World J Urol*. 2023 Nov;41(11):3231-3237. doi: 10.1007/s00345-023-04365-4. Epub 2023 Mar 21. PMID: 36943477.
87. Ghezso S, Mapelli P, Bezzi C, Samanes Gajate AM, Brembilla G, Gotuzzo I, Russo T, Preza E, Cucchiara V, Ahmed N, Neri I, Mongardi S, Freschi M, **Briganti A**, De Cobelli F, Gianolli L, Scifo P, Picchio M. Role of [⁶⁸Ga]Ga-PSMA-11 PET radiomics to predict post-surgical ISUP grade in primary prostate cancer. *Eur J Nucl Med Mol Imaging*. 2023 Jul;50(8):2548-2560. doi: 10.1007/s00259-023-06187-3. Epub 2023 Mar 18. PMID: 36933074.
88. Chierigo F, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Shariat SF, Guano G, Mantica G, Borghesi M, Suardi N, Terrone C, Karakiewicz PI. The association of type and number of high-risk criteria with cancer specific mortality in prostate cancer patients treated with radiotherapy. *Prostate*. 2023 May;83(7):695-700. doi: 10.1002/pros.24505. Epub 2023 Mar 15. PMID: 36919872.
89. Grobet-Jeandin E, Lenfant L, Mir C, Giannarini G, Alcaraz A, Albersen M, Breda A, **Briganti A**, Rouprêt M, Seisen T; EAU Section of Oncological Urology (ESOU) Board. A Systematic Review of Oncological Outcomes Associated with Bladder-sparing Strategies in Patients Achieving Complete Clinical Response to Initial Systemic Treatment for Localized Muscle-invasive Bladder Cancer. *Eur Urol Oncol*. 2023 Jun;6(3):251-262. doi: 10.1016/j.euo.2023.02.008. Epub 2023 Mar 9. PMID: 36906510.
90. Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Parodi S, Dell'Oglio P, Palumbo C, **Briganti A**, De Cobelli O, Chun FKH, Graefen M, Longo N, Ahyai S, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm. *Eur Urol Focus*. 2023 Mar 9:S2405-4569(23)00059-7. doi: 10.1016/j.euf.2023.02.010. Epub ahead of print. PMID: 36906483
91. Flammia RS, Tufano A, Chierigo F, Würnschimmel C, Hoeh B, Sorce G, Tian Z, Anceschi U, Leonardo C, Del Giudice F, Terrone C, Giordano A, Morrione A, Saad F, Shariat SF, **Briganti A**, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. The Effect of Sex on Disease Stage and Survival after Radical

- Cystectomy in Non-Urothelial Variant-Histology Bladder Cancer. *J Clin Med.* 2023 Feb 23;12(5):1776. doi: 10.3390/jcm12051776. PMID: 36902562; PMCID: PMC10003431.
92. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, **Briganti A**, Mandel P, Montorsi F, Chun FKH, Karakiewicz PI. Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Prostate Cancer Prostatic Dis.* 2023 Dec;26(4):807-808. doi: 10.1038/s41391-023-00656-4. Erratum for: *Prostate Cancer Prostatic Dis.* 2022 Feb;25(2):139-148. PMID: 36899091; PMCID: PMC10638077.
 93. Tappero S, Barletta F, Piccinelli ML, Cano Garcia C, Incesu RB, Morra S, Scheipner L, Tian Z, Parodi S, Dell'Oglio P, **Briganti A**, de Cobelli O, Chun FKH, Graefen M, Mirone V, Ahyai S, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer. *Urol Oncol.* 2023 Jul;41(7):326.e9-326.e16. doi: 10.1016/j.urolonc.2023.01.015. Epub 2023 Mar 5. PMID: 36882338.
 94. Larcher A, Cei F, Belladelli F, Rosiello G, Andrea Bravi C, Fallara G, Basile G, Lucianò R, Karakiewicz P, Mottrie A, Breda A, **Briganti A**, Salonia A, Bertini R, Montorsi F, Capitanio U; Junior ERUS/Young Academic Urologists Working Group on Robotic Surgery. The Learning Curve for Radical Nephrectomy for Kidney Cancer: Implications for Surgical Training. *Eur Urol Open Sci.* 2023 Jan 19;49:11-14. doi: 10.1016/j.euros.2022.12.007. PMID: 36874599; PMCID: PMC9975008.
 95. Villa L, Dioni P, Candela L, Ventimiglia E, De Angelis M, Corsini C, Robesti D, Fantin M, D'Arma A, Proietti S, Giusti G, Kartalas Goumas I, **Briganti A**, Montorsi F, Salonia A. Understanding the Role of Ureteral Access Sheath in Preventing Post-Operative Infectious Complications in Stone Patients Treated with Ureteroscopy and Ho:YAG Laser Lithotripsy: Results from a Tertiary Care Referral Center. *J Clin Med.* 2023 Feb 12;12(4):1457. doi: 10.3390/jcm12041457. PMID: 36835992; PMCID: PMC9963298.
 96. Cano Garcia C, Piccinelli ML, Tappero S, Panunzio A, Barletta F, Incesu RB, Tian Z, Saad F, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, De Cobelli O, Kosiba M, Banek S, Kluth LA, Chun FKH, Karakiewicz PI. Differences in overall survival of T2N0M0 bladder cancer patients vs. population-based controls according to treatment modalities. *Int Urol Nephrol.* 2023 Feb 23. doi: 10.1007/s11255-023-03517-0. Epub ahead of print. PMID: 36813873.
 97. Gandaglia G, **Briganti A**, Raggi D, Marandino L, Necchi A, Di Maio M, Montorsi F. Re: Philipp Mandel, Benedikt Hoeh, Mike Wenzel, et al. Triplet or Doublet Therapy in Metastatic Hormone-sensitive Prostate Cancer Patients: A Systematic Review and Network Meta-analysis. *Eur Urol Focus.* In press. <https://doi.org/10.1016/j.euf.2022.08.007>. *Eur Urol Focus.* 2023 Feb 20:S2405-4569(23)00044-5. doi: 10.1016/j.euf.2023.01.024. Epub ahead of print. PMID: 36813620.
 98. de Angelis M, **Briganti A**, Montorsi F, Moschini M. Re: A Randomized Trial of PHOTodynamic Surgery in Non-muscle-invasive Bladder Cancer. *Eur Urol.* 2023 Feb 16:S0302-2838(23)02571-X. doi: 10.1016/j.eururo.2023.02.001. Epub ahead of print. PMID: 36806362.
 99. Sarkis J, Diamand R, Aoun F, Assenmacher G, Assenmacher C, Verhoest G, Holz S, Naudin M, Ploussard G, Mari A, Minervini A, Tay A, Issa R, Roumiguié M, Bajot AS, Simone G, Anceschi U, Umari P, Sridhar A, Kelly J, Hendricksen K, Einerhand S, Mertens LS, Sanchez-Salas R, Colomer A, Quackels T, Peltier A, Montorsi F, **Briganti A**, Pradere B, Moschini M, Roumeguère T, Albisinni S; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Do perioperative blood transfusions impact oncological outcomes of robot-assisted radical cystectomy with intracorporeal urinary diversion? Results from a large multi-institutional registry. *Minerva Urol Nephrol.* 2023 Feb;75(1):50-58. doi: 10.23736/S2724-6051.22.05109-6. PMID: 36800680.
 100. Montorsi F, Scuderi S, **Briganti A**, Gandaglia G. Re: Kerrington Powell, Michael C. Burns, Vinay Prasad. Relugolix: Five Reasons Why the US Food and Drug Administration Should Have Exercised Restraint. *Eur Urol.* 2023;83:101-2. *Eur Urol.* 2023 Feb 9:S0302-2838(23)02566-6. doi: 10.1016/j.eururo.2023.01.025. Epub ahead of print. PMID: 36774225.
 101. Montorsi F, Scuderi S, **Briganti A**, Gandaglia G. Re: Melline G.M. Schilham, Mark Rijpkema, Tom Scheenen, et al. How Advanced Imaging Will Guide Therapeutic Strategies for Patients with

- Newly Diagnosed Prostate Cancer in the Years to Come. *Eur Urol* 2022;82:578-80. *Eur Urol*. 2023 Feb 9;S0302-2838(23)02563-0. doi: 10.1016/j.eururo.2022.12.038. Epub ahead of print. PMID: 36774224.
102. Cano Garcia C, Barletta F, Incesu RB, Piccinelli ML, Tappero S, Panunzio A, Tian Z, Saad F, Shariat SF, Antonelli A, Terrone C, De Cobelli O, Graefen M, Tilki D, **Briganti A**, Wenzel M, Banek S, Kluth LA, Chun FKH, Karakiewicz PI. Survival of Testicular Pure Teratoma vs. Mixed Germ Cell Tumor Patients in Primary Tumor Specimens across All Stages. *Cancers (Basel)*. 2023 Jan 23;15(3):694. doi: 10.3390/cancers15030694. PMID: 36765653; PMCID: PMC9913474.
 103. Zattoni F, Marra G, Martini A, Kasivisvanathan V, Grummet J, Harkin T, Ploussard G, Olivier J, Chiu PK, Valerio M, Marquis A, Gontero P, Guo H, Zhuang J, Frydenberg M, Moon D, Morlacco A, Kretschmer A, Barletta F, Heidegger I, Tilki D, van den Bergh R, Dal Moro F, **Briganti A**, Montorsi F, Novara G, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Is There an Impact of Transperineal Versus Transrectal Magnetic Resonance Imaging-targeted Biopsy on the Risk of Upgrading in Final Pathology in Prostate Cancer Patients Undergoing Radical Prostatectomy? An European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-institutional Study. *Eur Urol Focus*. 2023 Feb 4:S2405-4569(23)00032-9. doi: 10.1016/j.euf.2023.01.016. Epub ahead of print. PMID: 36746729.
 104. Bandini M, Nini A, **Briganti A**, Necchi A, Montorsi F. Is chemoradiotherapy worth it in metastatic seminoma as first-line treatment? *Lancet Oncol*. 2023 Feb;24(2):e65. doi: 10.1016/S1470-2045(22)00743-4. PMID: 36725145.
 105. Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Sorce G, Tian Z, Leonardo C, Graefen M, Terrone C, Saad F, Shariat SF, **Briganti A**, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. Differences in rates of pelvic lymph node dissection in National Comprehensive Cancer Network favorable, unfavorable intermediate- and high-risk prostate cancer across United States SEER registries. *Curr Urol*. 2022 Dec;16(4):191-196. doi: 10.1097/CU9.000000000000132. Epub 2022 Aug 22. PMID: 36714227; PMCID: PMC9875209.
 106. Rajwa P, Zattoni F, Maggi M, Marra G, Kroyer P, Shariat SF, **Briganti A**, Montorsi F, Heidegger I, Gandaglia G; EAU-Young Academic Urologists (YAU) Prostate Cancer Working Party. Cytoreductive Radical Prostatectomy for Metastatic Hormone-sensitive Prostate Cancer-Evidence from Recent Prospective Reports. *Eur Urol Focus*. 2023 Jan 23:S2405-4569(23)00024-X. doi: 10.1016/j.euf.2023.01.011. Epub ahead of print. PMID: 36697321.
 107. Martini A, Touzani A, Mazzone E, Roumiguié M, Marra G, Valerio M, Beauval JB, Campi R, Minervini A, van den Berg RCN, Soeterik TFW, Zhuang J, Guo H, Gontero P, Montorsi F, **Briganti A**, Gandaglia G, Ploussard G; Young Academic Urologists Working Group on Prostate Cancer of the European Association of Urology. Correction to: Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions. *Prostate Cancer Prostatic Dis*. 2023 Jan 20. doi: 10.1038/s41391-022-00637-z. Epub ahead of print. Erratum for: *Prostate Cancer Prostatic Dis*. 2022 Apr;25(4):794-796. PMID: 36670304.
 108. Huelster HL, Chang A, Rose KM, Bandini M, Albersen M, Roussel E, Chipollini J, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Marandino L, Pederzoli F, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Ahmed ME, Karnes JR, **Briganti A**, Kim Y, Montorsi F, Necchi A, Spiess PE. Concomitant vs Staged Therapeutic Inguinal Lymphadenectomy in Clinically Node Positive Penile Squamous Cell Carcinoma: Does It Make a Difference? *J Urol*. 2023 Mar;209(3):557-564. doi: 10.1097/JU.0000000000003099. Epub 2023 Jan 18. PMID: 36652397.
 109. Cano Garcia C, Nimer N, Piccinelli ML, Tappero S, Panunzio A, Barletta F, Incesu RB, Tian Z, Saad F, Kapoor A, **Briganti A**, Terrone C, Shariat SF, Tilki D, Antonelli A, De Cobelli O, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Differences in overall survival between clear cell metastatic renal cell carcinoma patients versus population-based controls according to race/ethnicity in the United States. *Ann Epidemiol*. 2023 Mar;79:65-70. doi: 10.1016/j.annepidem.2023.01.003. Epub 2023 Jan 11. PMID: 36640918.
 110. MacLennan S, Azevedo N, Duncan E, Dunsmore J, Fullwood L, Lumen N, Plass K, Ribal MJ, Roobol MJ, Nieboer D, Schouten N, Skolarus TA, Smith EJ, N'Dow J, Mottet N, **Briganti A**; Pan-European National Urological Society IMAGINE Collaborative (see Supplemental material for group

- members affiliations):. Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries. *Eur Urol*. 2023 Jan 11:S0302-2838(22)02919-0. doi: 10.1016/j.eururo.2022.12.031. Epub ahead of print. PMID: 36639296.
111. Bianchi L, Ceci F, Costa F, Balestrazzi E, Droghetti M, Piazza P, Pissavini A, Mei R, Farolfi A, Castellucci P, Puliatti S, Larcher A, Gandaglia G, Robesti D, Mottrie A, **Briganti A**, Morganti AG, Fanti S, Montorsi F, Schiavina R, Brunocilla E. The Impact of PSMA-PET on Oncologic Control in Prostate Cancer Patients Who Experienced PSA Persistence or Recurrence. *Cancers (Basel)*. 2022 Dec 30;15(1):247. doi: 10.3390/cancers15010247. PMID: 36612242; PMCID: PMC9818949.
 112. Rajwa P, Quhal F, Pradere B, Gandaglia G, Ploussard G, Leapman MS, Gore JL, Paradysz A, Tilki D, Merseburger AS, Morgan TM, **Briganti A**, Palapattu GS, Shariat SF. Prostate cancer risk, screening and management in patients with germline BRCA1/2 mutations. *Nat Rev Urol*. 2023 Jan 4. doi: 10.1038/s41585-022-00680-4. Epub ahead of print. PMID: 36600087.
 113. Bravi CA, Heidenreich A, Fossati N, Gandaglia G, Suardi N, Mazzone E, Stabile A, Cucchiara V, Osmonov D, Juenemann KP, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat S, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, **Briganti A**, Pfister D. Combining PSA and PET features to select candidates for salvage lymph node dissection in recurrent prostate cancer. *BJUI Compass*. 2022 Aug 4;4(1):123-129. doi: 10.1002/bco2.182. PMID: 36569505; PMCID: PMC9766859.
 114. Nocera L, Stolzenbach LF, Collà Ruvolo C, Wenzel M, Wurnschimmel C, Tian Z, Gandaglia G, Fossati N, Mirone V, Chun FKH, Shariat SF, Graefen M, Saad F, Montorsi F, **Briganti A**, Karakiewicz PI. Predicting the probability of pT3 or higher pathological stage at radical prostatectomy: COVID19-specific considerations. *Front Oncol*. 2022 Dec 6;12:990851. doi: 10.3389/fonc.2022.990851. PMID: 36561531; PMCID: PMC9763886.
 115. Bravi CA, Mottrie A, **Briganti A**, Montorsi F. Re: Pawel Rajwa, Takafumi Yanagisawa, Manuel Gruber, et al. Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-review. *Eur Urol Focus*. In press. <https://doi.org/10.1016/j.euf.2022.10.013>. *Eur Urol Focus*. 2022 Dec 15:S2405-4569(22)00289-9. doi: 10.1016/j.euf.2022.12.005. Epub ahead of print. PMID: 36528510.
 116. Barletta F, Tappero S, Panunzio A, Incesu RB, Cano Garcia C, Piccinelli ML, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun FKH, de Cobelli O, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Differences in Cancer-Specific Mortality after Trimodal Therapy for T2N0M0 Bladder Cancer according to Histological Subtype. *Cancers (Basel)*. 2022 Nov 23;14(23):5766. doi: 10.3390/cancers14235766. PMID: 36497246; PMCID: PMC9736026.
 117. Gillessen S, Bossi A, Davis ID, de Bono J, Fizazi K, James ND, Mottet N, Shore N, Small E, Smith M, Sweeney C, Tombal B, Antonarakis ES, Aparicio AM, Armstrong AJ, Attard G, Beer TM, Beltran H, Bjartell A, Blanchard P, **Briganti A**, Bristow RG, Bulbul M, Caffo O, Castellano D, Castro E, Cheng HH, Chi KN, Chowdhury S, Clarke CS, Clarke N, Daugaard G, De Santis M, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ngozi Ekeke O, Evans CP, Fanti S, Feng FY, Fonteyne V, Fossati N, Frydenberg M, George D, Gleave M, Gravis G, Halabi S, Heinrich D, Herrmann K, Higanio C, Hofman MS, Horvath LG, Hussain M, Jerezek-Fossa BA, Jones R, Kanesvaran R, Kellokumpu-Lehtinen PL, Khauli RB, Klotz L, Kramer G, Leibowitz R, Logothetis CJ, Mahal BA, Maluf F, Mateo J, Matheson D, Mehra N, Merseburger A, Morgans AK, Morris MJ, Mrabti H, Mukherji D, Murphy DG, Murthy V, Nguyen PL, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Pezaro C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin MA, Ryan CJ, Saad F, Pablo Sade J, Sartor OA, Scher HI, Sharifi N, Skoneczna I, Soule H, Spratt DE, Srinivas S, Sternberg CN, Steuber T, Suzuki H, Sydes MR, Taplin ME, Tilki D, Türkeri L, Turco F, Uemura H, Uemura H, Ürün Y, Vale CL, van Oort I, Vapiwala N, Walz J, Yamoah K, Ye D, Yu EY, Zapatero A, Zilli T, Omlin A. Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022. *Eur Urol*. 2023 Mar;83(3):267-293. doi: 10.1016/j.eururo.2022.11.002. Epub 2022 Dec 6. PMID: 36494221.
 118. Panunzio A, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Barletta F, Tian Z, Tafuri A, **Briganti A**, De Cobelli O, Chun FKH, Tilki D, Terrone C, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Collecting duct carcinoma: Epidemiology, clinical characteristics and

- survival. *Urol Oncol*. 2023 Feb;41(2):110.e7-110.e14. doi: 10.1016/j.urolonc.2022.11.009. Epub 2022 Nov 28. PMID: 36456452.
119. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Cancer-specific Mortality After Cryoablation vs Heat-based Thermal Ablation in T1a Renal Cell Carcinoma. *J Urol*. 2023 Jan;209(1):81-88. doi: 10.1097/JU.0000000000002984. Epub 2022 Nov 28. PMID: 36440817.
120. Panunzio A, Barletta F, Tappero S, Cano Garcia C, Piccinelli M, Incesu RB, Law KW, Tian Z, Tafuri A, Tilki D, De Cobelli O, Chun FKH, Terrone C, **Briganti A**, Saad F, Shariat SF, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Contemporary conditional cancer-specific survival rates in surgically treated adrenocortical carcinoma patients: A stage-specific analysis. *J Surg Oncol*. 2023 Mar;127(4):560-567. doi: 10.1002/jso.27161. Epub 2022 Nov 26. PMID: 36434748.
121. Barletta F, Tappero S, Panunzio A, Incesu RB, Cano Garcia C, Piccinelli ML, Tian Z, Gandaglia G, Moschini M, Terrone C, Antonelli A, Tilki D, Chun FKH, De Cobelli O, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Conditional survival after radical cystectomy for non-metastatic muscle-invasive squamous cell carcinoma of the urinary bladder: A population-based analysis. *Urol Oncol*. 2023 Mar;41(3):147.e1-147.e6. doi: 10.1016/j.urolonc.2022.10.027. Epub 2022 Nov 22. PMID: 36428165.
122. Panunzio A, Sorce G, Tappero S, Hohenhorst L, Garcia CC, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun FKH, Tilki D, Terrone C, **Briganti A**, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Cancer specific mortality in patients with collecting duct vs. clear cell renal carcinoma. *Cancer Epidemiol*. 2023 Feb;82:102297. doi: 10.1016/j.canep.2022.102297. Epub 2022 Nov 16. PMID: 36401949.
123. Lorenzo G, di Muzio N, Deantoni CL, Cozzarini C, Fodor A, **Briganti A**, Montorsi F, Pérez-García VM, Gomez H, Reali A. Patient-specific forecasting of postradiotherapy prostate-specific antigen kinetics enables early prediction of biochemical relapse. *iScience*. 2022 Oct 25;25(11):105430. doi: 10.1016/j.isci.2022.105430. PMID: 36388979; PMCID: PMC9641236.
124. Bravi CA, Piazza P, Mazzone E, Dell'Oglio P, Rosiello G, Martini A, Stabile A, Moschini M, Amato M, Sarchi L, Peraire M, Farinha R, Scarcella S, Puliatti S, Knipper S, Berquin C, Develtere D, Sinatti C, Van Puyvelde H, De Groote R, De Naeyer G, D'Hondt F, Schatteman P, **Briganti A**, Montorsi F, Mottrie A. Long-term oncologic outcomes of robot-assisted radical cystectomy: update series from a high-volume robotic center beyond 10 years of follow-up. *J Robot Surg*. 2022 Nov 15. doi: 10.1007/s11701-022-01473-y. Epub ahead of print. PMID: 36380261.
125. Rajwa P, Yanagisawa T, Gruber M, Heidenreich A, Joniau S, **Briganti A**, Shariat SF, Marra G, Gandaglia G. Surgical Metastasectomy for Visceral and Bone Prostate Cancer Metastases: A Mini-Review. *Eur Urol Focus*. 2022 Nov 9:S2405-4569(22)00241-3. doi: 10.1016/j.euf.2022.10.013. Epub ahead of print. PMID: 36371377.
126. Rosiello G, Larcher A, Fallara G, Cignoli D, Re C, Martini A, Tian Z, Karakiewicz PI, Mottrie A, Boarin M, Villa G, Trevisani F, Marandino L, Raggi D, Necchi A, Bertini R, Salonia A, **Briganti A**, Montorsi F, Capitanio U. A comprehensive assessment of frailty status on surgical, functional and oncologic outcomes in patients treated with partial nephrectomy-A large, retrospective, single-center study. *Urol Oncol*. 2023 Mar;41(3):149.e17-149.e25. doi: 10.1016/j.urolonc.2022.10.008. Epub 2022 Nov 9. PMID: 36369233.
127. Mantica G, Suardi N, Smelzo S, Esperto F, Chierigo F, Tappero S, Borghesi M, La Rocca R, Oderda M, Ennas M, Stabile A, De Cobelli F, Napolitano L, Papalia R, Gontero P, Introini C, **Briganti A**, Scarpa RM, Mirone V, Montorsi F, Gaboardi F, Terrone C, Cardone G. Are Urologists Ready for Interpretation of Multiparametric MRI Findings? A Prospective Multicentric Evaluation. *Diagnostics (Basel)*. 2022 Nov 1;12(11):2656. doi: 10.3390/diagnostics12112656. PMID: 36359499; PMCID: PMC9689928.
128. Panunzio A, Sorce G, Hoeh B, Hohenhorst L, Tappero S, Nimer N, Rajwa P, Tian Z, Terrone C, Chun FKH, **Briganti A**, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Effect of positive surgical margins at radical prostatectomy on cancer-specific mortality in high/very high-risk prostate

- cancer patients with Gleason Grade Group 4-5. *Prostate*. 2023 Feb;83(3):268-276. doi: 10.1002/pros.24458. Epub 2022 Nov 6. PMID: 36336728.
129. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, Kosiba M, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. IO-IO vs IO-TKI efficacy in metastatic kidney cancer patients: A structured systematic review over time. *Semin Oncol*. 2022 Oct;49(5):394-399. doi:m10.1053/j.seminoncol.2022.10.001. Epub 2022 Oct 23. PMID: 36333148.
130. Wenzel M, Hoeh B, Rührup J, Gambetta H, Nocera L, Würnschimmel C, Tian Z, Karakiewicz PI, **Briganti A**, Chun FKH, Roos FC, Becker A, Krimphove MJ. An external validation of the nocera nomogram: Predicting non-organ confined stage of \geq pT3 in cT1 clear cell renal cell carcinoma. *Front Oncol*. 2022 Oct 10;12:1019057. doi: 10.3389/fonc.2022.1019057. PMID: 36300101; PMCID: PMC9589884.
131. Ratti MM, Gandaglia G, Sisca ES, Derevianko A, Alleva E, Beyer K, Moss C, Barletta F, Scuderi S, Omar MI, MacLennan S, Williamson PR, Zong J, MacLennan SJ, Mottet N, Cornford P, Aiyegbusi OL, Van Hemelrijck M, N'Dow J, **Briganti A**. A Systematic Review to Evaluate Patient-Reported Outcome Measures (PROMs) for Metastatic Prostate Cancer According to the COnsensus-Based Standard for the Selection of Health Measurement INstruments (COSMIN) Methodology. *Cancers (Basel)*. 2022 Oct 19;14(20):5120. doi: 10.3390/cancers14205120. PMID: 36291905; PMCID: PMC9600015.
132. Panunzio A, Tappero S, Garcia CC, Piccinelli M, Barletta F, Incesu RB, Tian Z, Tafuri A, Tilki D, **Briganti A**, DE Cobelli O, Chun FKH, Terrone C, Saad F, Shariat SF, Bourdeau I, Cerruto MA, Antonelli A, Karakiewicz PI. Hispanic vs. Caucasian Race/Ethnicity in Adrenocortical Carcinoma Patients. *Anticancer Res*. 2022 Nov;42(11):5579-5585. doi: 10.21873/anticancer.16065. PMID: 36288855.
133. Bravi CA, Mazzone E, Dell'oglio P, Covas Moschovas M, Martini A, Rosiello G, Piazza P, Mottaran A, Paciotti M, Sarchi L, Puliatti S, Knipper S, DE Groote R, Schiavina R, Rocco B, Galfano A, **Briganti A**, Montorsi F, Patel V, Mottrie A. A nomogram to predict pathologic T2 stage in candidates to robot-assisted radical prostatectomy with iT3 prostate cancer on preoperative multiparametric MRI: results from a multi-institutional collaboration. *Minerva Urol Nephrol*. 2022 Oct 26. doi: 10.23736/S2724-6051.22.04992-8. Epub ahead of print. PMID: 36286397.
134. Rajwa P, Yanagisawa T, Heidegger I, Zattoni F, Marra G, Soeterik TFW, van den Bergh RCN, Valerio M, Ceci F, Kesch CV, Kasivisvanathan V, Laukhtina E, Kawada T, Nyiriadi P, Trinh QD, Chlosta P, Karakiewicz PI, Ploussard G, **Briganti A**, Montorsi F, Shariat SF, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Association between age and efficacy of combination systemic therapies in patients with metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2022 Oct 25. doi: 10.1038/s41391-022-00607-5. Epub ahead of print. PMID: 36284192.
135. Pellegrino F, Tin AL, Martini A, Vertosick EA, Porwal SP, Stabile A, Gandaglia G, Eastham JA, **Briganti A**, Montorsi F, Vickers AJ. Prostate-specific Antigen Density Cutoff of 0.15 ng/ml/cc to Propose Prostate Biopsies to Patients with Negative Magnetic Resonance Imaging: Efficient Threshold or Legacy of the Past? *Eur Urol Focus*. 2022 Oct 18:S2405-4569(22)00230-9. doi: 10.1016/j.euf.2022.10.002. Epub ahead of print. PMID: 36270887.
136. Vitale V, Vezzosi T, Di Franco C, **Briganti A**, Tognetti R, Conte G, Bucchioni E, Sgorbini M. Equine echocardiography: Can dobutamine infusion correct alterations due to sedation with alpha-2 agonists? *PLoS One*. 2022 Oct 18;17(10):e0276256. doi: 10.1371/journal.pone.0276256. PMID: 36256667; PMCID: PMC9578622.
137. Tappero S, Piccinelli M, Barletta F, Panunzio A, Cano Garcia C, Incesu RB, Tian Z, Parodi S, Dell'Oglio P, De Cobelli O, **Briganti A**, Antonelli A, Chun FKH, Graefen M, Saad F, Shariat SF, Suardi NR, Borghesi M, Terrone C, Karakiewicz PI. Effect of inguinal lymph node dissection in lymph node negative patients with squamous cell carcinoma of the penis. *World J Urol*. 2023 Jan;41(1):119-125. doi: 10.1007/s00345-022-04184-z. Epub 2022 Oct 14. PMID: 36239810.
138. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Nimer N, Tian Z, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Contemporary vs historical survival rates in metastatic clear cell renal carcinoma according to

- race/ethnicity. *World J Urol.* 2022 Dec;40(12):2971-2978. doi:10.1007/s00345-022-04183-0. Epub 2022 Oct 12. PMID: 36222885.
139. Martini A, Touzani A, Mazzone E, Roumiguié M, Marra G, Valerio M, Beauval JB, Campi R, Minervini A, van den Berg RCN, Soeterik TFW, Zhuang J, Guo H, Gontero P, Montorsi F, **Briganti A**, Gandaglia G, Ploussard G; Young Academic Urologists Working Group on Prostate Cancer of the European Association of Urology. Overdiagnosis and stage migration of ISUP 2 disease due to mpMRI-targeted biopsy: facts or fictions. *Prostate Cancer Prostatic Dis.* 2022 Apr;25(4):794-796. doi: 10.1038/s41391-022-00606-6. Epub 2022 Oct 8. Erratum in: *Prostate Cancer Prostatic Dis.* 2023 Jan 20;: PMID: 36209238.
 140. Tappero S, Panunzio A, Hohenhorst L, Cano Garcia C, Barletta F, Piccinelli M, Tian Z, Parodi S, Antonelli A, Graefen M, Chun FKH, **Briganti A**, De Cobelli O, Saad F, Shariat SF, Suardi N, Borghesi M, Terrone C, Karakiewicz PI. Radical cystectomy in non-metastatic sarcomatoid bladder cancer: A direct comparison vs urothelial bladder cancer. *Eur J Surg Oncol.* 2022 Sep 24:S0748-7983(22)00683-7. doi: 10.1016/j.ejso.2022.09.013. Epub ahead of print. PMID: 36192262.
 141. Basile G, Bandini M, Gibb EA, Ross JS, Raggi D, Marandino L, Costa de Padua T, Crupi E, Colombo R, Colecchia M, Lucianò R, Nocera L, Moschini M, **Briganti A**, Montorsi F, Necchi A. Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial. *Clin Cancer Res.* 2022 Oct 3:CCR-22-2158. doi: 10.1158/1078-0432.CCR-22-2158. Epub ahead of print. PMID: 36190522.
 142. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Tappero S, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, Kosiba M, Mandel P, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Effect of Inferior Vena Cava Tumor Thrombus on Overall Survival in Metastatic Renal Cell Carcinoma Patients Treated with Cytoreductive Nephrectomy. *Eur Urol Open Sci.* 2022 Aug 30;44:94-101. doi: 10.1016/j.euros.2022.08.011. PMID: 36185586; PMCID: PMC9520505.
 143. Bravi CA, Gandaglia G, Mazzone E, Fossati N, Gallina A, Stabile A, Scuderi S, Barletta F, Nocera L, Rosiello G, Martini A, Pellegrino F, Cucchiara V, Dehò F, Capitanio U, Scattoni V, Salonia A, **Briganti A**, Montorsi F. Impact of Early Dorsal Venous Complex Ligation on Urinary Continence Recovery after Robot-assisted Radical Prostatectomy: Results from a Phase 3 Randomized Controlled Trial. *Eur Urol Focus.* 2022 Sep 22:S2405-4569(22)00210-3. doi: 10.1016/j.euf.2022.09.003. Epub ahead of print. PMID: 36154808.
 144. Barletta F, Mazzone E, Stabile A, Scuderi S, Brembilla G, de Angelis M, Cirulli GO, Cucchiara V, Gandaglia G, Karnes RJ, Roupert M, De Cobelli F, Montorsi F, **Briganti A**. Assessing the need for systematic biopsies in addition to targeted biopsies according to the characteristics of the index lesion at mpMRI. Results from a large, multi-institutional database. *World J Urol.* 2022 Sep 23. doi: 10.1007/s00345-022-04155-4. Epub ahead of print. PMID: 36149448.
 145. Fallara G, Larcher A, Rosiello G, Raggi D, Marandino L, Martini A, Basile G, Colandrea G, Cignoli D, Belladelli F, Re C, Musso G, Cei F, Bertini R, **Briganti A**, Salonia A, Montorsi F, Necchi A, Capitanio U. How to optimize the use of adjuvant pembrolizumab in renal cell carcinoma: which patients benefit the most? *World J Urol.* 2022 Sep 20. doi: 10.1007/s00345-022-04153-6. Epub ahead of print. PMID: 36125505.
 146. Panunzio A, Sorce G, Tappero S, Hohenhorst L, Cano Garcia C, Piccinelli M, Tian Z, Tafuri A, De Cobelli O, Chun FKH, Tilki D, Terrone C, **Briganti A**, Kapoor A, Saad F, Shariat SF, Cerruto MA, Antonelli A, Karakiewicz PI. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma. *Clin Genitourin Cancer.* 2022 Aug 26:S1558-7673(22)00178-1. doi: 10.1016/j.clgc.2022.08.010. Epub ahead of print. PMID: 36117092.
 147. Mossa F, Robesti D, Sumankalai R, Corey E, Titus M, Kang Y, Zhang J, **Briganti A**, Montorsi F, Vellano CP, Marszalek JR, Frigo DE, Logothetis CJ, Gujral TS, Dondossola E. Subtype and site specific-induced metabolic vulnerabilities in prostate cancer. *Mol Cancer Res.* 2022 Sep 16:MCR-22-0250. doi: 10.1158/1541-7786.MCR-22-0250. Epub ahead of print. PMID: 36112348.
 148. Gandaglia G, Giannarini G, Stabile A, Montorsi F, **Briganti A**. Should we combine systematic with MRI-targeted biopsy? Implications for the management of patients with prostate cancer. *Eur Radiol.* 2022 Sep 15. doi:10.1007/s00330-022-09096-5. Epub ahead of print. PMID: 36107203.

149. Zattoni F, Marra G, Kasivisvanathan V, Grummet J, Nandurkar R, Ploussard G, Olivier J, Chiu PK, Valerio M, Gontero P, Guo H, Zhuang J, Barletta F, Leni R, Frydenberg M, Moon D, Hanegbi U, Landaumailto A, Snow R, Apfelbeck M, Kretschmer A, van den Bergh R, Novara G, **Briganti A**, Dal Moro F, Gandaglia G. The Detection of Prostate Cancer with Magnetic Resonance Imaging-Targeted Prostate Biopsies is Superior with the Transperineal vs the Transrectal Approach. A European Association of Urology-Young Academic Urologists Prostate Cancer Working Group Multi-Institutional Study. *J Urol*. 2022 Oct;208(4):830-837. doi: 10.1097/JU.0000000000002802. Epub 2022 Sep 9. PMID: 36082555.
150. Montorsi F, Bravi CA, Gandaglia G, Mottrie A, **Briganti A**. Re: Sophie Knipper, Mehrdad Mehdi Irai, Ricarda Simon, et al. Cohort Study of Oligorecurrent Prostate Cancer Patients: Oncological Outcomes of Patients Treated with Salvage Lymph Node Dissection via Prostate-specific Membrane Antigen-radioguided Surgery. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2022.05.031>. *Eur Urol*. 2022 Sep 2:S0302-2838(22)02612-4. doi: 10.1016/j.eururo.2022.07.036. Epub ahead of print. PMID: 36064476.
151. Wenzel M, Würnschimmel C, Nocera L, Colla Ruvolo C, Hoeh B, Tian Z, Shariat SF, Saad F, **Briganti A**, Graefen M, Preisser F, Becker A, Mandel P, Chun FKH, Karakiewicz PI. The effect of race/ethnicity on cancer-specific mortality after salvage radical prostatectomy. *Front Oncol*. 2022 Aug 19;12:874945. doi: 10.3389/fonc.2022.874945. PMID: 36059656; PMCID: PMC9437357.
152. Gandaglia G, Barletta F, Montorsi F, **Briganti A**. Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy: Extended, of Course. *Eur Urol Open Sci*. 2022 Aug 19;44:13-14. doi: 10.1016/j.euros.2022.05.016. PMID: 36043188; PMCID: PMC9420501.
153. Pellegrino F, Sjoberg DD, Tin AL, Benfante NE, **Briganti A**, Montorsi F, Eastham JA, Mulhall JP, Vickers AJ. Relationship Between Age, Comorbidity, and the Prevalence of Erectile Dysfunction. *Eur Urol Focus*. 2022 Aug 25:S2405-4569(22)00175-4. doi: 10.1016/j.euf.2022.08.006. Epub ahead of print. PMID: 36031560.
154. Montorsi F, Gandaglia G, Robesti D, Dehò F, **Briganti A**. Re: Kathia De Man, Nick Van Laeken, Vanessa Schelfhout, et al. ¹⁸F-PSMA-11 Versus ⁶⁸Ga-PSMA-11 Positron Emission Tomography/Computed Tomography for Staging and Biochemical Recurrence of Prostate Cancer: A Prospective Double-blind Randomised Cross-over Trial. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2022.05.010>. *Eur Urol*. 2022 Aug 18:S0302-2838(22)02557-X. doi: 10.1016/j.eururo.2022.07.035. Epub ahead of print. PMID: 35989206.
155. Padua TC, Moschini M, Martini A, Pederzoli F, Nocera L, Marandino L, Raggi D, **Briganti A**, Montorsi F, Necchi A. Efficacy and toxicity of antibody-drug conjugates in the treatment of metastatic urothelial cancer: A scoping review. *Urol Oncol*. 2022 Oct;40(10):413-423. doi: 10.1016/j.urolonc.2022.07.006. Epub 2022 Aug 13. PMID: 35973928.
156. Peters M, Eldred-Evans D, Kurver P, Falagario UG, Connor MJ, Shah TT, Verhoeff JJC, Taimen P, Aronen HJ, Knaapila J, Montoya Perez I, Ettala O, Stabile A, Gandaglia G, Fossati N, Martini A, Cucchiara V, Briganti A, Lantz A, Picker W, Haug ES, Nordström T, Tanaka MB, Reddy D, Bass E, van Rossum PSN, Wong K, Tam H, Winkler M, Gordon S, Qazi H, Boström PJ, Jambor I, Ahmed HU. Predicting the Need for Biopsy to Detect Clinically Significant Prostate Cancer in Patients with a Magnetic Resonance Imaging-detected Prostate Imaging Reporting and Data System/Likert ≥ 3 Lesion: Development and Multinational External Validation of the Imperial Rapid Access to Prostate Imaging and Diagnosis Risk Score. *Eur Urol*. 2022 Aug 10:S0302-2838(22)02537-4. doi: 10.1016/j.eururo.2022.07.022. Epub ahead of print. PMID: 35963650.
157. Pellegrino A, Cirulli GO, Mazzone E, Barletta F, Scuderi S, de Angelis M, Rosiello G, Gandaglia G, Montorsi F, **Briganti A**, Stabile A. Focal therapy for prostate cancer: what is really needed to move from investigational to valid therapeutic alternative?-a narrative review. *Ann Transl Med*. 2022 Jul;10(13):755. doi: 10.21037/atm-22-50. PMID: 35957731; PMCID: PMC9358522.
158. Cozzarini C, Olivieri M, Magli A, Cante D, Noris Chiorda B, Munoz F, Faiella A, Olivetta E, Deantoni C, Fodor A, Signor MA, Petrucci E, Avuzzi B, Ferella L, Pastorino A, Garibaldi E, Gatti M, Rago L, Statuto T, Rancati T, **Briganti A**, Montorsi F, Valdagni R, Sanguineti G, Di Muzio NG, Fiorino C. Accurate prediction of long-term risk of biochemical failure after salvage radiotherapy including the

- impact of pelvic node irradiation. *Radiother Oncol.* 2022 Aug 4;175:26-32. doi: 10.1016/j.radonc.2022.08.001. Epub ahead of print. PMID: 35934169.
159. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Kokorovic A, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy. *Eur Urol Focus.* 2022 Jul 30:S2405-4569(22)00167-5. doi: 10.1016/j.euf.2022.07.005. Epub ahead of print. PMID: 35918270.
160. Sorce G, Hoeh B, Hohenhorst L, Panunzio A, Tappero S, Tian Z, Larcher A, Capitanio U, Tilki D, Terrone C, Chun FKH, Antonelli A, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity. *Urol Oncol.* 2022 Jul 27:S1078-1439(22)00241-1. doi: 10.1016/j.urolonc.2022.06.022. Epub ahead of print. PMID: 35907705.
161. Collà Ruvolo C, Deuker M, Wenzel M, Nocera L, Würnschimmel C, Califano G, Tian Z, Saad F, **Briganti A**, Xylinas E, Verze P, Musi G, Shariat SF, Mirone V, Karakiewicz PI. Impact of the primary tumor location on secondary sites and overall mortality in patients with metastatic upper tract urothelial carcinoma. *Urol Oncol.* 2022 Sep;40(9):411.e1-411.e8. doi: 10.1016/j.urolonc.2022.06.009. Epub 2022 Jul 25. PMID: 35902301.
162. Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Hoeh B, Tian Z, Saad F, **Briganti A**, Tilki D, Banek S, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Epidemiology of Unconventional Histological Subtypes of Urethral Cancer. *Urol Int.* 2022 Jul 26:1-8. doi: 10.1159/000525673. Epub ahead of print. PMID: 35882213.
163. Gandaglia G, Mazzone E, Stabile A, Pellegrino A, Cucchiara V, Barletta F, Scuderi S, Robesti D, Leni R, Samanes Gajate AM, Picchio M, Gianolli L, Brembilla G, De Cobelli F, van Oosterom MN, van Leeuwen FWB, Montorsi F, **Briganti A**. Prostate-specific membrane antigen Radioguided Surgery to Detect Nodal Metastases in Primary Prostate Cancer Patients Undergoing Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection: Results of a Planned Interim Analysis of a Prospective Phase 2 Study. *Eur Urol.* 2022 Oct;82(4):411-418. doi: 10.1016/j.eururo.2022.06.002. Epub 2022 Jul 22. PMID: 35879127.
164. Lonati C, Simeone C, Suardi N, **Briganti A**, Montorsi F, Moschini M. Micropapillary bladder cancer: an evolving biology. *Curr Opin Urol.* 2022 Sep 1;32(5):504-510. doi: 10.1097/MOU.0000000000001023. Epub 2022 Jul 18. PMID: 35855578.
165. Bravi CA, Dell'Oglio P, Mazzone E, Moschovas MC, Falagario U, Piazza P, Scarcella S, Bednarz C, Sarchi L, Tappero S, Knipper S, De Groot R, Sjoberg D, Schiavina R, Suardi N, Terrone C, Autorino R, Carrieri G, Galosi A, Galfano A, **Briganti A**, Montorsi F, Patel V, Vickers A, Motttrie A. The Surgical Learning Curve for Biochemical Recurrence After Robot-assisted Radical Prostatectomy. *Eur Urol Oncol.* 2022 Jul 15:S2588-9311(22)00113-4. doi: 10.1016/j.euo.2022.06.010. Epub ahead of print. PMID: 35850976.
166. Flammia RS, Hoeh B, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Leonardo C, **Briganti A**, Antonelli A, Terrone C, Shariat SF, Anceschi U, Graefen M, Chun FKH, Montorsi F, Gallucci M, Karakiewicz PI. Adverse upgrading and/or upstaging in contemporary low-risk prostate cancer patients. *Int Urol Nephrol.* 2022 Oct;54(10):2521-2528. doi: 10.1007/s11255-022-03250-0. Epub 2022 Jul 15. PMID: 35838831; PMCID: PMC9463257.
167. Mazzone E, Gandaglia G, Stabile A, Bravi CA, Barletta F, Scuderi S, Cirulli GO, Fossati N, Cucchiara V, Raggi D, Necchi A, Montorsi F, **Briganti A**. Not All Adverse Pathology Features Are Equal: Identifying Optimal Candidates for Adjuvant Radiotherapy Among Patients With Adverse Pathology at Radical Prostatectomy. *J Urol.* 2022 Nov;208(5):1046-1055. doi: 10.1097/JU.0000000000002855. Epub 2022 Jul 5. PMID: 35830554.
168. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Treatment patterns and rates of upgrading and upstaging in prostate cancer patients with single GGG1 positive biopsy core. *Urol Oncol.* 2022 Sep;40(9):407.e9-407.e19. doi: 10.1016/j.urolonc.2022.06.003. Epub 2022 Jul 9. PMID: 35817649.

169. Parekh S, Ratnani P, Falagario U, Lundon D, Kewlani D, Nasri J, Dovey Z, Stroumbakis D, Ranti D, Grauer R, Sobotka S, Pedraza A, Wagaskar V, Mistry L, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Martini A, Picker W, Haug E, Cormio L, Nordström T, **Briganti A**, Boström PJ, Carrieri G, Haines K, Gorin MA, Wiklund P, Menon M, Tewari A. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator. *Eur Urol Open Sci.* 2022 May 20;41:45-54. doi: 10.1016/j.euros.2022.04.017. PMID: 35813258; PMCID: PMC9257660.
170. Tutolo M, Rosiello G, Stabile G, Tasso G, Oreggia D, De Wever L, De Ridder D, Pellegrino A, Esposito A, De Cobelli F, Salonia A, **Briganti A**, Montorsi F, Everaerts W, Van der Aa F. The key role of levator ani thickness for early urinary continence recovery in patients undergoing robot-assisted radical prostatectomy: A multi-institutional study. *Neurourol Urodyn.* 2022 Jul 3. doi: 10.1002/nau.25001. Epub ahead of print. PMID: 35781824.
171. Stangl-Kremser J, Lambertini L, Di Maida F, Martinez-Fundichely A, Ferro M, Pradere B, Soria F, Albisinni S, Wu Z, Del Giudice F, Cacciamani GE, Valerio M, **Briganti A**, Rouprêt M, Shariat SF, Lee C, Minervini A, Moschini M, Mari A; European Association of Urology-Young Academic Urologists Urothelial Carcinoma Working Group. Enhancing Recovery After Major Bladder Cancer Surgery: Comprehensive Review and Assessment of Application of the Enhanced Recovery After Surgery Guidelines. *Eur Urol Focus.* 2022 Jun 27:S2405-4569(22)00133-X. doi: 10.1016/j.euf.2022.06.004. Epub ahead of print. PMID: 35773181.
172. Bicchetti M, Simone G, Giannarini G, Girometti R, **Briganti A**, Brunocilla E, Cardone G, De Cobelli F, Gaudio C, Del Giudice F, Flammia S, Leonardo C, Pecoraro M, Schiavina R, Catalano C, Panebianco V. A novel pathway to detect muscle-invasive bladder cancer based on integrated clinical features and VI-RADS score on MRI: results of a prospective multicenter study. *Radiol Med.* 2022 Jun 28. doi: 10.1007/s11547-022-01513-5. Epub ahead of print. PMID: 35763251.
173. Afferi L, Lonati C, Montorsi F, **Briganti A**, Necchi A, Mari A, Minervini A, Tellini R, Campi R, Schulz GB, Black PC, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Mondini F, Simeone C, Antonelli A, Tafuri A, Krajewski W, Małkiewicz B, Xylinas E, Soria F, Sanchez Salas R, Arora A, Cathelineau X, Hendricksen K, Ammiwala M, Borghesi M, Chierigo F, Teoh JY, Mattei A, Albisinni S, Roghmann F, Roumiguié M, Bajaj AS, Maier E, Aziz A, Hurle R, Contieri R, Pradere B, Carando R, Poyet C, Alvarez-Maestro M, D'Andrea D, Shariat SF, Moschini M; European Association of Urology Young Academic Urologists Urothelial Carcinoma Working Group. Selecting the Best Candidates for Cisplatin-based Adjuvant Chemotherapy After Radical Cystectomy Among Patients with pN+ Bladder Cancer. *Eur Urol Oncol.* 2022 Jun 14:S2588-9311(22)00062-1. doi: 10.1016/j.euo.2022.04.001. Epub ahead of print. PMID: 35715319.
174. Fanti S, **Briganti A**, Emmett L, Fizazi K, Gillissen S, Goffin K, Hadaschik BA, Herrmann K, Kunikowska J, Maurer T, MacLennan S, Mottet N, Murphy DG, Oprea- Lager DE, O'Sullivan JM, Oyen WJG, Rouvière O, Sartor O, Stenzl A, Van Poppel H, Walz J, Witjes W, Bjartell A. EAU-EANM Consensus Statements on the Role of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in Patients with Prostate Cancer and with Respect to [¹⁷⁷Lu]-PSMA Radioligand Therapy. *Eur Urol Oncol.* 2022 Jun 10:S2588-9311(22)00086-4. doi: 10.1016/j.euo.2022.05.003. Epub ahead of print. PMID: 35697600.
175. Capitanio U MD, Fallara G MD, Raggi D MD, Nocera L MD, Larcher A MD, Belladelli F MD, Rowe I PhD, **Briganti A** MD, PhD, Salonia A MD, PhD, Karakiewicz P MD, Montorsi F MD, Martini A MD, Necchi A MD. Pembrolizumab in advanced renal cell carcinoma: a meta-analysis providing level 1a evidence. *Curr Probl Cancer.* 2022 Jun 1;46(4):100875. doi: 10.1016/j.currproblcancer.2022.100875. Epub ahead of print. PMID: 35679628.
176. Basile G, Rosiello G, Larcher A, Fallara G, Martini A, Re C, Cignoli D, Tian Z, Karakiewicz PI, Mottre A, Bertini R, Necchi A, Raggi D, Salonia A, **Briganti A**, Montorsi F, Capitanio U. Clinical, pathological and long-term oncologic outcomes of papillary type I vs. type II renal cell carcinoma. *Urol Oncol.* 2022 May 31:S1078-1439(22)00183-1. doi: 10.1016/j.urolonc.2022.05.012. Epub ahead of print. PMID: 35662498.

177. Montorsi F, Stabile A, Mazzone E, Gandaglia G, **Briganti A**. Re: Deepika Reddy, Max Peters, Taimur T. Shah, et al. Cancer Control Outcomes Following Focal Therapy Using High-intensity Focused Ultrasound in 1379 Men with Nonmetastatic Prostate Cancer: A Multi-institute 15-year Experience. *Eur Urol* 2022;81:407-13. *Eur Urol*. 2022 Jun 2:S0302-2838(22)02394-6. doi: 10.1016/j.eururo.2022.05.020. Epub ahead of print. PMID: 35661628.
178. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Outcomes of robotic- assisted versus open radical cystectomy in a large-scale, contemporary cohort of bladder cancer patients. *J Surg Oncol*. 2022 Jun 4. doi: 10.1002/jso.26973. Epub ahead of print. PMID: 35661361.
179. Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, **Briganti A**, Rink M, Gust KM, Hassler MR, Foerster B, Abufarraj M, Haitel A, Klatte T, Shariat SF. Corrigendum to < Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer>, urologic oncology: Seminars and original investigations volume 35, issue 6, June 2017, pages 356-362. *Urol Oncol*. 2022 Jun 1:S1078-1439(22)00176-4. doi: 10.1016/j.urolonc.2022.05.006. Epub ahead of print. Erratum for: *Urol Oncol*. 2017 Jun;35(6):356-362. PMID: 35659481.
180. Sorce G, Hoeh B, Flammia RS, Chierigo F, Hohenhorst L, Panunzio A, Nimer N, Tian Z, Gandaglia G, Tilki D, Terrone C, Gallucci M, Chun FKH, Antonelli A, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Rates of metastatic prostate cancer in newly diagnosed patients: Numbers needed to image according to risk level. *Prostate*. 2022 Jun 2. doi: 10.1002/pros.24376. Epub ahead of print. PMID: 35652586.
181. Valenza C, Antonarelli G, Giugliano F, Aurilio G, Verri E, **Briganti A**, Curigliano G, Necchi A. Emerging treatment landscape of non-muscle invasive bladder cancer. *Expert Opin Biol Ther*. 2022 Jun;22(6):717-734. doi: 10.1080/14712598.2022.2082869. Epub 2022 May 31. PMID: 35634893.
182. Beyer K, Straten V, Remmers S, MacLennan S, MacLennan S, Gandaglia G, Willemse PM, Herrera R, Omar MI, Russell B, Huber J, Kreuz M, Asiimwe A, Abbott T, **Briganti A**, Van Hemelrijck M, Roobol MJ, The Prias Consortium, The Erspc Rotterdam Study Group, The Pioneer Consortium. Secondary Treatment for Men with Localized Prostate Cancer: A Pooled Analysis of PRIAS and ERSPC-Rotterdam Data within the PIONEER Data Platform. *J Pers Med*. 2022 May 5;12(5):751. doi: 10.3390/jpm12050751. PMID: 35629173; PMCID: PMC9146310.
183. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Sorce G, Hoeh B, Hohenhorst L, Tian Z, Saad F, Tilki D, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Shariat SF, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Contemporary Pathological Stage Distribution After Radical Prostatectomy in North American High-Risk Prostate Cancer Patients. *Clin Genitourin Cancer*. 2022 Apr 21:S1558-7673(22)00080-5. doi: 10.1016/j.clgc.2022.04.005. Epub ahead of print. PMID: 35618597.
184. Flammia RS, Hoeh B, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Leonardo C, **Briganti A**, Antonelli A, Terrone C, Shariat SF, Graefen M, Chun FKH, Montorsi F, Gallucci M, Karakiewicz PI. Cancer-specific mortality in patients with non-metastatic renal cell carcinoma who have undergone a nephrectomy and are eligible for adjuvant pembrolizumab. *Semin Oncol*. 2022 Apr;49(2):136-140. doi: 10.1053/j.seminoncol.2022.04.002. Epub 2022 Apr 29. PMID: 35610060.
185. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Panunzio A, Chierigo F, Nimer N, Tian Z, Saad F, Gallucci M, **Briganti A**, Shariat SF, Graefen M, Tilki D, Antonelli A, Terrone C, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Metastatic stage vs complications at radical nephrectomy with inferior vena cava thrombectomy. *Surg Oncol*. 2022 Jun;42:101783. doi: 10.1016/j.suronc.2022.101783. Epub 2022 May 16. PMID: 35605557.
186. Pellegrino F, Stabile A, Mazzone E, Sorce G, Barletta F, De Angelis M, Brembilla G, Gandaglia G, De Cobelli F, Montorsi F, **Briganti A**. Does previous prostate surgery affect multiparametric magnetic resonance imaging accuracy in detecting clinically significant prostate cancer? Results from a single institution series. *Prostate*. 2022 May 10. doi: 10.1002/pros.24368. Epub ahead of print. PMID: 35538401.
187. Aydh A, Motlagh RS, Abufaraj M, Mori K, Katayama S, Grossmann N, Rajwa P, Mostafai H, Laukhina E, Pradere B, Quhal F, Schuettfort VM, **Briganti A**, Karakiewicz PI, Fajkovic H, Shariat SF.

- Radiation therapy compared to radical prostatectomy as first-line definitive therapy for patients with high-risk localised prostate cancer: An updated systematic review and meta-analysis. *Arab J Urol*. 2022 Mar 30;20(2):71-80. doi: 10.1080/2090598X.2022.2026010. PMID: 35530569; PMCID: PMC9067961.
188. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Shariat SF, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Life expectancy in metastatic urothelial bladder cancer patients according to race/ethnicity. *Int Urol Nephrol*. 2022 Jul;54(7):1521-1527. doi: 10.1007/s11255-022-03221-5. Epub 2022 May 4. PMID: 35508792.
189. Martini A, Lonati C, Nocera L, Fallara G, Raggi D, Herout R, Zamboni S, Ploussard G, Predere B, Mattei A, Simeone C, Krajewski W, Simone G, Soria F, Gontero P, Roupret M, Montorsi F, **Briganti A**, Shariat SF, Necchi A, Moschini M. Oncologic Surveillance After Radical Nephroureterectomy for High-risk Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2022 Apr 30:S2588-9311(22)00061-X. doi: 10.1016/j.euo.2022.04.003. Epub ahead of print. PMID: 35504834.
190. Arora A, Zugail AS, Pugliesi F, Cathelineau X, Macek P, Barbé Y, Karnes RJ, Ahmed M, Di Trapani E, Soria F, Alvarez-Maestro M, Montorsi F, **Briganti A**, Necchi A, Pradere B, D'Andrea D, Krajewski W, Roumiguié M, Bajeot AS, Hurle R, Contieri R, Carando R, Teoh JY, Roupret M, Benamran D, Ploussard G, Mir MC, Sanchez-Salas R, Moschini M. Neoadjuvant chemotherapy does not increase peri-operative morbidity following radical cystectomy. *World J Urol*. 2022 Jul;40(7):1697-1705. doi: 10.1007/s00345-022-04012-4. Epub 2022 Apr 30. PMID: 35488914.
191. Rajwa P, Pradere B, Gandaglia G, van den Bergh RCN, Tsaur I, Shim SR, Yanagisawa T, Laukhtina E, Mori K, Mostafaei H, Quhal F, Bryniarski P, Compérat E, Roubaud G, Massard C, Merseburger AS, Leapman MS, Spratt DE, Saad F, Joniau S, D'Amico AV, **Briganti A**, Shariat SF, Ploussard G; European Association of Urology Young Academic Urologists Prostate Cancer Working Party. Intensification of Systemic Therapy in Addition to Definitive Local Treatment in Nonmetastatic Unfavourable Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*. 2022 Jul;82(1):82-96. doi: 10.1016/j.eururo.2022.03.031. Epub 2022 Apr 22. PMID: 35465985.
192. Gillessen S, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, **Briganti A**, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke CS, Clarke N, Davis ID, de Bono JS, Duran I, Eeles R, Efstathiou E, Efstathiou J, Ekeke ON, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khamis MM, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt DE, Sternberg CN, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zaporozhny A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol*. 2022 Jul;82(1):115-141. doi: 10.1016/j.eururo.2022.04.002. Epub 2022 Apr 18. PMID: 35450732.
193. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, **Briganti A**, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khamis MM, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ekeke ON, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort I, Yamoah K, Ye D, Zaporozhny A, Gillessen S, Omlin A. Corrigendum to "What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021" [*Eur Urol* 82(1):6-11]. *Eur Urol*. 2022 Jul;82(1):e18-e19. doi: 10.1016/j.eururo.2022.04.004. Epub 2022 Apr 16. Erratum for: *Eur Urol*. 2022 Jul;82(1):6-11. PMID: 35440417; PMCID: PMC9012951.

194. Sorce G, Chierigo F, Flammia RS, Hoeh B, Hohenhorst L, Tian Z, Goyal JA, Graefen M, Terrone C, Gallucci M, Chun FKH, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Survival trends in chemotherapy exposed metastatic bladder cancer patients and chemotherapy effect across different age, sex, and race/ethnicity. *Urol Oncol*. 2022 Apr 14:S1078-1439(22)00105-3. doi: 10.1016/j.urolonc.2022.03.014. Epub ahead of print. PMID: 35431135.
195. Flammia RS, Hoeh B, Sorce G, Chierigo F, Hohenhorst L, Tian Z, Goyal JA, Leonardo C, **Briganti A**, Graefen M, Terrone C, Saad F, Shariat SF, Montorsi F, Chun FKH, Gallucci M, Karakiewicz PI. Contemporary seminal vesicle invasion rates in NCCN high-risk prostate cancer patients. *Prostate*. 2022 Jun;82(10):1051-1059. doi: 10.1002/pros.24350. Epub 2022 Apr 11. PMID: 35403734.
196. Turco F, Armstrong A, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, **Briganti A**, Bristow RG, Bulbul M, Caffo O, Chi KN, Clarke C, Clarke N, Davis ID, de Bono J, Duran I, Eeles R, Efstathiou E, Efstathiou J, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, George D, Gleave M, Halabi S, Heinrich D, Higano C, Hofman MS, Hussain M, James N, Jones R, Kanesvaran R, Khamis MM, Klotz L, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Onyiah N, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Rabah DM, Rathkopf D, Reiter RE, Rubin M, Ryan CJ, Saad F, Sade J, Sartor O, Scher HI, Shore N, Skoneczna I, Small E, Smith M, Soule H, Spratt D, Sternberg CN, Suzuki H, Sweeney C, Sydes M, Taplin ME, Tilki D, Tombal B, Türkeri L, Uemura H, Uemura H, van Oort RP, Yamoah K, Ye D, Zapatero A, Gillessen S, Omlin A. What Experts Think About Prostate Cancer Management During the COVID-19 Pandemic: Report from the Advanced Prostate Cancer Consensus Conference 2021. *Eur Urol*. 2022 Jul;82(1):6-11. doi: 10.1016/j.eururo.2022.02.010. Epub 2022 Feb 17. Erratum in: *Eur Urol*. 2022 Apr 16;: PMID: 35393158; PMCID: PMC8849852.
197. Martini A, Lonati C, Necchi A, Galsky MD, Ploussard G, Fallara G, Pellegrino A, Simeone C, Suardi N, Zamboni S, Krajewski W, Simone G, **Briganti A**, Montorsi F, Mattei A, Shariat SF, Moschini M; European Association of Urology – Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Metastasis Within Three Years from Radical Nephroureterectomy as a Potential Surrogate for Overall Survival. *Clin Genitourin Cancer*. 2022 Mar 10:S1558-7673(22)00051-9. doi: 10.1016/j.clgc.2022.03.007. Epub ahead of print. PMID: 35383003.
198. Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Molnar M, Herrera R, Rauf A, Campi R, Greco I, Shiranov K, Dabestani S, van den Broeck T, Arun S, Gacci M, Gandaglia G, Omar MI, MacLennan S, Roobol MJ, Farahmand B, Vradi E, Devecseri Z, Asiimwe A, Zong J, MacLennan SJ, Collette L, NDow J, **Briganti A**, Bjartell A, Van Hemelrijck M; the PIONEER Consortium. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review. *BMJ Open*. 2022 Apr 4;12(4):e058267. doi: 10.1136/bmjopen-2021-058267. PMID: 35379637; PMCID: PMC8981333.
199. Sorce G, Flammia RS, Hoeh B, Chierigo F, Hohenhorst L, Panunzio A, Stabile A, Gandaglia G, Tian Z, Tilki D, Terrone C, Gallucci M, Chun FKH, Antonelli A, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Grade and stage misclassification in intermediate unfavorable-risk prostate cancer radiotherapy candidates. *Prostate*. 2022 Jun;82(10):1040-1050. doi: 10.1002/pros.24349. Epub 2022 Apr 1. PMID: 35365851.
200. Montorsi F, Mazzone E, Gandaglia G, Stabile A, Salonia A, **Briganti A**. Survival after Radical Prostatectomy versus Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer. *Letter. J Urol*. 2022 Jul;208(1):223-224. doi: 10.1097/JU.0000000000002680. Epub 2022 Mar 29. PMID: 35348370.
201. Cianflone F, Lazarevic D, Palmisano A, Fallara G, Larcher A, Freschi M, Dell'Antonio G, Scotti GM, Morelli MJ, Ferrara AM, Trevisani F, Cinque A, Esposito A, **Briganti A**, Tacchetti C, Doglioni C, Del Maschio A, de Cobelli F, Bertini R, Salonia A, Montorsi F, Tonon G, Capitanio U. Radiomic and gEnomic approaches for the enhanced Diagnosis of clear cell Renal Cancer (REDIRECT): a translational pilot methodological study. *Transl Androl Urol*. 2022 Feb;11(2):149-158. doi: 10.21037/tau-21-713. PMID: 35280651; PMCID: PMC8899146.
202. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Panunzio A, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Antonelli A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of Neoadjuvant Chemotherapy on Complications, in-Hospital Mortality, Length of Stay and Total Hospital Costs in Bladder Cancer Patients Undergoing Radical Cystectomy. *Cancers*

- (Basel). 2022 Feb 26;14(5):1222. doi: 10.3390/cancers14051222. PMID: 35267529; PMCID: PMC8909906.
203. Hoeh B, Flammia R, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Up- and downgrading in single intermediate- risk positive biopsy core prostate cancer. *Prostate Int*. 2022 Mar;10(1):21-27. doi: 10.1016/j.pnil.2022.01.004. Epub 2022 Jan 26. PMID: 35261911; PMCID: PMC8866049.
204. Stangl-Kremser J, Muto G, Grosso AA, **Briganti A**, Comperat E, Di Maida F, Montironi R, Remzi M, Pradere B, Soria F, Albisinni S, Roupert M, Shariat SF, Minervini A, Teoh JY, Moschini M, Cimadamore A, Mari A; European Association of Urology-Young Academic Urologists (EAU-YAU): Urothelial carcinoma working group. The impact of lymphovascular invasion in patients treated with radical nephroureterectomy for upper tract urothelial carcinoma: An extensive updated systematic review and meta-analysis. *Urol Oncol*. 2022 Jun;40(6):243-261. doi: 10.1016/j.urolonc.2022.01.014. Epub 2022 Feb 28. PMID: 35241364.
205. Lonati C, Mordasini L, Afferi L, De Cobelli O, Di Trapani E, Necchi A, Colombo R, **Briganti A**, Montorsi F, Simeone C, Zamboni S, Simone G, Karnes RJ, Marra G, Soria F, Gontero P, Shariat SF, Pradere B, Hendricksen K, Ammiwala M, Rink M, Poyet C, Krajewski W, Baumeister P, Mattei A, Moschini M, Carando R; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Diagnostic accuracy of preoperative lymph node staging of bladder cancer according to different lymph node locations: A multicenter cohort from the European Association of Urology – Young Academic Urologists. *Urol Oncol*. 2022 May;40(5):195.e27-195.e35. doi: 10.1016/j.urolonc.2022.01.002. Epub 2022 Feb 27. PMID: 35236621.
206. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Horlemann B, Tian Z, Saad F, **Briganti A**, Shariat SF, Gallucci M, Suardi N, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Radiation therapy after radical prostatectomy is associated with higher other-cause mortality. *Cancer Causes Control*. 2022 May;33(5):769-777. doi: 10.1007/s10552-022-01564-z. Epub 2022 Mar 1. PMID: 35230576; PMCID: PMC9010398.
207. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Hoeh B, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Shariat SF, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Survival after radical prostatectomy versus radiation therapy in clinical node-positive prostate cancer. *Prostate*. 2022 May;82(6):740-750. doi: 10.1002/pros.24317. Epub 2022 Feb 28. PMID: 35226380.
208. Lonati C, Afferi L, Mari A, Minervini A, Krajewski W, Borghesi M, Schulz GB, Rink M, Montorsi F, **Briganti A**, Colombo R, Martini A, Necchi A, Contieri R, Hurler R, Umari P, Zamboni S, Simeone C, Soria F, Marra G, Gontero P, Teoh JY, Klatte T, Bajot AS, Roumigué M, Rouprêt M, Masson-Lecomte A, Laukhtina E, Valiquette AS, Mir MC, Antonelli A, Einerhand SMH, Hendricksen K, Carando R, Fankhauser CD, Baumeister P, Mattei A, Shariat SF, Moschini M; European Association of Urology—Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Immediate radical cystectomy versus BCG immunotherapy for T1 high-grade non-muscle-invasive squamous bladder cancer: an international multi- centre collaboration. *World J Urol*. 2022 May;40(5):1167-1174. doi: 10.1007/s00345-022-03958-9. Epub 2022 Feb 26. PMID: 35218372.
209. Cimadamore A, Lonati C, Di Trapani E, De Cobelli O, Rink M, Zamboni S, Simeone C, Soria F, **Briganti A**, Montorsi F, Afferi L, Mattei A, Carando R, Ornaghi PI, Tafuri A, Antonelli A, Karnes RJ, Colomer A, Sanchez-Salas R, Contieri R, Hurler R, Poyet C, Simone G, D'Andrea D, Shariat SF, Galfano A, Umari P, Francavilla S, Roumigué M, Terrone C, Hendricksen K, Krajewski W, Buisan O, Laukhtina E, Xylinas E, Alvarez-Maestro M, Rouprêt M, Montironi R, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Variant histologies in bladder cancer: Does the centre have an impact in detection accuracy? *Urol Oncol*. 2022 Jun;40(6):273.e11-273.e20. doi: 10.1016/j.urolonc.2022.01.008. Epub 2022 Feb 23. PMID: 35216892.
210. Gandaglia G, Pellegrino A, Montorsi F, **Briganti A**. Prostate Cancer: Is There Still a Role for Systematic Biopsies? Yes. *Eur Urol Open Sci*. 2022 Feb 10;38:10-11. doi: 10.1016/j.euros.2021.06.016. PMID: 35199040; PMCID: PMC8844839.

211. Montorsi F, Stabile A, Gandaglia G, **Briganti A**. Re: K.R. Seetharam Bhat, Marcio Covas Moschovas, Marco Sandri, et al. Outcomes of Salvage Robot-assisted Radical Prostatectomy After Focal Ablation for Prostate Cancer in Comparison to Primary Robot-assisted Radical Prostatectomy: A Matched Analysis. *Eur Urol Focus*. In press. <https://doi.org/10.1016/j.euf.2021.10.005>. *Eur Urol Focus*. 2022 Feb 18:S2405-4569(22)00046-3. doi: 10.1016/j.euf.2022.01.022. Epub ahead of print. PMID: 35190294.
212. Hoeh B, Flammia RS, Hohenhorst L, Sorce G, Chierigo F, Tian Z, Saad F, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Graefen M, Tilki D, Kluth LA, Mandel P, Becker A, Chun FKH, Karakiewicz PI. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients. *Prostate*. 2022 May;82(6):687-694. doi: 10.1002/pros.24313. Epub 2022 Feb 21. PMID: 35188982.
213. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of chemotherapy in metastatic prostate cancer according to race/ethnicity groups. *Prostate*. 2022 May;82(6):676-686. doi: 10.1002/pros.24312. Epub 2022 Feb 21. PMID: 35188981.
214. Beyer K, Moris L, Lardas M, Omar MI, Healey J, Tripathi S, Gandaglia G, Venderbos LDF, Vradi E, van den Broeck T, Willemsse PP, Antunes-Lopes T, Pacheco-Figueiredo L, Monagas S, Esperto F, Flaherty S, Deveseri Z, Lam TBL, Williamson PR, Heer R, Smith EJ, Asiimwe A, Huber J, Roobol MJ, Zong J, Mason M, Cornford P, Mottet N, MacLennan SJ, N'Dow J, **Briganti A**, MacLennan S, Van Hemelrijck M; PIONEER Consortium. Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. *Eur Urol*. 2022 May;81(5):503-514. doi: 10.1016/j.eururo.2022.01.042. Epub 2022 Feb 17. PMID: 35184906.
215. Würnschimmel C, Nocera L, Wenzel M, Ruvolo CC, Tian Z, Saad F, **Briganti A**, Shariat SF, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity may be an Important Predictor of Life Expectancy in Localized Prostate Cancer Patients: Novel Analyses Using Social Security Administration Life Tables. *J Racial Ethn Health Disparities*. 2022 Feb 18. doi: 10.1007/s40615-022-01257-y. Epub ahead of print. PMID: 35182370.
216. Martini A, Raggi D, Fallara G, Nocera L, Schultz JG, Belladelli F, Marandino L, Salonia A, **Briganti A**, Montorsi F, Powles T, Necchi A. Immunotherapy versus chemotherapy as first-line treatment for advanced urothelial cancer: A systematic review and meta-analysis. *Cancer Treat Rev*. 2022 Mar;104:102360. doi: 10.1016/j.ctrv.2022.102360. Epub 2022 Feb 10. PMID: 35176685.
217. Bravi CA, Cazzaniga W, Simonini M, Larcher A, Messaggio E, Zagato L, Carenci C, Bertini R, **Briganti A**, Manunta P, Vezzoli G, Salonia A, Lanzani C, Capitanio U, Zangrillo A, Landoni G, Rovere-Querini P, Tresoldi M, Montorsi F, Ciceri F. Acute Kidney Injury at Hospital Admission for SARS-CoV-2 Infection as a Marker of Poor Prognosis: Clinical Implications for Triage Risk Stratification. *Kidney Blood Press Res*. 2022;47(2):147-150. doi: 10.1159/000518271. Epub 2022 Jan 10. PMID: 35158352; PMCID: PMC8805049.
218. Montorsi F, Gandaglia G, Dehò F, Mazzone E, Stabile A, **Briganti A**. Re: Dries Develtere, Giuseppe Rosiello, Pietro Piazza, et al. Early Catheter Removal on Postoperative Day 2 After Robot-assisted Radical Prostatectomy: Updated Real-life Experience with the Aalst Technique. *Eur Urol Focus*. In press. <https://doi.org/10.1016/j.euf.2021.10.003>. *Eur Urol Focus*. 2022 Feb 10:S2405-4569(22)00043-8. doi: 10.1016/j.euf.2022.01.020. Epub ahead of print. PMID: 35153172.
219. Montorsi F, Stabile A, Gandaglia G, **Briganti A**. Re: Jana S. Hopstaken, Joyce G.R. Bomers, Michiel J.P. Sedelaar, et al. An Updated Systematic Review on Focal Therapy in Localized Prostate Cancer: What Has Changed over the Past 5 Years? *Eur Urol* 2022;81:5-33. *Eur Urol*. 2022 May;81(5):e122. doi: 10.1016/j.eururo.2022.01.037. Epub 2022 Feb 10. PMID: 35151512.
220. Marra G, Stabile A, Gontero P, Montorsi F, **Briganti A**, Gandaglia G; Young Academic Urologists Prostate Cancer Working Party. Re: Valentin H. Meissner, Isabel Rauscher, Kristina Schwamborn, et al. Radical Prostatectomy Without Prior Biopsy Following Multiparametric Magnetic Resonance Imaging and Prostate-specific Membrane Antigen Positron Emission Tomography. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2021.11.019>: A Storm in a Teacup. *Eur Urol*. 2022 May;81(5):e115-e116. doi: 10.1016/j.eururo.2021.12.041. Epub 2022 Feb 9. PMID: 35151511.

221. Afferi L, Lonati C, Montorsi F, **Briganti A**, Necchi A, Mari A, Minervini A, Campi R, di Trapani E, de Cobelli O, Karnes RJ, Ahmed M, Mir MC, Algarra MA, Rink M, Zamboni S, Simeone C, Krajewski W, Xylinas E, Soria F, Hendricksen K, Einerhand S, Mattei A, Carando R, Roumiguié M, Bajet AS, Black PC, Shariat SF, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Carboplatin-based adjuvant chemotherapy versus observation after radical cystectomy in patients with pN1-3 urothelial bladder cancer. *World J Urol.* 2022 Jun;40(6):1489-1496. doi: 10.1007/s00345-022-03948-x. Epub 2022 Feb 10. PMID: 35142865.
222. Rosiello G, Larcher A, Fallara G, Giancristofaro C, Martini A, Re C, Cei F, Musso G, Tian Z, Karakiewicz PI, Mottrie A, Bertini R, Salonia A, Necchi A, Raggi D, **Briganti A**, Montorsi F, Capitanio U. Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinoma. *Urol Oncol.* 2022 Jun;40(6):271.e19-271.e27. doi: 10.1016/j.urolonc.2021.12.010. Epub 2022 Feb 6. PMID: 35140049.
223. Kasivisvanathan V, Chan VW, Clement KD, Levis B, Haider M, Agarwal R, Emberton M, Pond GR, Takwoingi Y, Klotz L, Moore CM; VISION study collaborators. A protocol for the VISION study: An individual patient data meta-analysis of randomised trials comparing MRI-targeted biopsy to standard transrectal ultrasound guided biopsy in the detection of prostate cancer. *PLoS One.* 2022 Feb 3;17(2):e0263345. doi: 10.1371/journal.pone.0263345. PMID: 35113918; PMCID: PMC8812968.
224. Albisinni S, Diamand R, Mjaess G, Aoun F, Assenmacher G, Assenmacher C, Verhoest G, Holz S, Naudin M, Ploussard G, Mari A, Minervini A, Tay A, Issa R, Roumiguié M, Bajet AS, Simone G, Anceschi U, Umari P, Sridhar A, Kelly J, Hendricksen K, Einerhand S, Sandel N, Sanchez-Salas R, Colomer A, Quackels T, Peltier A, Montorsi F, **Briganti A**, Teoh JYC, Pradere B, Moschini M, Roumeguère T. Defining the Morbidity of Robot-Assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Adoption of the Comprehensive Complication Index. *J Endourol.* 2022 Jun;36(6):785-792. doi: 10.1089/end.2021.0843. Epub 2022 May 17. PMID: 35109696.
225. Martini A, Lonati C, Montorsi F, **Briganti A**, Colombo R, Necchi A, Simeone C, Zamboni S, Afferi L, Mattei A, Carando R, Ploussard G, Soria F, Marra G, Rouprêt M, Xylinas E, Pradere B, Abufaraj M, D'Andrea D, Shariat SF, Moschini M. The Role of Prior Bladder Cancer on Recurrence in Patients Treated with Radical Nephroureterectomy. *Clin Genitourin Cancer.* 2022 Jun;20(3):e190-e198. doi: 10.1016/j.clgc.2021.12.006. Epub 2021 Dec 11. PMID: 35105509.
226. Sorce G, Flammia RS, Hoeh B, Chierigo F, Horlemann B, Würnschimmel C, Tian Z, Graefen M, Terrone C, Gallucci M, Chun FKH, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Plasmacytoid variant urothelial carcinoma of the bladder: effect of radical cystectomy and chemotherapy in non-metastatic and metastatic patients. *World J Urol.* 2022 Jun;40(6):1481-1488. doi: 10.1007/s00345-022-03940-5. Epub 2022 Jan 27. PMID: 35084543.
227. Mapelli P, Ghezzi S, Samanes Gajate AM, Preza E, Palmisano A, Cucchiara V, Brembilla G, Bezzi C, Rigamonti R, Magnani P, Toninelli E, Bettinardi V, Suardi N, Gianolli L, Scifo P, **Briganti A**, De Cobelli F, Esposito A, Picchio M. ⁶⁸Ga-PSMA and ⁶⁸Ga-DOTA-RM2 PET/MRI in Recurrent Prostate Cancer: Diagnostic Performance and Association with Clinical and Histopathological Data. *Cancers (Basel).* 2022 Jan 11;14(2):334. doi: 10.3390/cancers14020334. PMID: 35053499; PMCID: PMC8773792.
228. Rosiello G, Re C, Larcher A, Fallara G, Sorce G, Baiamonte G, Mazzone E, Bravi CA, Martini A, Tian Z, Mottrie A, Bertini R, Salonia A, **Briganti A**, Montorsi F, Capitanio U, Karakiewicz PI. The effect of frailty on post-operative outcomes and health care expenditures in patients treated with partial nephrectomy. *Eur J Surg Oncol.* 2022 Jan 7:S0748-7983(22)00002-6. doi: 10.1016/j.ejso.2022.01.001. Epub ahead of print. PMID: 35027234.
229. Lonati C, Necchi A, Gómez Rivas J, Afferi L, Laukhtina E, Martini A, Ventimiglia E, Colombo R, Gandaglia G, Salonia A, **Briganti A**, Montorsi F, Mattei A, Simeone C, Carlo MI, Shariat SF, Spiess PE, Moschini M; European Association of Urology Young Academic Urologists EAU-YAU: Urothelial Carcinoma Working Group, the Global Society of Rare Genitourinary Tumors GSRGT. Upper Tract Urothelial Carcinoma in the Lynch Syndrome Tumour Spectrum: A Comprehensive Overview from the European Association of Urology - Young Academic Urologists and the Global Society of Rare

- Genitourinary Tumors. *Eur Urol Oncol*. 2022 Feb;5(1):30-41. doi: 10.1016/j.euo.2021.11.001. Epub 2021 Dec 9. PMID: 34896051.
230. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Effect of Chemotherapy on Overall Survival in Contemporary Metastatic Prostate Cancer Patients. *Front Oncol*. 2021 Nov 23;11:778858. doi: 10.3389/fonc.2021.778858. PMID: 34888250; PMCID: PMC8649656.
231. Basile G, Bandini M, Raggi D, Marandino L, Pederzoli F, Salonia A, **Briganti A**, Montorsi F, Kulkarni SB, Necchi A. Bladder-sparing combination treatments for muscle-invasive bladder cancer: A plea for standardized assessment and definition of clinical trials endpoints. *Urol Oncol*. 2022 Feb;40(2):37-44. doi: 10.1016/j.urolonc.2021.10.012. Epub 2021 Nov 25. PMID: 34840076.
232. Mapelli P, Ghezzi S, Samanes Gajate AM, Preza E, Brembilla G, Cucchiara V, Ahmed N, Bezzi C, Presotto L, Bettinardi V, Savi A, Magnani P, Menichini R, Coliva A, Neri I, Di Gaeta E, Gianolli L, Freschi M, **Briganti A**, De Cobelli F, Scifo P, Picchio M. Preliminary Results of an Ongoing Prospective Clinical Trial on the Use of ⁶⁸Ga-PSMA and ⁶⁸Ga-DOTA-RM2 PET/MRI in Staging of High-Risk Prostate Cancer Patients. *Diagnostics (Basel)*. 2021 Nov 9;11(11):2068. doi: 10.3390/diagnostics11112068. PMID: 34829417; PMCID: PMC8622332.
233. Rosiello G, Piazza P, Puliatti S, Mazzone E, Amato M, Tames V, Farinha R, De Groote R, Berquin C, Develtere D, Sinatti C, Larcher A, Capitanio U, D'Hondt F, Schatteman P, **Briganti A**, Montorsi F, De Naeyer G, Mottrie A. Simplified PADUA renal (SPARE) nephrometry score validation and long-term outcomes after robot- assisted partial nephrectomy. *Urol Oncol*. 2022 Feb;40(2):65.e1-65.e9. doi: 10.1016/j.urolonc.2021.09.021. Epub 2021 Nov 22. PMID: 34824015.
234. Chierigo F, Borghesi M, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Höh B, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Montorsi F, Chun FKH, Shariat SF, Mantica G, Suardi N, Terrone C, Karakiewicz PI. Survival after radical prostatectomy vs. radiation therapy in ductal carcinoma of the prostate. *Int Urol Nephrol*. 2022 Jan;54(1):89-95. doi: 10.1007/s11255-021-03070-8. Epub 2021 Nov 19. PMID: 34797483.
235. Würnschimmel C, Wenzel M, Chierigo F, Simone Flammia R, Tian Z, Saad F, **Briganti A**, Shariat SF, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Response to Re: External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. *Int J Urol*. 2022 Jan;29(1):96. doi: 10.1111/iju.14743. Epub 2021 Nov 17. PMID: 34788899.
236. Ratti MM, Gandaglia G, Alleva E, Leardini L, Sisca ES, Derevianko A, Furnari F, Mazzoleni Ferracini S, Beyer K, Moss C, Pellegrino F, Sorce G, Barletta F, Scuderi S, Omar MI, MacLennan S, Williamson PR, Zong J, MacLennan SJ, Mottet N, Cornford P, Aiyegbusi OL, Van Hemelrijck M, N'Dow J, **Briganti A**; PIONEER Consortium. Standardising the Assessment of Patient-reported Outcome Measures in Localised Prostate Cancer. A Systematic Review. *Eur Urol Oncol*. 2022 Apr;5(2):153-163. doi: 10.1016/j.euo.2021.10.004. Epub 2021 Nov 14. PMID: 34785188.
237. Hoeh B, Hohenhorst JL, Flammia R, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Kluth LA, Becker A, Chun FKH, Karakiewicz PI. Cancer-specific mortality after radical prostatectomy vs external beam radiotherapy in high-risk Hispanic/Latino prostate cancer patients. *Int Urol Nephrol*. 2022 Jan;54(1):81-87. doi: 10.1007/s11255-021-03055-7. Epub 2021 Nov 16. PMID: 34783982; PMCID: PMC8732979.
238. Zattoni F, Marra G, Kretschmer A, Preisser F, Tilki D, Kesch C, Radtke JP, Hoffmann N, Morlacco A, Dal Moro F, Soeterik TFW, van den Bergh RCN, Barletta F, **Briganti A**, Montorsi F, Gandaglia G. Has the COVID-19 outbreak changed the way we are treating prostate cancer? An EAU - YAU Prostate Cancer Working Group multi-institutional study. *Cent European J Urol*. 2021;74(3):362-365. doi: 10.5173/cej.2021.0211. Epub 2021 Sep 18. PMID: 34729226; PMCID: PMC8552935.
239. MacLennan S, Duncan E, Skolarus TA, Roobol MJ, Kasivisvanathan V, Gallagher K, Gandaglia G, Sakalis V, Smith EJ, Plass K, Ribal MJ, N'Dow J, **Briganti A**. Improving Guideline Adherence in Urology. *Eur Urol Focus*. 2021 Oct 23:S2405-4569(21)00279-0. doi: 10.1016/j.euf.2021.10.007. Epub ahead of print. PMID: 34702647.

240. Wenzel M, Nocera L, Würnschimmel C, Collà Ruvolo C, Tian Z, Saad F, **Briganti A**, Tilki D, Graefen M, Becker A, Roos FC, Chun FKH, Karakiewicz PI. The Effect of 10 Most Common Nonurological Primary Cancers on Survival in Men With Secondary Prostate Cancer. *Front Oncol.* 2021 Oct 6;11:754996. doi: 10.3389/fonc.2021.754996. PMID: 34692543; PMCID: PMC8526938.
241. Barletta F, Stabile A, Mazzone E, Brembilla G, Sorce G, Pellegrino F, Scuderi S, Cannoletta D, Cirulli GO, Cucchiara V, Gandaglia G, De Cobelli F, Montorsi F, **Briganti A**. How to optimize follow-up in patients with a suspicious multiparametric MRI and a subsequent negative targeted prostate biopsy. Results from a large, single-institution series. *Urol Oncol.* 2022 Mar;40(3):103.e17-103.e24. doi: 10.1016/j.urolonc.2021.09.015. Epub 2021 Oct 27. PMID: 34688534.
242. Martini A, Gandaglia G, **Briganti A**. Evidence-based Urology: Surrogate Endpoints - For. *Eur Urol Focus.* 2021 Nov;7(6):1217-1218. doi: 10.1016/j.euf.2021.09.023. Epub 2021 Oct 19. PMID: 34686470.
243. Gandaglia G, **Briganti A**, Montorsi F. Reimagining prostate cancer screening: the IMPACT of germline mutations. *Lancet Oncol.* 2021 Nov;22(11):1491-1492. doi: 10.1016/S1470-2045(21)00571-4. Epub 2021 Oct 19. PMID: 34678157.
244. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Cancer-specific survival after radical prostatectomy versus external beam radiotherapy in high-risk and very high-risk African American prostate cancer patients. *Prostate.* 2022 Jan;82(1):120-131. doi: 10.1002/pros.24253. Epub 2021 Oct 18. PMID: 34662443.
245. Wenzel M, Collà Ruvolo C, Würnschimmel C, Nocera L, Tian Z, Saad F, **Briganti A**, Tilki D, Graefen M, Becker A, Roos F, Mandel P, Chun FKH, Karakiewicz PI. Survival rates with external beam radiation therapy in newly diagnosed elderly metastatic prostate cancer patients. *Prostate.* 2022 Jan;82(1):78-85. doi: 10.1002/pros.24249. Epub 2021 Oct 11. PMID: 34633102.
246. Horlemann B, Würnschimmel C, Hoeh B, Sorce G, Chierigo F, Flammia RS, Tian Z, Saad F, **Briganti A**, Shariat SF, Galucci M, Chun FKH, Graefen M, Karakiewicz PI. Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly Patients. *Clin Genitourin Cancer.* 2022 Feb;20(1):93.e1-93.e9. doi: 10.1016/j.clgc.2021.08.003. Epub 2021 Sep 1. PMID: 34620567.
247. Pernigoni N, Zagato E, Calcinotto A, Troiani M, Mestre RP, Cali B, Attanasio G, Troisi J, Minini M, Mosole S, Revandkar A, Pasquini E, Elia AR, Bossi D, Rinaldi A, Rescigno P, Flohr P, Hunt J, Neeb A, Buroni L, Guo C, Welti J, Ferrari M, Grioni M, Gauthier J, Gharaibeh RZ, Palmisano A, Lucchini GM, D'Antonio E, Merler S, Bolis M, Grassi F, Esposito A, Bellone M, **Briganti A**, Rescigno M, Theurillat JP, Jobin C, Gillessen S, de Bono J, Alimonti A. Commensal bacteria promote endocrine resistance in prostate cancer through androgen biosynthesis. *Science.* 2021 Oct 8;374(6564):216-224. doi: 10.1126/science.abf8403. Epub 2021 Oct 7. PMID: 34618582.
248. Beyer K, MacLennan SJ, Moris L, Lardas M, Mastris K, Hooker G, Greene R, Briers E, Omar MI, Healey J, Tripathi S, Gandaglia G, Venderbos LDF, Smith EJ, Bjorkqvist J, Asiimwe A, Huber J, Roobol MJ, Zong J, Bjartell A, N'Dow J, **Briganti A**, MacLennan S, Van Hemelrijck M; PIONEER Consortium; EAU; LU; UNISR; Erasmus; UKE; TAU; KCL; EORTC; TTOP; ICHOM; ECPC; ASSOC EISBM; ICL; Hyve; EAPM; PM; WI; UoA; TUD; Fraunhofer; UGOT; Radboud; IHE; Bayer AG; SANOFI; ASTELLAS; SAS; Janssen; IQVIA; eGF-eCancer; AstraZeneca; HelmHoltz. The Key Role of Patient Involvement in the Development of Core Outcome Sets in Prostate Cancer. *Eur Urol Focus.* 2021 Sep;7(5):943-946. doi: 10.1016/j.euf.2021.09.008. Epub 2021 Oct 1. PMID: 34602368.
249. Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, **Briganti A**, Salvioni R, Montorsi F, Necchi A, Spiess PE. Risk factors and survival outcomes for upstaging after inguinal lymph node dissection for cN1 penile squamous cell carcinoma. *Urol Oncol.* 2021 Dec;39(12):838.e7-838.e13. doi: 10.1016/j.urolonc.2021.08.028. Epub 2021 Sep 30. PMID: 34602362.
250. Montorsi F, Gandaglia G, **Briganti A**. Re: Andrew J. Vickers. Effects of Magnetic Resonance Imaging Targeting on Overdiagnosis and Overtreatment of Prostate Cancer. *Eur Urol* 2021;80:567-

72. *Eur Urol.* 2021 Dec;80(6):e147-e148. doi: 10.1016/j.eururo.2021.09.021. Epub 2021 Sep 29. PMID: 34598832.
251. Montorsi F, Stabile A, Gandaglia G, Fossati N, Deho' F, Gallina A, **Briganti A**. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicenter prospective study of 1014 cases'. *BJU Int.* 2021 Oct;128(4):523. doi: 10.1111/bju.15387. PMID: 34581480.
252. Albisinni S, Diamand R, Mjaess G, Assenmacher G, Assenmacher C, Loos S, Verhoest G, Holz S, Naudin M, Ploussard G, Mari A, Di Maida F, Minervini A, Aoun F, Tay A, Issa R, Roumiguié M, Bajot AS, Simone G, Anceschi U, Umari P, Sridhar A, Kelly J, Hendricksen K, Einerhand S, Sanchez-Salas R, Colomer A, Quackels T, Peltier A, Montorsi F, **Briganti A**, Pradere B, Moschini M, Roumeguère T. Continuing acetylsalicylic acid during Robotic-Assisted Radical Cystectomy with intracorporeal urinary diversion does not increase hemorrhagic complications: results from a large multicentric cohort. *Urol Oncol.* 2022 Apr;40(4):163.e11-163.e17. doi: 10.1016/j.urolonc.2021.08.023. Epub 2021 Sep 25. PMID: 34580028.
253. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Tian Z, Saad F, **Briganti A**, Shariat SF, Suardi N, Terrone C, Gallucci M, Chun FK, Tilki D, Graefen M, Karakiewicz PI. External beam radiotherapy and radical prostatectomy are associated with better survival in Asian prostate cancer patients. *Int J Urol.* 2022 Jan;29(1):17-24. doi: 10.1111/iju.14701. Epub 2021 Sep 22. PMID: 34553428.
254. Martini A, Soeterik TFW, Haverdings H, Rahota RG, Checcucci E, De Cillis S, Hermanns T, Fankhauser CD, Afferi L, Moschini M, Mattei A, Kesch C, Heidegger I, Preisser F, Zattoni F, Marquis A, Marra G, Gontero P, **Briganti A**, Montorsi F, Porpiglia F, Van Basten JP, Van den Bergh RCN, Van Melick HHE, Ploussard G, Gandaglia G, Valerio M. An Algorithm to Personalize Nerve Sparing in Men with Unilateral High-Risk Prostate Cancer. *J Urol.* 2022 Feb;207(2):350-357. doi: 10.1097/JU.0000000000002205. Epub 2021 Sep 22. PMID: 34547922.
255. Nocera L, Karakiewicz PI, Wenzel M, Tian Z, Shariat SF, Saad F, Chun FKH, **Briganti A**, Kapoor A, Lalani AK. Clinical Outcomes and Adverse Events after First-Line Treatment in Metastatic Renal Cell Carcinoma: A Systematic Review and Network Meta-Analysis. *J Urol.* 2022 Jan;207(1):16-24. doi: 10.1097/JU.0000000000002252. Epub 2021 Sep 21. PMID: 34546767.
256. Stabile A, Pellegrino A, Mazzone E, Cannoletta D, de Angelis M, Barletta F, Scuderi S, Cucchiara V, Gandaglia G, Raggi D, Necchi A, Karakiewicz P, Montorsi F, **Briganti A**. Can Negative Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography Avoid the Need for Pelvic Lymph Node Dissection in Newly Diagnosed Prostate Cancer Patients? A Systematic Review and Meta-analysis with Backup Histology as Reference Standard. *Eur Urol Oncol.* 2022 Feb;5(1):1-17. doi: 10.1016/j.euo.2021.08.001. Epub 2021 Sep 17. PMID: 34538770.
257. Montorsi F, Leni R, **Briganti A**, Gandaglia G. Association of Negative Followup Biopsy and Reclassification during Active Surveillance of Prostate Cancer: A Systematic Review and Meta-Analysis. *Letter. J Urol.* 2022 Jan;207(1):242. doi: 10.1097/JU.0000000000002245. Epub 2021 Sep 16. PMID: 34529496.
258. Hoeh B, Würnschimmel C, Flammia RS, Horlemann B, Sorce G, Chierigo F, Tian Z, Saad F, Graefen M, Gallucci M, **Briganti A**, Terrone C, Shariat SF, Tilki D, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Improvement in overall and cancer-specific survival in contemporary, metastatic prostate cancer chemotherapy-exposed patients. *Prostate.* 2021 Dec;81(16):1374-1381. doi: 10.1002/pros.24235. Epub 2021 Sep 15. PMID: 34523162.
259. Montorsi F, Moschini M, Necchi A, Deho F, Gandaglia G, **Briganti A**. Contemporary Outcomes of Patients With Nonmuscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin: Implications for Clinical Trial Design. *Letter. J Urol.* 2021 Dec;206(6):1528. doi: 10.1097/JU.0000000000002237. Epub 2021 Aug 29. PMID: 34520222.
260. Collà Ruvolo C, Würnschimmel C, Nocera L, Wenzel M, Tian Z, Shariat SF, Saad F, Verze P, Imbimbo C, **Briganti A**, Mirone V, Karakiewicz PI. Stage and cancer-specific mortality differ within specific Asian ethnic groups for upper tract urothelial carcinoma: North American population-based study. *Int J Urol.* 2021 Dec;28(12):1247-1252. doi: 10.1111/iju.14682. Epub 2021 Sep 3. PMID: 34480378.

261. Wenzel M, Siron N, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Banek S, Kluth LA, Roos FC, Chun FKH, Karakiewicz PI. Temporal trends, tumor characteristics and stage-specific survival in penile non-squamous cell carcinoma vs. squamous cell carcinoma. *Cancer Causes Control*. 2022 Jan;33(1):25-35. doi: 10.1007/s10552-021-01493-3. Epub 2021 Sep 2. PMID: 34476653; PMCID: PMC8738356.
262. Pellegrino F, Coghi A, Lavorgna G, Cazzaniga W, Guazzoni E, Locatelli I, Villa I, Bolamperti S, Finocchio N, Alfano M, Lucianò R, **Briganti A**, Montorsi F, Salonia A, Cavarretta I. A mechanistic insight into the anti-metastatic role of the prostate specific antigen. *Transl Oncol*. 2021 Nov;14(11):101211. doi: 10.1016/j.tranon.2021.101211. Epub 2021 Aug 26. PMID: 34455373; PMCID: PMC8403584.
263. Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FKH, Mirone V, Graefen M, Saad F, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. The impact of race/ethnicity on upstaging and/or upgrading rates among intermediate risk prostate cancer patients treated with radical prostatectomy. *World J Urol*. 2022 Jan;40(1):103-110. doi: 10.1007/s00345-021-03816-0. Epub 2021 Aug 26. PMID: 34436637.
264. Grubmüller B, Jahrreiss V, Brönimann S, Quhal F, Mori K, Heidenreich A, **Briganti A**, Tilki D, Shariat SF. Salvage Radical Prostatectomy for Radio- Recurrent Prostate Cancer: An Updated Systematic Review of Oncologic, Histopathologic and Functional Outcomes and Predictors of Good Response. *Curr Oncol*. 2021 Jul 29;28(4):2881-2892. doi: 10.3390/curroncol28040252. PMID: 34436018; PMCID: PMC8395524.
265. Lonati C, Baumeister P, Afferi L, Mari A, Minervini A, Krajewski W, Azizi S, Hendricksen K, Martini A, Necchi A, Montorsi F, **Briganti A**, Colombo R, Tafuri A, Antonelli A, Cerruto MA, Rouprêt M, Masson-Lecomte A, Laukhtina E, D'Andrea D, Shariat SF, Soria F, Marra G, Gontero P, Contieri R, Hurle R, Valiquette AS, Mir MC, Zamboni S, Simeone C, Klatte T, Teoh JY, Yoshida S, Fujii Y, Carando R, Schulz GB, Mordasini L, Mattei A, Moschini M; European Association of Urology Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group. Survival Outcomes After Immediate Radical Cystectomy Versus Conservative Management with Bacillus Calmette-Guérin Among T1 High-grade Micropapillary Bladder Cancer Patients: Results from a Multicentre Collaboration. *Eur Urol Focus*. 2021 Aug 18:S2405-4569(21)00195-4. doi: 10.1016/j.euf.2021.07.015. Epub ahead of print. PMID: 34419381.
266. Wenzel M, Würnschimmel C, Nocera L, Ruvolo CC, Tian Z, Saad F, **Briganti A**, Tilki D, Graefen M, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. The effect of primary urological cancers on survival in men with secondary prostate cancer. *Prostate*. 2021 Nov;81(15):1149-1158. doi: 10.1002/pros.24209. Epub 2021 Aug 16. PMID: 34402086.
267. Mazzone E, Gandaglia G, Ploussard G, Marra G, Valerio M, Campi R, Mari A, Minervini A, Serni S, Moschini M, Marquis A, Beauval JB, van den Bergh R, Rahota RG, Soeterik T, Roumiguiè M, Afferi L, Zhuang J, Guo H, Mattei A, Gontero P, Cucchiara V, Stabile A, Fossati N, Montorsi F, **Briganti A**. Risk Stratification of Patients Candidate to Radical Prostatectomy Based on Clinical and Multiparametric Magnetic Resonance Imaging Parameters: Development and External Validation of Novel Risk Groups. *Eur Urol*. 2022 Feb;81(2):193-203. doi: 10.1016/j.eururo.2021.07.027. Epub 2021 Aug 13. PMID: 34399996.
268. Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Graefen M, Kluth LA, Becker A, Roos FC, Chun FKH, Karakiewicz PI. Median time to progression with TKI-based therapy after failure of immuno-oncology therapy in metastatic kidney cancer: A systematic review and meta-analysis. *Eur J Cancer*. 2021 Sep;155:245-255. doi: 10.1016/j.ejca.2021.07.014. Epub 2021 Aug 12. PMID: 34392067.
269. Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, **Briganti A**, Salvioni R, Montorsi F, Necchi A, Spiess PE. Reply by Authors. *J Urol*. 2021 Oct;206(4):969. doi: 10.1097/JU.0000000000001790.02. Epub 2021 Aug 11. PMID: 34379451.
270. Wenzel M, Collà Ruvolo C, Nocera L, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Graefen M, Becker A, Mandel P, Chun FKH, Karakiewicz PI. Regional differences in patient age and prostate cancer characteristics and rates of treatment modalities in favorable and unfavorable

- intermediate risk prostate cancer across United States SEER registries. *Cancer Epidemiol.* 2021 Oct;74:101994. doi: 10.1016/j.canep.2021.101994. Epub 2021 Aug 5. PMID: 34364187.
271. Di Marco F, Pani A, Floris M, Martini A, Dell'Antonio G, Capitanio U, Bettiga A, Larcher A, Cinque A, Bertini R, **Briganti A**, Salonia A, Montorsi F, Trevisani F. Unexpected Outcomes of Renal Function after Radical Nephrectomy: Histology Relevance along with Clinical Aspects. *J Clin Med.* 2021 Jul 28;10(15):3322. doi: 10.3390/jcm10153322. PMID: 34362105; PMCID: PMC8347310.
272. Montorsi F, Stabile A, Gandaglia G, Dehò F, Salonia A, **Briganti A**. Followup of Men with PI-RADS™ 4 or 5 Abnormality on Prostate Magnetic Resonance Imaging and Nonmalignant Pathological Findings on Initial Targeted Prostate Biopsy. Letter. *J Urol.* 2021 Nov;206(5):1335. doi: 10.1097/JU.0000000000002144. Epub 2021 Aug 4. PMID: 34347539.
273. De Meerleer G, Berghen C, **Briganti A**, Vulsteke C, Murray J, Joniau S, Leliveld AM, Cozzarini C, Decaestecker K, Rans K, Fonteyne V, De Hertogh O, Bossi A. Elective nodal radiotherapy in prostate cancer. *Lancet Oncol.* 2021 Aug;22(8):e348-e357. doi: 10.1016/S1470-2045(21)00242-4. PMID: 34339655.
274. Collà Ruvolo C, Wenzel M, Nocera L, Würnschimmel C, Tian Z, Shariat SF, Saad F, Longo N, Imbimbo C, **Briganti A**, Mirone V, Karakiewicz PI. The effect of race on stage at presentation and survival in upper tract urothelial carcinoma. *Urol Oncol.* 2021 Nov;39(11):788.e7-788.e13. doi: 10.1016/j.urolonc.2021.07.001. Epub 2021 Jul 27. PMID: 34330651.
275. Mori K, Quhal F, Katayama S, Mostafaei H, Laukhtina E, Schuetfort VM, Sari Motlagh R, Grossmann NC, Rajwa P, Ploussard G, **Briganti A**, Kimura T, Egawa S, Papalia R, Carrion DM, Fiori C, Shariat SF, Esperto F, Pradere B. Androgen receptor axis-targeted agents for non-metastatic castration-resistant prostate cancer impact on overall survival and safety profile. *Minerva Urol Nephrol.* 2022 Jun;74(3):292-301. doi: 10.23736/S2724-6051.21.04431-1. Epub 2021 Jul 26. PMID: 34308608.
276. Necchi A, Raggi D, Gallina A, Bandini M, de Jong JJ, Marandino L, **Briganti A**, Montorsi F, Davicioni E, Lotan Y, Gibb EA. Molecular subtyping and immune- gene signatures identify a subset of early bladder tumors as candidates for single-agent immune-checkpoint inhibition. *Urol Oncol.* 2021 Oct;39(10):734.e11-734.e17. doi: 10.1016/j.urolonc.2021.06.011. Epub 2021 Jul PMID: 34301456.
277. Bersanelli M, Buti S, Cortellini A, Bandini M, Banna GL, Pederzoli F, Farè E, Raggi D, Giannatempo P, De Giorgi U, Basso U, Losanno T, Santini D, Mucciarini C, Tucci M, Tambaro R, Farnesi A, Caffo O, Veccia A, Naglieri E, **Briganti A**, Procopio G, Pignata S, Necchi A. Clinical Outcomes of Patients With Metastatic Urothelial Carcinoma After Progression to Immune Checkpoint Inhibitors: A Retrospective Analysis by the Meet-Uro Group (Meet-URO 1 Study). *Clin Med Insights Oncol.* 2021 Jul 8;15:11795549211021667. doi: 10.1177/11795549211021667. PMID: 34290538; PMCID: PMC8274126.
278. Lonati C, Esperto F, Scarpa RM, Papalia R, Gómez Rivas J, Alvarez-Maestro M, Afferi L, Fankhauser CD, Mattei A, Colombo R, Montorsi F, **Briganti A**, Krajewski W, Carando R, Laukhtina E, Teoh JY, Zamboni S, Simeone C, Moschini M; European Association of Urology - Young Academic Urologists (EAU-YAU): Urothelial Carcinoma Working Group; European Association of Urology – European Society of Resident Urologists (EAU-ESRU). Bladder perforation during transurethral resection of the bladder: a comprehensive algorithm for diagnosis, management and follow up. *Minerva Urol Nephrol.* 2021 Jul 15. doi: 10.23736/S2724-6051.21.04436-0. Epub ahead of print. PMID: 34263743.
279. Wenzel M, Würnschimmel C, Ruvolo CC, Nocera L, Tian Z, Saad F, **Briganti A**, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Increasing rates of NCCN high and very high-risk prostate cancer versus number of prostate biopsy cores. *Prostate.* 2021 Sep;81(12):874-881. doi: 10.1002/pros.24184. Epub 2021 Jun 29. PMID: 34184780.
280. Aydh A, Mori K, D'Andrea D, Motlagh RS, Abufaraj M, Pradere B, Mostafaei H, Laukhtina E, Quhal F, Karakiewicz PI, Luzzago S, **Briganti A**, Trinh QD, Parizi MK, Tilki D, Enikeev DV, Shariat SF. Prognostic value of the pre-operative serum albumin to globulin ratio in patients with non-metastatic prostate cancer undergoing radical prostatectomy. *Int J Clin Oncol.* 2021 Sep;26(9):1729-1735. doi: 10.1007/s10147-021-01952-6. Epub 2021 Jun 28. PMID: 34184136; PMCID: PMC8364901.

281. Bravi CA, Droghetti M, Fossati N, Gandaglia G, Suardi N, Mazzone E, Cucchiara V, Scuderi S, Barletta F, Schiavina R, Osmonov D, Juenemann KP, Boeri L, Karnes RJ, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Grubmüller B, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, **Briganti A**. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. *Eur Urol Oncol*. 2022 Jun;5(3):285-295. doi: 10.1016/j.euo.2021.06.003. Epub 2021 Jun 24. PMID: 34176768.
282. Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, Rodríguez Faba Ó, **Briganti A**, Steinberg GD. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. *Urol Oncol*. 2021 Oct;39(10):642-663. doi: 10.1016/j.urolonc.2021.05.015. Epub 2021 Jun 22. PMID: 34167873.
283. Giannarini G, Agarwal N, Apolo AB, **Briganti A**, Grivas P, Gupta S, Kamat AM, Montorsi F, Rouprêt M, Necchi A. Urologists, You'll Never Walk Alone! How Novel Immunotherapy and Modern Imaging May Change the Management of Non-muscle-invasive Bladder Cancer. *Eur Urol Oncol*. 2022 Jun;5(3):268-272. doi: 10.1016/j.euo.2021.05.008. Epub 2021 Jun 17. PMID: 34147473.
284. Necchi A, Martini A, Raggi D, Cucchiara V, Colecchia M, Lucianò R, Villa L, Mazzone E, Basile G, Scuderi S, Pederzoli F, Bandini M, Barletta F, Larcher A, Capitanio U, Salonia A, **Briganti A**, Ross JS, Messina A, Montorsi F. A feasibility study of preoperative pembrolizumab before radical nephroureterectomy in patients with high-risk, upper tract urothelial carcinoma: PURE-02. *Urol Oncol*. 2022 Jan;40(1):10.e1-10.e6. doi: 10.1016/j.urolonc.2021.05.014. Epub 2021 Jun 17. PMID: 34147313.
285. Fallara G, Bandini M, Larcher A, Pederzoli F, Karakiewicz P, Tian Z, **Briganti A**, Necchi A, Salonia A, Bertini R, Montorsi F, Bex A, Capitanio U High-risk Surgically Resected Renal Cell Carcinoma: Is There a Role for Adjuvant VEGF-TKI Inhibitors? *Curr Probl Cancer*. 2021 Dec;45(6):100759. doi: 10.1016/j.currproblcancer.2021.100759. Epub 2021 Jun 5. PMID: 34130863.
286. Stabile A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, Pellegrino F, Gandaglia G, Moschini M, Cathala N, Mombet A, Montorsi F, **Briganti A**, Cathelineau X. Reply by Authors. *J Urol*. 2021 Sep;206(3):645. doi:10.1097/JU.0000000000001787.02. Epub 2021 Jun 15. PMID: 34126782.
287. Rajwa P, Schuettfort VM, D'Andrea D, Quhal F, Mori K, Katayama S, Laukhtina E, Pradere B, Motlagh RS, Mostafaei H, Grossmann NC, Huebner N, Aulitzky A, Mundh, **Briganti A**, Karakiewicz PI, Fajkovic H, Shariat SF. Impact of system immune-inflammation Index on oncologic outcomes in patients treated with radical prostatectomy for clinically nonmetastatic prostate cancer. *Urol Oncol*. 2021 Nov;39(11):785.e19-785.e27. doi: 10.1016/j.urolonc.2021.05.002. Epub 2021 Jun 8. PMID: 34116934.
288. Ruvolo CC, Nocera L, Stolzenbach FL, Wenzel M, Würnschimmel C, Fusco F, Palmieri A, Tian Z, Shariat SF, Saad F, **Briganti A**, Imbimbo C, Mirone V, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival in upper tract urothelial carcinoma patients treated with radical nephroureterectomy: A population-based study. *Urol Oncol*. 2021 Nov;39(11):789.e9-789.e17. doi: 10.1016/j.urolonc.2021.04.040. Epub 2021 Jun 4. PMID: 34092481.
289. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Celentano G, Mangiapia F, Tian Z, Shariat SF, Saad F, Chun FHC, **Briganti A**, Longo N, Mirone V, Karakiewicz PI. Comparison between 1973 and 2004/2016 World Health Organization grading in upper tract urothelial carcinoma treated with radical nephroureterectomy. *Int J Clin Oncol*. 2021 Sep;26(9):1707-1713. doi:10.1007/s10147-021-01941-9. Epub 2021 Jun 6. PMID: 34091795; PMCID: PMC8364897.
290. Martini A, Turri F, Barod R, Rocco B, Capitanio U, **Briganti A**, Montorsi F, Mottrie A, Challacombe B, Lagerveld BW, Bensalah K, Abaza R, Badani KK, Mehrazin R, Buscarini M, Larcher A; Junior ERUS/YAU Working Group on Robot-assisted Surgery of the European Association of Urology. Salvage Robot-assisted Renal Surgery for Local Recurrence After Surgical Resection or Renal Mass Ablation: Classification, Techniques, and Clinical Outcomes. *Eur Urol*. 2021 Dec;80(6):730-737. doi: 10.1016/j.eururo.2021.04.003. Epub 2021 Jun 2. PMID: 34088520.
291. Capitanio U, Autorino R, Bandini M, **Briganti A**, Cheng L, Cooperberg MR, Dehò F, Gallina A, Klotz L, Lane BR, Montironi R, Salonia A, Stief C, Tombal B, Montorsi F. Reply to Nicolas Mottet, Olivier

- Rouviere, and Theodorus H. van derKwast. Incidental Prostate Cancer: A Real Need for Expansion in Guidelines? *EurUrol Oncol*. In press: Incidental Prostate Cancer: An Example of How Important Guidelines Are, Especially When Evidence Is Limited. *Eur Urol Oncol*. 2022Apr;5(2):261-262. doi: 10.1016/j.euo.2021.05.004. Epub 2021 Jun 1. PMID:34083164.
292. Martini A, Larcher A, Bravi CA, Capogrosso P, Falagario UG, Fallara G, Pellegrino F, Muttin F, Re C, **Briganti A**, Salonia A, Bertini R, Montorsi F, Capitanio U; Young Academic Urologists working groups on robotic surgery and kidney cancer of the European Association of Urology. How to Select the Optimal Candidates for Renal Mass Biopsy. *Eur Urol Oncol*. 2021 Jun;4(3):506-509. doi:10.1016/j.euo.2020.10.001. Epub 2020 Oct 21. PMID: 34074486.
293. Quhal F, Rajwa P, Mori K, Laukhtina E, Grossmann NC, Schuettfort VM, König F, Aydh A, Motlagh RS, Katayama S, Mostafai H, Pradere B, Marra G, Gontero P, Mathieu R, Karakiewicz PI, **Briganti A**, Shariat SF, Heidenreich A. The role of lymph node dissection in salvage radical prostatectomy for patients with radiation recurrent prostate cancer. *Prostate*. 2021 Aug;81(11):765-771. doi:10.1002/pros.24173. Epub 2021 May 31. PMID: 34057227; PMCID: PMC8361975.
294. Würnschimmel C, Wenzel M, Chierigo F, Flammia RS, Mori K, Tian Z, Shariat SF, Saad F, **Briganti A**, Suardi N, Terrone C, Gallucci M, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Presence of biopsy Gleason pattern 5 + 3 is associated with higher mortality after radical prostatectomy but not after external beam radiotherapy compared to other Gleason Grade Group IV patterns. *Prostate*. 2021 Aug;81(11):778-784. doi: 10.1002/pros.24175. Epub 2021 May 31. PMID: 34057220.
295. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, Tilki D, Graefen M, Kluth LA, **Briganti A**, Mandel P, Montorsi F, Chu FKH, Karakiewicz PI. Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis. *Prostate Cancer Prostatic Dis*. 2022 Feb;25(2):139-148. doi:10.1038/s41391-021-00395-4. Epub 2021 May 30. PMID: 34054128; PMCID: PMC9184262.
296. Montorsi F, Gandaglia G, Dehò F, Gallina A, Moschini M, Salonia A, **Briganti A**. Re: Paolo Dell'Oglio, Elio Mazzone, Edward Lambert, et al. The Effect of Surgical Experience on Perioperative and Oncological Outcomes After Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion: Evidence from a Referral Centre with Extensive Experience in Robotic Surgery. *Eur Urol Focus* 2021;7:352-8. *Eur Urol Focus*. 2021 May 28;S2405-4569(21)00159-0. doi:10.1016/j.euf.2021.05.007. Epub ahead of print. PMID: 34053905.
297. Pederzoli F, Bandini M, Raggi D, Marandino L, Basile G, Alfano M, Colombo R, Salonia A, **Briganti A**, Gallina A, Montorsi F, Necchi A. Is There a Detrimental Effect of Antibiotic Therapy in Patients with Muscle-invasive Bladder Cancer Treated with Neoadjuvant Pembrolizumab? *Eur Urol*. 2021 Sep;80(3):319-322. doi: 10.1016/j.eururo.2021.05.018. Epub 2021 May 27. PMID:34053782.
298. Laukhtina E, Sari Motlagh R, Mori K, Quhal F, Schuettfort VM, Mostafaei H, Katayama S, Grossmann NC, Ploussard G, Karakiewicz PI, **Briganti A**, Abufaraj M, Enikeev D, Pradere B, Shariat SF. Oncologic impact of delaying radical prostatectomy in men with intermediate- and high-risk prostate cancer: a systematic review. *World J Urol*. 2021 Nov;39(11):4085-4099. doi:10.1007/s00345-021-03703-8. Epub 2021 May 28. PMID: 34047825; PMCID: PMC8160557.
299. Stolzenbach LF, Deuker M, Collà Ruvolo C, Nocera L, Tian Z, Maurer T, Steuber T, Tilki D, **Briganti A**, Saad F, Chun FK, Graefen M, Karakiewicz PI. Radical prostatectomy improves survival in selected metastatic prostate cancer patients: A North American population-based study. *Int J Urol*. 2021 Aug;28(8):834-839. doi:10.1111/iju.14586. Epub 2021 May 28. PMID: 34047401.
300. Sorce G, Stabile A, Lucianò R, Motterle G, Scuderi S, Barletta F, Pellegrino F, Cucchiara V, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Jeffrey Karnes R, Guccini I, **Briganti A**. Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions. *BJU Int*. 2022 Feb;129(2):201-207. doi: 10.1111/bju.15498. Epub 2021 Jun 13. PMID: 34038039.
301. Drago D, Andolfo A, Mosca E, Orro A, Nocera L, Cucchiara V, Bellone M, Montorsi F, **Briganti A**. A novel expressed prostatic secretion (EPS)-urine metabolomic signature for the diagnosis of clinically significant prostate cancer. *Cancer Biol Med*. 2021 May 26;18(2):604-15.

doi:10.20892/j.issn.2095-3941.2020.0617. Epub ahead of print. PMID: 34037347; PMCID:PMC8185872.

302. Martini A, Afferi L, Zamboni S, Schultz JG, Lonati C, Mattei A, Karnes RJ, Soligo M, Stabile A, Di Trapani E, De Cobelli O, Simone G, Simeone C, Alvarez-Maestro M, Gandaglia G, Gallina A, Colombo R, **Briganti A**, Montorsi F, Xylinas E, Shariat SF, Moschini M. Oncologic Surveillance for Variant Histology Bladder Cancer after Radical Cystectomy. *J Urol.* 2021 Oct;206(4):885-893. doi:10.1097/JU.0000000000001886. Epub 2021 May 25. PMID: 34032498.
303. Chakiryan NH, Dahmen A, Bandini M, Pederzoli F, Marandino L, Albersen M, Roussel E, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Chahoud J, **Briganti A**, Salvioni R, Montorsi F, Necchi A, Spiess PE. Patterns of Recurrence following Inguinal Lymph Node Dissection for Penile Cancer: Optimizing Surveillance Strategies. *J Urol.* 2021 Oct;206(4):960-969. doi: 10.1097/JU.0000000000001790. Epub 2021 May 25. PMID:34032492.
304. Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Marcq G, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Roupêt M, Krabbe LM, Hendricksen K, Egawa S, **Briganti A**, Moschini M, Graffelle V, Kassouf W, Autorino R, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF. Pretreatment Risk Stratification for Endoscopic Kidney-sparing Surgery in Upper Tract Urothelial Carcinoma: An International Collaborative Study. *Eur Urol.* 2021 Oct;80(4):507-515. doi: 10.1016/j.eururo.2021.05.004. Epub 2021 May 20. PMID:34023164.
305. Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, **Briganti A**, Shariat SF, Mirone V, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Life expectancy in metastatic prostate cancer patients according to
306. racial/ethnic groups. *Int J Urol.* 2021 Aug;28(8):862-869. doi:10.1111/iju.14595. Epub 2021 May 15. PMID: 33993551.
307. Nocera L, Wenzel M, Collà Ruvolo C, Würnschimmel C, Tian Z, Gandaglia G, Fossati N, Chun FK, Mirone V, Graefen M, Shariat SF, Saad F, Montorsi F, **Briganti A**, Karakiewicz PI. The effect of race/ethnicity on active treatment rates among septuagenarian or older low risk prostate cancer patients. *UroOncol.* 2021 Nov;39(11):785.e11-785.e17. doi: 10.1016/j.urolonc.2021.04.004. Epub 2021 May 13. PMID: 33992522.
308. Trevisani F, Di Marco F, Capitanio U, Dell'Antonio G, Cinque A, Larcher A, Lucianò R, Bettiga A, Vago R, **Briganti A**, Salonia A, Montorsi F, Porrini E. Correction to: Renal histology across the stages of chronic kidney disease. *J Nephrol.* 2021 Jun;34(3):961. doi: 10.1007/s40620-021-01059-1. Erratum for: *J Nephrol.* 2021 Jun;34(3):699-707. PMID: 33983625
309. Würnschimmel C, Wenzel M, Collà Ruvolo C, Nocera L, Tian Z, Saad F, **Briganti A**, Shariat SF, Mandel P, Chun FK, Tilki D, Graefen M, Karakiewicz PI. Survival advantage of Asian metastatic prostate cancer patients treated with external beam radiotherapy over other races/ethnicities. *World J Urol.* 2021 Oct;39(10):3781-3787. doi: 10.1007/s00345-021-03720-7. Epub 2021 May 12. PMID:33978812; PMCID: PMC8519889.
310. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher A, Capitanio U, Montorsi F, Shariat SF, Kapoor A, Saad F, **Briganti A**, Karakiewicz PI. Partial nephrectomy in frail patients: Benefits of robot-assisted surgery. *Surg Oncol.* 2021 Sep;38:101588. doi:10.1016/j.suronc.2021.101588. Epub 2021 Apr 22. PMID: 33945961.
311. Stabile A, Barletta F, Motterle G, Pellegrino F, Sorce G, Mazzone E, Scuderi S, Cirulli GO, Cucchiara V, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, **Briganti A**. Optimizing prostate-targeted biopsy schemes in men with multiple mpMRI visible lesions: should we target all suspicious areas? Results of a two institution series. *Prostate Cancer Prostatic Dis.* 2021 Dec;24(4):1137-1142. doi: 10.1038/s41391-021-00371-y. Epub 2021 May 3. PMID: 33941867.
312. Stabile A, Sanchez-Salas R, Tourinho-Barbosa R, Macek P, Pellegrino F, Gandaglia G, Moschini M, Cathala N, Mombet A, Montorsi F, **Briganti A**, Cathelineau X. Association between Lesion Location and Oncologic Outcomes after Focal Therapy for Localized Prostate Cancer Using Either High Intensity Focused Ultrasound or Cryotherapy. *J Urol.* 2021 Sep;206(3):638-645. doi:10.1097/JU.0000000000001787. Epub 2021 Apr 23. PMID: 33890485.

313. Nocera L, Collà Ruvolo C, Stolzenbach LF, Deuker M, Tian Z, Gandaglia G, Fossati N, Abdollah F, Suardi N, Mirone V, Graefen M, Chun FK, Saad F, Montorsi F, **Briganti A**, Karakiewicz PI. Improving the stratification of intermediate risk prostate cancer. *Minerva Urol Nephrol*. 2021 Apr 22. doi:10.23736/S2724-6051.21.04314-7. Epub ahead of print. PMID: 33887893.
314. Rosiello G, Gandaglia G, Scuderi S, Barletta F, Fossati N, Stabile A, Gallina A, Mazzone E, Vitale LM, Pellegrino A, Bravi C, Martini A, Cucchiara V, Karakiewicz PI, Motttrie A, **Briganti A**, Montorsi F. Reducing the Risk of Postoperative Complications After Robot-assisted Radical Prostatectomy in Prostate Cancer Patients: Results of an Audit and Feedback Intervention Following the Implementation of Prospective Data Collection. *Eur Urol Focus*. 2022 Mar;8(2):431-437. doi: 10.1016/j.euf.2021.03.026. Epub 2021 Apr 18. PMID: 33879394.
315. Lonati C, Baumeister P, Ornaghi PI, Di Trapani E, De Cobelli O, Rink M, Karnes RJ, Poyet C, Simone G, Afferi L, Necchi A, **Briganti A**, Montorsi F, Krajewski W, Antonelli A, Cerruto MA, Zamboni S, Simeone C, Mordasini L, Mattei A, Moschini M; EAU-YAU Urothelial Cancer Working Party. Accuracy of Transurethral Resection of the Bladder in Detecting Variant Histology of Bladder Cancer Compared with Radical Cystectomy. *Eur Urol Focus*. 2022 Mar;8(2):457-464. doi: 10.106/j.euf.2021.04.005. Epub 2021 Apr 16. PMID: 33867307.
316. Mazzone E, Stabile A, Sorce G, Pellegrino F, Barletta F, Motterle G, Scuderi S, Cirulli GO, Cucchiara V, Brembilla G, Esposito A, Gandaglia G, Fossati N, De Cobelli F, Montorsi F, Karnes RJ, Guccini I, **Briganti A**. Age and gleason score upgrading between prostate biopsy and radical prostatectomy: Is this still true in the multiparametric resonance imaging era? *Urol Oncol*. 2021 Nov;39(11):784.e1-784.e9. doi: 10.1016/j.urolonc.2021.03.013. Epub 2021 Apr 15. PMID: 33865687.
317. Bravi CA, Fossati N, Gandaglia G, Suardi N, Montorsi F, **Briganti A**. The Importance of an Adequate Surgical Template During Salvage Lymph Node Dissection for Node-Recurrent Prostate Cancer. *J Nucl Med*. 2021 Jul 1;62(7):1021. doi: 10.2967/jnumed.121.262104. Epub 2021 Apr 16. PMID: 33863822.
318. Bandini M, Barbagli G, Leni R, Cirulli GO, Basile G, Balò S, Montorsi F, Sansalone S, Salonia A, **Briganti A**, Butnaru D, Lazzeri M. Assessing in-hospital morbidity after urethroplasty using the European Association of Urology Quality Criteria for standardized reporting. *World J Urol*. 2021 Oct;39(10):3921-3930. doi: 10.1007/s00345-021-03692-8. Epub 2021 Apr 15. PMID: 33855598.
319. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Graefen M, Kluth LA, Roos FC, Mandel P, Chun FKH, Karakiewicz PI. Overall Survival After Systemic Treatment in High-volume Versus Low-volume Metastatic Hormone-sensitive Prostate Cancer: Systematic Review and Network Meta-analysis. *Eur Urol Focus*. 2022 Mar;8(2):399-408. doi: 10.1016/j.euf.2021.04.003. Epub 2021 Apr 11. PMID: 33853754.
320. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, **Briganti A**, Graefen M, Becker A, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Salvage Radical Prostatectomy: Baseline Prostate Cancer Characteristics and Survival Across SEER Registries. *Clin Genitourin Cancer*. 2021 Aug;19(4):e255 e263. doi: 10.1016/j.clgc.2021.03.015. Epub 2021 Mar 19. PMID: 33849813.
321. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Reply by Authors. *J Urol*. 2021 Jul;206(1):79. doi: 10.1097/JU.0000000000001695.03. Epub 2021 Apr 6. PMID: 33820427.
322. Capitanio U, Autorino R, Bandini M, **Briganti A**, Cheng L, Cooperberg MR, Dehò F, Gallina A, Klotz L, Lane B, Montironi R, Salonia A, Stief C, Tombal B, Montorsi F. Incidental Prostate Cancer (cT1a-cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. *Eur Urol Oncol*. 2021 Apr 1:S2588-9311(21)00049-3. doi: 10.1016/j.euo.2021.03.005. Epub ahead of print. PMID: 33814342.
323. Damascelli A, Gallivanone F, Cristel G, Cava C, Interlenghi M, Esposito A, Brembilla G, **Briganti A**, Montorsi F, Castiglioni I, De Cobelli F. Advanced Imaging Analysis in Prostate MRI: Building a Radiomic Signature to Predict Tumor Aggressiveness. *Diagnostics (Basel)*. 2021 Mar 26;11(4):594. doi: 10.3390/diagnostics11040594. PMID: 33810222; PMCID: PMC8065545.
324. Necchi A, de Jong JJ, Raggi D, **Briganti A**, Marandino L, Gallina A, Bandini M, Dabbas B, Davicioni E, Capitanio U, Montorsi F, Seiler R, Wright JL, Lotan Y, Black PC, Gibb EA. Molecular

- Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. *Eur Urol*. 2021 Aug;80(2):149-159. doi: 10.1016/j.eururo.2021.03.014. Epub 2021 Mar 28. PMID: 33785257.
325. Marcq G, Foerster B, Abufaraj M, Matin SF, Azizi M, Gupta M, Li WM, Seisen T, Clinton T, Xylinas E, Mir MC, Schweitzer D, Mari A, Kimura S, Bandini M, Mathieu R, Ku JH, Guruli G, Grabbert M, Czech AK, Muilwijk T, Pycha A, D'Andrea D, Petros FG, Spiess PE, Bivalacqua T, Wu WJ, Rouprêt M, Krabbe LM, Hendricksen K, Egawa S, **Briganti A**, Moschini M, Graffelle V, Autorino R, John P, Heidenreich A, Chlosta P, Joniau S, Soria F, Pierorazio PM, Shariat SF, Kassouf W. Novel Classification for Upper Tract Urothelial Carcinoma to Better Risk- stratify Patients Eligible for Kidney-sparing Strategies: An International Collaborative Study. *Eur Urol Focus*. 2022 Mar;8(2):491-497. doi: 10.1016/j.euf.2021.03.018. Epub 2021 Mar 26. PMID: 33773965.
326. Basile G, Pederzoli F, Bandini M, Raggi D, Gallina A, Salonia A, **Briganti A**, Montorsi F, Spiess PE, Necchi A. Intermediate- and high-risk nonmuscle invasive bladder cancer: Where do we stand? *Urol Oncol*. 2021 Oct;39(10):631-641. doi: 10.1016/j.urolonc.2021.02.020. Epub 2021 Mar 22. PMID: 33766463.
327. Moschini M, Zamboni S, Afferi L, Pradere B, Abufaraj M, Soria F, D'Andrea D, Roupret M, De la Taille A, Simeone C, Mattei A, Mathieu R, Bensalah K, Wirth MP, Montorsi F, **Briganti A**, Gallina A, Simone G, Gallucci M, Di Bona C, Marra G, Mari A, Di Trapani E, Alvarez Maestro M, Krajewski W, Shariat SF, Xylinas E, Baumeister P. Comparing oncological outcomes of laparoscopic vs open radical nephroureterectomy for the treatment of upper tract urothelial carcinoma: A propensity score-matched analysis. *Arab J Urol*. 2020 Sep 4;19(1):31-36. doi: 10.1080/2090598X.2020.1817720. PMID: 33763246; PMCID: PMC7954493.
328. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Mandel P, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Incidence rates and contemporary trends in primary urethral cancer. *Cancer Causes Control*. 2021 Jun;32(6):627-634. doi: 10.1007/s10552-021-01416-2. Epub 2021 Mar 22. PMID: 33751293; PMCID: PMC8089076.
329. Cacciamani GE, Maas M, Nassiri N, Ortega D, Gill K, Dell'Oglio P, Thalmann GN, Heidenreich A, Eastham JA, Evans CP, Karnes RJ, De Castro Abreu AL, **Briganti A**, Artibani W, Gill I, Montorsi F. Impact of Pelvic Lymph Node Dissection and Its Extent on Perioperative Morbidity in Patients Undergoing Radical Prostatectomy for Prostate Cancer: A Comprehensive Systematic Review and Meta analysis. *Eur Urol Oncol*. 2021 Apr;4(2):134-149. doi: 10.1016/j.euo.2021.02.001 Epub 2021 Mar 6. PMID: 33745687.
330. Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Califano G, Tian Z, Verze P, Shariat SF, Saad F, **Briganti A**, Mirone V, Karakiewicz PI. Tumor Size Predicts Muscle-invasive and Non-organ-confined Disease in Upper Tract Urothelial Carcinoma at Radical Nephroureterectomy. *Eur Urol Focus*. 2022 Mar;8(2):498-505. doi: 10.1016/j.euf.2021.03.003. Epub 2021 Mar 15. PMID: 33737024.
331. Montorsi F, Martini A, Gandaglia G, Fossati N, Stabile A, Dehò F, Salonia A, **Briganti A**. Metastatic hormone-sensitive prostate cancer: local treatment strategies. *World J Urol*. 2022 Mar;40(3):881-882. doi: 10.1007/s00345-021-03605-9. Epub 2021 Mar 17. PMID: 33730240.
332. Trevisani F, Di Marco F, Raggi D, Bettiga A, Vago R, Larcher A, Cinque A, Salonia A, **Briganti A**, Capitanio U, Necchi A, Montorsi F. Renal function outcomes in patients with muscle-invasive bladder cancer treated with neoadjuvant pembrolizumab and radical cystectomy in the PURE-01 study. *Int J Cancer*. 2021 Jul 1;149(1):186-190. doi: 10.1002/ijc.33554. Epub 2021 Mar 26. PMID: 33720424.
333. Collà Ruvolo C, Stolzenbach LF, Nocera L, Deuker M, Wenzel M, Tian Z, La Rocca R, Creta M, Capece M, Saad F, Shariat SF, Tilki D, **Briganti A**, Mirone V, Karakiewicz PI. Higher Cancer Mortality in Rural Upper Urinary Tract Urothelial Carcinoma Patients. *Urol Int*. 2021;105(7-8):624-630. doi: 10.1159/000513361. Epub 2021 Mar 12. PMID: 33709970.
334. Montorsi F, Gandaglia G, **Briganti A**. The Long-Term Risks of Metastases in Men on Active Surveillance for Early Stage Prostate Cancer. *Letter. J Urol*. 2021 Jul;206(1):173. doi: 10.1097/JU.0000000000001710. Epub 2021 Mar 8. PMID: 33683935.
335. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. Racial/Ethnic Disparities in Tumor Characteristics and Treatments in Favorable and Unfavorable Intermediate Risk Prostate Cancer. *J*

- Urol. 2021 Jul;206(1):69-79. doi: 10.1097/JU.0000000000001695. Epub 2021 Mar 8. PMID: 33683934.
336. Manafi-Farid R, Harsini S, Saidi B, Ahmadzadehfar H, Herrmann K, **Briganti A**, Walz J, Beheshti M. Factors predicting biochemical response and survival benefits following radioligand therapy with [¹⁷⁷Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review. *Eur J Nucl Med Mol Imaging*. 2021 Nov;48(12):4028-4041. doi: 10.1007/s00259-021-05237-y. Epub 2021 Mar 6. PMID: 33677734; PMCID: PMC8484081.
337. Miura N, Mori K, Laukhtina E, Schuettfort VM, Abufaraj M, Teoh JYC, Luzzago S, Stolzenbach F, Deuker M, Karakiewicz PI, **Briganti A**, Enikeev DV, Rouprêt M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, Saika T, Shariat SF. Prognostic value of the preoperative albumin-globulin ratio in patients with upper urinary tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Jpn J Clin Oncol*. 2021 Jul 1;51(7):1149-1157. doi: 10.1093/jjco/hyab023. PMID: 33667307.
338. Wenzel M, Würnschimmel C, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, **Briganti A**, Graefen M, Kluth LA, Mandel P, Chun FKH, Karakiewicz PI. The effect of lymph node dissection on cancer-specific survival in salvage radical prostatectomy patients. *Prostate*. 2021 May;81(6):339-346. doi: 10.1002/pros.24112. Epub 2021 Mar 5. PMID: 33666271.
339. Nocera L, Collà Ruvolo C, Stolzenbach LF, Wenzel M, Tian Z, Larcher A, Capitanio U, Mirone V, Tilki D, Chun FKH, Kapoor A, Shariat SF, Saad F, Montorsi F, **Briganti A**, Karakiewicz PI. Tumor Stage and Substage Predict Cancer-specific Mortality After Nephrectomy for Nonmetastatic Renal Cancer: Histological Subtype-specific Validation. *Eur Urol Focus*. 2022 Jan;8(1):182-190. doi: 10.1016/j.euf.2021.02.009. Epub 2021 Feb 27. PMID: 33653677.
340. **Briganti A**, Gandaglia G, Graefen M, Joniau S, Karnes RJ, Montorsi F. Re: Jean F.P. Lestingi, Giuliano B, Guglielmetti, Quoc-Dien Trinh, et al. Extended Versus Limited Pelvic Lymph Node Dissection During Radical Prostatectomy for Intermediate- and High-risk Prostate Cancer: Early Oncological Outcomes from a Randomized Phase 3 Trial. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2020.11.040>: Time for a Change? Clinically Meaningful Reasons Why We Will Continue Performing Extended Pelvic Lymph Node Dissection in Selected Patients with Prostate Cancer. *Eur Urol*. 2021 May;79(5):e154-e156. doi: 10.1016/j.eururo.2021.02.024. Epub 2021 Feb 23. PMID: 33637367.
341. Collà Ruvolo C, Würnschimmel C, Wenzel M, Nocera L, Califano G, Tian Z, Shariat SF, Saad F, Chun FKH, **Briganti A**, Verze P, Imbimbo C, Mirone V, Karakiewicz PI. Comparison between 1973 and 2004/2016 WHO grading systems in patients with Ta urothelial carcinoma of urinary bladder. *J Clin Pathol*. 2022 May;75(5):333-337. doi: 10.1136/jclinpath-2021-207400. Epub 2021 Feb 23. PMID: 33622681.
342. Chakiryan NH, Dahmen A, Cucchiara V, **Briganti A**, Montorsi F, Salonia A, Spiess PE, Necchi A. Reliability of Serum Tumor Marker Measurement to Diagnose Recurrence in Patients with Clinical Stage I Nonseminomatous Germ Cell Tumors Undergoing Active Surveillance: A Systematic Review. *J Urol*. 2021 Jun;205(6):1569-1576. doi: 10.1097/JU.0000000000001685. Epub 2021 Feb 22. PMID: 33617328.
343. Würnschimmel C, Collà Ruvolo C, Nocera L, Wenzel M, Tian Z, Saad F, **Briganti A**, Shariat SF, Mirone V, Chun FKH, Tilki D, Graefen M, Karakiewicz PI. Race/Ethnicity Determines Life Expectancy in Surgically Treated T1aN0M0 Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2022 Jan;8(1):191-199. doi: 10.1016/j.euf.2021.02.004. Epub 2021 Feb 18. PMID: 33610487.
344. Pecoraro A, Deuker M, Rosiello G, Stolzenbach F, Luzzago S, Tian Z, Shariat SF, Saad F, **Briganti A**, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Comparison between small renal masses 0-2 cm vs. 2.1-4 cm in size: A population-based study. *Urol Oncol*. 2021 Apr;39(4):239.e1-239.e7. doi: 10.1016/j.urolonc.2021.01.003. Epub 2021 Feb 16. PMID: 33602621.
345. Mori K, Resch I, Miura N, Laukhtina E, Schuettfort VM, Pradere B, Katayama S, D'Andrea D, Kardoust Parizi M, Abufaraj M, Fukuokaya W, Collà Ruvolo C, Luzzago S, Knipper S, Palumbo C, Karakiewicz PI, **Briganti A**, Enikeev DV, Rouprêt M, Margulis V, Egawa S, Shariat SF. Prognostic role of the systemic immune-inflammation index in upper tract urothelial carcinoma treated with radical nephroureterectomy: results from a large multicenter international collaboration. *Cancer Immunol*

- Immunother. 2021 Sep;70(9):2641-2650. doi: 10.1007/s00262-021-02884-w. Epub 2021 Feb 16. PMID: 33591412; PMCID: PMC8360829.
346. Wenzel M, Deuker M, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, **Briganti A**, Becker A, Kluth LA, Chun FKH, Karakiewicz PI. Comparison Between Urothelial and Non-Urothelial Urethral Cancer. *Front Oncol.* 2021 Jan 29;10:629692. doi: 10.3389/fonc.2020.629692. PMID: 33585257; PMCID: PMC788005
347. Devos G, Vansevenant B, De Meerleer G, Clinckaert A, Devlies W, Claessens F, Graefen M, Steuber T, **Briganti A**, de la Taille A, Van Poppel H, Joniau S. Neoadjuvant treatment with androgen receptor signaling inhibitors prior to radical prostatectomy: a systematic review. *World J Urol.* 2021 Sep;39(9):3177-3185. doi: 10.1007/s00345-021-03611-x. Epub 2021 Feb 12. PMID: 33580296.
348. Montorsi F, Fossati N, Bravi CA, Gandaglia G, Suardi N, **Briganti A**. Re: Sophie Knipper, Luigi Ascalone, Benjamin Ziegler, et al. Salvage Surgery in Patients with Local Recurrence After Radical Prostatectomy. *Eur Urol* 2021;79:537-44: Surgical Treatment of Local Recurrence Following Radical Prostatectomy: Reality or Illusion? *Eur Urol.* 2021 May;79(5):e132-e133. doi: 10.1016/j.eururo.2021.01.035. Epub 2021 Feb 9. PMID: 33579576.
349. Beyer K, Moris L, Lardas M, Haire A, Barletta F, Scuderi S, Vradi E, Gandaglia G, Omar MI, MacLennan S, Zong J, Farahmand B, MacLennan SJ, Devcseri Z, Asiimwe A, Collette L, Bjartell A, Ndow J, **Briganti A**, Van Hemelrijck M; PIONEER Consortium. Diagnostic and prognostic factors in patients with prostate cancer: a systematic review protocol. *BMJ Open.* 2021 Feb 11;11(2):e040531. doi: 10.1136/bmjopen-2020-040531. PMID: 33574142; PMCID: PMC7880102.
350. Krajewski W, Nowak Ł, Moschini M, Poletajew S, Chorbińska J, Necchi A, Montorsi F, **Briganti A**, Sanchez-Salas R, Shariat SF, Palou J, Babjuk M, Teoh JY, Soria F, Pradere B, Ornaghi PI, Pawlak A, Dembowski J, Zdrojowy R. Impact of Adjuvant Chemotherapy on Survival of Patients with Advanced Residual Disease at Radical Cystectomy following Neoadjuvant Chemotherapy: Systematic Review and Meta-Analysis. *J Clin Med.* 2021 Feb 8;10(4):651. doi: 10.3390/jcm10040651. PMID: 33567656; PMCID: PMC7915645.
351. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Sex- and age-related differences in the distribution of bladder cancer metastases. *Jpn J Clin Oncol.* 2021 May 28;51(6):976-983. doi: 10.1093/jjco/hyaa273. PMID: 33558890.
352. Montorsi F, Stabile A, Gandaglia G, Deho F, Gallina A, **Briganti A**. Letter - Can micro-ultrasound be the new first-choice test for patients with a suspicion of prostate cancer? RE: Comparison of micro-ultrasound and multiparametric magnetic resonance imaging for prostate cancer, *CUAJ*, Jan 2021 (with author reply). *Can Urol Assoc J.* 2021 Feb;15(2):E127-E128. doi: 10.5489/cuaj.7038. PMID: 33556314; PMCID: PMC7864719.
353. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Martin T, Tian Z, Gallina A, Montorsi F, Black P, Kassouf W, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Racial differences in the distribution of bladder cancer metastases: a population-based analysis. *Cent European J Urol.* 2020;73(4):407-415. doi: 10.5173/cej.2020.0269. Epub 2020 Oct 31. PMID: 33552564; PMCID: PMC7848828.
354. Mazzone E, Dell'Oglio P, Grivas N, Wit E, Donswijk M, **Briganti A**, Leeuwen FV, Poel HV. Diagnostic Value, Oncologic Outcomes, and Safety Profile of Image- Guided Surgery Technologies During Robot-Assisted Lymph Node Dissection with Sentinel Node Biopsy for Prostate Cancer. *J Nucl Med.* 2021 Oct;62(10):1363-1371. doi: 10.2967/jnumed.120.259788. Epub 2021 Feb 5. PMID: 33547208; PMCID: PMC8724888.
355. Ventimiglia E, Villa L, Doizi S, **Briganti A**, Proietti S, Giusti G, Montorsi F, Montanari E, Traxer O, Salonia A. Laser Lithotripsy: The Importance of Peak Power and Pulse Modulation. *Eur Urol Focus.* 2021 Jan;7(1):22-25. doi: 10.1016/j.euf.2021.01.012. Epub 2021 Jan 30. PMID: 33531287.
356. Wenzel M, Nocera L, Collà Ruvolo C, Würnschimmel C, Tian Z, Shariat SF, Saad F, **Briganti A**, Tilki D, Mandel P, Kluth LA, Chun FKH, Karakiewicz PI. Sex- Related Differences Include Stage, Histology, and Survival in Urethral Cancer Patients. *Clin Genitourin Cancer.* 2021 Apr;19(2):135-143. doi: 10.1016/j.clgc.2020.12.001. Epub 2021 Jan 6. PMID: 33526327.
357. Rosiello G, Pecoraro A, Deuker M, Stolzenbach LF, Martin T, Tian Z, Larcher A, Capitanio U, Montorsi F, Shariat SF, Kapoor A, Saad F, **Briganti A**, Karakiewicz PI. The impact of sex and age on

- distribution of metastases in patients with renal cell carcinoma. *Int J Clin Oncol*. 2021 May;26(5):962-970. doi: 10.1007/s10147-021-01874-3. Epub 2021 Jan 30. PMID: 33515351.
358. Dunsmore J, Duncan E, Mariappan P, de Bruin M, MacLennan S, Dimitropoulos K, Kasivisvanathan V, Mostafid H, **Briganti A**, N'Dow J, MacLennan S. What influences adherence to guidance for postoperative instillation of intravesical chemotherapy to patients with bladder cancer? *BJU Int*. 2021 Aug;128(2):225-235. doi: 10.1111/bju.15336. Epub 2021 Mar 28. PMID: 33450116
359. Afferi L, Abufaraj M, Soria F, D'Andrea D, Xylinas E, Seisen T, Roupret M, Lonati C, DE LA Taille A, Peyronnet B, Laukhtina E, Pradere B, Mari A, Krajewski W, Alvarez-Maestro M, Kikuchi E, Shigeta K, Chlosta P, Montorsi F, **Briganti A**, Simone G, Ornaghi PI, Cerruto MA, Antonelli A, Matsumoto K, Karakiewicz PI, Mordasini L, Mattei A, Shariat SF, Moschini M. A comparison of perioperative outcomes of laparoscopic versus open nephroureterectomy for upper tract urothelial carcinoma: a propensity score matching analysis. *Minerva Urol Nephrol*. 2022 Feb;74(1):49-56. doi: 10.23736/S2724-6051.20.04127-2. Epub 2021 Jan 13. PMID: 33439575.
360. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. *Surg Oncol*. 2021 Jun;37:101519. doi: 10.1016/j.suronc.2020.12.013. Epub 2021 Jan 3. PMID: 33429324.
361. Gandaglia G, Leni R, Fossati N, Cucchiara V, Montorsi F, **Briganti A**. Prostate-specific Membrane Antigen Imaging in Clinical Guidelines: European Association of Urology, National Comprehensive Cancer Network, and Beyond. *Eur Urol Focus*. 2021 Mar;7(2):245-249. doi: 10.1016/j.euf.2020.12.014. Epub 2021 Jan 7. PMID: 33423971.
362. Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. *Surg Oncol*. 2021 Mar;36:131-137. doi: 10.1016/j.suronc.2020.12.004. Epub 2020 Dec 11. PMID: 33401103.
363. Trevisani F, Di Marco F, Capitanio U, Dell'Antonio G, Cinque A, Larcher A, Lucianò R, Bettiga A, Vago R, **Briganti A**, Salonia A, Montorsi F, Porrini E. Renal histology across the stages of chronic kidney disease. *J Nephrol*. 2021 Jan 4. doi: 10.1007/s40620-020-00905-y. Epub ahead of print. PMID: 33394348.
364. Mazzone E, Stabile A, Pellegrino F, Basile G, Cignoli D, Cirulli GO, Sorce G, Barletta F, Scuderi S, Bravi CA, Cucchiara V, Fossati N, Gandaglia G, Montorsi F, **Briganti A**. Positive Predictive Value of Prostate Imaging Reporting and Data System Version 2 for the Detection of Clinically Significant Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2020 Dec 23:S2588-9311(20)30212-1. doi: 10.1016/j.euo.2020.12.004. Epub ahead of print. PMID: 33358543.
365. Busetto GM, Del Giudice F, Mari A, Sperduti I, Longo N, Antonelli A, Cerruto MA, Costantini E, Carini M, Minervini A, Rocco B, Artibani W, Porreca A, Porphiglia F, Damiano R, De Sio M, Arcaniolo D, Cimino S, Russo GI, Lucarelli G, Di Tonno P, Gontero P, Soria F, Trombetta C, Liguori G, Scarpa RM, Papalia R, Terrone C, Borghesi M, Verze P, Madonia M, De Lisa A, Bove P, Guazzoni G, Lughezzani G, Racioppi M, Di Gianfrancesco L, Brunocilla E, Schiavina R, Simeone C, Vecchia A, Montorsi F, **Briganti A**, Dal Moro F, Pavone C, Serretta V, Di Stasi SM, Galosi AB, Schips L, Marchioni M, Montanari E, Carrieri G, Cormio L, Greco F, Musi G, Maggi M, Conti SL, Tubaro A, De Berardinis E, Sciarra A, Gallucci M, Mirone V, de Cobelli O, Ferro M. How Can the COVID-19 Pandemic Lead to Positive Changes in Urology Residency? *Front Surg*. 2020 Nov 24;7:563006. doi: 10.3389/fsurg.2020.563006. PMID: 33330604; PMCID: PMC7732553.
366. Wenzel M, Deuker M, Stolzenbach F, Nocera L, Collà Ruvolo C, Tian Z, Shariat SF, Saad F, **Briganti A**, Kluth LA, Chun FKH, Karakiewicz PI. The effect of race/ethnicity on histological subtype distribution, stage at presentation and cancer specific survival in urethral cancer. *Urol Oncol*. 2020 Dec 10:S1078-1439(20)30618-9. doi: 10.1016/j.urolonc.2020.11.031. Epub ahead of print. PMID: 33309509.
367. Montorsi F, Ventimiglia E, Capogrosso P, **Briganti A**, Salonia A. Re: Thulium Laser Transurethral Vaporesection of the Prostate Versus Transurethral Resection of the Prostate for Men

- with Lower Urinary Tract Symptoms or Urinary Retention (UNBLOCS): A Randomised Controlled Trial. *Eur Urol*. 2020 Dec 9:S0302-2838(20)30936-2. doi: 10.1016/j.eururo.2020.11.035. Epub ahead of print. PMID: 33309032.
368. Collà Ruvolo C, Nocera L, Stolzenbach LF, Wenzel M, Cucchiara V, Tian Z, Shariat SF, Saad F, Longo N, Montorsi F, **Briganti A**, Mirone V, Karakiewicz PI. Incidence and Survival Rates of Contemporary Patients with Invasive Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2020 Dec 5:S2588-9311(20)30181-4. doi: 10.1016/j.euo.2020.11.005. Epub ahead of print. PMID: 33293235.
369. Montorsi F, Gandaglia G, Fossati N, Dehò F, **Briganti A**. Re: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and 68Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. *BJU Int*. 2020 Nov 29. doi: 10.1111/bju.15308. Epub ahead of print. PMID: 33249715.
370. Nini A, Muttin F, Cianflone F, Carenci C, Lucianò R, Catena M, Larcher A, Salvioni M, Cazzaniga W, Pederzoli F, Matloob R, Colombo R, Paganelli M, Salonia A, **Briganti A**, Doglioni C, Zangrillo A, De Cobelli F, Rigatti P, Freschi M, Cornero G, Nicoletti R, Aldrighetti L, Montorsi F, Capitanio U, Bertini R. Perioperative and oncologic outcomes of open radical nephrectomy and inferior vena cava thrombectomy with liver mobilization and Pringle maneuver for Mayo III level tumor thrombus: single institution experience. *Minerva Urol Nefrol*. 2020 Nov 27. doi: 10.23736/S0393-2249.20.03844-8. Epub ahead of print. PMID: 33242949.
371. Gacci M, Greco I, Artibani W, Bassi P, Bertoni F, Bracarda S, **Briganti A**, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Maggi S, Magrini SM, Mirone V, Montironi R, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Salonia A, Simonato A, Serni S, Tubaro A, Zagonel V, Crepaldi G; Pros-IT CNR Study Group. The waiting time for prostate cancer treatment in Italy: analysis from the Pros-IT CNR study. *Minerva Urol Nefrol*. 2020 Nov 17. doi: 10.23736/S0393-2249.20.03925-9. Epub ahead of print. PMID: 33200896.
372. Bandini M, Ross JS, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres BA, Hakenberg OW, Heidenreich A, Salvioni R, Catanzaro M, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, **Briganti A**, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Association Between Human Papillomavirus Infection and Outcome of Perioperative Nodal Radiotherapy for Penile Carcinoma. *Eur Urol Oncol*. 2020 Nov 13:S2588-9311(20)30176-0. doi: 10.1016/j.euo.2020.10.011. Epub ahead of print. PMID: 33199252.
373. Zuppone S, Bresolin A, Spinelli AE, Fallara G, Lucianò R, Scarfò F, Benigni F, Di Muzio N, Fiorino C, **Briganti A**, Salonia A, Montorsi F, Vago R, Cozzarini C. Pre-clinical Research on Bladder Toxicity After Radiotherapy for Pelvic Cancers: State-of-the Art and Challenges. *Front Oncol*. 2020 Oct 22;10:527121. doi: 10.3389/fonc.2020.527121. PMID: 33194587; PMCID: PMC7642999.
374. Stolzenbach LF, Rosiello G, Deuker M, Martin T, Knipper S, Tian Z, **Briganti A**, Zorn KC, Saad F, Chun FKH, Graefen M, Karakiewicz PI. External beam radiation therapy improves survival in elderly metastatic prostate cancer patients with low PSA. *Urol Oncol*. 2020 Nov 11:S1078-1439(20)30483-X. doi: 10.1016/j.urolonc.2020.10.011. Epub ahead of print. PMID: 33189532.
375. Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, **Briganti A**, Montorsi F, Alessi A, Necchi A. Incidence and Clinical Impact of Inflammatory Fluorodeoxyglucose Positron Emission Tomography Uptake After Neoadjuvant Pembrolizumab in Patients with Organ-confined Bladder Cancer Undergoing Radical Cystectomy. *Eur Urol Focus*. 2020 Nov 7:S2405-4569(20)30287-X. doi: 10.1016/j.euf.2020.10.003. Epub ahead of print. PMID: 33172772.
376. Rosiello G, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, Shariat SF, Kapoor A, Saad F, **Briganti A**, Karakiewicz PI. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1-4 cm renal cell carcinomas. *Cancer Causes Control*. 2020 Nov 9. doi: 10.1007/s10552-020-01364-3. Epub ahead of print. PMID: 33169306.
377. Nocera L, Stolzenbach LF, Ruvolo CC, Wenzel M, Tian Z, Rosiello G, Bravi CA, Candela L, Basile G, Larcher A, Shariat SF, Bertini R, Capitanio U, Salonia A, Montorsi F, **Briganti A**, Karakiewicz PI. Predicting the risk of pT3a stage in cT1 clear cell renal cell carcinoma. *Eur J Surg Oncol*. 2020 Nov 5:S0748-7983(20)30877-5. doi: 10.1016/j.ejso.2020.10.040. Epub ahead of print. PMID: 33168336.

378. Tellini R, Mari A, Muto G, Cacciamani GE, Ferro M, Stangl-Kremser J, Campi R, Soria F, Rink M, Xylinas E, Minervini A, **Briganti A**, Montorsi F, Roupret M, Shariat SF, Moschini M; European Association of Urology–Young Academic Urologists Urothelial Carcinoma Working Group (EAU-YAU). Impact of Smoking Habit on Perioperative Morbidity in Patients Treated with Radical Cystectomy for Urothelial Bladder Cancer: A Systematic Review and Meta-analysis. *Eur Urol Oncol*. 2020 Nov 4:S2588-9311(20)30171-1. doi: 10.1016/j.euo.2020.10.006. Epub ahead of print. PMID: 33160975.
379. Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, Tilki D, **Briganti A**, Saad F, Mirone V, Chun FKH, Graefen M, Karakiewicz PI. Differences between rural and urban prostate cancer patients. *World J Urol*. 2020 Nov 5. doi: 10.1007/s00345-020-03483-7. Epub ahead of print. PMID: 33155063.
380. Surcel C, Mirvald C, Tsaor I, Borgmann H, Heidegger I, Labanaris AP, Sinescu I, Tilki D, Ploussard G, **Briganti A**, Montorsi F, Mathieu R, Valerio M, Jinga V, Badescu D, Radavoi D, van den Bergh RCN, Gandaglia G, Kretschmer A; as part of the EAU-YAU PCa Working Party. Contemporary role of palliative cystoprostatectomy or pelvic exenteration in advanced symptomatic prostate cancer. *World J Urol*. 2020 Nov 1. doi: 10.1007/s00345-020-03493-5. Epub ahead of print. PMID: 33135127.
381. Cornford P, Smith EJ, MacLennan S, Pereira-Azevedo N, Roobol MJ, Lumen N, Fullwood L, Duncan E, Dunsmore J, Plass K, Ribal MJ, Knoll T, Bjartell A, Van Poppel H, N'Dow J, **Briganti A**; Pan-European National Urological Society IMAGINE Collaborative. IMAGINE-IMPACT Assessment of Guidelines Implementation and Education: The Next Frontier for Harmonising Urological Practice Across Europe by Improving Adherence to Guidelines. *Eur Urol*. 2020 Oct 29:S0302-2838(20)30788-0. doi: 10.1016/j.eururo.2020.10.011. Epub ahead of print. PMID: 33129581.
382. Rosiello G, Larcher A, Fallara G, Basile G, Cignoli D, Colandrea G, Re C, Trevisani F, Karakiewicz PI, Salonia A, Bertini R, **Briganti A**, Montorsi F, Capitanio U. The impact of intraoperative bleeding on the risk of chronic kidney disease after nephron-sparing surgery. *World J Urol*. 2020 Oct 29. doi: 10.1007/s00345-020-03504-5. Epub ahead of print. PMID: 33123741.
383. Dess RT, Suresh K, Zelefsky MJ, Freedland SJ, Mahal BA, Cooperberg MR, Davis BJ, Horwitz EM, Terris MK, Amling CL, Aronson WJ, Kane CJ, Jackson WC, Hearn JWD, Deville C, DeWeese TL, Greco S, McNutt TR, Song DY, Sun Y, Mehra R, Kaffenberger SD, Morgan TM, Nguyen PL, Feng FY, Sharma V, Tran PT, Stish BJ, Pisansky TM, Zaorsky NG, Moraes FY, Berlin A, Finelli A, Fossati N, Gandaglia G, **Briganti A**, Carroll PR, Karnes RJ, Kattan MW, Schipper MJ, Spratt DE. Development and Validation of a Clinical Prognostic Stage Group System for Nonmetastatic Prostate Cancer Using Disease-Specific Mortality Results From the International Staging Collaboration for Cancer of the Prostate. *JAMA Oncol*. 2020 Dec 1;6(12):1912-1920. doi: 10.1001/jamaoncol.2020.4922. PMID: 33090219; PMCID: PMC7582232.
384. Marandino L, Capozza A, Bandini M, Raggi D, Farè E, Pederzoli F, Gallina A, Capitanio U, Bianchi M, Gandaglia G, Fossati N, Colecchia M, Giannatempo P, Serafini G, Padovano B, Salonia A, **Briganti A**, Montorsi F, Alessi A, Necchi A. [18F]Fluoro-Deoxy-Glucose positron emission tomography to evaluate lymph node involvement in patients with muscle-invasive bladder cancer receiving neoadjuvant pembrolizumab. *Urol Oncol*. 2020 Oct 15:S1078-1439(20)30472-5. doi: 10.1016/j.urolonc.2020.09.035. Epub ahead of print. PMID: 33071107.
385. Pradere B, D'Andrea D, Schuettfort VM, Foerster B, Quhal F, Mori K, Abufaraj M, Margulis V, Deuker M, **Briganti A**, Muilwijk T, Hendricksen K, Lotan Y, Karakiewicz P, F Shariat S; UTUC collaboration. Pre-therapy serum albumin-to-globulin ratio in patients treated with neoadjuvant chemotherapy and radical nephroureterectomy for upper tract urothelial carcinoma. *World J Urol*. 2020 Oct 16. doi: 10.1007/s00345-020-03479-3. Epub ahead of print. PMID: 33067726.
386. Montorsi F, Gandaglia G, Würnschimmel C, Graefen M, **Briganti A**, Huland H. Re: Paolo Afonso de Carvalho, João A.B.A. Barbosa, Giuliano B. Guglielmetti, et al. Retrograde Release of the Neurovascular Bundle with Preservation of Dorsal Venous Complex During Robot-assisted Radical Prostatectomy: Optimizing Functional Outcomes. *Eur Urol* 2020;77:628-35: Incredible Results for Robot-assisted Nerve-sparing Radical Prostatectomy in Prostate Cancer Patients. *Eur Urol*. 2020 Oct 6:S0302-2838(20)30690-4. doi: 10.1016/j.eururo.2020.08.039. Epub ahead of print. PMID: 33067018.

387. Foerster B, Abufaraj M, Mari A, Seisen T, Bandini M, Schweitzer D, Czech AK, Moschini M, D'Andrea D, Bianchi M, Hendricksen K, Rouprêt M, **Briganti A**, van Rhijn BWG, Chłosta P, Colin P, John H, Shariat SF. The Performance of Tumor Size as Risk Stratification Parameter in Upper Tract Urothelial Carcinoma (UTUC). *Clin Genitourin Cancer*. 2020 Sep 18:S1558-7673(20)30218-4. doi: 10.1016/j.clgc.2020.09.002. Epub ahead of print. PMID: 33046411.
388. Rosiello G, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. The effect of sex on disease stage and survival after radical cystectomy: a population-based analysis. *Urol Oncol*. 2020 Oct 6:S1078-1439(20)30435-X. doi: 10.1016/j.urolonc.2020.09.004. Epub ahead of print. PMID: 33036900.
389. Montorsi F, Gandaglia G, Fossati N, **Briganti A**. Re: Long-Term Outcomes of Active Surveillance for Prostate Cancer: The Memorial Sloan Kettering Cancer Center Experience. *J Urol*. 2020;203(6):1122-7. *J Urol*. 2020 Oct 9:101097JU0000000000001420. doi: 10.1097/JU.0000000000001420. Epub ahead of print. PMID: 33035136.
390. Bravi CA, Montorsi F, **Briganti A**. Reply to V erane Achard, Alan Dal Pra, and Thomas Zilli's Letter to the Editor re: Carlo A. Bravi, Nicola Fossati, Giorgio Gandaglia, et al. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. *Eur Urol* 2020;78:661-9. *Eur Urol*. 2020 Dec;78(6):e223-e224. doi: 10.1016/j.eururo.2020.09.036. Epub 2020 Oct 3. PMID: 33023772.
391. Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, Shariat SF, Saad F, **Briganti A**, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Small Renal Masses With Tumor Size 0 to 2 cm: A SEER-Based Study and Validation of NCCN Guidelines. *J Natl Compr Canc Netw*. 2020 Oct 1;18(10):1340-1347. doi: 10.6004/jnccn.2020.7577. PMID: 33022641.
392. Moschini M, Afferi L, Gandaglia G, D'Andrea D, Zamboni S, Di Bona C, Mordasini L, Mattei A, Baumeister P, Martini A, Burgio G, Shariat SF, Sanchez- Salas R, Cathelineau X, Stabile A, Zaffuto E, Salonia A, Colombo R, Necchi A, Montorsi F, **Briganti A**, Gallina A. Prediction of the Need for an Extended Lymphadenectomy at the Time of Radical Cystectomy in Patients with Bladder Cancer. *Eur Urol Focus*. 2020 Oct 2:S2405-4569(20)30268-6. doi: 10.1016/j.euf.2020.09.009. Epub ahead of print. PMID: 33020030.
393. Caputo S, Grioni M, Brambillasca CS, Monno A, Brevi A, Freschi M, Piras IS, Elia AR, Pieri V, Baccega T, Lombardo A, Galli R, **Briganti A**, Doglioni C, Jachetti E, Bellone M. Galectin-3 in Prostate Cancer Stem-Like Cells Is Immunosuppressive and Drives Early Metastasis. *Front Immunol*. 2020 Sep 10;11:1820. doi: 10.3389/fimmu.2020.01820. PMID: 33013832; PMCID: PMC7516304.
394. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Tian Z, Perrotte P, Montorsi F, Shariat SF, Saad F, Simeone C, **Briganti A**, Antonelli A, Karakiewicz PI. Primary lymphomas of the genitourinary tract: A population-based study. *Asian J Urol*. 2020 Oct;7(4):332-339. doi: 10.1016/j.ajur.2019.11.002. Epub 2019 Nov 27. PMID: 32995277; PMCID: PMC7498952.
395. Quhal F, Pradere B, Sari Motlagh R, Mori K, Laukhtina E, Aydh A, Mostafaei H, Lysenko I, Schuettfort VM, Stolzenbach F, Palumbo C, Heidenreich A, **Briganti A**, Karakiewicz PI, Chłosta P, Shariat SF. Prognostic value of preoperative albumin to globulin ratio in patients treated with salvage radical prostatectomy for radiation recurrent prostate cancer. *Minerva Urol Nefrol*. 2020 Sep 29. doi: 10.23736/S0393-2249.20.03938-7. Epub ahead of print. PMID: 32993278.
396. Giannatempo P, Raggi D, Marandino L, Bandini M, Far e E, Calareso G, Colecchia M, Gallina A, Ross JS, Alessi A, **Briganti A**, Montorsi F, Madison R, Necchi A. Pembrolizumab and nab-paclitaxel as salvage therapy for platinum- treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study. *Ann Oncol*. 2020 Dec;31(12):1764-1772. doi: 10.1016/j.annonc.2020.09.012. Epub 2020 Sep 23. PMID: 32979512.
397. Bandini M, Gibb EA, Gallina A, Raggi D, Marandino L, Bianchi M, Ross JS, Colecchia M, Gandaglia G, Fossati N, Pederzoli F, Lucian  R, Colombo R, Salonia A, **Briganti A**, Montorsi F, Necchi A. Does the administration of preoperative pembrolizumab lead to sustained remission post-cystectomy? First survival outcomes from the PURE-01 study[☆]. *Ann Oncol*. 2020 Dec;31(12):1755-1763. doi: 10.1016/j.annonc.2020.09.011. Epub 2020 Sep 23. PMID: 32979511.

398. Luzzago S, Knipper S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder: A Population-based Competing-risks Analysis Across Disease Stages. *Am J Clin Oncol*. 2020 Sep 23. doi: 10.1097/COC.0000000000000766. Epub ahead of print. PMID: 32976177.
399. Tutolo M, **Briganti A**, Montorsi F. Re: Kathrin Meisterhofer, Sereina Herzog, Karin A. Strini, Luca Sebastianelli, Ricarda Bauer, Orietta Dalpiaz. Male Slings for Postprostatectomy Incontinence: A Systematic Review and Meta-analysis. *Eur Urol Focus* 2020;6:575-92. *Eur Urol Focus*. 2020 Sep 21:S2405-4569(20)30262-5. doi: 10.1016/j.euf.2020.08.017. Epub ahead of print. PMID: 32972897.
400. Falagario UG, Jambor I, Lantz A, Ettala O, Stabile A, Taimen P, Aronen HJ, Knaapila J, Perez IM, Gandaglia G, Fossati N, Martini A, Cucchiara V, Picker W, Haug E, Ratnani P, Haines K, Lewis S, Sujit N, Selvaggio O, Sanguedolce F, Macarini L, Cormio L, Nordström T, Tewari A, **Briganti A**, Boström PJ, Carrieri G. Combined Use of Prostate-specific Antigen Density and Magnetic Resonance Imaging for Prostate Biopsy Decision Planning: A Retrospective Multi-institutional Study Using the Prostate Magnetic Resonance Imaging Outcome Database (PROMOD). *Eur Urol Oncol*. 2020 Sep 21:S2588-9311(20)30142-5. doi: 10.1016/j.euo.2020.08.014. Epub ahead of print. PMID: 32972896.
401. Kretschmer A, Mazzone E, Barletta F, Leni R, Heidegger I, Tsaor I, van den Bergh RCN, Valerio M, Marra G, Kasivisvanathan V, Buchner A, Stief CG, **Briganti A**, Montorsi F, Tilki D, Gandaglia G; EAU-YAU Prostate Cancer Working Party. Initial Experience with Radical Prostatectomy Following Holmium Laser Enucleation of the Prostate. *Eur Urol Focus*. 2020 Sep 19:S2405-4569(20)30260-1. doi: 10.1016/j.euf.2020.09.003. Epub ahead of print. PMID: 32962962.
402. Giannarini G, Valotto C, Girometti R, Dal Moro F, **Briganti A**, Padhani AR. Measuring the Quality of Diagnostic Prostate Magnetic Resonance Imaging: A Urologist's Perspective. *Eur Urol*. 2020 Sep 17:S0302-2838(20)30707-7. doi: 10.1016/j.eururo.2020.09.015. Epub ahead of print. PMID: 32951929.
403. Collà Ruvolo C, Stolzenbach LF, Nocera L, Deuker M, Mistretta FA, Luzzago S, Tian Z, Longo N, Graefen M, Chun FKH, Saad F, **Briganti A**, De Cobelli O, Mirone V, Karakiewicz PI. Comparison of Mexican-American vs Caucasian prostate cancer active surveillance candidates. *Urol Oncol*. 2020 Sep 17:S1078-1439(20)30379-3. doi: 10.1016/j.urolonc.2020.08.012. Epub ahead of print. PMID: 32950397.
404. Baboudjian M, Ploussard G, Shariat SF, Ost P, **Briganti A**, Roupert M, Pradere B. How to deal with steroids use in the management of metastatic prostate cancer during pandemic. *Transl Androl Urol*. 2020 Aug;9(4):1546-1549. doi: 10.21037/tau-20-1011. PMID: 32944516; PMCID: PMC7475678.
405. Bandini M, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ayres B, Hakenberg OW, Heidenreich A, Raggi D, Giannatempo P, Marandino L, Haidl F, Pederzoli F, **Briganti A**, Montorsi F, Chipollini J, Azizi M, De Meerleer G, Brouwer OR, Grass GD, Johnstone PA, Albersen M, Spiess PE, Necchi A. Contemporary Treatment Patterns and Outcomes for Patients with Penile Squamous Cell Carcinoma: Identifying Management Gaps to Promote Multi-institutional Collaboration. *Eur Urol Oncol*. 2020 Sep 14:S2588-9311(20)30122-X. doi: 10.1016/j.euo.2020.07.007. Epub ahead of print. PMID: 32943378.
406. Tutolo M, Van der Aa F, Bruyneel L, Van Damme N, Van Cleynenbreugel B, Joniau S, Ammirati E, Vos G, **Briganti A**, De Ridder D, Everaerts W; Belgian RALP consortium. A novel tool to predict functional outcomes after RARP and the value of additional surgery for incontinence. *BJU Int*. 2020 Sep 15. doi: 10.1111/bju.15242. Epub ahead of print. PMID: 32929874.
407. Bordini J, Morisi F, Elia AR, Santambrogio P, Pagani A, Cucchiara V, Ghia P, Bellone M, **Briganti A**, Camaschella C, Campanella A. Iron induces cell death and strengthens the efficacy of anti-androgen therapy in prostate cancer models. *Clin Cancer Res*. 2020 Sep 14:clincanres.3182.2020. doi: 10.1158/1078-0432.CCR-20-3182. Epub ahead of print. PMID: 32928793.
408. Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Mansour M, Tian Z, Tilki D, Steuber T, **Briganti A**, Saad F, Chun FKH, Graefen M, Karakiewicz PI. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study. *Prostate Cancer Prostatic Dis*. 2020 Sep 1. doi: 10.1038/s41391-020-00276-2. Epub ahead of print. PMID: 32873918.

409. Necchi A, Marandino L, Raggi D, Bandini M, Gallina A, Moschini M, **Briganti A**, Montorsi F. Is it Time to Consider Eliminating Surgery from the Treatment of Locally Advanced Bladder Cancer? *Eur Urol*. 2020 Aug 27:S0302-2838(20)30639-4. doi: 10.1016/j.eururo.2020.08.022. Epub ahead of print. PMID: 32861574.
410. Gandaglia G, Ploussard G, Valerio M, Marra G, Moschini M, Martini A, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Afferi L, Rakauskas A, Gontero P, Mattei A, Montorsi F, **Briganti A**. Prognostic Implications of Multiparametric Magnetic Resonance Imaging and Concomitant Systematic Biopsy in Predicting Biochemical Recurrence After Radical Prostatectomy in Prostate Cancer Patients Diagnosed with Magnetic Resonance Imaging-targeted Biopsy. *Eur Urol Oncol*. 2020 Aug 23:S2588-9311(20)30123-1. doi: 10.1016/j.euo.2020.07.008. Epub ahead of print. PMID: 32847747.
411. Pederzoli F, Bandini M, Marandino L, Raggi D, Giannatempo P, Salonia A, Gallina A, **Briganti A**, Montorsi F, Necchi A. Neoadjuvant Chemotherapy or Immunotherapy for Clinical T2N0 Muscle-invasive Bladder Cancer: Time to Change the Paradigm? *Eur Urol Oncol*. 2020 Aug 23:S2588-9311(20)30121-8. doi: 10.1016/j.euo.2020.07.006. Epub ahead of print. PMID: 32847746.
412. Nocera L, **Briganti A**, Karakiewicz PI. Re: Hiten D. Patel, Farzana A. Faisal, Bruce J. Trock, et al. Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. *Eur Urol*. In press. <https://doi.org/10.1016/j.eururo.2020.05.001>. *Eur Urol*. 2020 Aug 22:S0302-2838(20)30629-1. doi: 10.1016/j.eururo.2020.08.012. Epub ahead of print. PMID: 32843244.
413. Bandini M, Sekulovic S, Spiridonescu B, Dangi AD, Krishnappa P, **Briganti A**, Salonia A, Montorsi F, Djinnovic R. Vacuum physiotherapy after first stage buccal mucosa graft (BMG) urethroplasty in children with proximal hypospadias. *Int Braz J Urol*. 2020 Nov-Dec;46(6):1029-1041. doi: 10.1590/S1677-5538.IBJU.2019.0845. PMID: 32822133.
414. **Briganti A**, Gandaglia G, Montorsi F. Metastasis-Directed Therapy for Oligorecurrent Prostate Cancer-Not All That Glitters Is Gold. *JAMA Oncol*. 2020 Aug 20. doi: 10.1001/jamaoncol.2020.2829. Epub ahead of print. PMID: 32815997.
415. Preisser F, Gandaglia G, Arad F, Karakiewicz PI, Bandini M, Pompe RS, Montorsi F, Graefen M, Huland H, **Briganti A**, Tilki D. Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer. *Prostate Cancer Prostatic Dis*. 2020 Aug 19. doi: 10.1038/s41391-020-00266-4. Epub ahead of print. PMID: 32814844.
416. Pecoraro A, Knipper S, Palumbo C, Rosiello G, Luzzago S, Tian Z, Shariat SF, Saad F, **Briganti A**, Fiori C, Porpiglia F, Karakiewicz PI. Assessment of other- cause mortality in localized renal cell carcinoma patients within 15 years: A population-based analysis. *J Surg Oncol*. 2020 Aug 18. doi: 10.1002/jso.26149. Epub ahead of print. PMID: 32812284.
417. Telo S, Fanti S, Nanni C, Lambertini A, Picchio M, Gianolli L, Schiavina R, Bianchi L, **Briganti A**, Mapelli P, Castellucci P, Farolfi A. Negative 11C-choline PET/computed tomography imaging in restaging of patients with prostate cancer with serum prostate-specific antigen values >20 ng/mL. *Nucl Med Commun*. 2020 Aug 13. doi: 10.1097/MNM.0000000000001266. Epub ahead of print. PMID: 32804916.
418. Montorsi F, Salonia A, **Briganti A**. Re: Lisa Moris, Marcus G. Cumberbatch, Thomas Van den Broeck, et al. Benefits and Risks of Primary Treatments for High- risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. *Eur Urol* 2020;77:614-27. *Eur Urol*. 2020 Aug 13:S0302-2838(20)30603-5. doi: 10.1016/j.eururo.2020.07.031. Epub ahead of print. PMID: 32800728.
419. Gandaglia G, Montorsi F, **Briganti A**. Reply to Jonathan Aning, Paul McCoubrie, and Jon Oxley's Letter to the Editor re: Giorgio Gandaglia, Guillaume Ploussard, Massimo Valerio, et al. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. *Eur Urol* 2020;77:733-41. *Eur Urol*. 2020 Aug 13:S0302-2838(20)30619-9. doi: 10.1016/j.eururo.2020.07.039. Epub ahead of print. PMID: 32800726.

420. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Dzyuba-Negrean C, Shariat SF, Saad F, Simeone C, Berruti A, **Briganti A**, Kapoor A, Antonelli A, Karakiewicz PI. Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2020 May 20:S1558-7673(20)30117-8. doi: 10.1016/j.clgc.2020.05.009. Epub ahead of print. PMID: 32800473.
421. Montorsi F, Gandaglia G, Fossati N, Salonia A, **Briganti A**. Re: Vasilis Stavrinides, Francesco Giganti, Bruce Trock, et al. Five-year Outcomes of Magnetic Resonance Imaging-based Active Surveillance for Prostate Cancer: A Large Cohort Study. *Eur Urol* 2020;78:443-51. *Eur Urol*. 2020 Oct;78(4):e165. doi: 10.1016/j.eururo.2020.07.008. Epub 2020 Aug 11. PMID: 32798145.
422. Martini A, Falagarino UG, Villers A, Dell'Oglio P, Mazzone E, Autorino R, Moschovas MC, Buscarini M, Bravi CA, **Briganti A**, Sawczyn G, Kaouk J, Menon M, Secco S, Bocciardi AM, Wang G, Zhou X, Porpiglia F, Mottrie A, Patel V, Tewari AK, Montorsi F, Gaston R, Wiklund NP, Hemal AK. Contemporary Techniques of Prostate Dissection for Robot-assisted Prostatectomy. *Eur Urol*. 2020 Oct;78(4):583-591. doi: 10.1016/j.eururo.2020.07.017. Epub 2020 Aug 1. PMID: 32747200.
423. Gacci M, Artibani W, Bassi P, Bertoni F, Bracarda S, **Briganti A**, Carmignani G, Carmignani L, Conti G, Corvò R, De Nunzio C, Fusco F, Graziotti P, Greco I, Maggi S, Magrini SM, Mirone V, Montironi R, Morgia G, Muto G, Noale M, Pecoraro S, Porreca A, Ricardi U, Russi E, Russo G, Salonia A, Simonato A, Serni S, Tomasini D, Tubaro A, Zagonel V, Crepaldi G; MIRROR-SIU/LUNA Study Group and the Pros-IT CNR Study Group. How radical prostatectomy procedures have changed over the last 10 years in Italy: a comparative analysis based on more than 1500 patients participating in the MIRROR-SIU/LUNA and the Pros-IT CNR study. *World J Urol*. 2020 Aug 1. doi: 10.1007/s00345-020-03350-5. Epub ahead of print. PMID: 32740803.
424. Montorsi F, Bandini M, **Briganti A**, Dasgupta P, Gallina A, Gallucci M, Gill IS, Guru KA, Hemal A, Menon M, Moschini M, Murphy DG, Parekh DJ, Patel HD, Patel HRH, Stöckle M, Tewari AK, Wijburg CJ, Wiklund P, Wilson TG, Mottrie A; EAU Robotic Urology Section Scientific Working Group. Re-establishing the Role of Robot-assisted Radical Cystectomy After the 2020 EAU Muscle-invasive and Metastatic Bladder Cancer Guideline Panel Recommendations. *Eur Urol*. 2020 Oct;78(4):489-491. doi: 10.1016/j.eururo.2020.06.035. Epub 2020 Jul 28. PMID: 32736929.
425. Mori K, Abufaraj M, Mostafaei H, Quhal F, Karakiewicz PI, **Briganti A**, Kimura S, Egawa S, Shariat SF. A Systematic Review and Meta-Analysis of Variant Histology in Urothelial Carcinoma of the Bladder Treated with Radical Cystectomy. *J Urol*. 2020 Jul 27:101097JU0000000000001305. doi: 10.1097/JU.0000000000001305. Epub ahead of print. PMID: 32716694.
426. Zamboni S, Afferi L, Soria F, Aziz A, Abufaraj M, Poyet C, Necchi A, D'Andrea D, Simone G, Ferriero M, Di Trapani E, Simeone C, Antonelli A, Gallina A, Montorsi F, **Briganti A**, Colombo R, Gandaglia G, Mattei A, Baumeister P, Mordasini L, Hendricksen K, Voskuilen CS, Rink M, Shariat SF, Xylinas E,
427. Moschini M. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy with curative intent. *World J Urol*. 2020 Jul 25. doi: 10.1007/s00345-020-03362-1. Epub ahead of print. PMID: 32712850.
428. Brönimann S, Pradere B, Karakiewicz P, Huebner NA, **Briganti A**, Shariat SF. An up-to-date catalogue of urinary markers for the management of prostate cancer. *Curr Opin Urol*. 2020 Sep;30(5):684-688. doi: 10.1097/MOU.0000000000000807. PMID: 32701725.
429. Bandini M, Spiess PE, Pederzoli F, Marandino L, Brouwer OR, Albersen M, Roussel E, de Vries HM, Chipollini J, Zhu Y, Ye DW, Ornellas AA, Catanzaro M, Hakenberg OW, Heidenreich A, Haidl F, Watkin N, Ager M, Ahmed ME, Karnes JR, **Briganti A**, Salvioni R, Montorsi F, Azizi M, Necchi A. A risk calculator predicting recurrence in lymph node metastatic penile cancer. *BJU Int*. 2020 Jul 14. doi: 10.1111/bju.15177. Epub ahead of print. PMID: 32662205.
430. Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Bladder cancer incidence rates and trends in young adults aged 20-39 years. *Urol Oncol*. 2020 Jul 8:S1078-1439(20)30280-5. doi: 10.1016/j.urolonc.2020.06.009. Epub ahead of print. PMID: 32653412.
431. Kreuz M, Otto DJ, Fuessel S, Blumert C, Bertram C, Bartsch S, Loeffler D, Puppel SH, Rade M, Buschmann T, Christ S, Erdmann K, Friedrich M, Froehner M, Muders MH, Schreiber S, Specht M,

- Toma MI, Benigni F, Freschi M, Gandaglia G, **Briganti A**, Baretton GB, Loeffler M, Hackermüller J, Reiche K, Wirth M, Horn F. ProstaTrend-A Multivariable Prognostic RNA Expression Score for Aggressive Prostate Cancer. *Eur Urol.* 2020 Sep;78(3):452-459. doi: 10.1016/j.eururo.2020.06.001. Epub 2020 Jul 4. PMID: 32631745.
432. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, **Briganti A**. Long-term Outcomes of Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: Not as Good as Previously Thought. *Eur Urol.* 2020 Jul 2:S0302-2838(20)30472-3. doi: 10.1016/j.eururo.2020.06.043. Epub ahead of print. PMID: 32624288.
433. Bravi CA, Fossati N, Gandaglia G, Suardi N, Mazzone E, Robesti D, Osmonov D, Juenemann KP, Boeri L, Jeffrey Karnes R, Kretschmer A, Buchner A, Stief C, Hiester A, Nini A, Albers P, Devos G, Joniau S, Van Poppel H, Shariat SF, Heidenreich A, Pfister D, Tilki D, Graefen M, Gill IS, Mottrie A, Karakiewicz PI, Montorsi F, **Briganti A**. Assessing the Best Surgical Template at Salvage Pelvic Lymph Node Dissection for Nodal Recurrence of Prostate Cancer After Radical Prostatectomy: When Can Bilateral Dissection be Omitted? Results from a Multi-institutional Series. *Eur Urol.* 2020 Jul 2:S0302-2838(20)30507-8. doi: 10.1016/j.eururo.2020.06.047. Epub ahead of print. PMID: 32624281.
434. Montorsi F, Gandaglia G, Fossati N, **Briganti A**. Re: The Magnetic Resonance Imaging in Active Surveillance (MRIAS) Trial: Use of Baseline Multiparametric Magnetic Resonance Imaging and Saturation Biopsy to Reduce the Frequency of Surveillance Prostate Biopsies. *Amin, M. J. Scheltema, R. Shnier, A. Blazeovski, D. Moses, T. Cusick, A. Siriwardena, B. Yuen, P. J. van Leeuwen, A. M. Haynes, J. Matthews, P. Brenner, G. O'Neill, C. Yuen, W. Delprado, P. Stricker and J. Thompson* *J Urol.* 2020; 203: 910-917. *J Urol.* 2020 Oct;204(4):843. doi: 10.1097/JU.0000000000001190. Epub 2020 Jul 1. PMID: 32609573.
435. Bandini M, Calareso G, Raggi D, Marandino L, Colecchia M, Gallina A, Giannatempo P, Pederzoli F, Gandaglia G, Fossati N, Capitanio U, Colombo R, Salonia A, **Briganti A**, Montorsi F, De Cobelli F, Messina A, Necchi A. The Value of Multiparametric Magnetic Resonance Imaging Sequences to Assist in the Decision Making of Muscle-invasive Bladder Cancer. *Eur Urol Oncol.* 2020 Jun 27:S2588-9311(20)30082-1. doi: 10.1016/j.euo.2020.06.004. Epub ahead of print. PMID: 32605888.
436. Abufaraj M, Iwata T, Kimura S, Haddad A, Al-Ani H, Abusubaih L, Moschini M, **Briganti A**, Karakiewicz PI, Shariat SF. Differential Impact of Gonadotropin-releasing Hormone Antagonist Versus Agonist on Clinical Safety and Oncologic Outcomes on Patients with Metastatic Prostate Cancer: A Meta-analysis of Randomized Controlled Trials. *Eur Urol.* 2020 Jun 27:S0302-2838(20)30429-2. doi: 10.1016/j.eururo.2020.06.002. Epub ahead of print. PMID: 32605859.
437. Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Beyer K, Bernini C, Bjartell A, **Briganti A**, Butler-Ransohoff JE, Campi R, Cavelaars M, De Meulder B, Deveseri Z, Voss MD, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Smith EJ,
438. Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira MM, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, N'Dow J; PIONEER Consortium. Author Correction: Introducing PIONEER: a project to harness big data in prostate cancer research. *Nat Rev Urol.* 2020 Aug;17(8):482. doi: 10.1038/s41585-020-0355-3. Erratum for: *Nat Rev Urol.* 2020 Jun;17(6):351-362. PMID: 32587405.
439. Palumbo C, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Stolzenbach F, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Renal cell carcinoma incidence rates and trends in young adults aged 20-39 years. *Cancer Epidemiol.* 2020 Aug;67:101762. doi: 10.1016/j.canep.2020.101762. Epub 2020 Jun 22. PMID: 32585430.
440. Brönimann S, Pradere B, Karakiewicz P, Abufaraj M, **Briganti A**, Shariat SF. An overview of current and emerging diagnostic, staging and prognostic markers for prostate cancer. *Expert Rev Mol*

Diagn. 2020 Aug;20(8):841-850. doi: 10.1080/14737159.2020.1785288. Epub 2020 Jun 25. PMID: 32552088.

441. Bandini M, Ross JS, Raggi D, Gallina A, Colecchia M, Lucianò R, Giannatempo P, Farè E, Pederzoli F, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Deho' F, Ali SM, Madison R, Chung JH, Salonia A, **Briganti A**, Montorsi F, Necchi A. Predicting the pathologic complete response after neoadjuvant pembrolizumab in muscle-invasive bladder cancer. *J Natl Cancer Inst.* 2020 Jun 9:djaa076. doi: 10.1093/jnci/djaa076. Epub ahead of print. PMID: 32516377.
442. Giri VN, Knudsen KE, Kelly WK, Cheng HH, Cooney KA, Cookson MS, Dahut W, Weissman S, Soule HR, Petrylak DP, Dicker AP, AlDubayan SH, Toland AE, Pritchard CC, Pettaway CA, Daly MB, Mohler JL, Parsons JK, Carroll PR, Pilarski R, Blanco A, Woodson A, Rahm A, Taplin ME, Polascik TJ, Helfand BT, Hyatt C, Morgans AK, Feng F, Mullane M, Powers J, Concepcion R, Lin DW, Wender R, Mark JR, Costello A, Burnett AL, Sartor O, Isaacs WB, Xu J, Weitzel J, Andriole GL, Beltran H, **Briganti A**, Byrne L, Calvaresi A, Chandrasekar T, Chen DYT, Den RB, Dobi A, Crawford ED, Eastham J, Eggener S, Freedman ML, Garnick M, Gomella PT, Handley N, Hurwitz MD, Izes J, Karnes RJ, Lallas C, Languino L, Loeb S, Lopez AM, Loughlin KR, Lu-Yao G, Malkowicz SB, Mann M, Mille P, Miner MM, Morgan T, Moreno J, Mucci L, Myers RE, Nielsen SM, O'Neil B, Pinover W, Pinto P, Poage W, Raj GV, Rebbeck TR, Ryan C, Sandler H, Schiewer M, Scott EMD, Szymaniak B, Tester W, Trabulsi EJ, Vapiwala N, Yu EY, Zeigler-Johnson C, Gomella LG. Implementation of Germline Testing for Prostate Cancer: Philadelphia Prostate Cancer Consensus Conference 2019. *J Clin Oncol.* 2020 Aug 20;38(24):2798-2811. doi: 10.1200/JCO.20.00046. Epub 2020 Jun 9. PMID: 32516092; PMCID: PMC7430215.
443. Larcher A, Fallara G, Rosiello G, Re C, Baiamonte G, Agnesi S, Cignoli D, Colandrea G, Basile G, **Briganti A**, Salonia A, Bertini R, Montorsi F, Capitanio U. Cytoreductive Nephrectomy in Metastatic Patients with Signs or Symptoms: Implications for Renal Cell Carcinoma Guidelines. *Eur Urol.* 2020 Sep;78(3):321-326. doi: 10.1016/j.eururo.2020.05.014. Epub 2020 Jun 2. PMID: 32507335.
444. Palumbo C, Mazzone E, Mistretta FA, Knipper S, Perrotte P, Shariat SF, Saad F, Kapoor A, Lattouf JB, Simeone C, **Briganti A**, Antonelli A, Karakiewicz PI. A Plea for Optimizing Selection in Current Adjuvant Immunotherapy Trials for High-risk Nonmetastatic Renal Cell Carcinoma According to Expected Cancer-specific Mortality. *Clin Genitourin Cancer.* 2020 Aug;18(4):314-321.e1. doi: 10.1016/j.clgc.2019.11.010. Epub 2019 Dec 5. PMID: 32482565.
445. Campi R, Amparore D, Capitanio U, Checucci E, Salonia A, Fiori C, Minervini A, **Briganti A**, Carini M, Montorsi F, Serni S, Porpiglia F. Reply to Vincenzo Ficarra, Giuseppe Mucciardi, and Gianluca Giannarini's Letter to the Editor re: Riccardo Campi, Daniele Amparore, Umberto Capitanio, et al. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. *Eur Urol* 2020;78:11-15. *Eur Urol.* 2020 Oct;78(4):e169-e170. doi: 10.1016/j.eururo.2020.05.017. Epub 2020 May 22. PMID: 32475746; PMCID: PMC7242972.
446. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. *Am J Clin Oncol.* 2020 Aug;43(8):567-574. doi: 10.1097/COC.0000000000000704. PMID: 32467527.
447. Omar MI, Roobol MJ, Ribal MJ, Abbott T, Agapow PM, Araujo S, Asiimwe A, Auffray C, Balaur I, Beyer K, Bernini C, Bjartell A, **Briganti A**, Butler-Ransohoff JE, Campi R, Cavelaars M, De Meulder B, Devecseri Z, Voss MD, Dimitropoulos K, Evans-Axelsson S, Franks B, Fullwood L, Horgan D, Smith EJ,
448. Kiran A, Kivinummi K, Lambrecht M, Lancet D, Lindgren P, MacLennan S, MacLennan S, Nogueira MM, Moen F, Moinat M, Papineni K, Reich C, Reiche K, Rogiers S, Sartini C, van Bochove K, van Diggelen F, Van Hemelrijck M, Van Poppel H, Zong J, N'Dow J; PIONEER Consortium. Introducing PIONEER: a project to harness big data in prostate cancer research. *Nat Rev Urol.* 2020 Jun;17(6):351-362. doi: 10.1038/s41585-020-0324-x. Epub 2020 May 27. Erratum in: *Nat Rev Urol.* 2020 Aug;17(8):482. PMID: 32461687.
449. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Luzzago S, Deuker M, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Contemporary Age-adjusted

- Incidence and Mortality Rates of Renal Cell Carcinoma: Analysis According to Gender, Race, Stage, Grade, and Histology. *Eur Urol Focus*. 2020 May 23:S2405-4569(20)30114-0. doi: 10.1016/j.euf.2020.05.003. Epub ahead of print. PMID: 32456993.
450. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, **Briganti A**, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Comp erat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubm uller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jerezek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espin os E, L ogager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, M uller AC, M uller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Roupr et M, Rouvi ere O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskim ae E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Willemse PM, Williams A, Zigeuner R, Horwich A. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [*European Urology* 77 (2020) 223-250]. *Eur Urol*. 2020 Jul;78(1):e48-e50. doi: 10.1016/j.eururo.2020.03.017. Epub 2020 May 21. Erratum for: *Eur Urol*. 2020 Feb;77(2):223-250. PMID: 32446863.
451. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, Souli eres D, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients. *Eur Urol Focus*. 2020 May 19:S2405-4569(20)30108-5. doi: 10.1016/j.euf.2020.04.009. Epub ahead of print. PMID: 32444303.
452. Stabile A, Orczyk C, Giganti F, Moschini M, Allen C, Punwani S, Cathala N, Ahmed HU, Cathelineau X, Montorsi F, Emberton M, **Briganti A**, Sanchez-Salas R, Moore CM. The Role of Percentage of Prostate-specific Antigen Reduction After Focal Therapy Using High-intensity Focused Ultrasound for Primary Localised Prostate Cancer. Results from a Large Multi-institutional Series. *Eur Urol*. 2020 Aug;78(2):155-160. doi: 10.1016/j.eururo.2020.04.068. Epub 2020 May 19. PMID: 32444261.
453. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, **Briganti A**. Reply by Authors. *J Urol*. 2020 Aug;204(2):302. doi: 10.1097/JU.0000000000000800.03. Epub 2020 May 19. PMID: 32427046.
454. Rosiello G, Pecoraro A, Palumbo C, Knipper S, Luzzago S, Deuker M, Tian Z, Gandaglia G, Fossati N, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study. *World J Urol*. 2020 May 18. doi: 10.1007/s00345-020-03247-3. Epub ahead of print. PMID: 32424515.
455. Necchi A, Raggi D, Giannatempo P, Marandino L, Far e E, Gallina A, Colecchia M, Lucian o R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Dittamore R, Liu Y, Davicioni E, Ross JS, de Jong JJ, **Briganti A**, Montorsi F, Gibb EA. Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study. *Eur Urol Oncol*. 2020 May 14:S2588-9311(20)30053-5. doi: 10.1016/j.euo.2020.04.005. Epub ahead of print. PMID: 32417369.
456. Stolzenbach LF, Rosiello G, Deuker M, Coll a-Ruvolo C, Nocera L, Tian Z, Tilki D, **Briganti A**, Saad F, Chun FKH, Graefen M, Karakiewicz PI. The Impact of Race and Age on Distribution of

- Metastases in Patients with Prostate Cancer. *J Urol*. 2020 May 12;101097JU0000000000001131. doi: 10.1097/JU.0000000000001131. Epub ahead of print. PMID: 32396050.
457. Abufaraj M, Kimura S, Haitel A, Iwata T, Isleem U, D'Andrea D, Soria F, Mori K, Rink M, Bensalah K, Rouprêt M, Margulis V, **Briganti A**, Karakiewicz PI, Shariat SF. The expression of urokinase-type plasminogen activator system in upper tract urothelial carcinoma and its prognostic value after radical nephroureterectomy. *Urol Oncol*. 2020 Aug;38(8):685.e17-685.e25. doi: 10.1016/j.urolonc.2020.03.030. Epub 2020 May 4. PMID: 32381392.
458. Ribal MJ, Cornford P, **Briganti A**, Knoll T, Gravas S, Babjuk M, Harding C, Breda A, Bex A; GORRG Group, Rassweiler JJ, Gözen AS, Pini G, Liatsikos E, Giannarini G, Motttrie A, Subramaniam R, Sofikitis N, Rocco BMC, Xie LP, Witjes JA, Mottet N, Ljungberg B, Rouprêt M, Laguna MP, Salonia A, Bonkat G, Blok BFM, Türk C, Radmayr C, Kitrey ND, Engeler DS, Lumen N, Hakenberg OW, Watkin N, Hamid R, Olsburgh J, Darraugh J, Shepherd R, Smith EJ, Chapple CR, Stenzl A, Van Poppel H, Wirth M, Sønksen J, N'Dow J; EAU Section Offices and the EAU Guidelines Panels. European Association of Urology Guidelines Office Rapid Reaction Group: An Organisation-wide Collaborative Effort to Adapt the European Association of Urology Guidelines Recommendations to the Coronavirus Disease 2019 Era. *Eur Urol*. 2020 Jul;78(1):21-28. doi: 10.1016/j.eururo.2020.04.056. Epub 2020 Apr 27. PMID: 32376137; PMCID: PMC7183974.
459. Gandaglia G, **Briganti A**, Fossati N, Montorsi F. Re: Comparison of Initial Experience with Transrectal Magnetic Resonance Imaging Cognitive Guided Micro- Ultrasound Biopsies versus Established Transperineal Robotic Ultrasound Magnetic Resonance Imaging Fusion Biopsies for Prostate Cancer. R. Claros, R. R. Tourinho-Barbosa, A. Fregeville, A. C. Gallardo, F. Muttin, A. Carneiro, A.
460. Stabile, M. Moschini, P. Macek, N. Cathala, A. Mombet, R. Sanchez-Salas and X. Cathelineau. *J Urol* 2020; 203: 918-925. *J Urol*. 2020 Sep;204(3):587. doi: 10.1097/JU.0000000000001122. Epub 2020 May 5. PMID: 32364834.
461. Afferi L, Moschini M, Mattei A, Montorsi F, **Briganti A**, Cathelineau X, Sanchez-Salas R. Re: Adjuvant Chemotherapy in Upper Tract Urothelial Carcinoma (the POUT Trial): A Phase 3, Open-label, Randomised Controlled Trial. *Eur Urol*. 2020 Aug;78(2):289-290. doi: 10.1016/j.eururo.2020.04.006. Epub 2020 Apr 28. PMID: 32359702.
462. Afferi L, Zamboni S, Karnes RJ, Roghmann F, Sargos P, Montorsi F, **Briganti A**, Gallina A, Mattei A, Schulz GB, Hendricksen K, Voskuilen CS, Rink M, Poyet C, De Cobelli O, di Trapani E, Simeone C, Soligo M, Simone G, Tuderti G, Alvarez- Maestro M, Martínez-Piñero L, Aziz A, Shariat SF, Abufaraj M, Xylinas E, Moschini M; European Association of Urology-Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. The impact of treatment modality on survival in patients with clinical node-positive bladder cancer: results from a multicenter collaboration. *World J Urol*. 2020 Apr 30. doi: 10.1007/s00345-020-03205-z. Epub ahead of print. PMID: 32356226.
463. Pederzoli F, Ferrarese R, Amato V, Locatelli I, Alchera E, Lucianò R, Nebuloni M, **Briganti A**, Gallina A, Colombo R, Necchi A, Clementi M, Montorsi F, Mancini N, Salonia A, Alfano M. Sex-specific Alterations in the Urinary and Tissue Microbiome in Therapy-naïve Urothelial Bladder Cancer Patients. *Eur Urol Oncol*. 2020 Apr 25:S2588-9311(20)30050-X. doi: 10.1016/j.euo.2020.04.002. Epub ahead of print. PMID: 32345542.
464. Campi R, Amparore D, Capitanio U, Checcucci E, Salonia A, Fiori C, Minervini A, **Briganti A**, Carini M, Montorsi F, Serni S, Porpiglia F. Assessing the Burden of Nondeferrable Major Uro-oncologic Surgery to Guide Prioritisation Strategies During the COVID-19 Pandemic: Insights from Three Italian High-volume Referral Centres. *Eur Urol*. 2020 Jul;78(1):11-15. doi: 10.1016/j.eururo.2020.03.054. Epub 2020 Apr 11. PMID: 32307215; PMCID: PMC7151319.
465. Montorsi F, Fossati N, Gandaglia G, **Briganti A**. ⁶⁸Ga-PSMA-PET/CT Scan as Primary Staging for Prostate Cancer and Its Related Clinical Implications. *J Urol*. 2020 Apr 13;101097JU0000000000001081. doi: 10.1097/JU.0000000000001081. Epub ahead of print. PMID: 32282267.
466. Stensland KD, Morgan TM, Moinzadeh A, Lee CT, **Briganti A**, Catto JWF, Canes D. Considerations in the Triage of Urologic Surgeries During the COVID-19 Pandemic. *Eur Urol*. 2020

- Jun;77(6):663-666. doi: 10.1016/j.eururo.2020.03.027. Epub 2020 Apr 9. PMID: 32279903; PMCID: PMC7146681.
467. Gandaglia G, Martini A, Ploussard G, Fossati N, Stabile A, De Visschere P, Borgmann H, Heidegger I, Steinkohl F, Kretschmer A, Marra G, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, Van den Bergh R, Ost P, Gontero P, Montorsi F, **Briganti A**; EAU-YAU Prostate Cancer Working Group. External Validation of the 2019 Briganti Nomogram for the Identification of Prostate Cancer Patients Who Should Be Considered for an Extended Pelvic Lymph Node Dissection. *Eur Urol.* 2020 Aug;78(2):138-142. doi: 10.1016/j.eururo.2020.03.023. Epub 2020 Apr 5. PMID: 32268944.
468. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, St-Hilaire PA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis. *World J Urol.* 2020 Apr 6. doi: 10.1007/s00345-020-03187-y. Epub ahead of print. PMID: 32253579.
469. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Stolzenbach LF, Tian Z, Gallina A, Gandaglia G, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Rates of other-cause mortality after radical cystectomy are decreasing over time-A population-based analysis over two decades. *J Surg Oncol.* 2020 Jun;121(8):1329-1336. doi: 10.1002/jso.25919. Epub 2020 Apr 4. PMID: 32246846.
470. Martini A, Marqueen KE, Falagario UG, Waingankar N, Wajswol E, Khan F, Fossati N, **Briganti A**, Montorsi F, Tewari AK, Stock R, Rastinehad AR. Estimated Costs Associated With Radiation Therapy for Positive Surgical Margins During Radical Prostatectomy. *JAMA Netw Open.* 2020 Mar 2;3(3):e201913. doi: 10.1001/jamanetworkopen.2020.1913. PMID: 32232450; PMCID: PMC7109597.
471. Lysenko I, Mori K, Mostafaei H, Enikeev DV, Karakiewicz PI, **Briganti A**, Quhal F, Janisch F, Shariat SF. Prognostic Value of Gleason Score at Positive Surgical Margin in Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer.* 2020 Mar 4:S1558-7673(20)30045-8. doi: 10.1016/j.clgc.2020.02.011. Epub ahead of print. PMID: 32229268.
472. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Differences in short-term outcomes between open versus robot-assisted radical cystectomy in frail malnourished patients. *Eur J Surg Oncol.* 2020 Jul;46(7):1347-1352. doi: 10.1016/j.ejso.2020.03.204. Epub 2020 Mar 14. PMID: 32220544.
473. Chys B, Devos G, Everaerts W, Albersen M, Moris L, Claessens F, De Meerleer G, Haustermans K, **Briganti A**, Chlosta P, Gontero P, Graefen M, Gratzke C, Karnes RJ, Kneitz B, Marchioro G, Salas RS, Spahn M, Tombal B, Van Der Poel H, Walz J, Van Poppel H, Joniau S. Preoperative Risk-Stratification of High-Risk Prostate Cancer: A Multicenter Analysis. *Front Oncol.* 2020 Mar 6;10:246. doi: 10.3389/fonc.2020.00246. PMID: 32211317; PMCID: PMC7068909.
474. Rosiello G, Palumbo C, Knipper S, Deuker M, Stolzenbach LF, Tian Z, Gandaglia G, Fossati N, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis.* 2020 Mar 18. doi: 10.1038/s41391-020-0225-3. Epub ahead of print. PMID: 32203071.
475. Necchi A, Gallina A, Dyrskjøt L, Roupret M, Kamat AM, Spiess PE, Grivas P, Gibb EA, **Briganti A**, Montorsi F. Converging Roads to Early Bladder Cancer. *Eur Urol.* 2020 Aug;78(2):127-130. doi: 10.1016/j.eururo.2020.02.031. Epub 2020 Mar 17. PMID: 32197887.
476. Luzzago S, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. *J Endourol.* 2020 May;34(5):600-607. doi: 10.1089/end.2020.0074. Epub 2020 Apr 14. PMID: 32178532.
477. Bandini M, Albersen M, Chipollini J, Pederzoli F, Zhu Y, Ye DW, Ornellas AA, Watkin N, Ager M, Hakenberg OW, Heidenreich A, Raggi D, Catanzaro M, Haidl F, Mazzone E, Marandino L, **Briganti A**, Montorsi F, Azizi M, Spiess PE, Necchi A. Optimising the selection of candidates for neoadjuvant chemotherapy amongst patients with node-positive penile squamous cell carcinoma. *BJU Int.* 2020 Jun;125(6):867-875. doi: 10.1111/bju.15054. Epub 2020 Apr 1. PMID: 32175663.

478. Pecoraro A, Palumbo C, Knipper S, Rosiello G, Luzzago S, Tian Z, Shariat SF, Saad F, Lavallée L, **Briganti A**, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Histologic Subtype, Tumor Grade, Tumor Size, and Race Can Accurately Predict the Probability of Synchronous Metastases in T2 Renal Cell Carcinoma. *Clin Genitourin Cancer*. 2020 Feb 8:S1558-7673(20)30035-5. doi: 10.1016/j.clgc.2020.02.001. Epub ahead of print. PMID: 32173357.
479. Mistretta FA, Negrean-Dzyuba C, Palumbo C, Pecoraro A, Knipper S, Tian Z, Musi G, Montanari E, Perrotte P, **Briganti A**, Shariat SF, Saad F, de Cobelli O, Karakiewicz PI. Adherence to guideline recommendations for multimodality treatment of patients with pT2-3 M0 non-urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. *Int J Urol*. 2020 May;27(5):402-407. doi: 10.1111/iju.14206. Epub 2020 Mar 14. PMID: 32172530.
480. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Rosiello G, Tian Z, St-Hilaire PA, Shariat SF, Saad F, Lavallée L, **Briganti A**, Kapoor A, Fiori C, Porpiglia F, Karakiewicz PI. Synchronous Metastasis Rates in T1 Renal Cell Carcinoma: A Surveillance, Epidemiology, and End Results Database-based Study. *Eur Urol Focus*. 2020 Mar 10:S2405-4569(20)30068-7. doi: 10.1016/j.euf.2020.02.011. Epub ahead of print. PMID: 32169361.
481. Necchi A, Raggi D, Gallina A, Ross JS, Farè E, Giannatempo P, Marandino L, Colecchia M, Lucianò R, Bianchi M, Colombo R, Salonia A, Gandaglia G, Fossati N, Bandini M, Pederzoli F, Capitanio U, Montorsi F, de Jong JJ, Dittamore R, Liu Y, Davicioni E, Boormans JL, **Briganti A**, Black PC, Gibb EA. Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer. *Eur Urol*. 2020 Jun;77(6):701-710. doi: 10.1016/j.eururo.2020.02.028. Epub 2020 Mar 9. PMID: 32165065.
482. Mori K, Miura N, Mostafaei H, Quhal F, Sari Motlagh R, Pradere B, Kimura S, Kimura T, Egawa S, **Briganti A**, Karakiewicz PI, Shariat SF. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2020 Mar 9. doi: 10.1038/s41391-020-0222-6. Epub ahead of print. PMID: 32152435.
483. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Stolzenbach F, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. *Urology*. 2020 Jun;140:91-97. doi: 10.1016/j.urology.2020.02.019. Epub 2020 Mar 6. PMID: 32151650.
484. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. *Clin Genitourin Cancer*. 2020 Aug;18(4):e450-e456. doi: 10.1016/j.clgc.2019.12.001. Epub 2019 Dec 13. PMID: 32146153.
485. Bandini M, Pederzoli F, Madison R, **Briganti A**, Ross JS, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Rosenberg JE, Bellmunt J, Pal SK, Galsky MD, Lucianò R, Gallina A, Salonia A, Montorsi F, Ali SM, Chung JH, Necchi A. Unfavorable Cancer-specific Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients With Bladder Cancer and Squamous Cell Variant: A Multi-institutional Study. *Clin Genitourin Cancer*. 2020 Feb 8:S1558-7673(20)30033-1. doi: 10.1016/j.clgc.2020.01.007. Epub ahead of print. PMID: 32144050.
486. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. *Urol Oncol*. 2020 May;38(5):506-514. doi: 10.1016/j.urolonc.2020.02.004. Epub 2020 Mar 2. PMID: 32139292.
487. Mori K, Janisch F, Mostafaei H, Kimura S, Lysenko I, Karakiewicz PI, **Briganti A**, Enikeev DV, Rouprêt M, Margulis V, Chlosta P, Nyirady P, Babjuk M, Egawa S, Shariat SF. Prognostic role of preoperative De Ritis ratio in upper tract urothelial carcinoma treated with nephroureterectomy. *Urol Oncol*. 2020 Jun;38(6):601.e17-601.e24. doi: 10.1016/j.urolonc.2020.02.008. Epub 2020 Feb 29. PMID: 32127252.
488. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Tian Z, Larcher A, Capitanio U, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Histotype predicts the rate of lymph node

- invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma. *Urol Oncol*. 2020 May;38(5):537-544. doi: 10.1016/j.urolonc.2020.01.013. Epub 2020 Feb 29. PMID: 32122729.
489. Montorsi F, Gandaglia G, Fossati N, Salonia A, **Briganti A**. Re: Ola Bratt, Erik Holmberg, Ove André, et al. The Value of an Extensive Transrectal Repeat Biopsy with Anterior Sampling in Men on Active Surveillance for Low-risk Prostate Cancer: A Comparison from the Randomised Study of Active Monitoring in Sweden (SAMS). *Eur Urol* 2019;76:461-6. *Eur Urol*. 2020 May;77(5):e136. doi: 10.1016/j.eururo.2020.01.023. Epub 2020 Feb 25. PMID: 32111414.
490. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Luzzago S, Deuker M, Mistretta FA, Tian Z, Fossati N, Gallina A, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Contemporary conditional cancer-specific survival after radical nephroureterectomy in patients with nonmetastatic urothelial carcinoma of upper urinary tract. *J Surg Oncol*. 2020 Jun;121(7):1154-1161. doi: 10.1002/jso.25877. Epub 2020 Feb 27. PMID: 32107785.
491. Bravi CA, Rosiello G, Fallara G, Vertosick E, Tin A, Sjoberg D, Bianchi M, Mazzone E, Martini A, Dell'oglio P, Stabile A, Gandaglia G, Fossati N, **Briganti A**, Montorsi F, Vickers A. Predictive value of preoperative neutrophil-to-lymphocyte ratio in localized prostate cancer: results from a surgical series at a high-volume institution. *Minerva Urol Nefrol*. 2020 Feb 19. doi: 10.23736/S0393-2249.20.03662-0. Epub ahead of print. PMID: 32083416.
492. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, Heidenreich A, Pfister D, Kretschmer A, Buchner A, Stief C, Battaglia A, Joniau S, Van Poppel H, Osmonov D, Juenemann KP, Shariat S, Hiester A, Nini A, Albers P, Tilki D, Graefen M, Gill IS, Mottrie A, Galosi AB, Montorsi F, **Briganti A**. Underestimation of Positron Emission Tomography/Computerized Tomography in Assessing Tumor Burden in Prostate Cancer Nodal Recurrence: Head-to-Head Comparison of ⁶⁸Ga-PSMA and ¹¹C-Choline in a Large, Multi-Institutional Series of Extended Salvage Lymph Node Dissections. *J Urol*. 2020 Aug;204(2):296-302. doi: 10.1097/JU.0000000000000800. Epub 2020 Feb 18. PMID: 32068488.
493. Brembilla G, Dell'Oglio P, Stabile A, Damascelli A, Brunetti L, Ravelli S, Cristel G, Schiani E, Venturini E, Grippaldi D, Mendola V, Rancoita PMV, Esposito A, **Briganti A**, Montorsi F, Del Maschio A, De Cobelli F. Interreader variability in prostate MRI reporting using Prostate Imaging Reporting and Data System version 2.1. *Eur Radiol*. 2020 Jun;30(6):3383-3392. doi: 10.1007/s00330-019-06654-2. Epub 2020 Feb 12. PMID: 32052171.
494. Sood A, Keeley J, Palma-Zamora I, Dalela D, Arora S, Peabody JO, Rogers CG, Montorsi F, Menon M, **Briganti A**, Abdollah F. Extended pelvic lymph-node dissection is independently associated with improved overall survival in patients with prostate cancer at high-risk of lymph-node invasion. *BJU Int*. 2020 Jun;125(6):756-758. doi: 10.1111/bju.15034. Epub 2020 Mar 3. PMID: 32045096.
495. Soria F, Giordano A, D'Andrea D, Moschini M, Rouprêt M, Margulis V, Karakiewicz PI, **Briganti A**, Bensalah K, Mathieu R, Chlosta P, Babjuk M, Glybochko PV, Enikeev DV, Remzi M, Gust K, Gontero P, Shariat SF. Prognostic value of the systemic inflammation modified Glasgow prognostic score in patients with upper tract urothelial carcinoma (UTUC) treated with radical nephroureterectomy: Results from a large multicenter international collaboration. *Urol Oncol*. 2020 Jun;38(6):602.e11-602.e19. doi: 10.1016/j.urolonc.2020.01.004. Epub 2020 Feb 7. PMID: 32037197.
496. Montorsi F, Fossati N, Gandaglia G, **Briganti A**. Re: Aurélie De Bruycker, Elise De Bleser, Karel Decaestecker, et al. Nodal Oligorecurrent Prostate Cancer: Anatomic Pattern of Possible Treatment Failure in Relation to Elective Surgical and Radiotherapy Treatment Templates. *Eur Urol* 2019;75:826-33: Nodal Recurrence of Prostate Cancer in Patients Treated with Radical Intent: Tailoring the Best Salvage Treatment. *Eur Urol*. 2020 May;77(5):e137. doi: 10.1016/j.eururo.2020.01.030. Epub 2020 Feb 7. PMID: 32037141.
497. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. *Clin Genitourin Cancer*. 2020 Apr;18(2):117-128.e5. doi: 10.1016/j.clgc.2019.10.016. Epub 2019 Oct 16. PMID: 32035800.
498. Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, **Briganti A**, Montorsi F, Leonardi F, Bandini M. Author Correction: Validation of the GRade, Age, Nodes and

- Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. *Sci Rep.* 2020 Feb 5;10(1):2304. doi: 10.1038/s41598-020-59358-9. Erratum for: *Sci Rep.* 2019 Sep 13;9(1):13218. PMID: 32024910; PMCID: PMC7002482.
499. Mori K, Janisch F, Mostafaei H, Lysenko I, Karakiewicz PI, Enikeev DV, **Briganti A**, Kimura S, Egawa S, Shariat SF. Prognostic Value of Hemoglobin in Metastatic Hormone-sensitive Prostate Cancer: A Systematic Review and Meta-analysis. *Clin Genitourin Cancer.* 2020 Aug;18(4):e402-e409. doi: 10.1016/j.clgc.2019.12.002. Epub 2019 Dec 13. PMID: 32007439.
500. Mistretta FA, Cyr SJ, Luzzago S, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, **Briganti A**, Shariat SF, de Cobelli O, Karakiewicz PI. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes. *Clin Genitourin Cancer.* 2020 Apr;18(2):129-137.e3. doi: 10.1016/j.clgc.2019.09.008. Epub 2019 Sep 26. PMID: 32001182.
501. Gillissen S, Attard G, Beer TM, Beltran H, Bjartell A, Bossi A, **Briganti A**, Bristow RG, Chi KN, Clarke N, Davis ID, de Bono J, Drake CG, Duran I, Eeles R, Efstathiou E, Evans CP, Fanti S, Feng FY, Fizazi K, Frydenberg M, Gleave M, Halabi S, Heidenreich A, Heinrich D, Higano CTS, Hofman MS, Hussain M, James N, Kanesvaran R, Kantoff P, Khaulib RB, Leibowitz R, Logothetis C, Maluf F, Millman R, Morgans AK, Morris MJ, Mottet N, Mrabti H, Murphy DG, Murthy V, Oh WK, Ost P, O'Sullivan JM, Padhani AR, Parker C, Poon DMC, Pritchard CC, Reiter RE, Roach M, Rubin M, Ryan CJ, Saad F, Sade JP, Sartor O, Scher HI, Shore N, Small E, Smith M, Soule H, Sternberg CN, Steuber T, Suzuki H, Sweeney C, Sydes MR, Taplin ME, Tombal B, Türkeri L, van Oort I, Zapatero A, Omlin A. Management of Patients with Advanced Prostate Cancer: Report of the Advanced Prostate Cancer Consensus Conference 2019. *Eur Urol.* 2020 Apr;77(4):508-547. doi: 10.1016/j.eururo.2020.01.012. Epub 2020 Jan 27. PMID: 32001144.
502. Luzzago S, Palumbo C, Rosiello G, Knipper S, Pecoraro A, Nazzani S, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. *Cancer Causes Control.* 2020 Mar;31(3):263-272. doi: 10.1007/s10552-020-01270-8. Epub 2020 Jan 28. PMID: 31993859.
503. Smith EJ, Plass K, Darraugh J, Shepherd R, **Briganti A**, Cornford P, Knoll T, Lumen N, N'Dow J, Ribal MJ, Sylvester R, van Poppel H, Bjartell A; EAU Guidelines Office Panel Chairs. European Association of Urology Guidelines Office: How We Ensure Transparent Conflict of Interest Disclosure and Management. *Eur Urol.* 2020 Apr;77(4):397-399. doi: 10.1016/j.eururo.2020.01.010. Epub 2020 Jan 25. PMID: 31992464.
504. Trevisani F, Di Marco F, Capitanio U, Larcher A, Bettiga A, Dosio F, Ghidini M, Del Conte G, Vago R, Cinque A, Gianolli L, Salonia A, **Briganti A**, Luis-Lima S, Negrín-Mena N, Montorsi F, Porrini E. Renal Function Assessment Gap in Clinical Practice: An Awkward Truth. *Kidney Blood Press Res.* 2020;45(2):166-179. doi: 10.1159/000504649. Epub 2020 Jan 24. PMID: 31982867.
505. Montorsi F, Fossati N, Gandaglia G, **Briganti A**. Re: Felix Preisser, Felix K.H. Chun, Raisa S. Pompe, et al. Persistent Prostate-Specific Antigen After Radical Prostatectomy and Its Impact on Oncologic Outcomes. *Eur Urol* 2019;76:106-14. *Eur Urol.* 2020 Apr;77(4):e107. doi: 10.1016/j.eururo.2020.01.015. Epub 2020 Jan 21. PMID: 31980310.
506. Luzzago S, Palumbo C, Rosiello G, Pecoraro A, Deuker M, Mistretta FA, Tian Z, Musi G, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. *World J Urol.* 2020 Jan 20. doi: 10.1007/s00345-020-03083-5. Epub ahead of print. PMID: 31960108.
507. Stangl-Kremser J, Mari A, Suarez-Ibarrola R, D'Andrea D, Korn SM, Pones M, Kramer G, Karakiewicz P, Enikeev DV, Glybochko PV, **Briganti A**, Shariat SF. Development of a prognostic model for survival time prediction in castration-resistant prostate cancer patients. *Urol Oncol.* 2020 Jun;38(6):600.e9-600.e15. doi: 10.1016/j.urolonc.2019.11.005. Epub 2020 Jan 14. PMID: 31953003.
508. Rosiello G, Palumbo C, Deuker M, Stolzenbach LF, Tian Z, Larcher A, Capitanio U, Montorsi F, Shariat SF, Kapoor A, Saad F, **Briganti A**, Karakiewicz PI. Preoperative frailty predicts adverse short-

- term postoperative outcomes in patients treated with radical nephroureterectomy. *J Surg Oncol*. 2020 Mar;121(4):688-696. doi: 10.1002/jso.25840. Epub 2020 Jan 12. PMID: 31930511.
509. **Briganti A**, Gandaglia G, Scuderi S, Gallina A, Colombo R, Fossati N, Barletta F, Pellegrino A, Nocera L, Montorsi F, Necchi A. Surgical Safety of Radical Cystectomy and Pelvic Lymph Node Dissection Following Neoadjuvant Pembrolizumab in Patients with Bladder Cancer: Prospective Assessment of Perioperative Outcomes from the PURE-01 Trial. *Eur Urol*. 2020 May;77(5):576-580. doi: 10.1016/j.eururo.2019.12.019. Epub 2020 Jan 3. PMID: 31911010.
510. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, **Briganti A**, Antonelli A, Karakiewicz PI. Conditional Survival of Patients With Nonmetastatic Renal Cell Carcinoma: How Cancer-Specific Mortality Changes After Nephrectomy. *J Natl Compr Canc Netw*. 2020 Jan;18(1):44-51. doi: 10.6004/jnccn.2019.7350. PMID: 31910387.
511. Foerster B, Abufaraj M, Petros F, Azizi M, Gupta M, Schweitzer D, Margulis V, Iwata T, Kimura S, Shabsigh A, **Briganti A**, Ku JH, Muilwijk T, Kassouf W, Matin SF, Spiess PE, Pierorazio PM, Hendricksen K, Shariat SF; UTUC Collaboration. Efficacy of Preoperative Chemotherapy for High Risk Upper Tract Urothelial Carcinoma. *J Urol*. 2020 Jun;203(6):1101-1108. doi: 10.1097/JU.0000000000000737. Epub 2020 Jan 2. PMID: 31898919.
512. Necchi A, Bandini M, Calareso G, Raggi D, Pederzoli F, Farè E, Colecchia M, Marandino L, Bianchi M, Gallina A, Colombo R, Fossati N, Gandaglia G, Capitanio U, Dehò F, Giannatempo P, Lucianò R, Salonia A, Madison R, Ali SM, Chung JH, Ross JS, **Briganti A**, Montorsi F, De Cobelli F, Messina A. Multiparametric Magnetic Resonance Imaging as a Noninvasive Assessment of Tumor Response to Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer: Preliminary Findings from the PURE-01 Study. *Eur Urol*. 2020 May;77(5):636-643. doi: 10.1016/j.eururo.2019.12.016. Epub 2019 Dec 25. PMID: 31882281.
513. Martini A, Fossati N, Karnes RJ, Boorjian SA, Boeri L, Bossi A, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Robesti D, Bartkowiak D, Böhmer D, Shariat SF, Goldner G, Battaglia A, Joniau S, Berghen C, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, **Briganti A**. Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol Oncol*. 2019 Dec 3:S2588-9311(19)30162-2. doi: 10.1016/j.euo.2019.11.003. Epub ahead of print. PMID: 31810893.
514. Bandini M, Sekulovic S, Stanojevic N, Spiridonescu B, Pesic V, Sansalone S, Slavkovic M, **Briganti A**, Salonia A, Montorsi F, Djinojic R. Prevalence and surgical management of pubic hypertrophy in hypospadias patients: results from a high-volume surgeon. *Int Braz J Urol*. 2019 Nov-Dec;45(6):1238-1248. doi: 10.1590/S1677-5538.IBJU.2019.0267. PMID: 31808413; PMCID: PMC6909876.
515. Kimura S, D'Andrea D, Iwata T, Foerster B, Janisch F, Parizi MK, Moschini M, **Briganti A**, Babjuk M, Chlosta P, Karakiewicz PI, Enikeev D, Rapoport LM, Seebacher V, Egawa S, Abufaraj M, Shariat SF. Expression of urokinase-type plasminogen activator system in non-metastatic prostate cancer. *World J Urol*. 2020 Oct;38(10):2501-2511. doi: 10.1007/s00345-019-03038-5. Epub 2019 Dec 4. PMID: 31797075.
516. Preisser F, Mazzone E, Knipper S, Nazzani S, Bandini M, Shariat SF, Marchioni M, Tian Z, Saad F, Taussky D, **Briganti A**, Huland H, Graefen M, Tilki D, Karakiewicz PI. Effect of external beam radiotherapy on second primary cancer risk after radical prostatectomy. *Can Urol Assoc J*. 2020 May;14(5):E173-E179. doi: 10.5489/cuaj.6087. Epub 2019 Nov 29. PMID: 31793866; PMCID: PMC7197960.
517. Rosiello G, Palumbo C, Knipper S, Pecoraro A, Dzyuba-Negrean C, Luzzago S, Tian Z, Gallina A, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Unmarried men have worse oncologic outcomes after radical cystectomy for nonmetastatic urothelial bladder cancer. *Urol Oncol*. 2020 Mar;38(3):76.e1-76.e9. doi: 10.1016/j.urolonc.2019.10.018. Epub 2019 Nov 21. PMID: 31761614.
518. Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, **Briganti A**, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B,

- De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort[†]: Under the Auspices of the EAU-ESMO Guidelines Committees. *Eur Urol.* 2020 Feb;77(2):223-250. doi: 10.1016/j.eururo.2019.09.035. Epub 2019 Nov 19. Erratum in: *Eur Urol.* 2020 Jul;78(1):e48-e50. PMID: 31753752.
519. Horwich A, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, **Briganti A**, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, DeBlok W, De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Carmen Mir M, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Vahr Lauridsen S, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Vives Rivera FA, Wiegel T, Wiklund P, Williams A, Zigeuner R, Witjes JA. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer-an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees[†]. *Ann Oncol.* 2019 Nov 1;30(11):1697-1727. doi: 10.1093/annonc/mdz296. PMID: 31740927; PMCID: PMC7360152.
520. Maurer T, Graefen M, van der Poel H, Hamdy F, **Briganti A**, Eiber M, Wester HJ, van Leeuwen FWB. Prostate-Specific Membrane Antigen-Guided Surgery. *J Nucl Med.* 2020 Jan;61(1):6-12. doi: 10.2967/jnumed.119.232330. Epub 2019 Nov 15. PMID: 31732677.
521. Rosiello G, Knipper S, Palumbo C, Pecoraro A, Luzzago S, Deuker M, Tian Z, Gandaglia G, Gallina A, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion. *Clin Genitourin Cancer.* 2020 Feb;18(1):35-44.e1. doi: 10.1016/j.clgc.2019.10.012. Epub 2019 Oct 17. PMID: 31711842.
522. Necchi A, Raggi D, Gallina A, Madison R, Colecchia M, Lucianò R, Montironi R, Giannatempo P, Farè E, Pederzoli F, Bandini M, Bianchi M, Colombo R, Gandaglia G, Fossati N, Marandino L, Capitanio U, Dehò F, Ali SM, Chung JH, Ross JS, Salonia A, **Briganti A**, Montorsi F. Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies. *Eur Urol.* 2020 Apr;77(4):439-446. doi: 10.1016/j.eururo.2019.10.026. Epub 2019 Nov 8. PMID: 31708296.
523. Mistretta FA, Cyr SJ, Palumbo C, Mazzone E, Knipper S, Tian Z, Nazzani S, Montanari E, Tilki D, **Briganti A**, Shariat SF, Perrotte P, Saad F, de Cobelli O, Karakiewicz PI. Adherence to Guideline Recommendations for Perioperative Chemotherapy in Patients with pN2-3 M0 Squamous Cell Carcinoma of the Penis: Temporal Trends and Survival Outcomes. *Clin Oncol (R Coll Radiol).* 2020 Apr;32(4):e93-e101. doi: 10.1016/j.clon.2019.10.001. Epub 2019 Nov 7. PMID: 31706712.

524. Mazzone E, Knipper S, Mistretta FA, Palumbo C, Tian Z, Gallina A, Tilki D, Shariat SF, Montorsi F, Saad F, **Briganti A**, Karakiewicz PI. Trends and Social Barriers for Inpatient Palliative Care in Patients With Metastatic Bladder Cancer Receiving Critical Care Therapies. *J Natl Compr Canc Netw*. 2019 Nov 1;17(11):1344-1352. doi: 10.6004/jnccn.2019.7319. PMID: 31693981.
525. Gontero P, Pisano F, Palou J, Joniau S, Albersen M, Colombo R, **Briganti A**, Pellucchi F, Faba OR, van Rhijn BW, van de Putte EF, Babjuk M, Fritsche HM, Mayr R, Albers P, Niegisch G, Anract J, Masson-Lecomte A, De la Taille A, Roupret M, Peyronnet B, Cai T, Witjes AJ, Bruins M, Baniel J, Mano R, Lapini A, Sessa F, Irani J, Brausi M, Stenzl A, Karnes JR, Scherr D, O'Malley P, Taylor B, Shariat SF, Black P, Abdi H, Matveev VB, Samuseva O, Parekh D, Gonzalgo M, Vetterlein MW, Aziz A, Fisch M, Catto J, Pang KH, Xylinas E, Rink M; Young Academic Urologists Urothelial Carcinoma Group of the European Association of Urology. Complication rate after cystectomy following pelvic radiotherapy: an international, multicenter, retrospective series of 682 cases. *World J Urol*. 2020 Aug;38(8):1959-1968. doi: 10.1007/s00345-019-02982-6. Epub 2019 Nov 6. PMID: 31691084.
526. Cacciamani GE, Dell'Oglio P, Cocci A, Russo GI, De Castro Abreu A, Gill IS, **Briganti A**, Artibani W. Asking "Dr. Google" for a Second Opinion: The Devil Is in the Details. *Eur Urol Focus*. 2019 Nov 2:S2405-4569(19)30333-5. doi: 10.1016/j.euf.2019.10.011. Epub ahead of print. PMID: 31690539.
527. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Fossati N, Shariat SF, Saad F, Montorsi F, Graefen M, **Briganti A**, Karakiewicz PI. Temporal trends and social barriers for inpatient palliative care delivery in metastatic prostate cancer patients receiving critical care therapies. *Prostate Cancer Prostatic Dis*. 2020 Jun;23(2):260-268. doi: 10.1038/s41391-019-0183-9. Epub 2019 Nov 4. PMID: 31685982.
528. Palumbo C, Knipper S, Pecoraro A, Rosiello G, Luzzago S, Deuker M, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy. *Surg Oncol*. 2020 Mar;32:8-13. doi: 10.1016/j.suronc.2019.10.014. Epub 2019 Oct 25. PMID: 31683158.
529. Montorsi F, Moschini M, Gallina A, **Briganti A**, Necchi A. Re: Ten-Year Oncologic Outcomes following Robot-Assisted Radical Cystectomy: Results from the International Robotic Cystectomy Consortium. *J Urol*. 2020 Mar;203(3):624. doi: 10.1097/JU.0000000000000631. Epub 2019 Nov 4. PMID: 31682537.
530. Bandini M, Sekulovic S, Spiridonescu B, Krishnappa P, Dangi AD, Slavkovic M, Pesic V, Salonia A, **Briganti A**, Montorsi F, Djinojic R. Prevalence, assessment and surgical correction of penile curvature in hypospadias patients treated at one European Referral Center: description of the technique and surgical outcomes. *World J Urol*. 2020 Aug;38(8):2041-2048. doi: 10.1007/s00345-019-02961-x. Epub 2019 Oct 25. PMID: 31654219.
531. Bravi CA, Tin A, Vertosick E, Mazzone E, Bandini M, Dell'Oglio P, Stabile A, Gandaglia G, Fossati N, Sjoberg D, Touijer K, Cozzarini C, **Briganti A**, Montorsi F, Eastham J, Vickers A. Androgen deprivation therapy in men with node- positive prostate cancer treated with postoperative radiotherapy. *Urol Oncol*. 2020 Apr;38(4):204-209. doi: 10.1016/j.urolonc.2019.09.018. Epub 2019 Oct 23. PMID: 31653565.
532. Knipper S, Palumbo C, Pecoraro A, Rosiello G, Tian Z, **Briganti A**, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI. Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysis. *Urol Oncol*. 2020 Mar;38(3):79.e9-79.e14. doi: 10.1016/j.urolonc.2019.09.015. Epub 2019 Oct 23. PMID: 31653563.
533. Montorsi F, Moschini M, **Briganti A**. Re: Evaluation of the Fluorescence In Situ Hybridization Test to Predict Recurrence and/or Progression of Disease after bacillus Calmette-Guérin for Primary High Grade Nonmuscle Invasive Bladder Cancer: Results from a Prospective Multicenter Trial. *J Urol*. 2020 Mar;203(3):625. doi: 10.1097/JU.0000000000000624. Epub 2019 Oct 24. PMID: 31647387.
534. Villa L, Ventimiglia E, Proietti S, Giusti G, **Briganti A**, Salonia A, Montorsi F, Doizi S, Traxer O. Does working channel position influence the effectiveness of flexible ureteroscopy? Results from an in vitro study. *BJU Int*. 2020 Mar;125(3):449-456. doi: 10.1111/bju.14923. Epub 2019 Nov 7. PMID: 31610080.

535. Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Graefen M, Montorsi F, Saad F, Shariat SF, Schips L, **Briganti A**, Karakiewicz PI. Comprehensive analysis of in-hospital delirium after major surgical oncology procedures: A population-based study. *Can Urol Assoc J*. 2020 Mar;14(3):E84-E93. doi: 10.5489/cuaj.6030. Epub 2019 Sep 27. PMID: 31599720; PMCID: PMC7053373.
536. Voskuilen CS, Schweitzer D, Jensen JB, Nielsen AM, Joniau S, Muilwijk T, Necchi A, Azizi M, Spiess PE, **Briganti A**, Bandini M, Goffin K, Bouchelouche K, van Werkhoven E, Shariat SF, Xylinas E, Azawi NH, Ku JH, Foerster B, van Rhijn BWG, Vegt E, Hendricksen K. Diagnostic Value of ¹⁸F-fluorodeoxyglucose Positron Emission Tomography with Computed Tomography for Lymph Node Staging in Patients with Upper Tract Urothelial Carcinoma. *Eur Urol Oncol*. 2020 Feb;3(1):73-79. doi: 10.1016/j.euo.2019.09.004. Epub 2019 Oct 5. PMID: 31591037.
537. Lam TBL, MacLennan S, Willemse PM, Mason MD, Plass K, Shepherd R, Baanders R, Bangma CH, Bjartell A, Bossi A, Briers E, **Briganti A**, Buddingh KT, Catto JWF, Colecchia M, Cox BW, Cumberbatch MG, Davies J, Davis NF, De Santis M, Dell'Oglio P, Deschamps A, Donaldson JF, Egawa S, Fankhauser CD, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Gross T, Grummet JP, Henry AM, Ingels A, Irani J, Lardas M, Liew M, Lin DW, Moris L, Omar MI, Pang KH, Paterson CC, Renard-Penna R, Ribal MJ, Roobol MJ, Rouprêt M, Rouvière O, Sancho Pardo G, Richenberg J, Schoots IG, Sedelaar JPM, Stricker P, Tilki D, Vahr Lauridsen S, van den Bergh RCN, Van den Broeck T, van der Kwast TH, van der Poel HG, van Leenders GJLH, Varma M, Violette PD, Wallis CJD, Wiegel T, Wilkinson K, Zattoni F, N'Dow JMO, Van Poppel H, Cornford P, Mottet N. EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). *Eur Urol*. 2019 Dec;76(6):790-813. doi: 10.1016/j.eururo.2019.09.020. Epub 2019 Oct 3. PMID: 31587989.
538. Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Roumiguié M, Fossati N, Stabile A, Beauval JB, Malavaud B, Scuderi S, Barletta F, Moschini M, Zamboni S, Rakauskas A, Tian Z, Karakiewicz PI, De Cobelli F, Porpiglia F, Montorsi F, **Briganti A**. The Key Combined Value of Multiparametric Magnetic Resonance Imaging, and Magnetic Resonance Imaging-targeted and Concomitant Systematic Biopsies for the Prediction of Adverse Pathological Features in Prostate Cancer Patients Undergoing Radical Prostatectomy. *Eur Urol*. 2020 Jun;77(6):733-741. doi: 10.1016/j.eururo.2019.09.005. Epub 2019 Sep 21. PMID: 31547938.
539. Knipper S, Dzyuba-Negrean C, Palumbo C, Pecoraro A, Rosiello G, Tian Z, **Briganti A**, Saad F, Tilki D, Graefen M, Karakiewicz PI. External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patients. *Int Urol Nephrol*. 2020 Jan;52(1):59-66. doi: 10.1007/s11255-019-02284-1. Epub 2019 Sep 21. PMID: 31542882.
540. Soria F, D'Andrea D, Moschini M, Giordano A, Mazzoli S, Pizzuto G, Hurle R, Colombo R, **Briganti A**, Altieri V, Shariat SF, Gontero P. Predictive factors of the absence of residual disease at repeated transurethral resection of the bladder. Is there a possibility to avoid it in well-selected patients? *Urol Oncol*. 2020 Mar;38(3):77.e1-77.e7. doi: 10.1016/j.urolonc.2019.08.010. Epub 2019 Sep 14. PMID: 31526650.
541. Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, **Briganti A**, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. Reply by Authors. *J Urol*. 2019 Dec;202(6):1181. doi: 10.1097/01.JU.0000582680.86998.12. Epub 2019 Sep 16. PMID: 31524577.
542. Buti S, Karakiewicz PI, Bersanelli M, Capitanio U, Tian Z, Cortellini A, Taguchi S, **Briganti A**, Montorsi F, Leonardi F, Bandini M. Validation of the GRade, Age, Nodes and Tumor (GRANT) score within the Surveillance Epidemiology and End Results (SEER) database: A new tool to predict survival in surgically treated renal cell carcinoma patients. *Sci Rep*. 2019 Sep 13;9(1):13218. doi: 10.1038/s41598-019-49250-6. Erratum in: *Sci Rep*. 2020 Feb 5;10(1):2304. PMID: 31519981; PMCID: PMC6744465.
543. Mazzone E, Mistretta FA, Knipper S, Tian Z, Palumbo C, Gandaglia G, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Contemporary Assessment of Long-Term Survival Rates in Patients With Stage I Nonseminoma Germ-Cell Tumor of the Testis: Population-Based Comparison Between Surveillance and Active Treatment After Initial Orchiectomy. *Clin*

- Genitourin Cancer. 2019 Dec;17(6):e1153-e1162. doi: 10.1016/j.clgc.2019.08.009. Epub 2019 Aug 21. PMID: 31515197.
544. Rosiello G, Bandini M, **Briganti A**. Salvage pelvic lymph node dissection for lymph node recurrent prostate cancer. *Curr Opin Urol*. 2019 Nov;29(6):629-635. doi: 10.1097/MOU.0000000000000674. PMID: 31503189.
545. Ceci F, Bianchi L, Borghesi M, Polverari G, Farolfi A, **Briganti A**, Schiavina R, Brunocilla E, Castellucci P, Fanti S. Prediction nomogram for ⁶⁸Ga-PSMA-11 PET/CT in different clinical settings of PSA failure after radical treatment for prostate cancer. *Eur J Nucl Med Mol Imaging*. 2020 Jan;47(1):136-146. doi: 10.1007/s00259-019-04505-2. Epub 2019 Sep 6. PMID: 31492993.
546. Palumbo C, Mistretta FA, Knipper S, Mazzone E, Pecoraro A, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, **Briganti A**, Lavallee LT, Karakiewicz PI. Assessment of local tumor ablation and non-interventional management versus partial nephrectomy in T1a renal cell carcinoma. *Minerva Urol Nefrol*. 2020 Jun;72(3):350-359. doi: 10.23736/S0393-2249.19.03496-9. Epub 2019 Sep 4. PMID: 31487976.
547. Schifano N, Capogrosso P, Pozzi E, Ventimiglia E, Cazzaniga W, Matloob R, Gandaglia G, Dehò F, **Briganti A**, Montorsi F, Salonia A. Impact of time from diagnosis to treatment on erectile function outcomes after radical prostatectomy. *Andrology*. 2020 Mar;8(2):337-341. doi: 10.1111/andr.12699. Epub 2019 Sep 3. PMID: 31478610.
548. Stabile A, Muttin F, Zamboni S, Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Capitanio U, Cucchiara V, Mazzone E, Bravi CA, Mirone V, Montorsi F, **Briganti A**. Therapeutic approaches for lymph node involvement in prostate, bladder and kidney cancer. *Expert Rev Anticancer Ther*. 2019 Sep;19(9):739-755. doi: 10.1080/14737140.2019.1659135. Epub 2019 Aug 30. PMID: 31469021.
549. Rosiello G, Knipper S, Palumbo C, Dzyuba-Negrean C, Pecoraro A, Mazzone E, Mistretta FA, Tian Z, Capitanio U, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Unmarried status is a barrier for access to treatment in patients with metastatic renal cell carcinoma. *Int Urol Nephrol*. 2019 Dec;51(12):2181-2188. doi: 10.1007/s11255-019-02266-3. Epub 2019 Aug 29. PMID: 31468289.
550. Mazzone E, Knipper S, Mistretta FA, Tian Z, Palumbo C, Soulieres D, De Cobelli O, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Contemporary North-American population-based validation of the International Germ Cell Consensus Classification for metastatic germ cell tumors of the testis. *World J Urol*. 2020 Jun;38(6):1535-1544. doi: 10.1007/s00345-019-02927-z. Epub 2019 Aug 28. PMID: 31463562.
551. Zamboni S, Moschini M, Antonelli A, Simeone C, Belotti S, Cristinelli L, Montorsi F, **Briganti A**, Gallina A, Salonia A, Colombo R, Mordasini L, Mattei A, Baumeister P. How to improve patient selection for neoadjuvant chemotherapy in bladder cancer patients candidate for radical cystectomy and pelvic lymph node dissection. *World J Urol*. 2020 May;38(5):1229-1233. doi: 10.1007/s00345-019-02916-2. Epub 2019 Aug 28. PMID: 31463561.
552. Cristel G, Esposito A, Damascelli A, **Briganti A**, Ambrosi A, Brembilla G, Brunetti L, Antunes S, Freschi M, Montorsi F, Del Maschio A, De Cobelli F. Can DCE-MRI reduce the number of PI-RADS v.2 false positive findings? Role of quantitative pharmacokinetic parameters in prostate lesions characterization. *Eur J Radiol*. 2019 Sep;118:51-57. doi: 10.1016/j.ejrad.2019.07.002. Epub 2019 Jul 2. PMID: 31439258.
553. Preisser F, van den Bergh RCN, Gandaglia G, Ost P, Surcel CI, Sooriakumaran P, Montorsi F, Graefen M, van der Poel H, de la Taille A, **Briganti A**, Salomon L, Ploussard G, Tilki D; EAU-YAUWP. Effect of Extended Pelvic Lymph Node Dissection on Oncologic Outcomes in Patients with D'Amico Intermediate and High Risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-Institutional Study. *J Urol*. 2020 Feb;203(2):338-343. doi: 10.1097/JU.0000000000000504. Epub 2019 Aug 22. PMID: 31437119.
554. Knipper S, Pecoraro A, Palumbo C, Rosiello G, Luzzago S, Tian Z, **Briganti A**, Saad F, Tilki D, Graefen M, Karakiewicz PI. A 25-year Period Analysis of Other-cause Mortality in Localized Prostate Cancer. *Clin Genitourin Cancer*. 2019 Oct;17(5):395-401. doi: 10.1016/j.clgc.2019.07.008. Epub 2019 Jul 19. PMID: 31416752.

555. Bravi CA, Tin A, Benfante N, Salonia A, **Briganti A**, Montorsi F, Mulhall JP, Eastham JA, Vickers AJ. Comparison of Two Methods for Assessing Erectile Function Before Radical Prostatectomy. *Eur Urol Oncol*. 2019 Mar 9:S2588-9311(19)30027-6. doi: 10.1016/j.euo.2019.02.003. Epub ahead of print. PMID: 31412005.
556. Capitanio U, Larcher A, Cianflone F, Trevisani F, Nini A, Mottrie A, Mari A, Campi R, Tellini R, **Briganti A**, Veccia A, Van Poppel H, Carini M, Simeone C, Salonia A, Minervini A, Antonelli A, Montorsi F, Bertini R. Hypertension and Cardiovascular Morbidity Following Surgery for Kidney Cancer. *Eur Urol Oncol*. 2020 Apr;3(2):209-215. doi: 10.1016/j.euo.2019.02.006. Epub 2019 Mar 25. PMID: 31411993.
557. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Montorsi F, Graefen M, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. The Effect of Lymph Node Dissection in Metastatic Prostate Cancer Patients Treated with Radical Prostatectomy: A Contemporary Analysis of Survival and Early Postoperative Outcomes. *Eur Urol Oncol*. 2019 Sep;2(5):541-548. doi: 10.1016/j.euo.2018.10.010. Epub 2018 Nov 22. PMID: 31411992.
558. Bravi CA, Vertosick E, Tin A, Scuderi S, Fallara G, Rosiello G, Mazzone E, Bandini M, Gandaglia G, Fossati N, Freschi M, Montironi R, **Briganti A**, Montorsi F, Vickers A. Relative Contribution of Sampling and Grading to the Quality of Prostate Biopsy: Results from a Single High-volume Institution. *Eur Urol Oncol*. 2020 Aug;3(4):474-480. doi: 10.1016/j.euo.2018.10.007. Epub 2018 Nov 24. PMID: 31411978.
559. Preisser F, Bandini M, Nazzani S, Mazzone E, Marchioni M, Tian Z, Chun FKH, Saad F, **Briganti A**, Haese A, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade Groups. *Eur Urol Oncol*. 2019 Mar 28:S2588-9311(19)30035-5. doi: 10.1016/j.euo.2019.03.003. Epub ahead of print. PMID: 31411975.
560. Dell'Oglio P, Stabile A, Soligo M, Brembilla G, Esposito A, Gandaglia G, Fossati N, Bravi CA, Dehò F, De Cobelli F, Montorsi F, Karnes RJ, **Briganti A**. There Is No Way to Avoid Systematic Prostate Biopsies in Addition to Multiparametric Magnetic Resonance Imaging Targeted Biopsies. *Eur Urol Oncol*. 2020 Feb;3(1):112-118. doi: 10.1016/j.euo.2019.03.002. Epub 2019 Mar 27. PMID: 31411973.
561. Martini A, Gandaglia G, Fossati N, Scuderi S, Bravi CA, Mazzone E, Stabile A, Scarcella S, Robesti D, Barletta F, Cucchiara V, Mirone V, Montorsi F, **Briganti A**. Defining Clinically Meaningful Positive Surgical Margins in Patients Undergoing Radical Prostatectomy for Localised Prostate Cancer. *Eur Urol Oncol*. 2019 Apr 4:S2588-9311(19)30039-2. doi: 10.1016/j.euo.2019.03.006. Epub ahead of print. PMID: 31411971.
562. Montorsi F, Gandaglia G, **Briganti A**. Re: Veeru Kasivisvanathan, Armando Stabile, Joana B. Neves, et al. Magnetic Resonance Imaging-targeted Biopsy Versus Systematic Biopsy in the Detection of Prostate Cancer: A Systematic Review And Meta-analysis. *Eur Urol* 2019;76:284-303. *Eur Urol*. 2019 Nov;76(5):e132. doi: 10.1016/j.eururo.2019.07.042. Epub 2019 Aug 8. PMID: 31400947.
563. Moschini M, Zamboni S, Soria F, Mathieu R, Xylinas E, Tan WS, Kelly JD, Simone G, Meraney A, Krishna S, Konety B, Mattei A, Baumeister P, Mordasini L, Montorsi F, **Briganti A**, Gallina A, Stabile A, Sanchez-Salas R, Cathelineau X, Rink M, Necchi A, Karakiewicz PI, Rouprêt M, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Lotan Y, Sooriakumaran P, Shariat SF. Open Versus Robotic Cystectomy: A Propensity Score Matched Analysis Comparing Survival Outcomes. *J Clin Med*. 2019 Aug 9;8(8):1192. doi: 10.3390/jcm8081192. PMID: 31395826; PMCID: PMC6722857.
564. Palumbo C, Mistretta FA, Mazzone E, Knipper S, Tian Z, Perrotte P, Antonelli A, Montorsi F, Shariat SF, Saad F, Simeone C, **Briganti A**, Lattouf JB, Karakiewicz PI. Contemporary Incidence and Mortality Rates in Patients With Testicular Germ Cell Tumors. *Clin Genitourin Cancer*. 2019 Oct;17(5):e1026-e1035. doi: 10.1016/j.clgc.2019.06.003. Epub 2019 Jun 13. PMID: 31378580.
565. Fossati N, Gandaglia G, **Briganti A**, Montorsi F. The emerging role of PET-CT scan after radical prostatectomy: still a long way to go. *Lancet Oncol*. 2019 Sep;20(9):1193-1195. doi: 10.1016/S1470-2045(19)30501-7. Epub 2019 Jul 30. PMID: 31375470.
566. Cacciamani GE, Bassi S, Sebben M, Marcer A, Russo GI, Cocci A, Dell'Oglio P, Medina LG, Nassiri N, Tafuri A, Abreu A, Porcaro AB, **Briganti A**, Montorsi F, Gill IS, Artibani W. Consulting "Dr.

- Google" for Prostate Cancer Treatment Options: A Contemporary Worldwide Trend Analysis. *Eur Urol Oncol.* 2020 Aug;3(4):481-488. doi: 10.1016/j.euo.2019.07.002. Epub 2019 Jul 31. PMID: 31375427.
567. Palumbo C, Pecoraro A, Knipper S, Rosiello G, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Survival and Complication Rates of Metastasectomy in Patients With Metastatic Renal Cell Carcinoma Treated Exclusively With Targeted Therapy: A Combined Population-based Analysis. *Anticancer Res.* 2019 Aug;39(8):4357-4361. doi: 10.21873/anticancer.13604. PMID: 31366530.
568. Pecoraro A, Palumbo C, Knipper S, Mistretta FA, Tian Z, Shariat SF, Saad F, **Briganti A**, Fiori C, Porpiglia F, Karakiewicz PI. Cryoablation Predisposes to Higher Cancer Specific Mortality Relative to Partial Nephrectomy in Patients with Nonmetastatic pT1b Kidney Cancer. *J Urol.* 2019 Dec;202(6):1120-1126. doi: 10.1097/JU.0000000000000460. Epub 2019 Jul 26. PMID: 31347950.
569. Knipper S, Mazzone E, Mistretta FA, Palumbo C, Tian Z, **Briganti A**, Saad F, Tilki D, Graefen M, Karakiewicz PI. Impact of Obesity on Perioperative Outcomes at Robotic-assisted and Open Radical Prostatectomy: Results From the National Inpatient Sample. *Urology.* 2019 Nov;133:135-144. doi: 10.1016/j.urology.2019.05.053. Epub 2019 Jul 20. PMID: 31336110.
570. Pederzoli F, Bandini M, **Briganti A**, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan UN, Théodore C, Rosenberg JE, Harshman LC, Bellmunt J, Galsky MD, Gallina A, Salonia A, Montorsi F, Necchi A; RISC Investigators. Incremental Utility of Adjuvant Chemotherapy in Muscle-invasive Bladder Cancer: Quantifying the Relapse Risk Associated with Therapeutic Effect. *Eur Urol.* 2019 Oct;76(4):425-429. doi: 10.1016/j.eururo.2019.06.032. Epub 2019 Jul 11. PMID: 31303258; PMCID: PMC6852645.
571. Mistretta FA, Palumbo C, Knipper S, Mazzone E, Pecoraro A, Tian Z, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Conditional survival of patients with stage I-III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. *World J Urol.* 2020 Mar;38(3):725-732. doi: 10.1007/s00345-019-02869-6. Epub 2019 Jul 11. PMID: 31297629.
572. Palumbo C, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, **Briganti A**, Antonelli A, Karakiewicz PI. How cancer-specific mortality changes over time after radical cystectomy: Conditional survival of patients with nonmetastatic urothelial carcinoma of the urinary bladder. *Urol Oncol.* 2019 Dec;37(12):893-899. doi: 10.1016/j.urolonc.2019.05.020. Epub 2019 Jul 8. PMID: 31296422.
573. Mistretta FA, Mazzone E, Palumbo C, Knipper S, Tian Z, Nazzani S, Tilki D, Musi G, Perrotte P, Montanari E, Shariat SF, Saad F, **Briganti A**, de Cobelli O, Karakiewicz PI. Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. *Urol Oncol.* 2019 Sep;37(9):578.e11-578.e19. doi: 10.1016/j.urolonc.2019.05.024. Epub 2019 Jul 8. PMID: 31296420.
574. Martini A, Gandaglia G, Karnes RJ, Zaffuto E, Bianchi M, Gontero P, Chlosta P, Gratzke C, Graefen M, Tilki D, Cucchiara V, Mirone V, Kneitz B, Sanchez Salas R, Van Der Poel H, Tombal B, Spahn M, Joniau TS, Montorsi F, **Briganti A**; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). Defining the Most Informative Intermediate Clinical Endpoints for Predicting Overall Survival in Patients Treated with Radical Prostatectomy for High-risk Prostate Cancer. *Eur Urol Oncol.* 2019 Jul;2(4):456-463. doi: 10.1016/j.euo.2018.12.002. Epub 2018 Dec 24. PMID: 31277783.
575. Palumbo C, Knipper S, Dzyuba-Negrean C, Pecoraro A, Rosiello G, Tian Z, Shariat SF, Simeone C, **Briganti A**, Saad F, Berruti A, Antonelli A, Karakiewicz PI. Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients. *J Geriatr Oncol.* 2020 May;11(4):718-723. doi: 10.1016/j.jgo.2019.06.005. Epub 2019 Jun 27. PMID: 31257163.
576. Farolfi A, Gafita A, Calais J, Eiber M, Afshar-Oromieh A, Spohn F, Barbato F, Weber M, Ilhan H, Cervati V, Wetter A, Hadaschik B, **Briganti A**, Walz J, Pianori D, Fanti S, Haberkorn U, Herrmann K, Fendler WP. ⁶⁸Ga-PSMA-11 Positron Emission Tomography Detects Residual Prostate Cancer after Prostatectomy in a Multicenter Retrospective Study. *J Urol.* 2019 Dec;202(6):1174-1181. doi: 10.1097/JU.0000000000000417. Epub 2019 Jun 24. PMID: 31233369.

577. Stabile A, Dell'Oglio P, Soligo M, De Cobelli F, Gandaglia G, Fossati N, Esposito A, Brembilla G, Karnes RJ, Montorsi F, **Briganti A**. Assessing the Clinical Value of Positive Multiparametric Magnetic Resonance Imaging in Young Men with a Suspicion of Prostate Cancer. *Eur Urol Oncol*. 2019 Jun 13:S2588-9311(19)30073-2. doi: 10.1016/j.euo.2019.05.006. Epub ahead of print. PMID: 31204312.
578. Ventimiglia E, Seisen T, Abdollah F, **Briganti A**, Fonteyne V, James N, Roach M 3rd, Thalmann GN, Touijer K, Chen RC, Cheng L. A Systematic Review of the Role of Definitive Local Treatment in Patients with Clinically Lymph Node-positive Prostate Cancer. *Eur Urol Oncol*. 2019 May;2(3):294-301. doi: 10.1016/j.euo.2019.02.001. Epub 2019 Mar 23. PMID: 31200844.
579. Bandini M, **Briganti A**, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Sridhar SS, Sternberg CN, Vaishampayan U, Théodore C, Rosenberg JE, Bellmunt J, Galsky MD, Montorsi F, Necchi A. Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2-4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials. *Eur Urol Oncol*. 2019 May;2(3):248-256. doi: 10.1016/j.euo.2018.08.009. Epub 2018 Sep 7. PMID: 31200838.
580. Kimura S, Abufaraj M, Janisch F, Iwata T, Parizi MK, Foerster B, Fossati N, **Briganti A**, Egawa S, Hartenbach M, Shariat SF. Performance of [⁶⁸Ga] Ga-PSMA 11 PET for detecting prostate cancer in the lymph nodes before salvage lymph node dissection: a systematic review and meta-analysis. *Prostate Cancer Prostatic Dis*. 2020 Mar;23(1):1-10. doi: 10.1038/s41391-019-0156-z. Epub 2019 May 30. PMID: 31147628.
581. Mazzone E, Mistretta FA, Knipper S, Palumbo C, Tian Z, Pecoraro A, Preisser F, Gallina A, Shariat SF, Saad F, Graefen M, Montorsi F, **Briganti A**, Karakiewi PI. Long-term incidence of secondary bladder and rectal cancer in patients treated with brachytherapy for localized prostate cancer: a large-scale population-based analysis. *BJU Int*. 2019 Dec;124(6):1006-1013. doi: 10.1111/bju.14841. Epub 2019 Jun 24. PMID: 31144770.
582. Zattoni F, Incerti E, Dal Moro F, Moschini M, Castellucci P, Panareo S, Picchio M, Fallanca F, **Briganti A**, Gallina A, Fanti S, Schiavina R, Brunocilla E, Rambaldi I, Lowe V, Karnes JR, Evangelista L. ¹⁸F-FDG PET/CT and Urothelial Carcinoma: Impact on Management and Prognosis-A Multicenter Retrospective Study. *Cancers (Basel)*. 2019 May 20;11(5):700. doi: 10.3390/cancers11050700. PMID: 31137599; PMCID: PMC6562413.
583. Knipper S, Tilki D, Mazzone E, Mistretta FA, Palumbo C, Pecoraro A, Tian Z, **Briganti A**, Saad F, Graefen M, Karakiewicz PI. Contemporary clinicopathological characteristics of pT0 prostate cancer at radical prostatectomy: A population- based study. *Urol Oncol*. 2019 Oct;37(10):696-701. doi: 10.1016/j.urolonc.2019.05.001. Epub 2019 May 22. PMID: 31129038.
584. Knipper S, Preisser F, Mazzone E, Mistretta FA, Palumbo C, Tian Z, **Briganti A**, Shariat SF, Saad F, Tilki D, Graefen M, Karakiewicz PI. Contemporary analysis of the effect of marital status on survival of prostate cancer patients across all stages: A population-based study. *Urol Oncol*. 2019 Oct;37(10):702-710. doi: 10.1016/j.urolonc.2019.04.023. Epub 2019 May 15. PMID: 31103337.
585. Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Mazzone E, Graefen M, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. The Effect of Other-cause Mortality Adjustment on Access to Alternative Treatment Modalities for Localized Prostate Cancer Among African American Patients. *Eur Urol Oncol*. 2018 Aug;1(3):215-222. doi: 10.1016/j.euo.2018.03.007. Epub 2018 May 15. PMID: 31102624.
586. Nazzani S, Preisser F, Bandini M, Marchioni M, Tian Z, Soulières D, Montanari E, Ratti D, Acquati P, **Briganti A**, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI. Surgically Treated Retroperitoneal Sarcoma: A Population- based Competing Risks Analysis. *Eur Urol Oncol*. 2018 Sep;1(4):346-351. doi: 10.1016/j.euo.2018.05.008. Epub 2018 May 31. PMID: 31100257.
587. Bandini M, Mazzone E, Preisser F, Nazzani S, Zaffuto E, Marchioni M, Tian Z, Pompe RS, Tilki D, Graefen M, Shariat SF, Montorsi F, Saad F, **Briganti A**, Karakiewicz P. Increase in the Annual Rate of Newly Diagnosed Metastatic Prostate Cancer: A Contemporary Analysis of the Surveillance, Epidemiology and End Results Database. *Eur Urol Oncol*. 2018 Sep;1(4):314-320. doi: 10.1016/j.euo.2018.04.013. Epub 2018 May 15. PMID: 31100253.

588. Zaffuto E, Bandini M, Moschini M, Leyh-Bannurah SR, Gazdovich S, Dell'Oglio P, Gallina A, Shariat SF, **Briganti A**, Montorsi F, Saad F, Karakiewicz PI. Location of Metastatic Bladder Cancer as a Determinant of In-hospital Mortality After Radical Cystectomy. *Eur Urol Oncol*. 2018 Jun;1(2):169-175. doi: 10.1016/j.euo.2018.02.001. Epub 2018 May 15. PMID: 31100242.
589. Preisser F, Marchioni M, Nazzani S, Bandini M, Tian Z, Saad F, Pompe RS, **Briganti A**, Budäus L, Montorsi F, Huland H, Graefen M, Tilki D, Karakiewicz PI. Trend of Adverse Stage Migration in Patients Treated with Radical Prostatectomy for Localized Prostate Cancer. *Eur Urol Oncol*. 2018 Jun;1(2):160-168. doi: 10.1016/j.euo.2018.03.006. Epub 2018 May 15. PMID: 31100241.
590. Stabile A, Dell'Oglio P, Gandaglia G, Fossati N, Brembilla G, Cristel G, Dehò F, Scattoni V, Maga T, Losa A, Gaboardi F, Cardone G, Esposito A, De Cobelli F, Del Maschio A, Montorsi F, **Briganti A**. Not All Multiparametric Magnetic Resonance Imaging-targeted Biopsies Are Equal: The Impact of the Type of Approach and Operator Expertise on the Detection of Clinically Significant Prostate Cancer. *Eur Urol Oncol*. 2018 Jun;1(2):120-128. doi: 10.1016/j.euo.2018.02.002. Epub 2018 May 15. PMID: 31100235.
591. Larcher A, Capitanio U, De Naeyer G, Fossati N, D'Hondt F, Muttin F, De Groote R, Guazzoni G, Salonia A, **Briganti A**, Montorsi F, Mottrie A. Is Robot- assisted Surgery Contraindicated in the Case of Partial Nephrectomy for Complex Tumours or Relevant Comorbidities? A Comparative Analysis of Morbidity, Renal Function, and Oncologic Outcomes. *Eur Urol Oncol*. 2018 May;1(1):61-68. doi: 10.1016/j.euo.2018.01.001. Epub 2018 May 15. PMID: 31100229.
592. Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, **Briganti A**, Karnes RJ. Cyto-reductive Radical Prostatectomy in Men with Prostate Cancer and Skeletal Metastases. *Eur Urol Oncol*. 2018 May;1(1):46-53. doi: 10.1016/j.euo.2018.03.002. Epub 2018 May 15. PMID: 31100228.
593. Stabile A, Dell'Oglio P, De Cobelli F, Esposito A, Gandaglia G, Fossati N, Brembilla G, Cristel G, Cardone G, Deho' F, Losa A, Suardi N, Gaboardi F, Del Maschio A, Montorsi F, **Briganti A**. Association Between Prostate Imaging Reporting and Data System (PI-RADS) Score for the Index Lesion and Multifocal, Clinically Significant Prostate Cancer. *Eur Urol Oncol*. 2018 May;1(1):29-36. doi: 10.1016/j.euo.2018.01.002. Epub 2018 May 15. PMID: 31100225.
594. **Briganti A**, Albiges L, Giannarini G, Kamat AM, Nguyen PL. Welcome to European Urology Oncology: Your New Journal, Where Multiple Disciplines Meet To Improve Care of Patients with Genitourinary Cancers. *Eur Urol Oncol*. 2018 May;1(1):1-2. doi: 10.1016/j.euo.2018.04.002. Epub 2018 May 15. PMID: 31100222.
595. Gandaglia G, Albers P, Abrahamsson PA, **Briganti A**, Catto JWF, Chapple CR, Montorsi F, Mottet N, Roobol MJ, Sønksen J, Wirth M, van Poppel H. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019. *Eur Urol*. 2019 Aug;76(2):142-150. doi: 10.1016/j.eururo.2019.04.033. Epub 2019 May 12. PMID: 31092338.
596. Kimura S, Iwata T, Foerster B, Fossati N, **Briganti A**, Nasu Y, Egawa S, Abufaraj M, Shariat SF. Comparison of perioperative complications and health- related quality of life between robot-assisted and open radical cystectomy: A systematic review and meta-analysis. *Int J Urol*. 2019 Aug;26(8):760-774. doi: 10.1111/iju.14005. Epub 2019 May 13. PMID: 31083783; PMCID: PMC6851708.
597. Knipper S, Preisser F, Mazzone E, Mistretta FA, Tian Z, **Briganti A**, Zorn KC, Saad F, Tilki D, Graefen M, Karakiewicz PI. Contemporary Comparison of Clinicopathologic Characteristics and Survival Outcomes of Prostate Ductal Carcinoma and Acinar Adenocarcinoma: A Population-Based Study. *Clin Genitourin Cancer*. 2019 Jun;17(3):231-237.e2. doi: 10.1016/j.clgc.2019.04.009. Epub 2019 Apr 16. PMID: 31080021.
598. Zamboni S, Soria F, Mathieu R, Xylinas E, Abufaraj M, D Andrea D, Tan WS, Kelly JD, Simone G, Gallucci M, Meraney A, Krishna S, Konety BR, Antonelli A, Simeone C, Baumeister P, Mattei A, **Briganti A**, Gallina A, Montorsi F, Rink M, Aziz A, Karakiewicz PI, Rouprêt M, Koupparis A, Scherr DS, Ploussard G, Sooriakumaran P, Shariat SF, Moschini M; European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Differences in trends in the use of robot-assisted and open radical cystectomy and changes over time in peri-operative outcomes

- among selected centres in North America and Europe: an international multicentre collaboration. *BJU Int.* 2019 May 4. doi: 10.1111/bju.14791. Epub ahead of print. PMID: 31055865.
599. Gandaglia G, Larcher A, Gallina A, Fossati N, **Briganti A**, Montorsi F. Requiem for Open Radical Cystectomy in Bladder Cancer Patients. *Eur Urol Oncol.* 2019 Mar;2(2):196-197. doi: 10.1016/j.euo.2018.07.004. Epub 2018 Aug 6. PMID: 31017096.
600. Mazzone E, Preisser F, Nazzani S, Tian Z, Zaffuto E, Gallina A, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. The effect of age and comorbidities on early postoperative complications after radical cystectomy: A contemporary population-based analysis. *J Geriatr Oncol.* 2019 Jul;10(4):623-631. doi: 10.1016/j.jgo.2019.04.011. Epub 2019 Apr 19. PMID: 31010691.
601. Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, **Briganti A**, Carmignani L, Karakiewicz PI. Survival Effect of Nephroureterectomy in Metastatic Upper Urinary Tract Urothelial Carcinoma. *Clin Genitourin Cancer.* 2019 Jun;17(3):e602-e611. doi: 10.1016/j.clgc.2019.03.003. Epub 2019 Mar 29. PMID: 31005472.
602. Palumbo C, Cyr SJ, Mazzone E, Mistretta FA, Knipper S, Pecoraro A, Tian Z, Shariat SF, Saad F, Simeone C, **Briganti A**, Kapoor A, Antonelli A, Karakiewicz PI. Impact of Tumor Size on Cancer-Specific Mortality Rate After Local Tumor Ablation in T1a Renal-Cell Carcinoma. *J Endourol.* 2019 Jul;33(7):606-613. doi: 10.1089/end.2019.0179. Epub 2019 May 17. PMID: 30990074.
603. Iwata T, Kimura S, Foerster B, Fossati N, **Briganti A**, Karakiewicz PI, Gust KM, Egawa S, Nasu Y, Abufaraj M, Shariat SF. Oncologic outcomes after robot- assisted versus open radical cystectomy: a systematic review and meta-analysis. *World J Urol.* 2019 Aug;37(8):1557-1570. doi: 10.1007/s00345-019-02708-8. Epub 2019 Apr 11. PMID: 30976902.
604. Mazzone E, Mistretta FA, Knipper S, Tian Z, Larcher A, Widmer H, Zorn K, Capitanio U, Graefen M, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Contemporary National Assessment of Robot-Assisted Surgery Rates and Total Hospital Charges for Major Surgical Uro-Oncological Procedures in the United States. *J Endourol.* 2019 Jun;33(6):438-447. doi: 10.1089/end.2018.0840. PMID: 30931607.
605. Dell'Oglio P, Tian Z, Leyh-Bannurah SR, Larcher A, Mazzone E, Moschini M, Trudeau V, Stabile A, Gallina A, Suardi N, Capitanio U, Mottrie A, **Briganti A**, Montorsi F, Rochefort CM, Karakiewicz PI. Development of a New Comorbidity Assessment Tool for Specific Prediction of Perioperative Mortality in Contemporary Patients Treated with Radical Cystectomy. *Ann Surg Oncol.* 2019 Jun;26(6):1942-1949. doi: 10.1245/s10434-019-07313-y. Epub 2019 Mar 27. PMID: 30919224.
606. Zamboni S, Moschini M, Gallina A, Colombo R, Montorsi F, **Briganti A**, Salonia A, Antonelli A, Simeone C, Belotti S, Cristinelli L, Mattei A, Baumeister P. The impact of completeness of last transurethral resection of bladder tumors on the outcomes of radical cystectomy. *World J Urol.* 2019 Dec;37(12):2707-2714. doi: 10.1007/s00345-019-02734-6. Epub 2019 Mar 25. PMID: 30911811.
607. Zamboni S, Foerster B, Abufaraj M, Seisen T, Roupert M, Colin P, De la Taille A, Di Bona C, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Soria F, Chlosta P, Antonelli A, Simeone C, Baumeister P, Mattei A, Montorsi F, Simone G, Gallucci M, Matsumoto K, Karakiewicz PI, **Briganti A**, Xylinas E, Shariat SF, Moschini M; Upper Tract Urothelial Carcinoma Collaboration Group; European Association of Urology - Young Academic Urologists (EAU-YAU), Urothelial carcinoma working group. Incidence and survival outcomes in patients with upper urinary tract urothelial carcinoma diagnosed with variant histology and treated with nephroureterectomy. *BJU Int.* 2019 Nov;124(5):738-745. doi: 10.1111/bju.14751. Epub 2019 Apr 7. PMID: 30908835.
608. Tsaor I, Heidegger I, Kretschmer A, Borgmann H, Gandaglia G, **Briganti A**, de Visschere P, Mathieu R, Valerio M, van den Bergh R, Ost P, Mirvald C, Tilki D, Ploussard G, Surcel C; EAU-YAU Prostate Cancer Working Party. Aggressive variants of prostate cancer - Are we ready to apply specific treatment right now? *Cancer Treat Rev.* 2019 May;75:20-26. doi: 10.1016/j.ctrv.2019.03.001. Epub 2019 Mar 11. PMID: 30875581.
609. Nazzani S, Bandini M, Preisser F, Mazzone E, Marchioni M, Tian Z, Stubinski R, Clementi MC, Saad F, Shariat SF, Montanari E, **Briganti A**, Carmignani L, Karakiewicz PI. Postoperative paralytic ileus after major oncological procedures in the enhanced recovery after surgery era: A population based

- analysis. *Surg Oncol*. 2019 Mar;28:201-207. doi: 10.1016/j.suronc.2019.01.011. Epub 2019 Jan 29. PMID: 30851901.
610. Moschini M, Martini A, Zamboni S, Mattei A, Baumeister P, Di Bona C, Dell'Oglio P, Zaffuto E, Burgio G, Shariat SF, Sanchez-Salas R, Cathelineau X, Salonia A, Montorsi F, **Briganti A**, Gallina A, Colombo R. Evaluation of Cause of Death After Radical Cystectomy for Patients With Bladder Cancer: The Impact of Age at the Time of Surgery. *Clin Genitourin Cancer*. 2019 Jun;17(3):e541-e548. doi: 10.1016/j.clgc.2019.02.001. Epub 2019 Feb 13. PMID: 30850337.
611. Fossati N, Robesti D, Karnes RJ, Soligo M, Boorjian SA, Bossi A, Coraggio G, Di Muzio N, Cozzarini C, Noris Chiorda B, Gandaglia G, Scarcella S, Bartkowiak D, Böhmer D, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, Wiegel T, **Briganti A**. Assessing the Role and Optimal Duration of Hormonal Treatment in Association with Salvage Radiation Therapy After Radical Prostatectomy: Results from a Multi-Institutional Study. *Eur Urol*. 2019 Oct;76(4):443-449. doi: 10.1016/j.eururo.2019.02.004. Epub 2019 Feb 22. PMID: 30799187.
612. Larcher A, Gandaglia G, Wiklund P, Mottrie A, **Briganti A**, Montorsi F; European Association of Urology Robotic Urology Section. Robot-assisted versus open cystectomy in the RAZOR trial. *Lancet*. 2019 Feb 16;393(10172):645. doi: 10.1016/S0140-6736(18)33006-X. Epub 2019 Feb 14. PMID: 30782339.
613. Mistretta FA, Mazzone E, Knipper S, Palumbo C, Tian Z, Nazzani S, Saad F, Montanari E, Tilki D, **Briganti A**, Shariat SF, de Cobelli O, Karakiewicz PI. Contemporary trends of pelvic lymph node dissection at radical cystectomy for urothelial carcinoma of urinary bladder and associated cancer specific mortality and complications: comparison between octogenarian versus younger patients. *Cancer Epidemiol*. 2019 Apr;59:135-142. doi: 10.1016/j.canep.2019.02.002. Epub 2019 Feb 13. PMID: 30771698.
614. Nazzani S, Bazinet A, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Saad F, Zorn KC, Montanari E, **Briganti A**, Carmignani L, Karakiewicz PI. Comparison of perioperative outcomes between open and minimally invasive nephroureterectomy: A population-based analysis. *Int J Urol*. 2019 Apr;26(4):487-492. doi: 10.1111/iju.13916. Epub 2019 Feb 12. PMID: 30756440.
615. Mazzone E, Nazzani S, Knipper S, Tian Z, Preisser F, Gallina A, Soulières D, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Wisnivesky J, Karakiewicz PI. Contemporary use and survival after perioperative systemic chemotherapy in patients with locally advanced non-metastatic urothelial carcinoma of the bladder treated with radical cystectomy. *Eur J Surg Oncol*. 2019 Jul;45(7):1253-1259. doi: 10.1016/j.ejso.2019.01.218. Epub 2019 Feb 3. PMID: 30755341.
616. Stabile A, Orczyk C, Hosking-Jervis F, Giganti F, Arya M, Hindley RG, Dickinson L, Allen C, Punwani S, Jameson C, Freeman A, McCartan N, Montorsi F, **Briganti A**, Ahmed HU, Emberton M, Moore CM. Medium-term oncological outcomes in a large cohort of men treated with either focal or hemi-ablation using high-intensity focused ultrasonography for primary localized prostate cancer. *BJU Int*. 2019 Sep;124(3):431-440. doi: 10.1111/bju.14710. Epub 2019 Mar 18. PMID: 30753756.
617. Bravi CA, Tin A, Vertosick E, Mazzone E, Martini A, Dell'Oglio P, Stabile A, Gandaglia G, Fossati N, Suardi N, Gallina A, **Briganti A**, Montorsi F, Vickers A. The Impact of Experience on the Risk of Surgical Margins and Biochemical Recurrence after Robot-Assisted Radical Prostatectomy: A Learning Curve Study. *J Urol*. 2019 Jul;202(1):108-113. doi: 10.1097/JU.000000000000147. Epub 2019 Jun 7. PMID: 30747873.
618. Cristel G, Esposito A, **Briganti A**, Damascelli A, Brembilla G, Freschi M, Ambrosi A, Montorsi F, Del Maschio A, De Cobelli F. MpMRI of the prostate: is there a role for semi-quantitative analysis of DCE-MRI and late gadolinium enhancement in the characterisation of prostate cancer? *Clin Radiol*. 2019 Apr;74(4):259-267. doi: 10.1016/j.crad.2018.08.017. Epub 2019 Feb 8. PMID: 30739715.
619. Ploussard G, **Briganti A**. MRI-targeted biopsies: What's next? *World J Urol*. 2019 Feb;37(2):219-220. doi: 10.1007/s00345-019-02659-0. PMID: 30712090.
620. Capogrosso P, Larcher A, Nini A, Muttin F, Cianflone F, Ripa F, **Briganti A**, Necchi A, Montorsi F, Salonia A, Bertini R, Capitanio U. The critical role of lymph node dissection in selecting high-risk nonmetastatic renal cancer candidates for adjuvant therapy after nephrectomy. *Urol Oncol*. 2019 Apr;37(4):293.e25-293.e30. doi: 10.1016/j.urolonc.2019.01.009. Epub 2019 Jan 28. PMID: 30704958.

621. Moschini M, Zamboni S, Mattei A, Baumeister P, Di Bona C, Cornelius J, Shariat SF, Freschi M, Zaffuto E, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A; Ospedale San Raffaele. Radical Cystectomy in Pathological T4a and T4b Bladder Cancer Patients: Is There Any Space for Sub Stratification? *Urol Int*. 2019;102(3):269-276. doi: 10.1159/000493899. Epub 2019 Jan 29. PMID: 30695782.
622. Berghen C, Albersen M, Blanchard P, Bossi A, **Briganti A**, Cozzarini C, Decaestecker K, Fonteyne V, Haustermans K, Joniau S, Lim Joon D, Khoo V, Nguyen PL, Ost P, Villeirs G, Vulsteke C, Zietman A, De Meerleer G. Readdressing the rationale of irradiation in stage I seminoma guidelines: a critical essay. *BJU Int*. 2019 Jul;124(1):35-39. doi: 10.1111/bju.14686. Epub 2019 Feb 20. PMID: 30680874.
623. Martini A, Gupta A, Cumarasamy S, Lewis SC, Haines KG 3rd, **Briganti A**, Montorsi F, Tewari AK. Novel nomogram for the prediction of seminal vesicle invasion including multiparametric magnetic resonance imaging. *Int J Urol*. 2019 Apr;26(4):458-464. doi: 10.1111/iju.13905. Epub 2019 Jan 18. PMID: 30659663.
624. Giovacchini G, Guglielmo P, Mapelli P, Incerti E, Gajate AMS, Giovannini E, Riondato M, **Briganti A**, Gianolli L, Ciarmiello A, Picchio M. ¹¹C-choline PET/CT predicts survival in prostate cancer patients with PSA < 1 NG/ml. *Eur J Nucl Med Mol Imaging*. 2019 Apr;46(4):921-929. doi: 10.1007/s00259-018-4253-3. Epub 2019 Jan 10. PMID: 30631911.
625. Ciriaco P, **Briganti A**, Bernabei A, Gandaglia G, Carretta A, Viola C, Montorsi F, Negri G. Safety and Early Oncologic Outcomes of Lung Resection in Patients with Isolated Pulmonary Recurrent Prostate Cancer: A Single-center Experience. *Eur Urol*. 2019 May;75(5):871-874. doi: 10.1016/j.eururo.2018.12.029. Epub 2019 Jan 4. PMID: 30616951.
626. Nazzani S, Mazzone E, Preisser F, Tian Z, Mistretta FA, Shariat SF, Montanari E, Acquati P, **Briganti A**, Saad F, Carmignani L, Karakiewicz PI. Rates of lymph node invasion and their impact on cancer specific mortality in upper urinary tract urothelial carcinoma. *Eur J Surg Oncol*. 2019 Jul;45(7):1238-1245. doi: 10.1016/j.ejso.2018.12.004. Epub 2018 Dec 11. PMID: 30563773.
627. Bianchi L, Gandaglia G, Fossati N, Larcher A, Pultrone C, Turri F, Selli C, de Groote R, de Naeyer G, Borghesi M, Schiavina R, Brunocilla E, **Briganti A**, Montorsi F, Mottrie A. Oncologic outcomes in prostate cancer patients treated with robot-assisted radical prostatectomy: results from a single institution series with more than 10 years follow up. *Minerva Urol Nefrol*. 2019 Feb;71(1):38-46. doi: 10.23736/S0393-2249.18.03285-X. Epub 2018 Dec 14. PMID: 30547906.
628. Villa L, Capogrosso P, Capitanio U, Martini A, **Briganti A**, Salonia A, Montorsi F. Silodosin: An Update on Efficacy, Safety and Clinical Indications in Urology. *Adv Ther*. 2019 Jan;36(1):1-18. doi: 10.1007/s12325-018-0854-2. Epub 2018 Dec 6. PMID: 30523608.
629. Vartolomei MD, D'Andrea D, Chade DC, Soria F, Kimura S, Foerster B, Abufaraj M, Mathieu R, Moschini M, Rouprêt M, **Briganti A**, Karakiewicz PI, Shariat SF. Role of serum cholinesterase in patients treated with salvage radical prostatectomy. *Urol Oncol*. 2019 Feb;37(2):123-129. doi: 10.1016/j.urolonc.2018.11.013. Epub 2018 Dec 3. PMID: 30522902.
630. Mazzone E, Knipper S, Mistretta FA, Tian Z, Preisser F, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Wisnivesky J, Karakiewicz PI. Is neoadjuvant chemotherapy for pT2 bladder cancer associated with a survival benefit in a population-based analysis? *Cancer Epidemiol*. 2019 Feb;58:83-88. doi: 10.1016/j.canep.2018.11.007. Epub 2018 Dec 6. PMID: 30528834.
631. Mazzone E, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Gallina A, Soulieres D, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. More Extensive Lymph Node Dissection Improves Survival Benefit of Radical Cystectomy in Metastatic Urothelial Carcinoma of the Bladder. *Clin Genitourin Cancer*. 2019 Apr;17(2):105-113.e2. doi: 10.1016/j.clgc.2018.11.003. Epub 2018 Nov 17. PMID: 30527745.
632. Fanti S, Minozzi S, Antoch G, Banks I, **Briganti A**, Carrio I, Chiti A, Clarke N, Eiber M, De Bono J, Fizazi K, Gillessen S, Gledhill S, Haberkorn U, Herrmann K, Hicks RJ, Lecouvet F, Montironi R, Ost P, O'Sullivan JM, Padhani AR, Schalken JA, Scher HI, Tombal B, van Moorselaar RJA, Van Poppel H, Vargas HA, Walz J, Weber WA, Wester HJ, Oyen WJG. Consensus on molecular imaging and theranostics in prostate cancer. *Lancet Oncol*. 2018 Dec;19(12):e696-e708. doi: 10.1016/S1470-2045(18)30604-1. PMID: 30507436.

633. Leyh-Bannurah SR, Zaffuto E, Dell'Oglio P, Tian Z, Moschini M, Capitanio U, **Briganti A**, Montorsi F, Fisch M, Chun F, Kachanov M, Budäus L, Graefen M, Huland H, Karakiewicz PI. Prediction of Complications in Radical Prostatectomy Prostate Cancer Patients: Simulated Annealing versus Co-Morbidity Indexes. *Urol Int*. 2019;102(1):51-59. doi: 10.1159/000495071. Epub 2018 Nov 27. PMID: 30481764.
634. Nini A, Larcher A, Cazzaniga W, Dell'Oglio P, Cianflone F, Muttin F, Ripa F, Salonia A, **Briganti A**, Montorsi F, Bertini R, Capitanio U. The side and the location of the primary tumor does not affect the probability of lymph node invasion in patients with renal cell carcinoma. *World J Urol*. 2019 Aug;37(8):1623-1629. doi: 10.1007/s00345-018-2573-3. Epub 2018 Nov 24. PMID: 30474699.
635. D'Andrea D, Soria F, Abufaraj M, Gust K, Foerster B, Vartolomei MD, Kimura S, Mari A, **Briganti A**, Remzi M, Seitz CK, Mathieu R, Karakiewicz PI, Shariat SF. Clinical value of cholinesterase in the prediction of biochemical recurrence after radical prostatectomy. *Urol Oncol*. 2018 Dec;36(12):528.e7-528.e13. doi: 10.1016/j.urolonc.2018.09.015. Epub 2018 Nov 13. PMID: 30446461.
636. Moschini M, Soria F, Mathieu R, Xylinas E, D'Andrea D, Tan WS, Kelly JD, Simone G, Tuderti G, Meraney A, Krishna S, Konety B, Zamboni S, Baumeister P, Mattei A, **Briganti A**, Montorsi F, Galucci M, Rink M, Karakiewicz PI, Rouprêt M, Aziz A, Perry M, Rowe E, Koupparis A, Kassouf W, Scherr DS, Ploussard G, Boorjian SA, Sooriakumaran P, Shariat SF; European Association of Urology – Young Academic Urologists (EAU-YAU), Urothelial Carcinoma Working Group. Propensity-score-matched comparison of soft tissue surgical margins status between open and robotic-assisted radical cystectomy. *Urol Oncol*. 2019 Mar;37(3):179.e1-179.e7. doi: 10.1016/j.urolonc.2018.10.012. Epub 2018 Nov 14. PMID: 30446442.
637. Gandaglia G, Soligo M, Battaglia A, Muilwijk T, Robesti D, Mazzone E, Barletta F, Fossati N, Moschini M, Bandini M, Joniau S, Karnes RJ, Montorsi F, **Briganti A**. Which Patients with Clinically Node-positive Prostate Cancer Should Be Considered for Radical Prostatectomy as Part of Multimodal Treatment? The Impact of Nodal Burden on Long-term Outcomes. *Eur Urol*. 2019 May;75(5):817-825. doi: 10.1016/j.eururo.2018.10.042. Epub 2018 Nov 5. PMID: 30409676.
638. Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, **Briganti A**, Salonia A, Rigatti P, Montorsi F. Corrigendum re "Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study" [*Eur Urol* 2012;62:797-802]. *Eur Urol*. 2019 Mar;75(3):e81. doi: 10.1016/j.eururo.2018.09.012. Epub 2018 Nov 5. Erratum for: *Eur Urol*. 2012 Nov;62(5):797-802. PMID: 30409675.
639. Rieken M, Boorjian SA, Kluth LA, Capitanio U, **Briganti A**, Thompson RH, Leibovich BC, Krabbe LM, Margulis V, Raman JD, Regelman M, Karakiewicz PI, Rouprêt M, Abufaraj M, Foerster B, Gönen M, Shariat SF. Development and external validation of a pathological nodal staging score for patients with clear cell renal cell carcinoma. *World J Urol*. 2019 Aug;37(8):1631-1637. doi: 10.1007/s00345-018-2555-5. Epub 2018 Nov 7. PMID: 30406477.
640. Ploussard G, Gandaglia G, Borgmann H, de Visschere P, Heidegger I, Kretschmer A, Mathieu R, Surcel C, Tilki D, Tsaur I, Valerio M, van den Bergh R, Ost P, **Briganti A**; EAU-YAU Prostate Cancer Working Group. Salvage Lymph Node Dissection for Nodal Recurrent Prostate Cancer: A Systematic Review. *Eur Urol*. 2019 Oct;76(4):493-504. doi: 10.1016/j.eururo.2018.10.041. Epub 2018 Oct 31. PMID: 30391078.
641. Necchi A, Anichini A, Raggi D, **Briganti A**, Massa S, Lucianò R, Colecchia M, Giannatempo P, Mortarini R, Bianchi M, Farè E, Monopoli F, Colombo R, Gallina A, Salonia A, Messina A, Ali SM, Madison R, Ross JS, Chung JH, Salvioni R, Mariani L, Montorsi F. Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study. *J Clin Oncol*. 2018 Dec 1;36(34):3353-3360. doi: 10.1200/JCO.18.01148. Epub 2018 Oct 20. PMID: 30343614.
642. Bandini M, Nazzani S, Marchioni M, Preisser F, Tian Z, Moschini M, Abdollah F, Suardi N, Graefen M, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Increasing Rate of Noninterventional Treatment Management in Localized Prostate Cancer Candidates for Active

- Surveillance: A North American Population- Based Study. *Clin Genitourin Cancer*. 2019 Feb;17(1):72-78.e4. doi: 10.1016/j.clgc.2018.09.011. Epub 2018 Sep 22. PMID: 30342845.
643. Gandaglia G, Ploussard G, Valerio M, Mattei A, Fiori C, Fossati N, Stabile A, Beauval JB, Malavaud B, Roumiguié M, Robesti D, Dell'Oglio P, Moschini M, Zamboni S, Rakauskas A, De Cobelli F, Porpiglia F, Montorsi F, **Briganti A**. A Novel Nomogram to Identify Candidates for Extended Pelvic Lymph Node Dissection Among Patients with Clinically Localized Prostate Cancer Diagnosed with Magnetic Resonance Imaging-targeted and Systematic Biopsies. *Eur Urol*. 2019 Mar;75(3):506-514. doi: 10.1016/j.eururo.2018.10.012. Epub 2018 Oct 17. PMID: 30342844.
644. Nazzani S, Preisser F, Mazzone E, Marchioni M, Bandini M, Tian Z, Mistretta FA, Shariat SF, Soulières D, Montanari E, Acquati P, **Briganti A**, Carmignani L, Karakiewicz PI. Survival Effect of Chemotherapy in Metastatic Upper Urinary Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2019 Feb;17(1):e97-e103. doi: 10.1016/j.clgc.2018.09.017. Epub 2018 Sep 27. PMID: 30337106.
645. Mazzone E, Bandini M, Preisser F, Nazzani S, Tian Z, Abdollah F, Soulières D, Graefen M, Montorsi F, Shariat S, Saad F, **Briganti A**, Karakiewicz PI. The effect of race on survival after local therapy in metastatic prostate cancer patients. *Can Urol Assoc J*. 2019 Jun;13(6):175-181. doi: 10.5489/cuaj.5399. PMID: 30332592; PMCID: PMC6570605.
646. Martini A, Gandaglia G, **Briganti A**. What is new in robot-assisted radical prostatectomy: a narrative review. *Curr Opin Urol*. 2019 Jan;29(1):14-18. doi: 10.1097/MOU.0000000000000564. PMID: 30325870.
647. Necchi A, Messina A, **Briganti A**. Re: Valeria Panebianco, Yoshifumi Narumi, Ersan Altun, et al. Multiparametric Magnetic Resonance Imaging for Bladder Cancer: Development of VI-RADS (Vesical Imaging-Reporting And Data System). *Eur Urol* 2018;74:294-306: Validating VI-RADS Criteria Within Immune-oncology Strategies (VI-RADS-IO). *Eur Urol*. 2018 Nov;74(5):e107-e108. doi: 10.1016/j.eururo.2018.06.030. Epub 2018 Jul 4. PMID: 30318068.
648. Marra G, Ploussard G, Ost P, De Visschere PJL, **Briganti A**, Gandaglia G, Tilki D, Surcel CI, Tsaour I, Van Den Bergh RCN, Kretschmer A, Borgmann H, Gontero P, Ahmed HU, Valerio M; EAU-YAU Prostate Cancer Working Party. Focal therapy in localised prostate cancer: Real-world urological perspective explored in a cross-sectional European survey. *Urol Oncol*. 2018 Dec;36(12):529.e11-529.e22. doi: 10.1016/j.urolonc.2018.08.013. Epub 2018 Oct 6. PMID: 30301698.
649. Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, **Briganti A**. Identifying the Optimal Candidate for Salvage Lymph Node Dissection for Nodal Recurrence of Prostate Cancer: Results from a Large, Multi-institutional Analysis. *Eur Urol*. 2019 Jan;75(1):176-183. doi: 10.1016/j.eururo.2018.09.009. Epub 2018 Oct 6. PMID: 30301694.
650. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Soulières D, Saad F, Montanari E, Luzzago S, **Briganti A**, Carmignani L, Karakiewicz PI. Survival effect of perioperative systemic chemotherapy on overall mortality in locally advanced and/or positive regional lymph node non- metastatic urothelial carcinoma of the upper urinary tract. *World J Urol*. 2019 Jul;37(7):1329-1337. doi: 10.1007/s00345-018-2516-z. Epub 2018 Oct 8. PMID: 30298285.
651. Moschini M, Zaffuto E, Karakiewicz PI, Andrea DD, Foerster B, Abufaraj M, Soria F, Mattei A, Montorsi F, **Briganti A**, Shariat SF. External Beam Radiotherapy Increases the Risk of Bladder Cancer When Compared with Radical Prostatectomy in Patients Affected by Prostate Cancer: A Population-based Analysis. *Eur Urol*. 2019 Feb;75(2):319-328. doi: 10.1016/j.eururo.2018.09.034. Epub 2018 Oct 4. PMID: 30293908.
652. Necchi A, Pond GR, Moschini M, Plimack ER, Niegisch G, Yu EY, Bamias A, Agarwal N, Vaishampayan U, Theodore C, Sridhar SS, Rosenberg JE, Bellmunt J, Gallina A, Colombo R, Montorsi F, **Briganti A**, Galsky MD. Development of a Prediction Tool for Exclusive Locoregional Recurrence After Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. *Clin Genitourin Cancer*. 2019 Feb;17(1):7-14.e3. doi: 10.1016/j.clgc.2018.09.008. Epub 2018 Sep 13. PMID: 30292628; PMCID: PMC6857172.
653. Tosco L, **Briganti A**, D'amico AV, Eastham J, Eisenberger M, Gleave M, Haustermans K, Logothetis CJ, Saad F, Sweeney C, Taplin ME, Fizazi K. Systematic Review of Systemic Therapies and

- Therapeutic Combinations with Local Treatments for High-risk Localized Prostate Cancer. *Eur Urol.* 2019 Jan;75(1):44-60. doi: 10.1016/j.eururo.2018.07.027. Epub 2018 Oct 2. PMID: 30286948.
654. Moschini M, Zaffuto E, Karakiewicz P, Mattei A, Gandaglia G, Fossati N, Montorsi F, **Briganti A**, Shariat SF. The effect of androgen deprivation treatment on subsequent risk of bladder cancer diagnosis in male patients treated for prostate cancer. *World J Urol.* 2019 Jun;37(6):1127-1135. doi: 10.1007/s00345-018-2504-3. Epub 2018 Oct 1. PMID: 30276543.
655. Tsaor I, Heidegger I, Kretschmer A, Borgmann H, Mirvald C, Gandaglia G, **Briganti A**, van den Bergh R, Tilki D, Ost P, Ploussard G, Surcel C; EAU-YAU Prostate Cancer Working Party. Combining anticancer drugs with osteoprotective agents in prostate cancer-A contemporary update. *Urol Oncol.* 2018 Nov;36(11):488-497. doi: 10.1016/j.urolonc.2018.08.016. Epub 2018 Sep 27. PMID: 30268712.
656. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Soulières D, Montanari E, Acquati P, **Briganti A**, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI. Nephroureterectomy with or without Bladder Cuff Excision for Localized Urothelial Carcinoma of the Renal Pelvis. *Eur Urol Focus.* 2020 Mar 15;6(2):298-304. doi: 10.1016/j.euf.2018.09.007. Epub 2018 Sep 25. PMID: 30266210.
657. Delporte G, Henon F, Ploussard G, **Briganti A**, Rizk J, Rozet F, Touijer K, Ouzzane A. Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature. *Prog Urol.* 2018 Dec;28(16):875-889. doi: 10.1016/j.purol.2018.08.007. Epub 2018 Sep 24. PMID: 30262263.
658. Suarez-Ibarrola R, Soria F, Abufaraj M, D'Andrea D, Preto M, Gust KM, **Briganti A**, Shariat SF, Gontero P. Surgical checklist impact on recurrence-free survival of patients with non-muscle-invasive bladder cancer undergoing transurethral resection of bladder tumour. *BJU Int.* 2019 Apr;123(4):646-650. doi: 10.1111/bju.14557. Epub 2018 Oct 23. PMID: 30248235.
659. Moschini M, Zamboni S, Mattei A, Martini A, Zaffuto E, **Briganti A**, Gallina A, Montorsi F. Evaluating the role of neoadjuvant chemotherapy in bladder cancer patients with occult lymph node metastases. *Transl Androl Urol.* 2018 Aug;7(4):742-744. doi: 10.21037/tau.2018.07.03. PMID: 30211066; PMCID: PMC6127544.
660. Mazzone E, Nazzani S, Preisser F, Tian Z, Marchioni M, Bandini M, Capitanio U, Kapoor A, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz P. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma. *Cancer Epidemiol.* 2018 Oct;56:118-125. doi: 10.1016/j.canep.2018.08.006. Epub 2018 Aug 30. PMID: 30173050. (2.179)
661. Soria F, Pisano F, Gontero P, Palou J, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes JA, Grotenhuis A, Colombo R, **Briganti A**, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha E, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Sylvester R. Predictors of oncological outcomes in T1G3 patients treated with BCG who undergo radical cystectomy. *World J Urol.* 2018 Nov;36(11):1775-1781. doi: 10.1007/s00345-018-2450-0. Epub 2018 Aug 31. PMID: 30171454.
663. Capogrosso P, Boeri L, Ventimiglia E, Camozzi I, Cazzaniga W, Chierigo F, Scano R, **Briganti A**, Montorsi F, Salonia A. Attitude towards active surveillance: a cross-sectional survey among patients with uroandrogenic disorders. *BMJ Open.* 2018 Aug 29;8(8):e022495. doi: 10.1136/bmjopen-2018-022495. PMID: 30158231; PMCID: PMC6119427.
664. Capogrosso P, Capitanio U, Vertosick EA, Ventimiglia E, Chierigo F, Oreggia D, Moretti D, **Briganti A**, Vickers AJ, Montorsi F, Salonia A. Temporal Trend in Incidental Prostate Cancer Detection at Surgery for Benign Prostatic Hyperplasia. *Urology.* 2018 Dec;122:152-157. doi: 10.1016/j.urology.2018.07.028. Epub 2018 Aug 20. PMID: 30138683; PMCID: PMC6724539.
665. Bandini M, Fossati N, **Briganti A**. Nomograms in urologic oncology, advantages and disadvantages. *Curr Opin Urol.* 2019 Jan;29(1):42-51. doi: 10.1097/MOU.0000000000000541. PMID: 30095562.
666. Futterer JJ, Surcel C, van den Bergh R, Borgmann H, **Briganti A**, Gandaglia G, Kretschmer A, Ost P, Sooriakumaran P, Tilki D, Valerio M, Ploussard G, De Visschere P, Tsaor I; EAU-YAU Prostate Cancer Working Party. Imaging modalities in synchronous oligometastatic prostate cancer. *World J*

- Urol. 2019 Dec;37(12):2573-2583. doi: 10.1007/s00345-018-2416-2. Epub 2018 Aug 1. PMID: 30069582; PMCID: PMC6868105.
667. Gigliarano C, Nonis A, **Briganti A**, Bonetti M, Serio CD. Effect of the number of removed lymph nodes on prostate cancer recurrence and survival: evidence from an observational study. *BMC Bioinformatics*. 2018 Jul 9;19(Suppl 7):200. doi: 10.1186/s12859-018-2180-8. PMID: 30066642; PMCID: PMC6069760.
668. Carobene A, Guerra E, Locatelli M, Cucchiara V, **Briganti A**, Aarsand AK, Coşkun A, Díaz-Garzón J, Fernandez-Calle P, Røraas T, Sandberg S, Jonker N, Ceriotti F; European Federation of Clinical Chemistry; Laboratory Medicine Working Group on Biological Variation. Biological variation estimates for prostate specific antigen from the European Biological Variation Study; consequences for diagnosis and monitoring of prostate cancer. *Clin Chim Acta*. 2018 Nov;486:185-191. doi: 10.1016/j.cca.2018.07.043. Epub 2018 Jul 29. PMID: 30063887.
669. Muttin F, Pecoraro A, Larcher A, Dell'Oglio P, Nini A, Cianflone F, Trevisani F, Dehò F, **Briganti A**, Salonia A, Montorsi F, Bertini R, Capitanio U. Predictive and prognostic effect of inflammatory lymphadenopathies in renal cell carcinoma. *World J Urol*. 2019 Apr;37(4):701-708. doi: 10.1007/s00345-018-2412-6. Epub 2018 Jul 25. PMID: 30046844.
670. Gandaglia G, Fossati N, Montorsi F, **Briganti A**. Reply to Riccardo Bertolo's Letter to the Editor re: Giorgio Gandaglia, Carlo Andrea Bravi, Paolo Dell'Oglio, et al. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. *Eur Urol* 2018;74:4-7. *Eur Urol*. 2018 Nov;74(5):e116-e117. doi: 10.1016/j.eururo.2018.06.041. Epub 2018 Jul 12. PMID: 30007820.
671. Leyh-Bannurah SR, Karakiewicz PI, Pompe RS, Preisser F, Zaffuto E, Dell'Oglio P, **Briganti A**, Nafez O, Fisch M, Steuber T, Graefen M, Budäus L. Inverse stage migration patterns in North American patients undergoing local prostate cancer treatment: a contemporary population-based update in light of the 2012 USPSTF recommendations. *World J Urol*. 2019 Mar;37(3):469-479. doi: 10.1007/s00345-018-2396-2. Epub 2018 Jul 10. PMID: 29992380.
672. Di Trapani E, Dell'oglio P, Larcher A, Nini A, Muttin F, Cianflone F, Dehò F, Matloob R, Di Trapani D, Freschi M, Salonia A, **Briganti A**, Montorsi F, Bertini R, Capitanio U. Pathological High-risk Renal Cell Carcinoma: Trends in Clinical Characteristics Over 25 Years. *Anticancer Res*. 2018 Jul;38(7):4123-4130. doi: 10.21873/anticancer.12703. PMID: 29970539.
673. Ploussard G, Borgmann H, **Briganti A**, de Visschere P, Fütterer JJ, Gandaglia G, Heidegger I, Kretschmer A, Mathieu R, Ost P, Sooriakumaran P, Surcel C, Tilki D, Tsaor I, Valerio M, van den Bergh R; EAU-YAU Prostate Cancer Working Group. Positive pre-biopsy MRI: are systematic biopsies still useful in addition to targeted biopsies? *World J Urol*. 2019 Feb;37(2):243-251. doi: 10.1007/s00345-018-2399-z. Epub 2018 Jul 2. PMID: 29967944.
674. Mazzone E, Preisser F, Nazzani S, Tian Z, Bandini M, Gandaglia G, Fossati N, Soulières D, Graefen M, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Location of Metastases in Contemporary Prostate Cancer Patients Affects Cancer-Specific Mortality. *Clin Genitourin Cancer*. 2018 Oct;16(5):376-384.e1. doi: 10.1016/j.clgc.2018.05.016. Epub 2018 Jun 5. PMID: 29954690.
675. Calcinotto A, Spataro C, Zagato E, Di Mitri D, Gil V, Crespo M, De Bernardis G, Losa M, Mirenda M, Pasquini E, Rinaldi A, Sumanasuriya S, Lambros MB, Neeb A, Lucianò R, Bravi CA, Nava-Rodrigues D, Dolling D, Prayer-Galetti T, Ferreira A, **Briganti A**, Esposito A, Barry S, Yuan W, Sharp A, de Bono J, Alimonti A. IL-23 secreted by myeloid cells drives castration-resistant prostate cancer. *Nature*. 2018 Jul;559(7714):363-369. doi: 10.1038/s41586-018-0266-0. Epub 2018 Jun 27. PMID: 29950727; PMCID: PMC6461206.
676. Dell'Oglio P, Stabile A, Dias BH, Gandaglia G, Mazzone E, Fossati N, Cucchiara V, Zaffuto E, Mirone V, Suardi N, Mottrie A, Montorsi F, **Briganti A**. Impact of multiparametric MRI and MRI-targeted biopsy on pre-therapeutic risk assessment in prostate cancer patients candidate for radical prostatectomy. *World J Urol*. 2019 Feb;37(2):221-234. doi: 10.1007/s00345-018-2360-1. Epub 2018 Jun 9. PMID: 29948044.
677. **Briganti A**, Fossati N, Catto JWF, Cornford P, Montorsi F, Mottet N, Wirth M, Van Poppel H. Active Surveillance for Low-risk Prostate Cancer: The European Association of Urology Position in

2018. *Eur Urol.* 2018 Sep;74(3):357-368. doi: 10.1016/j.eururo.2018.06.008. Epub 2018 Jun 22. PMID: 29937198.
678. Preisser F, Nazzani S, Bandini M, Marchioni M, Tian Z, Montorsi F, Saad F, **Briganti A**, Steuber T, Budäus L, Huland H, Graefen M, Tilki D, Karakiewicz PI. Increasing rate of lymph node invasion in patients with prostate cancer treated with radical prostatectomy and lymph node dissection. *Urol Oncol.* 2018 Aug;36(8):365.e1-365.e7. doi: 10.1016/j.urolonc.2018.05.019. Epub 2018 Jun 7. PMID: 29887241.
679. De Nunzio C, Lombardo R, Tema G, Alkhatatbeh H, Gandaglia G, **Briganti A**, Tubaro A. External validation of Chun, PCPT, ERSPC, Kawakami, and Karakiewicz nomograms in the prediction of prostate cancer: A single center cohort-study. *Urol Oncol.* 2018 Aug;36(8):364.e1-364.e7. doi: 10.1016/j.urolonc.2018.05.010. Epub 2018 Jun 5. PMID: 29880458.
680. Nazzani S, Mazzone E, Preisser F, Bandini M, Tian Z, Marchioni M, Ratti D, Motta G, Zorn KC, **Briganti A**, Shariat SF, Montanari E, Carmignani L, Karakiewicz PI. Comparison of Perioperative Outcomes Between Open and Robotic Radical Cystectomy: A Population-Based Analysis. *J Endourol.* 2018 Aug;32(8):701-709. doi: 10.1089/end.2018.0313. Epub 2018 Jul 2. PMID: 29845866.
681. Cocci A, Russo GI, **Briganti A**, Salonia A, Cacciamani G, Capece M, Falcone M, Timpano M, Cito G, Verze P, Giammusso B, Morgia G, Mirone V, Minervini A, Gacci M, Cai T, Serni S, Carini M, Giubilei G, Mondaini N. Predictors of treatment success after collagenase *Clostridium histolyticum* injection for Peyronie's disease: development of a nomogram from a multicentre single-arm, non-placebo controlled clinical study. *BJU Int.* 2018 Oct;122(4):680-687. doi: 10.1111/bju.14410. Epub 2018 Jun 20. PMID: 29791971.
682. Nazzani S, Preisser F, Mazzone E, Tian Z, Mistretta FA, Shariat SF, Saad F, Graefen M, Tilki D, Montanari E, Luzzago S, **Briganti A**, Carmignani L, Karakiewicz PI. In-hospital length of stay after major surgical oncological procedures. *Eur J Surg Oncol.* 2018 Jul;44(7):969-974. doi: 10.1016/j.ejso.2018.05.001. Epub 2018 May 9. PMID: 29784507.
683. Gandaglia G, van den Bergh RCN, Tilki D, Fossati N, Ost P, Surcel CI, Sooriakumaran P, Tsaour I, Valerio M, Kretschmer A, Zaffuto E, Salomon L, Montorsi F, Graefen M, van der Poel H, de la Taille A, **Briganti A**, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator. *BJU Int.* 2018 Nov;122(5):823-830. doi: 10.1111/bju.14391. Epub 2018 Jun 3. PMID: 29772103.
684. Nini A, Larcher A, Cianflone F, Trevisani F, Terrone C, Volpe A, Regis F, **Briganti A**, Salonia A, Montorsi F, Bertini R, Capitanio U. The Effect of Anatomical Location of Lymph Node Metastases on Cancer Specific Survival in Patients with Clear Cell Renal Cell Carcinoma. *Front Surg.* 2018 Mar 28;5:26. doi: 10.3389/fsurg.2018.00026. PMID: 29740587; PMCID: PMC5931172.
685. Marchioni M, Nazzani S, Preisser F, Bandini M, Tian Z, Kapoor A, Cindolo L, Primiceri G, Carmignani L, **Briganti A**, Montorsi F, Shariat SF, Schips L, Karakiewicz PI. The Effect of Institution Teaching Status on Perioperative Outcomes After Robotic Partial or Radical Nephrectomy. *J Endourol.* 2018 Jul;32(7):621-629. doi: 10.1089/end.2018.0025. Epub 2018 Jun 19. PMID: 29739253.
686. Veys R, Abdollah F, **Briganti A**, Albersen M, Poppel HV, Joniau S. Oncological and functional efficacy of nephron-sparing surgery versus radical nephrectomy in renal cell carcinoma stages \geq cT1b: a single institution, matched analysis. *Cent European J Urol.* 2018;71(1):48-57. doi: 10.5173/ceju.2017.1611. Epub 2017 Dec 22. PMID: 29732207; PMCID: PMC5926644.
687. Palou J, Pisano F, Sylvester R, Joniau S, Serretta V, Larré S, Di Stasi S, van Rhijn B, Witjes AJ, Grotenhuis A, Colombo R, **Briganti A**, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Dalbagni G, Shariat SF, Xylinas E, Karnes RJ, Gontero P. Recurrence, progression and cancer-specific mortality according to stage at re-TUR in T1G3 bladder cancer patients treated with BCG: not as bad as previously thought. *World J Urol.* 2018 Oct;36(10):1621-1627. doi: 10.1007/s00345-018-2299-2. Epub 2018 May 2. PMID: 29721611.
688. Abdollah F, Dalela D, Sood A, Keeley J, Alanee S, **Briganti A**, Montorsi F, Peabody JO, Menon M. Impact of Adjuvant Radiotherapy in Node-positive Prostate Cancer Patients: The Importance of

- Patient Selection. *Eur Urol.* 2018 Sep;74(3):253-256. doi: 10.1016/j.eururo.2018.04.017. Epub 2018 Apr 30. PMID: 29720348.
689. Bandini M, Marchioni M, Preisser F, Zaffuto E, Tian Z, Tilki D, Montorsi F, Shariat SF, Saad F, **Briganti A**, Karakiewicz PI. Survival after radical prostatectomy or radiotherapy for locally advanced (cT3) prostate cancer. *World J Urol.* 2018 Sep;36(9):1399-1407. doi: 10.1007/s00345-018-2310-y. Epub 2018 May 2. PMID: 29717358.
690. Marchioni M, Harmouch SS, Nazzani S, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, **Briganti A**, Shariat SF, Schips L, Karakiewicz PI. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma. *Cancer Epidemiol.* 2018 Jun;54:112-118. doi: 10.1016/j.canep.2018.04.006. Epub 2018 May 16. PMID: 29715680.
691. Vartolomei MD, Kimura S, Ferro M, Foerster B, Abufaraj M, **Briganti A**, Karakiewicz PI, Shariat SF. The impact of moderate wine consumption on the risk of developing prostate cancer. *Clin Epidemiol.* 2018 Apr 17;10:431-444. doi: 10.2147/CLEP.S163668. PMID: 29713200; PMCID: PMC5909789.
692. Zaffuto E, Bandini M, Gazdovich S, Valiquette AS, Leyh-Bannurah SR, Tian Z, Dell'Oglio P, Graefen M, Moschini M, Necchi A, Shariat SF, **Briganti A**, Montorsi F, Karakiewicz PI. Contemporary rates of adherence to international guidelines for pelvic lymph node dissection in radical cystectomy: a population-based study. *World J Urol.* 2018 Sep;36(9):1417-1422. doi: 10.1007/s00345-018-2306-7. Epub 2018 Apr 27. PMID: 29704059.
693. Ventimiglia E, **Briganti A**, Montorsi F. Lymph node dissection during radical prostatectomy for prostate cancer: extending the template in the right patients without increasing complications. *BJU Int.* 2018 May;121(5):677-678. doi: 10.1111/bju.14169. PMID: 29687951.
694. Martini A, Gupta A, Lewis SC, Kumarasamy S, Haines KG 3rd, **Briganti A**, Montorsi F, Tewari AK. Development and internal validation of a side-specific, multiparametric magnetic resonance imaging-based nomogram for the prediction of extracapsular extension of prostate cancer. *BJU Int.* 2018 Dec;122(6):1025-1033. doi: 10.1111/bju.14353. Epub 2018 May 14. PMID: 29676063.
695. Pompe RS, Tilki D, Preisser F, Leyh-Bannurah SR, Bandini M, Marchioni M, Gild P, Tian Z, Fossati N, Cindolo L, Shariat SF, Huland H, Graefen M, **Briganti A**, Karakiewicz PI. Survival benefit of local versus no local treatment for metastatic prostate cancer-Impact of baseline PSA and metastatic substages. *Prostate.* 2018 Jul;78(10):753-757. doi: 10.1002/pros.23519. Epub 2018 Apr 16. PMID: 29663462.
696. Rieken M, Kluth LA, Fajkovic H, Capitanio U, **Briganti A**, Krabbe LM, Margulis V, Abufaraj M, Mari A, Foerster B, Raman JD, Regelman M, Brookman-May S, Sjoberg DD, Karakiewicz PI, Shariat SF. Predictors of Cancer-specific Survival After Disease Recurrence in Patients With Renal Cell Carcinoma: The Effect of Time to Recurrence. *Clin Genitourin Cancer.* 2018 Aug;16(4):e903-e908. doi: 10.1016/j.clgc.2018.03.003. Epub 2018 Mar 24. PMID: 29653814.
697. Bandini M, Gandaglia G, Fossati N, Montorsi F, **Briganti A**. Anastomotic leaks and catheter time after salvage robot-assisted radical prostatectomy. *Transl Androl Urol.* 2018 Mar;7(Suppl 1):S141-S143. doi: 10.21037/tau.2017.03.86. PMID: 29644184; PMCID: PMC5881216.
698. Bianchi L, Schiavina R, Borghesi M, Bianchi FM, **Briganti A**, Carini M, Terrone C, Mottrie A, Gacci M, Gontero P, Imbimbo C, Marchioro G, Milanese G, Mirone V, Montorsi F, Morgia G, Novara G, Porreca A, Volpe A, Brunocilla E. Evaluating the predictive accuracy and the clinical benefit of a nomogram aimed to predict survival in node-positive prostate cancer patients: External validation on a multi-institutional database. *Int J Urol.* 2018 Jun;25(6):574-581. doi: 10.1111/iju.13565. Epub 2018 Apr 6. PMID: 29633372.
699. Nazzani S, Bandini M, Marchioni M, Preisser F, Tian Z, Soulières D, Montanari E, Motta G, Acquati P, **Briganti A**, Shariat SF, Abdollah F, Carmignani L, Karakiewicz PI. A contemporary analysis of radiotherapy effect in surgically treated retroperitoneal sarcoma. *Radiother Oncol.* 2018 May;127(2):318-325. doi: 10.1016/j.radonc.2018.03.027. Epub 2018 Apr 6. PMID: 29631934.
700. Giannarini G, Fossati N, Gandaglia G, Cucchiara V, Ficarra V, Mirone V, Montorsi F, **Briganti A**. Will Image-guided Metastasis-directed Therapy Change the Treatment Paradigm of Oligorecurrent

- Prostate Cancer? *Eur Urol.* 2018 Aug;74(2):131-133. doi: 10.1016/j.eururo.2018.03.021. Epub 2018 Apr 4. PMID: 29625757.
701. Bandini M, Marchioni M, Pompe RS, Tian Z, Martel T, Chun FK, Cindolo L, Kapoor A, Montorsi F, Shariat SF, **Briganti A**, Karakiewicz PI. The effect of age on cancer-specific mortality in patients with small renal masses: A population- based analysis. *Can Urol Assoc J.* 2018 Jul;12(7):E325-E330. doi: 10.5489/cuaj.4854. Epub 2018 Mar 19. PMID: 29603918; PMCID: PMC6118051.
702. Dell'oglio P, Valiquette AS, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, Shariat SF, Capitanio U, **Briganti A**, Graefen M, Montorsi F, Karakiewicz PI. Treatment trends and Medicare reimbursements for localized prostate cancer in elderly patients. *Can Urol Assoc J.* 2018 Jul;12(7):E338-E344. doi: 10.5489/cuaj.4865. Epub 2018 Mar 19. PMID: 29603911; PMCID: PMC6118049.
703. Moschini M, Arbelaez E, Cornelius J, Mattei A, Shariat SF, Dell'Oglio P, Zaffuto E, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Pattern of node metastases in patients treated with radical cystectomy and extended or superextended pelvic lymph node dissection due to bladder cancer. *Urol Oncol.* 2018 Jun;36(6):307.e9-307.e14. doi: 10.1016/j.urolonc.2018.03.002. Epub 2018 Mar 27. PMID: 29602638.
704. Kasivisvanathan V, Rannikko AS, Borghi M, Panebianco V, Mynderse LA, Vaarala MH, **Briganti A**, Budäus L, Hellawell G, Hindley RG, Roobol MJ, Eggener S, Ghei M, Villers A, Bladou F, Villeirs GM, Virdi J, Boxler S, Robert G, Singh PB, Venderink W, Hadaschik BA, Ruffion A, Hu JC, Margolis D, Crouzet S, Klotz L, Taneja SS, Pinto P, Gill I, Allen C, Giganti F, Freeman A, Morris S, Punwani S, Williams NR, Brew-Graves C, Deeks J, Takwoingi Y, Emberton M, Moore CM; PRECISION Study Group Collaborators. MRI-Targeted or Standard Biopsy for Prostate-Cancer Diagnosis. *N Engl J Med.* 2018 May 10;378(19):1767-1777. doi: 10.1056/NEJMoa1801993. Epub 2018 Mar 18. PMID: 29552975.
705. Farolfi A, Ceci F, Graziani T, Lambertini A, Cervati V, Basilico GL, Biraghi T, **Briganti A**, Castellucci P, Fanti S. Incidental Detection of Basaloid Thymic Carcinoma With ⁶⁸Ga-PSMA-11 PET/CT in a Patient With Recurrent Prostate Cancer. *Clin Genitourin Cancer.* 2018 Jun;16(3):e497-e499. doi: 10.1016/j.clgc.2018.02.019. Epub 2018 Feb 23. PMID: 29550202.
706. Fossati N, Parker WP, Karnes RJ, Colicchia M, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Bartkowiak D, Wiegel T, Shariat S, Goldner G, Battaglia A, Joniau S, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, **Briganti A**, Boorjian SA. More Extensive Lymph Node Dissection at Radical Prostatectomy is Associated with Improved Outcomes with Salvage Radiotherapy for Rising Prostate-specific Antigen After Surgery: A Long-term, Multi-institutional Analysis. *Eur Urol.* 2018 Aug;74(2):134-137. doi: 10.1016/j.eururo.2018.02.024. Epub 2018 Mar 12. PMID: 29544737.
707. Gandaglia G, Bravi CA, Dell'Oglio P, Mazzone E, Fossati N, Scuderi S, Robesti D, Barletta F, Grillo L, Maclennan S, N'Dow J, Montorsi F, **Briganti A**. The Impact of Implementation of the European Association of Urology Guidelines Panel Recommendations on Reporting and Grading Complications on Perioperative Outcomes after Robot-assisted Radical Prostatectomy. *Eur Urol.* 2018 Jul;74(1):4-7. doi: 10.1016/j.eururo.2018.02.025. Epub 2018 Mar 12. PMID: 29544735.
708. Cortesi F, Delfanti G, Grilli A, Calcinotto A, Gorini F, Pucci F, Lucianò R, Grioni M, Recchia A, Benigni F, **Briganti A**, Salonia A, De Palma M, Biccato S, Doglioni C, Bellone M, Casorati G, Dellabona P. Bimodal CD40/Fas-Dependent Crosstalk between iNKT Cells and Tumor-Associated Macrophages Impairs Prostate Cancer Progression. *Cell Rep.* 2018 Mar 13;22(11):3006-3020. doi: 10.1016/j.celrep.2018.02.058. PMID: 29539427.
709. D Andrea D, Abufaraj M, Susani M, Ristl R, Foerster B, Kimura S, Mari A, Soria F, **Briganti A**, Karakiewicz PI, Gust KM, Rouprêt M, Shariat SF. Accurate prediction of progression to muscle-invasive disease in patients with pT1G3 bladder cancer: A clinical decision-making tool. *Urol Oncol.* 2018 May;36(5):239.e1-239.e7. doi: 10.1016/j.urolonc.2018.01.018. Epub 2018 Mar 3. PMID: 29506941.
710. Preisser F, Bandini M, Marchioni M, Nazzani S, Tian Z, Pompe RS, Fossati N, **Briganti A**, Saad F, Shariat SF, Heinzer H, Huland H, Graefen M, Tilki D, Karakiewicz PI. Extent of lymph node dissection improves survival in prostate cancer patients treated with radical prostatectomy without lymph node

- invasion. *Prostate*. 2018 May;78(6):469-475. doi: 10.1002/pros.23491. Epub 2018 Feb 19. PMID: 29460290.
711. Bandini M, Smith A, Marchioni M, Pompe RS, Martel TF, Cindolo L, Montorsi F, Shariat SF, **Briganti A**, Kapoor A, Capitanio U, Karakiewicz PI. Adjuvant Therapies in Nonmetastatic Renal-Cell Carcinoma: A Review of the Literature. *Clin Genitourin Cancer*. 2018 Jun;16(3):176-183. doi: 10.1016/j.clgc.2018.01.003. Epub 2018 Feb 2. PMID: 29449091.
712. Dell'Oglio P, Bandini M, Leyh-Bannurah SR, Tian Z, Trudeau V, Larcher A, Fossati N, Moschini M, Gandaglia G, Capitanio U, **Briganti A**, Graefen M, Montorsi F, Saad F, Karakiewicz PI. External beam radiotherapy with or without androgen deprivation therapy in elderly patients with high metastatic risk prostate cancer. *Urol Oncol*. 2018 May;36(5):239.e9-239.e15. doi: 10.1016/j.urolonc.2018.01.004. Epub 2018 Feb 14. PMID: 29426698.
713. Marchioni M, Preisser F, Bandini M, Nazzani S, Tian Z, Kapoor A, Cindolo L, Abdollah F, Tilki D, **Briganti A**, Montorsi F, Shariat SF, Schips L, Karakiewicz PI. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years. *Eur Urol Focus*. 2019 May;5(3):467-473. doi: 10.1016/j.euf.2018.01.007. Epub 2018 Feb 3. PMID: 29398456.
714. Gandaglia G, Fossati N, Montorsi F, **Briganti A**. Reply to Mustafa Z. Temiz and Huseyin Besiroglu's Letter to the Editor re: Giorgio Gandaglia, Stephen A. Boorjian, William P. Parker, et al. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *Eur Urol* 2017;72:910-7. *Eur Urol*. 2018 May;73(5):e131-e132. doi: 10.1016/j.eururo.2018.01.015. Epub 2018 Feb 1. PMID: 29395499.
715. Moschini M, Mattei A, Cornelius J, Shariat SF, Dell'Oglio P, Zaffuto E, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Surgical treatment for clinical node-positive bladder cancer patients treated with radical cystectomy without neoadjuvant chemotherapy. *World J Urol*. 2018 Apr;36(4):639-644. doi: 10.1007/s00345-018-2190-1. Epub 2018 Jan 24. PMID: 29368231.
716. Bandini M, Preisser F, Nazzani S, Marchioni M, Tian Z, Fossati N, Gandaglia G, Gallina A, Abdollah F, Shariat SF, Montorsi F, Saad F, Tilki D, **Briganti A**, Karakiewicz PI. Contemporary Trends and Survival Outcomes After Aborted Radical Prostatectomy in Lymph Node Metastatic Prostate Cancer Patients. *Eur Urol Focus*. 2019 May;5(3):381-388. doi: 10.1016/j.euf.2018.01.009. Epub 2018 Feb 1. PMID: 29366856.
717. Bandini M, Fossati N, Gandaglia G, Preisser F, Dell'Oglio P, Zaffuto E, Stabile A, Gallina A, Suardi N, Shariat SF, Montorsi F, Karakiewicz PI, **Briganti A**. Neoadjuvant and adjuvant treatment in high-risk prostate cancer. *Expert Rev Clin Pharmacol*. 2018 Apr;11(4):425-438. doi: 10.1080/17512433.2018.1429265. Epub 2018 Jan 25. PMID: 29355037.
718. Cacciamani G, Artibani W, **Briganti A**, N'Dow J. Adherence to the European Association of Urology Guidelines: A National Survey among Italian Urologists. *Urol Int*. 2018;100(2):139-145. doi: 10.1159/000486344. Epub 2018 Jan 16. PMID: 29339653.
719. Zattoni F, Incerti E, Colicchia M, Castellucci P, Panareo S, Picchio M, Fallanca F, **Briganti A**, Moschini M, Gallina A, Karnes JR, Lowe V, Fanti S, Schiavina R, Rambaldi I, Ficarra V, Evangelista L. Comparison between the diagnostic accuracies of 18F-fluorodeoxyglucose positron emission tomography/computed tomography and conventional imaging in recurrent urothelial carcinomas: a retrospective, multicenter study. *Abdom Radiol (NY)*. 2018 Sep;43(9):2391-2399. doi: 10.1007/s00261-017-1443-6. PMID: 29302738.
720. Özsoy M, D'Andrea D, Moschini M, Foerster B, Abufaraj M, Mathieu R, **Briganti A**, Karakiewicz PI, Roupert M, Seitz C, Czech AK, Susani M, Shariat SF. Tertiary Gleason pattern in radical prostatectomy specimens is associated with worse outcomes than the next higher Gleason score group in localized prostate cancer. *Urol Oncol*. 2018 Apr;36(4):158.e1-158.e6. doi: 10.1016/j.urolonc.2017.12.003. Epub 2017 Dec 27. PMID: 29288003.
721. Brembilla G, Dell'Oglio P, Stabile A, Ambrosi A, Cristel G, Brunetti L, Damascelli A, Freschi M, Esposito A, **Briganti A**, Montorsi F, Del Maschio A, De Cobelli F. Preoperative multiparametric MRI of the prostate for the prediction of lymph node metastases in prostate cancer patients treated with

- extended pelvic lymph node dissection. *Eur Radiol.* 2018 May;28(5):1969-1976. doi: 10.1007/s00330-017-5229-6. Epub 2017 Dec 21. PMID: 29270644.
722. Bandini M, Marchioni M, Preisser F, Nazzani S, Tian Z, Fossati N, Gandaglia G, Shariat SF, Montorsi F, Saad F, **Briganti A**, Tilki D, Karakiewicz PI. A Head- to-head Comparison of Four Prognostic Models for Prediction of Lymph Node Invasion in African American and Caucasian Individuals. *Eur Urol Focus.* 2019 May;5(3):449-456. doi: 10.1016/j.euf.2017.11.013. Epub 2017 Dec 14. PMID: 29249688.
723. Leyh-Bannurah SR, Budäus L, Zaffuto E, Pompe RS, Bandini M, **Briganti A**, Montorsi F, Schiffmann J, Shariat SF, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. Adherence to pelvic lymph node dissection recommendations according to the National Comprehensive Cancer Network pelvic lymph node dissection guideline and the D'Amico lymph node invasion risk stratification. *Urol Oncol.* 2018 Feb;36(2):81.e17-81.e24. doi: 10.1016/j.urolonc.2017.10.022. Epub 2017 Dec 14. PMID: 29248430.
724. Mari A, Abufaraj M, Foerster B, Özsoy M, **Briganti A**, Rouprêt M, Karakiewicz PI, Mathieu R, D'Andrea D, Chade DC, Shariat SF. Oncologic Effect of Cumulative Smoking Exposure in Patients Treated With Salvage Radical Prostatectomy for Radiation-recurrent Prostate Cancer. *Clin Genitourin Cancer.* 2018 Jun;16(3):e619-e627. doi: 10.1016/j.clgc.2017.10.015. Epub 2017 Nov 10. PMID: 29239845.
725. Özsoy M, Moschini M, Fajkovic H, Soria F, Seitz C, Klatte T, Gust K, **Briganti A**, Karakiewicz PI, Roupret M, Kramer G, Shariat SF. Elevated preoperative neutrophil-lymphocyte ratio predicts upgrading at radical prostatectomy. *Prostate Cancer Prostatic Dis.* 2018 Apr;21(1):100-105. doi: 10.1038/s41391-017-0015-8. Epub 2017 Dec 11. PMID: 29230007.
726. Marchioni M, Bandini M, Preisser F, Tian Z, Kapoor A, Cindolo L, Primiceri G, Berardinelli F, **Briganti A**, Shariat SF, Schips L, Karakiewicz PI. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study. *Eur Urol Focus.* 2019 May;5(3):488-496. doi: 10.1016/j.euf.2017.11.012. Epub 2017 Dec 8. PMID: 29229582.
727. Gandaglia G, Fossati N, Karnes RJ, Boorjian SA, Colicchia M, Bossi A, Seisen T, Cozzarini C, Di Muzio N, Noris Chiorda B, Zaffuto E, Wiegel T, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Montorsi F, **Briganti A**. Use of Concomitant Androgen Deprivation Therapy in Patients Treated with Early Salvage Radiotherapy for Biochemical Recurrence After Radical Prostatectomy: Long-term Results from a Large, Multi-institutional Series. *Eur Urol.* 2018 Apr;73(4):512-518. doi: 10.1016/j.eururo.2017.11.020. Epub 2017 Dec 8. PMID: 29229176.
728. Gershman B, Thompson RH, Boorjian SA, Larcher A, Capitanio U, Montorsi F, Carenzi C, Bertini R, **Briganti A**, Lohse CM, Chevillat JC, Leibovich BC. Radical Nephrectomy with or without Lymph Node Dissection for High Risk Nonmetastatic Renal Cell Carcinoma: A Multi-Institutional Analysis. *J Urol.* 2018 May;199(5):1143-1148. doi: 10.1016/j.juro.2017.11.114. Epub 2017 Dec 7. PMID: 29225056.
729. Capogrosso P, Barret E, Sanchez-Salas R, Nunes-Silva I, Rozet F, Galiano M, Ventimiglia E, **Briganti A**, Salonia A, Montorsi F, Cathelineau X. Oncological and functional outcomes of elderly men treated with HIFU vs. minimally invasive radical prostatectomy: A propensity score analysis. *Eur J Surg Oncol.* 2018 Jan;44(1):185-191. doi: 10.1016/j.ejso.2017.11.008. Epub 2017 Dec 1. PMID: 29223469.
730. Capogrosso P, Ventimiglia E, Cazzaniga W, Stabile A, Pederzoli F, Boeri L, Gandaglia G, Dehò F, **Briganti A**, Montorsi F, Salonia A. Long-term penile morphometric alterations in patients treated with robot-assisted versus open radical prostatectomy. *Andrology.* 2018 Jan;6(1):136-141. doi: 10.1111/andr.12446. Epub 2017 Dec 1. PMID: 29195014.
731. Smith EJ, MacLennan S, Bjartell A, **Briganti A**, Knoll T, Loch T, Ribal MJ, Sylvester R, Van Poppel H, N'Dow J. Ensuring Consistent European-Wide Urological Care by the Use of Evidence-Based Clinical Practice Guidelines: Can We Do Better. *Biomed Hub.* 2017 Nov 21;2(Suppl 1):162-168. doi: 10.1159/000479725. PMID: 31988946; PMCID: PMC6945914.
732. Gandaglia G, Tilki D, Zaffuto E, Fossati N, Pompe RS, Dell'Oglio P, Graefen M, Montorsi F, **Briganti A**. Are the Results of the Prostate Testing for Cancer and Treatment Trial Applicable to

- Contemporary Prostate Cancer Patients Treated with Radical Prostatectomy? Results from Two High-volume European Institutions. *Eur Urol Focus*. 2019 Jul;5(4):545-549. doi: 10.1016/j.euf.2017.10.013. Epub 2017 Nov 17. PMID: 29153885.
733. Di Trapani E, Nini A, Locatelli I, Buono R, Russo A, Dell'Oglio P, Castiglione F, La Croce G, Benigni F, Montorsi F, Salonia A, Cavarretta I, **Briganti A**. Development of the First Model of Radical Prostatectomy in the Mouse: A Feasibility Study. *Eur Urol*. 2018 Mar;73(3):482-484. doi: 10.1016/j.eururo.2017.10.031. Epub 2017 Nov 15. PMID: 29150358.
734. Leyh-Bannurah SR, Dell'Oglio P, Zaffuto E, **Briganti A**, Schiffmann J, Pompe RS, Tilki D, Heinzer H, Graefen M, Karakiewicz PI, Budäus L. Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience. *Eur Urol Focus*. 2019 Jul;5(4):568-576. doi: 10.1016/j.euf.2017.10.015. Epub 2017 Nov 10. PMID: 29129756.
735. Bandini M, Pompe RS, Marchioni M, Zaffuto E, Gandaglia G, Fossati N, Cindolo L, Montorsi F, **Briganti A**, Saad F, Karakiewicz PI. Improved cancer-specific free survival and overall free survival in contemporary metastatic prostate cancer patients: a population-based study. *Int Urol Nephrol*. 2018 Jan;50(1):71-78. doi: 10.1007/s11255-017-1744-2. Epub 2017 Nov 11. PMID: 29129028.
736. Bandini M, Marchioni M, Pompe RS, Tian Z, Gandaglia G, Fossati N, Abdollah F, Graefen M, Montorsi F, Saad F, Shariat SF, **Briganti A**, Karakiewicz PI. First North American validation and head-to-head comparison of four preoperative nomograms for prediction of lymph node invasion before radical prostatectomy. *BJU Int*. 2018 Apr;121(4):592-599. doi: 10.1111/bju.14074. Epub 2017 Nov 29. PMID: 29124911.
737. Nocera L, Sood A, Dalela D, Gild P, Rogers CG, Peabody JO, Montorsi F, Menon M, **Briganti A**, Abdollah F. Rate and Extent of Pelvic Lymph Node Dissection in the US Prostate Cancer Patients Treated With Radical Prostatectomy. *Clin Genitourin Cancer*. 2018 Apr;16(2):e451-e467. doi: 10.1016/j.clgc.2017.10.003. Epub 2017 Oct 16. PMID: 29113771.
738. Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Mazzone E, Dell'Oglio P, Stabile A, Freschi M, Montorsi F, **Briganti A**. Identifying candidates for super-extended staging pelvic lymph node dissection among patients with high-risk prostate cancer. *BJU Int*. 2018 Mar;121(3):421-427. doi: 10.1111/bju.14066. Epub 2017 Nov 27. PMID: 29063734.
739. Bandini M, Pompe RS, Marchioni M, Tian Z, Gandaglia G, Fossati N, Tilki D, Graefen M, Montorsi F, Shariat SF, **Briganti A**, Saad F, Karakiewicz PI. Radical prostatectomy or radiotherapy reduce prostate cancer mortality in elderly patients: a population-based propensity score adjusted analysis. *World J Urol*. 2018 Jan;36(1):7-13. doi: 10.1007/s00345-017-2102-9. Epub 2017 Oct 23. PMID: 29063268.
740. Touijer KA, Karnes RJ, Passoni N, Sjoberg DD, Assel M, Fossati N, Gandaglia G, Eastham JA, Scardino PT, Vickers A, Cozzarini C, Montorsi F, **Briganti A**. Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies. *Eur Urol*. 2018 Jun;73(6):890-896. doi: 10.1016/j.eururo.2017.09.027. Epub 2017 Oct 16. PMID: 29042125; PMCID: PMC6049832.
741. Bandini M, Smith A, Zaffuto E, Pompe RS, Marchioni M, Capitanio U, Chun FK, Kapoor AB, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Effect of pathological high-risk features on cancer-specific mortality in non-metastatic clear cell renal cell carcinoma: a tool for optimizing patient selection for adjuvant therapy. *World J Urol*. 2018 Jan;36(1):51-57. doi: 10.1007/s00345-017-2093-6. Epub 2017 Oct 11. PMID: 29022072.
742. D'Andrea D, Moschini M, Soria F, Gust KM, **Briganti A**, Karakiewicz PI, Rouprêt M, Shariat SF. ABO Blood Group and Rhesus Factor Are Not Associated with Outcomes After Radical Cystectomy for Non-metastatic Urothelial Carcinoma of the Bladder. *Anticancer Res*. 2017 Oct;37(10):5747-5753.
743. Leyh-Bannurah SR, Karakiewicz PI, Dell'Oglio P, **Briganti A**, Schiffmann J, Pompe RS, Sauter G, Schlomm T, Heinzer H, Huland H, Graefen M, Budäus L. Comparison of 11 Active Surveillance Protocols in Contemporary European Men Treated With Radical Prostatectomy. *Clin Genitourin Cancer*. 2017 Aug 31. pii: S1558-7673(17)30246-X. doi: 10.1016/j.clgc.2017.08.005.
744. Marchioni M, Bandini M, Pompe RS, Martel T, Tian Z, Shariat SF, Kapoor A, Cindolo L, **Briganti A**, Schips L, Capitanio U, Karakiewicz PI. The impact of lymph node dissection and positive lymph

- nodes on cancer specific mortality in contemporary pT2-3 non-metastatic renal cell carcinoma treated with radical nephrectomy. *BJU Int.* 2017 Sep 20. doi: 10.1111/bju.14024.
745. Necchi A, Lo Vullo S, Mariani L, Moschini M, Hendricksen K, Rink M, Sosnowski R, Dobruch J, Raman JD, Wood CG, Margulis V, Roupret M, **Briganti A**, Montorsi F, Xylinas E, Shariat SF; European Association of Urology - Young Academic Urologists (EAU-YAU) Urothelial Cancer Group the Upper Tract Urothelial Carcinoma Collaboration group. Adjuvant chemotherapy after radical nephroureterectomy does not improve survival in patients with upper tract urothelial carcinoma: a joint study of the EAU-Young Academic Urologists and the Upper Tract Urothelial Carcinoma Collaboration. *BJU Int.* 2017 Sep 20. doi: 10.1111/bju.14020.
746. Marchioni M, Bandini M, Pompe RS, Tian Z, Martel T, Kapoor A, Cindolo L, Berardinelli F, **Briganti A**, Shariat SF, Schips L, Karakiewicz PI. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era. *Int Urol Nephrol.* 2017 Sep 20. doi: 10.1007/s11255-017-1703-y.
747. Malte R, Kluth LA, Kaushik D, Boorjian SA, Abufaraj M, Foerster B, Rink M, Gust K, Roghmann F, Noldus J, Vordos D, Hagiwara M, Kikuchi E, Ikeda M, Matsumoto K, Karakiewicz PI, Rouprêt M, **Briganti A**, Scherr DS, Shariat SF, Seebacher V. Frequency and prognostic significance of incidental prostate cancer at radical cystectomy: Results from an international retrospective study. *Eur J Surg Oncol.* 2017 Sep 7. pii: S0748-7983(17)30652-2. doi: 10.1016/j.ejso.2017.08.013.
748. Nini A, Capitanio U, Larcher A, Dell'Oglio P, Dehò F, Suardi N, Muttin F, Careni C, Freschi M, Lucianò R, La Croce G, **Briganti A**, Colombo R, Salonia A, Castiglioni A, Rigatti P, Montorsi F, Bertini R. Perioperative and Oncologic Outcomes of Nephrectomy and Caval Thrombectomy Using Extracorporeal Circulation and Deep Hypothermic Circulatory Arrest for Renal Cell Carcinoma Invading the Supradiaphragmatic Inferior Vena Cava and/or Right Atrium. *Eur Urol.* 2017 Sep 13. pii: S0302-2838(17)30712-1. doi: 10.1016/j.eururo.2017.08.019.
749. Rieken M, Kluth LA, Seitz C, Abufaraj M, Foerster B, Mathieu R, Karakiewicz PI, Bachmann A, **Briganti A**, Rouprêt M, Gönen M, Shariat SF, Seebacher V. External Validation of the Pathologic Nodal Staging Score for Prostate Cancer: A Population-based Study. *Clin Genitourin Cancer.* 2017 Aug 24. pii: S1558-7673(17)30243-4. doi: 10.1016/j.clgc.2017.08.002.
750. Larcher A, Muttin F, Fossati N, Dell'Oglio P, Di Trapani E, Stabile A, Ripa F, Trevisani F, Careni C, Picchio M, **Briganti A**, Salonia A, Mottrie A, Bertini R, Montorsi F, Capitanio U. When to Perform Preoperative Bone Scintigraphy for Kidney Cancer Staging: Indications for Preoperative Bone Scintigraphy. *Urology.* 2017 Sep 7. pii: S0090-4295(17)30961-5. doi: 10.1016/j.urology.2017.08.043.
751. Moschini M, Shariat SF, Abufaraj M, Foerster B, D Andrea D, Soria F, Dell'Oglio P, Mattei A, Montorsi F, Colombo R, **Briganti A**, Gallina A. Predicting local failure after radical cystectomy in patients with bladder cancer: Implications for the selection of candidates at adjuvant radiation therapy. *Urol Oncol.* 2017 Sep 5. pii: S1078-1439(17)30423-4. doi: 10.1016/j.urolonc.2017.08.013.
752. Boeri L, Capogrosso P, Ventimiglia E, Cazzaniga W, Pederzoli F, Gandaglia G, Finocchio N, Dehò F, **Briganti A**, Montanari E, Montorsi F, Salonia A. Depressive Symptoms and Low Sexual Desire After Radical Prostatectomy: Early and Long-Term Outcomes in a Real-Life Setting. *J Urol.* 2017 Aug 31. pii: S0022-5347(17)77423-X. doi: 10.1016/j.juro.2017.08.104.
753. Dell'Oglio P, Stabile A, Gandaglia G, Zaffuto E, Fossati N, Bandini M, Suardi N, Karakiewicz PI, Shariat SF, Montorsi F, **Briganti A**. New surgical approaches for clinically high-risk or metastatic prostate cancer. *Expert Rev Anticancer Ther.* 2017 Sep 1. doi: 10.1080/14737140.2017.1374858.
754. Abufaraj M, Haitel A, Moschini M, Gust K, Foerster B, Özsoy M, D'Andrea D, Karakiewicz PI, Rouprêt M, **Briganti A**, Shariat SF. Prognostic Role of N-cadherin Expression in Patients With Invasive Bladder Cancer. *Clin Genitourin Cancer.* 2017 Aug 15. pii: S1558-7673(17)30198-2. doi: 10.1016/j.clgc.2017.07.001.
755. Marchioni M, Martel T, Bandini M, Pompe RS, Tian Z, Kapoor A, Cindolo L, Autorino R, **Briganti A**, Shariat SF, Schips L, Karakiewicz PI. Marital status and gender affect stage, tumor grade, treatment type and cancer specific mortality in T1-2 N0 M0 renal cell carcinoma. *World J Urol.* 2017 Aug 28. doi: 10.1007/s00345-017-2082-9
756. Moschini M, Soria F, Susani M, Korn S, **Briganti A**, Roupret M, Seitz C, Gust K, Haitel A, Montorsi F, Wirth G, Robinson BD, Karakiewicz PI, Özsoy M, Rink M, Shariat SF. Impact of the Level

- of Urothelial Carcinoma Involvement of the Prostate on Survival after Radical Cystectomy. *Bladder Cancer*. 2017;3:161-169.
757. Villa L, Haddad M, Capitanio U, Somani BK, Cloutier J, Doizi S, Salonia A, **Briganti A**, Montorsi F, Traxer O. Which patients with upper tract urothelial carcinoma can be safely treated with conservative treatment by flexible ureteroscopy with Holmium:YAG laser photoablation? Long-term results from a high-volume institution. *J Urol*. 2017 Aug 14. pii: S0022-5347(17)77316-8. doi: 10.1016/j.juro.2017.07.088.
758. van den Bergh R, Gandaglia G, Tilki D, Borgmann H, Ost P, Surcel C, Valerio M, Sooriakumaran P, **Briganti A**, Graefen M, van der Poel H, de la Taille A, Montorsi F, Ploussard G; European Association of Urology Young Academic Urologists Working Party on Prostate Cancer (EAU-YAUWP). Trends in Radical Prostatectomy Risk Group Distribution in a European Multicenter Analysis of 28 572 Patients: Towards Tailored Treatment. *Eur Urol Focus*. 2017 Aug 8. pii: S2405-4569(17)30188-8. doi: 10.1016/j.euf.2017.07.003.
759. Dell'Oglio P, Larcher A, Muttin F, Di Trapani E, Trevisani F, Ripa F, Carezzi C, **Briganti A**, Salonia A, Montorsi F, Bertini R, Capitanio U. Lymph node dissection should not be dismissed in case of localized renal cell carcinoma in the presence of larger diseases. *Urol Oncol*. 2017 Aug 8. pii: S1078-1439(17)30355-1. doi: 10.1016/j.urolonc.2017.07.010.
760. Bandini M, Fossati N, **Briganti A**. Salvage surgery for nodal recurrent prostate cancer. *Curr Opin Urol*. 2017 Aug 5. doi: 10.1097/MOU.0000000000000437
761. Fossati N, Karnes RJ, Colicchia M, Boorjian SA, Bossi A, Seisen T, Di Muzio N, Cozzarini C, Noris Chiorda B, Fiorino C, Gandaglia G, Dell'Oglio P, Shariat SF, Goldner G, Joniau S, Battaglia A, Haustermans K, De Meerleer G, Fonteyne V, Ost P, Van Poppel H, Wiegel T, Montorsi F, **Briganti A**. Impact of Early Salvage Radiation Therapy in Patients with Persistently Elevated or Rising Prostate-specific Antigen After Radical Prostatectomy. *Eur Urol*. 2017 Aug 2. pii: S0302-2838(17)30655-3. doi: 10.1016/j.eururo.2017.07.026
762. Zaffuto E, Pompe R, Bondarenko HD, Moschini M, Dell'Oglio P, Gandaglia G, Fossati N, Shariat SF, Montorsi F, **Briganti A**, Karakiewicz PI. Hospitalization before surgery and subsequent risk of infective complications after radical cystectomy: A population-based analysis. *Urol Oncol*. 2017 Jul 26. pii: S1078-1439(17)30349-6. doi: 10.1016/j.urolonc.2017.07.004. .
763. Trevisani F, Larcher A, Cinque A, Capitanio U, Ripa F, Vago R, Bettiga A, Benigni F, Carezzi C, Muttin F, Bertini R, **Briganti A**, Salonia A, Rampoldi L, Montorsi F. The Association of Uromodulin Genotype with Renal Cancer Aggressiveness. *Eur Urol Focus*. 2017 May 12. pii: S2405-4569(17)30115-3. doi: 10.1016/j.euf.2017.04.009.
764. Dell'Oglio P, Bishr M, Boehm K, Trudeau V, Larcher A, Tian Z, Sosa J, Moschini M, Saad F, Capitanio U, **Briganti A**, Graefen M, Montorsi F, Karakiewicz PI. Survival Outcomes in Octogenarian and Nonagenarian Patients Treated with First-line Androgen Deprivation Therapy for Organ-confined Prostate Cancer. *Eur Urol Focus*. 2017 Feb 11. pii: S2405-4569(17)30026-3. doi: 10.1016/j.euf.2017.01.017
765. D'Andrea D, Moschini M, Foerster B, Abufaraj M, Margulis V, Karam J, Lotan Y, Raman J, Mathieu R, Rouprêt M, Karakiewicz PI, **Briganti A**, Haitel A, Shariat SF. Caveolin-1 Expression in Upper Tract Urothelial Carcinoma. *Eur Urol Focus*. 2017 Jul 1. pii: S2405-4569(17)30162-1. doi: 10.1016/j.euf.2017.06.011.
766. Tosco L, Laenen A, **Briganti A**, Gontero P, Karnes RJ, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Albersen M, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Van Der Poel H, Walz J, De Meerleer G, Bossi A, Haustermans K, Van Poppel H, Spahn M, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research group (EMPaCT). The EMPaCT Classifier: A Validated Tool to Predict Postoperative Prostate Cancer-related Death Using Competing-risk Analysis. *Eur Urol Focus*. 2017 Jan 17. pii: S2405-4569(17)30002-0. doi: 10.1016/j.euf.2016.12.008.
767. Leyh-Bannurah SR, Dell'Oglio P, Tian Z, Schiffmann J, Shariat SF, Suardi N, Montorsi F, **Briganti A**, Heinzer H, Huland H, Graefen M, Budäus L, Karakiewicz PI. A proposal of a new nomogram for predicting upstaging in contemporary D'Amico low-risk prostate cancer patients. *World J Urol*. 2017 Feb;35(2):189-19

768. Moschini M, Morlacco A, **Briganti A**, Hu B, Colombo R, Montorsi F, Frank I, Daneshmand S, Karnes RJ. Clinical Lymphadenopathy in Urothelial Cancer: A Transatlantic Collaboration on Performance of Cross-sectional Imaging and Oncologic Outcomes in Patients Treated with Radical Cystectomy Without Neoadjuvant Chemotherapy. *Eur Urol Focus*. 2016 Nov 23. pii: S2405-4569(16)30163-8. doi: 10.1016/j.euf.2016.11.005
769. Petitprez F, Fossati N, Vano Y, Freschi M, Becht E, Lucianò R, Calderaro J, Guédet T, Lacroix L, Rancoita PMV, Montorsi F, Fridman WH, Sautès-Fridman C, **Briganti A**, Doglioni C, Bellone M. PD-L1 Expression and CD8+ T-cell Infiltrate are Associated with Clinical Progression in Patients with Node-positive Prostate Cancer. *Eur Urol Focus*. 2017 Jun 21. pii: S2405-4569(17)30151-7. doi: 10.1016/j.euf.2017.05.013
770. Moschini M, Fossati N, Sood A, Lee JK, Sammon J, Sun M, Pucheril D, Dalela D, Montorsi F, Karnes RJ, **Briganti A**, Trinh QD, Menon M, Abdollah F. Contemporary Management of Prostate Cancer Patients suitable for Active Surveillance: A North-American Population-based study. *Eur Urol Focus*. 2016 Jun 14. pii: S2405-4569(16)30061-X. doi: 10.1016/j.euf.2016.06.001
771. Fossati N, Di Trapani E, Gandaglia G, Dell'Oglio P, Umari P, Buffi NM, Guazzoni G, Mottrie A, Gaboardi F, Montorsi F, **Briganti A**, Suardi N. Assessing the Impact of Surgeon Experience on Urinary Continence Recovery After Robot-Assisted Radical Prostatectomy: Results of Four High-Volume Surgeons. *J Endourol*. 2017 Jul 21. doi: 10.1089/end.2017.0085. [Epub ahead of print]
772. Moschini M, Bianchi M, Gandaglia G, Cucchiara V, Luzzago S, Pellucchi F, Damiano R, Serretta V, **Briganti A**, Montorsi F, Salonia A, Colombo R. The Impact of Perioperative Blood Transfusion on Survival of Bladder Cancer Patients Submitted to Radical Cystectomy: Role of Anemia Status. *Eur Urol Focus*. 2016 Apr;2(1):86-91. doi: 10.1016/j.euf.2015.03.002. Epub 2015 Jun 3.
773. Lucca I, Jichlinski P, Shariat SF, Rouprêt M, Rieken M, Kluth LA, Rink M, Mathieu R, Mbeutcha A, Maj-Hes A, Fajkovic H, **Briganti A**, Seitz C, Karakiewicz PI, de Martino M, Lotan Y, Babjuk M, Klatter T. The Neutrophil-to-lymphocyte Ratio as a Prognostic Factor for Patients with Urothelial Carcinoma of the Bladder Following Radical Cystectomy: Validation and Meta-analysis. *Eur Urol Focus*. 2016 Apr;2(1):79-85. doi: 10.1016/j.euf.2015.03.001. Epub 2015 May 29.
774. Giannarini G, **Briganti A**, Klatter T, Shariat SF, Catto JW. Reducing Complications After Surgery: Still a Long Way To Go. *Eur Urol Focus*. 2016 Apr;2(1):1-2. doi: 10.1016/j.euf.2015.12.007. Epub 2016 Jan 6. .
775. **Briganti A**, Giannarini G, Klatter T, Catto JW, Shariat SF. The Future of Prostate Cancer Diagnosis: Biomarkers, Biopsy, Both, or Neither? *Eur Urol Focus*. 2015 Sep;1(2):97-98. doi: 10.1016/j.euf.2015.07.007. Epub 2015 Sep 19. .
776. **Briganti A**. Case Presentation: Intermediate-risk Prostate Cancer in a Fit 66-year-old Man. *Eur Urol Focus*. 2015 Sep;1(2):207-208. doi: 10.1016/j.euf.2015.08.004. Epub 2015 Sep 19. .
777. Abdollah F, Karakiewicz PI, Gandaglia G, Dalela D, Klett DE, Shiffmann J, Montorsi F, **Briganti A**, Saad F, Graefen M, Peabody JO, Menon M, Sun M. Adjuvant Radiotherapy in Prostate Cancer Patients Treated with Surgery: The Impact of Age and Tumor Characteristics. *Eur Urol Focus*. 2015 Sep;1(2):191-199. doi: 10.1016/j.euf.2015.06.008. Epub 2015 Jul 10. .
778. Tsikkinis A, Cihoric N, Giannarini G, Hinz S, **Briganti A**, Wust P, Ost P, Ploussard G, Massard C, Surcel CI, Sooriakumaran P, Isbarn H, De Visschere PJJ, Futterer JJ, van der Bergh RCN, Dal Pra A, Aebbersold DM, Budach V, Ghadjari P. Clinical Perspectives from Randomized Phase 3 Trials on Prostate Cancer: An Analysis of the ClinicalTrials.gov Database. *Eur Urol Focus*. 2015 Sep;1(2):173-184. doi: 10.1016/j.euf.2015.05.003. Epub 2015 Jun 6. .
779. Klatter T, Shariat SF, **Briganti A**, Giannarini G, Catto JW. Adrenal Lesions: Progress on All Fronts. *Eur Urol Focus*. 2016 Feb;1(3):215-216. doi: 10.1016/j.euf.2015.11.003. Epub 2015 Nov 23. .
780. **Briganti A**, Giannarini G. Case Presentation: A Man with Two Synchronous and Symptomatic Malignancies Related to Smoking. *Eur Urol Focus*. 2015 Aug;1(1):90-91. doi: 10.1016/j.euf.2015.07.002. Epub 2015 Aug 1. .
781. Shariat SF, Catto JW, Klatter T, Giannarini G, **Briganti A**. There Are Cooler Ways to Die Than Smoking: Urologists of the World, Unite Against This Health Care Tragedy. *Eur Urol Focus*. 2015 Aug;1(1):1-2. doi: 10.1016/j.euf.2014.12.004. Epub 2015 May 18. .

782. Fossati N, Giannarini G, Klatte T, Catto JW, **Briganti A**. The Rapidly Evolving Role of Imaging in Urology: How to Balance Breakthroughs in Knowledge with Overuse. *Eur Urol Focus*. 2016 Jun;2(2):111-112. doi: 10.1016/j.euf.2016.04.012. Epub 2016 May 10. .
783. Bultijnck R, Surcel C, Ploussard G, **Briganti A**, De Visschere P, Fütterer J, Ghadjar P, Giannarini G, Isbarn H, Massard C, Sooriakumaran P, Valerio M, van den Bergh R, Ost P. Practice Patterns Compared with Evidence-based Strategies for the Management of Androgen Deprivation Therapy-Induced Side Effects in Prostate Cancer Patients: Results of a European Web-based Survey. *Eur Urol Focus*. 2016 Dec;2(5):514-521. doi: 10.1016/j.euf.2016.02.009. Epub 2016 Mar 5. .
784. **Briganti A**, De Santis M, Giannarini G, Sweeney CJ. Delivering Optimal Care for Metastatic Prostate Cancer: A Strengthening Alliance Between Urologists and Medical Oncologists. *Eur Urol Focus*. 2016 Dec;2(5):463-464. doi: 10.1016/j.euf.2016.11.017. Epub 2016 Dec 13. .
785. Klatte T, Giannarini G, **Briganti A**, Catto JW. Kidney Cancer: Many Important Advances but Still a Lot to Debate. *Eur Urol Focus*. 2016 Dec 15;2(6):565-566. doi: 10.1016/j.euf.2017.03.002. Epub 2017 Apr 14.
786. Giannarini G, Klatte T, Catto JW, **Briganti A**. Beware of Bugs! Hot Issues in Urinary Tract Infections and Inflammation. *Eur Urol Focus*. 2016 Oct;2(4):339-340. doi: 10.1016/j.euf.2016.08.014. Epub 2016 Sep 9.
787. Klatte T, Giannarini G, Catto JW, **Briganti A**. Urinary Incontinence: Moving the Field Forward. *Eur Urol Focus*. 2016 Aug;2(3):229-230. doi: 10.1016/j.euf.2016.06.012. Epub 2016 Jul 14. .
788. Foerster B, Moschini M, Abufaraj M, Soria F, Gust KM, Rouprêt M, Karakiewicz PI, **Briganti A**, Rink M, Kluth L, Mathieu R, Margulis V, Lotan Y, Aziz A, John H, Shariat SF; UTUC Collaboration. Predictive and Prognostic Value of Preoperative Thrombocytosis in Upper Tract Urothelial Carcinoma. *Clin Genitourin Cancer*. 2017 Jun 19. pii: S1558-7673(17)30169-6. doi: 10.1016/j.clgc.2017.06.003. [Epub ahead of print]
789. Bandini M, Gandaglia G, **Briganti A**. Obesity and prostate cancer. *Curr Opin Urol*. 2017 Jun 16. doi: 10.1097/MOU.0000000000000424.
790. Gandaglia G, Boorjian SA, Parker WP, Zaffuto E, Fossati N, Bandini M, Dell'Oglio P, Suardi N, Montorsi F, Karnes RJ, **Briganti A**. Impact of Postoperative Radiotherapy in Men with Persistently Elevated Prostate-specific Antigen After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *Eur Urol*. 2017 Jun 13. pii: S0302-2838(17)30496-7. doi: 10.1016/j.eururo.2017.06.001.]
791. Colicchia M, Sharma V, Abdollah F, **Briganti A**, Jeffrey Karnes R. Therapeutic Value of Standard Versus Extended Pelvic Lymph Node Dissection During Radical Prostatectomy for High-Risk Prostate Cancer. *Curr Urol Rep*. 2017 Jul;18(7):51. doi: 10.1007/s11934-017-0696-5. Review.
792. Morgans AK, Dale W, **Briganti A**. Screening and Treating Prostate Cancer in the Older Patient: Decision Making Across the Clinical Spectrum. *Am Soc Clin Oncol Educ Book*. 2017;37:370-381. doi: 10.14694/EDBK_175491.
793. Soria F, Moschini M, Wirth GJ, Gust KM, Klatte T, **Briganti A**, Gontero P, Abufaraj M, Özsoy M, Karakiewicz PI, Shariat SF. Characterization of Late Recurrence After Radical Cystectomy in a Large Multicenter Cohort of Bladder Cancer Patients. *Urology*. 2017 Aug;106:119-124. doi: 10.1016/j.urology.2017.05.049. Epub 2017 May 12.
794. Zaffuto E, Pompe R, Zanaty M, Bondarenko HD, Leyh-Bannurah SR, Moschini M, Dell'Oglio P, Gandaglia G, Fossati N, Stabile A, Zorn KC, Montorsi F, **Briganti A**, Karakiewicz PI. Contemporary Incidence and Cancer Control Outcomes of Primary Neuroendocrine Prostate Cancer: A SEER Database Analysis. *Clin Genitourin Cancer*. 2017 Apr 13. pii: S1558-7673(17)30090-3. doi: 10.1016/j.clgc.2017.05.006.
795. Fiorino C, Broggi S, Di Muzio NG, Fossati N, **Briganti A**, Cozzarini C. Salvage radiation therapy after prostatectomy: Understanding the dose-response effect. *Radiother Oncol*. 2017 Jun;123(3):486-487. doi: 10.1016/j.radonc.2017.02.020. Epub 2017 May 11.
796. Tosco L, Laenen A, **Briganti A**, Gontero P, Karnes RJ, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Everaerts W, Gratzke C, Graefen M, Kneitz B, Marchioro G, Salas RS, Tombal B, Van den Broeck T, Moris L, Battaglia A, van der Poel H, Walz J, Bossi A, De Meerleer G, Haustermans K, Van Poppel H, Spahn M, Joniau S. The survival impact of neoadjuvant hormonal therapy before

- radical prostatectomy for treatment of high-risk prostate cancer. *Prostate Cancer Prostatic Dis.* 2017 May 9. doi: 10.1038/pcan.2017.29.
797. Abdollah F, Dalela D, Sood A, Sammon J, Cho R, Nocera L, Diaz M, Jeong W, Peabody JO, Fossati N, Gandaglia G, **Briganti A**, Montorsi F, Menon M. Functional outcomes of clinically high-risk prostate cancer patients treated with robot-assisted radical prostatectomy: a multi-institutional analysis. *Prostate Cancer Prostatic Dis.* 2017 May 2. doi: 10.1038/pcan.2017.26.
798. Bandini M, Gandaglia G, Fossati N, Montorsi F, **Briganti A**. An Explanatory Case on the Limitations of Lymph Node Staging in Recurrent Prostate Cancer. *Urol Case Rep.* 2017 Mar 10;12:34-36. doi: 10.1016/j.eucr.2017.02.011. eCollection 2017 May.
799. Maj-Hes AB, Mathieu R, Özsoy M, Soria F, Moschini M, Abufaraj M, **Briganti A**, Roupret M, Karakiewicz PI, Klatte T, Shariat SF. Obesity is associated with biochemical recurrence after radical prostatectomy: A multi-institutional extended validation study. *Urol Oncol.* 2017 Jul;35(7):460.e1-460.e8. doi: 10.1016/j.urolonc.2017.01.022. Epub 2017 Apr 29. (
800. Cantiello F, Gangemi V, Cascini GL, Calabria F, Moschini M, Ferro M, Musi G, Buttice S, Salonia A, **Briganti A**, Damiano R. Diagnostic Accuracy of 64Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. *Urology.* 2017 Aug;106:139-145. doi: 10.1016/j.urology.2011.855.019. Epub 2017 Apr 21.
801. Cavarretta I, Ferrarese R, Cazzaniga W, Saita D, Lucianò R, Ceresola ER, Locatelli I, Visconti L, Lavorgna G, **Briganti A**, Nebuloni M, Doglioni C, Clementi M, Montorsi F, Canducci F, Salonia A. The Microbiome of the Prostate Tumor Microenvironment. *Eur Urol.* 2017 Apr 20. pii: S0302-2838(17)30250-6. doi: 10.1016/j.eururo.2017.03.029.
802. Moschini M, Shariat SF, Freschi M, Soria F, D'Andrea D, Abufaraj M, Foerster B, Dell'Oglio P, Zaffuto E, Mattei A, Salonia A, Montorsi F, **Briganti A**, Gallina A, Colombo R. Is transurethral resection alone enough for the diagnosis of histological variants? A single-center study. *Urol Oncol.* 2017 Apr 19. pii: S1078-1439(17)30133-3. doi: 10.1016/j.urolonc.2017.03.024.
803. D'Andrea D, Moschini M, Gust K, Abufaraj M, Özsoy M, Mathieu R, Soria F, **Briganti A**, Rouprêt M, Karakiewicz PI, Shariat SF. Prognostic Role of Neutrophil-to-Lymphocyte Ratio in Primary Non-muscle-invasive Bladder Cancer. *Clin Genitourin Cancer.* 2017 Mar 27. pii: S1558-7673(17)30069-1. doi: 10.1016/j.clgc.2017.03.007.
804. Gandaglia G, Fossati N, Zaffuto E, Bandini M, Dell'Oglio P, Bravi CA, Fallara G, Pellegrino F, Nocera L, Karakiewicz PI, Tian Z, Freschi M, Montironi R, Montorsi F, **Briganti A**. Development and Internal Validation of a Novel Model to Identify the Candidates for Extended Pelvic Lymph Node Dissection in Prostate Cancer. *Eur Urol.* 2017 Apr 12. pii: S0302-2838(17)30280-4. doi: 10.1016/j.eururo.2017.03.049.
805. Gandaglia G, Fossati N, Dell'Oglio P, Montorsi F, **Briganti A**. Is there a role for pure clinical prediction models in prostate cancer in the contemporary era? *BJU Int.* 2017 May;119(5):652-653. doi: 10.1111/bju.13833.
806. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, **Briganti A**, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Steuber T, Huland H, Graefen M, Karakiewicz PI. Local Therapy Improves Survival in Metastatic Prostate Cancer. *Eur Urol.* 2017 Jul;72(1):118-124. doi: 10.1016/j.eururo.2017.03.020. Epub 2017 Apr 3.
807. Beauval JB, Cabarrou B, Gandaglia G, Patard PM, Ouzzane A, de la Taille A, Soulié M, **Briganti A**, Ploussard G, Rozet F, Roumiguié M. External validation of a nomogram for identification of pathologically favorable disease in intermediate risk prostate cancer patients. *Prostate.* 2017 Jun;77(8):928-933. doi: 10.1002/pros.23348. Epub 2017 Apr 2.
808. Gandaglia G, Karnes RJ, Sivaraman A, Moschini M, Fossati N, Zaffuto E, Dell'Oglio P, Cathelineau X, Montorsi F, Sanchez-Salas R, **Briganti A**. Are all grade group 4 prostate cancers created equal? Implications for the applicability of the novel grade grouping. *Urol Oncol.* 2017 Jul;35(7):461.e7-461.e14. doi: 10.1016/j.urolonc.2017.02.012. Epub 2017 Mar 27.
809. Dalela D, Santiago-Jiménez M, Yousefi K, Karnes RJ, Ross AE, Den RB, Freedland SJ, Schaeffer EM, Dicker AP, Menon M, **Briganti A**, Davicioni E, Abdollah F. Genomic Classifier Augments the Role of Pathological Features in Identifying Optimal Candidates for Adjuvant Radiation Therapy in Patients

- With Prostate Cancer: Development and Internal Validation of a Multivariable Prognostic Model. *J Clin Oncol*. 2017 Jun 20;35(18):1982-1990. doi: 10.1200/JCO.2016.69.9918. Epub 2017 Mar 28.
810. Soria F, Lucca I, Moschini M, Mathieu R, Rouprêt M, Karakiewicz PI, **Briganti A**, Rink M, Gust KM, Hassler MR, Foerster B, Abufarraj M, Haitel A, Klatte T, Shariat SF. Caveolin-1 as prognostic factor of disease recurrence and survival in patients treated with radical cystectomy for bladder cancer. *Urol Oncol*. 2017 Jun;35(6):356-362. doi: 10.1016/j.urolonc.2017.02.009. Epub 2017 Mar 23.
811. Dell'Oglio P, Zaffuto E, Boehm K, Trudeau V, Larcher A, Tian Z, Moschini M, Shariat SF, Graefen M, Saad F, Capitanio U, **Briganti A**, Montorsi F, Karakiewicz PI. Long-term survival of patients aged 80 years or older treated with radical prostatectomy for prostate cancer. *Eur J Surg Oncol*. 2017 Aug;43(8):1581-1588. doi: 10.1016/j.ejso.2017.02.018. Epub 2017 Mar 10.
812. Dell'Oglio P, Tian Z, Leyh-Bannurah SR, Trudeau V, Larcher A, Moschini M, Di Trapani E, Capitanio U, **Briganti A**, Montorsi F, Saad F, Karakiewicz PI. Short-Form Charlson Comorbidity Index for Assessment of Perioperative Mortality After Radical Cystectomy. *J Natl Compr Canc Netw*. 2017 Mar;15(3):327-333.
813. Nehra A, Karnes RJ, Gandaglia G, **Briganti A**. Lymph node dissection in urological cancers: one topic, many controversies. *World J Urol*. 2017 Apr;35(4):493-495. doi: 10.1007/s00345-017-2027-3. Epub 2017 Mar 1.
814. Moschini M, Foerster B, Abufarraj M, Soria F, Seisen T, Roupert M, Colin P, De la Taille A, Peyronnet B, Bensalah K, Herout R, Wirth MP, Novotny V, Chlosta P, Bandini M, Montorsi F, Simone G, Gallucci M, Romeo G, Matsumoto K, Karakiewicz P, **Briganti A**, Shariat SF. Trends of lymphadenectomy in upper tract urothelial carcinoma (UTUC) patients treated with radical nephroureterectomy. *World J Urol*. 2017 Feb 28. doi: 10.1007/s00345-017-2026-4
815. Spahn M, Morlacco A, Boxler S, Joniau S, **Briganti A**, Montorsi F, Gontero P, Bader P, Frohneberg D, van Poppel H, Karnes RJ; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPAcT). Outcome predictors of radical cystectomy in patients with cT4 prostate cancer: a multi-institutional study of 62 patients. *BJU Int*. 2017 Feb 20. doi: 10.1111/bju.13818.
816. Abufarraj M, Shariat SF, Haitel A, Moschini M, Foerster B, Chłosta P, Gust K, Babjuk M, **Briganti A**, Karakiewicz PI, Albrecht W. Prognostic role of N-cadherin expression in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2017 May;35(5):264-271. doi: 10.1016/j.urolonc.2017.01.012. Epub 2017 Feb 14.
817. Gandaglia G, Fossati N, Montorsi F, **Briganti A**. Reply to Pascal Mouracade's Letter to the Editor re: Giorgio Gandaglia, Nicola Fossati, Armando Stabile, et al. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. *Eur Urol* 2017;72:289-92. Do the Data Violate Kaplan-Meier Assumptions? *Eur Urol*. 2017 Aug;72(2):e31. doi: 10.1016/j.eururo.2017.01.048. Epub 2017 Feb 15.
818. Gandaglia G, **Briganti A**, Clarke N, Karnes RJ, Graefen M, Ost P, Zietman AL, Roach M 3rd. Adjuvant and Salvage Radiotherapy after Radical Prostatectomy in Prostate Cancer Patients. *Eur Urol*. 2017 Feb 8. pii: S0302-2838(17)30064-7. doi: 10.1016/j.eururo.2017.01.039.
819. Moschini M, Soria F, Abufarraj M, Foerster B, D'Andrea D, Damiano R, Klatte T, Montorsi F, **Briganti A**, Colombo R, Gallina A, Shariat SF. Impact of Intra- and Postoperative Blood Transfusion on the Incidence, Timing, and Pattern of Disease Recurrence After Radical Cystectomy. *Clin Genitourin Cancer*. 2017 Jan 11. pii: S1558-7673(17)30001-0. doi: 10.1016/j.clgc.2017.01.001
820. Moschini M, Shariat SF, Freschi M, Soria F, Abufarraj M, Gandaglia G, Dell'Oglio P, Mattei A, Damiano R, Salonia A, Montorsi F, **Briganti A**, Gallina A, Colombo R. Impact of Prostate Involvement on Outcomes in Patients Treated with Radical Cystoprostatectomy for Bladder Cancer. *Urol Int*. 2017;98(3):290-297. doi: 10.1159/000454736. Epub 2017 Feb 1.
821. Seisen T, **Briganti A**, Blanchard P, Abdollah F. Salvage Radiation Therapy for Biochemical Recurrence After Radical Prostatectomy: Is Earlier Always Better? *J Clin Oncol*. 2017 May 1;35(13):1489-1490. doi: 10.1200/JCO.2016.70.6879. Epub 2017 Jan 30.
822. D'Andrea D, Moschini M, Gust KM, Abufarraj M, Özsoy M, Mathieu R, Soria F, **Briganti A**, Rouprêt M, Karakiewicz PI, Shariat SF. Lymphocyte-to-monocyte ratio and neutrophil-to-lymphocyte

- ratio as biomarkers for predicting lymph node metastasis and survival in patients treated with radical cystectomy. *J Surg Oncol*. 2017 Mar;115(4):455-461. doi: 10.1002/jso.24521. Epub 2017 Jan 20.
823. Leyh-Bannurah SR, Budäus L, Pompe R, Zaffuto E, **Briganti A**, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Huland H, Graefen M, Karakiewicz PI. North American Population-Based Validation of the National Comprehensive Cancer Network Practice Guideline Recommendation of Pelvic Lymphadenectomy in Contemporary Prostate Cancer. *Prostate*. 2017 Apr;77(5):542-548. doi: 10.1002/pros.23292. Epub 2017 Jan 17.
824. Moschini M, Dell'Oglio P, Luciano' R, Gandaglia G, Soria F, Mattei A, Klatte T, Damiano R, Shariat SF, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Incidence and effect of variant histology on oncological outcomes in patients with bladder cancer treated with radical cystectomy. *Urol Oncol*. 2017 Jun;35(6):335-341. doi: 10.1016/j.urolonc.2016.11.796. Epub 2017 Jan 10
825. Mathieu R, Moschini M, Beyer B, Gust KM, Seisen T, **Briganti A**, Karakiewicz P, Seitz C, Salomon L, de la Taille A, Rouprêt M, Graefen M, Shariat SF. Prognostic value of the new Grade Groups in Prostate Cancer: a multi-institutional European validation study. *Prostate Cancer Prostatic Dis*. 2017 Jun;20(2):197-202. doi: 10.1038/pcan.2016.66. Epub 2017 Jan 10.
826. Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, **Briganti A**. Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How? *J Clin Oncol*. 2016 Nov 7:JCO2016702118. [Epub ahead of print]
827. Suardi N, **Briganti A**, Gandaglia G, Fossati N, Montorsi F. Salvage Lymph Node Dissection for Node-only Recurrence of Prostate Cancer: Ready for Prime Time?
828. *Eur Urol*. 2016 Dec 30. pii: S0302-2838(16)30898-3. doi: 10.1016/j.eururo.2016.12.001. [Epub ahead of print]
829. Moschini M, Shariat SF, Lucianò R, D'Andrea D, Foerster B, Abufaraj M, Bandini M, Dell'Oglio P, Damiano R, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Pure but Not Mixed Histologic Variants Are Associated With Poor Survival at Radical Cystectomy in Bladder Cancer Patients. *Clin Genitourin Cancer*. 2016 Dec 14. pii: S1558-7673(16)30352-4. doi: 10.1016/j.clgc.2016.11.796 [Epub ahead of print]
830. MacLennan S, **Briganti A**, Grimshaw JM, N'Dow J. Re: Low Adherence to Guidelines in Nonmuscle-invasive Disease. *Eur Urol*. 2017 Apr;71(4):689. doi: 10.1016/j.eururo.2016.12.019. Epub 2016 Dec 29.
831. Moris L, Van den Broeck T, Tosco L, Van Baelen A, Gontero P, Karnes RJ, Everaerts W, Albersen M, Bastian PJ, Chlosta P, Claessens F, Chun FK, Graefen M, Gratzke C, Kneitz B, Marchioro G, Salas RS, Tombal B, Van Der Poel H, Walz JC, De Meerleer G, Bossi A, Haustermans K, Montorsi F, Van Poppel H, Spahn M, **Briganti A**, Joniau S. Impact of Lymph Node Burden on Survival of High-risk Prostate Cancer Patients Following Radical Prostatectomy and Pelvic Lymph Node Dissection. *Front Surg*. 2016 Dec 16;3:65. doi: 10.3389/fsurg.2016.00065. eCollection 2016.
832. Fossati N, Rossi MS, Cucchiara V, Gandaglia G, Dell'Oglio P, Moschini M, Suardi N, Dehò F, Montorsi F, Schiavina R, Mottrie A, **Briganti A**. Evaluating the effect of time from prostate cancer diagnosis to radical prostatectomy on cancer control: Can surgery be postponed safely? *Urol Oncol*. 2016 Dec 13. pii: S1078-1439(16)30395-7. doi: 10.1016/j.urolonc.2016.11.010. [Epub ahead of print] PubMed PMID: 27986374
833. Moschini M, Shariat SF, Abufaraj M, Soria F, Klatte T, Croce G, Mattei A, Damiano R, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. The presence of carcinoma in situ at radical cystectomy increases the risk of urothelial recurrence: Implications for follow-up schemes. *Urol Oncol*. 2016 Dec 5. pii: S1078-1439(16)30369-6. doi: 10.1016/j.urolonc.2016.11.003. [Epub ahead of print] PubMed PMID: 27932269
834. Soria F, Moschini M, Abufaraj M, Wirth GJ, Foerster B, Gust KM, Özsoy M, **Briganti A**, Gontero P, Mathieu R, Rouprêt M, Karakiewicz PI, Shariat SF. Preoperative anemia is associated with disease recurrence and progression in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Nov 28. pii: S1078-1439(16)30362-3. doi: 10.1016/j.urolonc.2016.10.021. [Epub ahead of print] PubMed PMID: 27908681

835. Gandaglia G, Zaffuto E, Fossati N, Cucchiara V, Mirone V, Montorsi F, **Briganti A**. The role of prostatic inflammation in the development and progression of benign and malignant diseases. *Curr Opin Urol*. 2016 Nov 30. [Epub ahead of print] PubMed PMID: 27906778
836. Tutolo M, Fossati N, Van der Aa F, Gandaglia G, Montorsi F, **Briganti A**. Magnetic Resonance Imaging for Membranous Urethral Length Assessment Prior to Radical Prostatectomy: Can it Really Improve Prostate Cancer Management? *Eur Urol*. 2016 Nov 22. pii: S0302-2838(16)30811-9. doi: 10.1016/j.eururo.2016.11.011. [Epub ahead of print] PubMed PMID: 27887943
837. Larcher A, Trudeau V, Dell'Oglio P, Tian Z, Boehm K, Fossati N, Capitanio U, **Briganti A**, Montorsi F, Karakiewicz P. Prediction of Competing Mortality for Decision Making between Surgery or Observation in Elderly Patients with T1 Kidney Cancer. *Urology*. 2016 Nov 21. pii: S0090-4295(16)30847-0. doi: 10.1016/j.urology.2016.08.069. [Epub ahead of print] PubMed PMID: 27884597
838. Zaffuto E, Gazdovich S, Leyh-Bannurah SR, Huland H, Abdollah F, Shariat SF, Menon M, **Briganti A**, Montorsi F, Karakiewicz PI. Contemporary rates of pathological features and mortality for adenocarcinoma of the urinary bladder in the USA. *Int J Urol*. 2016 Nov 22. doi: 10.1111/iju.13261. PubMed PMID: 27875858
839. Abufaraj M, Moschini M, Soria F, Gust K, Özsoy M, Mathieu R, Rouprêt M, Margulis V, Karam JA, Wood CG, **Briganti A**, Bensalah K, Haitel A, Shariat SF. Prognostic role of expression of N-cadherin in patients with upper tract urothelial carcinoma: a multi-institutional study. *World J Urol*. 2016 Nov 9. [Epub ahead of print] PubMed PMID: 27830374
840. Larcher A, Dell'Oglio P, Fossati N, Nini A, Muttin F, Suardi N, De Cobelli F, Salonia A, **Briganti A**, Zhang X, Montorsi F, Bertini R, Capitanio U. When to perform preoperative chest computed tomography for renal cancer staging. *BJU Int*. 2016 Sep 29. doi: 10.1111/bju.13670. [Epub ahead of print] PubMed PMID: 27684653
841. Trevisani F, Ghidini M, Larcher A, Lampis A, Lote H, Manunta P, Alibrandi MT, Zagato L, Citterio L, Dell'Antonio G, Carezzi C, Capasso G, Ruge M, Rigotti P, Bertini R, Cascione L, **Briganti A**, Salonia A, Benigni F, Braconi C, Fassan M, Hahne JC, Montorsi F, Valeri N. MicroRNA 193b-3p as a predictive biomarker of chronic kidney disease in patients undergoing radical nephrectomy for renal cell carcinoma. *Br J Cancer*. 2016 Nov 22;115(11):1343-1350. doi: 10.1038/bjc.2016.329. PubMed PMID: 27802451; PubMed Central PMCID: PMC5129818
842. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, **Briganti A**. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia*. 2015 Dec 16:0. doi: 10.5301/uro.5000139. [Epub ahead of print] PubMed PMID: 26689534.
843. Mbeutcha A, Mathieu R, Rouprêt M, Gust KM, **Briganti A**, Karakiewicz PI, Shariat SF. Predictive models and prognostic factors for upper tract urothelial carcinoma: a comprehensive review of the literature. *Transl Androl Urol*. 2016 Oct;5(5):720-734. Review. PubMed PMID: 27785429; PubMed Central PMCID: PMC5071205
844. Dell'Oglio P, Stabile A, Gandaglia G, **Briganti A**. Comment on 'Validation of a contemporary prostate cancer grading system using prostate cancer death as outcome'. *Br J Cancer*. 2016 Oct 25. doi: 10.1038/bjc.2016.346. [Epub ahead of print] PubMed PMID: 27780195
845. Moschini M, Soria F, **Briganti A**, Shariat SF. The impact of local treatment of the primary tumor site in node positive and metastatic prostate cancer patients. *Prostate Cancer Prostatic Dis*. 2016 Oct 25. doi: 10.1038/pcan.2016.52. [Epub ahead of print] Review. PubMed PMID: 27779202
846. Capogrosso P, Ventimiglia E, Moschini M, Boeri L, Farina E, Finocchietto N, Gandaglia G, Fossati N, **Briganti A**, Montorsi F, Salonia A. Testosterone Levels Correlate With Grade Group 5 Prostate Cancer: Another Step Toward Personalized Medicine. *Prostate*. 2017 Feb;77(2):234-241. doi: 10.1002/pros.23266. PubMed PMID: 27775173.
847. Moschini M, Sharma V, Gandaglia G, Dell'Oglio P, Fossati N, Zaffuto E, Montorsi F, **Briganti A**, Karnes RJ. Long-term utility of adjuvant hormonal and radiation therapy for patients with seminal vesicle invasion at radical prostatectomy. *BJU Int*. 2016 Oct 18. doi: 10.1111/bju.13683. [Epub ahead of print] PubMed PMID: 27753192

848. Dell'Oglio P, Karnes RJ, Gandaglia G, Fossati N, Stabile A, Moschini M, Cucchiara V, Zaffuto E, Karakiewicz PI, Suardi N, Montorsi F, **Briganti A**. The New Prostate Cancer Grading System Does Not Improve Prediction of Clinical Recurrence After Radical Prostatectomy: Results of a Large, Two-Center Validation Study. *Prostate*. 2016 Oct 18. doi: 10.1002/pros.23265. [Epub ahead of print] PubMed PMID: 27753114
849. Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, **Briganti A**, McCormack M, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Use of adjuvant chemotherapy in radical cystectomy patients aged >65 years: a population-based study from the surveillance epidemiology and end results (SEER)-medicare database. *Minerva Urol Nefrol*. 2016 Oct 12. [Epub ahead of print] PubMed PMID: 27733752
850. Wirth GJ, Haitel A, Moschini M, Soria F, Klatte T, Hassler MR, Bensalah K, **Briganti A**, Karam JA, Lotan Y, Margulis V, Raman JD, Remzi M, Rioux-Leclercq N, Robinson BD, Rouprêt M, Wood CG, Shariat SF. Androgen receptor expression is associated with adverse pathological features in ureteral but not in pelvicalyceal urothelial carcinomas of the upper urinary tract. *World J Urol*. 2016 Oct 11. [Epub ahead of print] PubMed PMID: 27730305
851. Moschini M, Luzzago S, Zaffuto E, Dell'Oglio P, Gandaglia G, Mattei A, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, **Briganti A**, Gallina A, Colombo R. The surgical management of patients with clinical stage T4 bladder cancer: A single institution experience. *Eur J Surg Oncol*. 2016 Sep 28. pii: S0748-7983(16)30897-6. doi: 10.1016/j.ejso.2016.08.024. [Epub ahead of print] PubMed PMID: 27720312
852. Larcher A, Sun M, Dell'Oglio P, Trudeau V, Boehm K, Schiffmann J, Tian Z, Fossati N, Capitanio U, **Briganti A**, Montorsi F, Karakiewicz P. Mortality, morbidity and healthcare expenditures after local tumour ablation or partial nephrectomy for T1A kidney cancer. *Eur J Surg Oncol*. 2016 Sep 17. pii: S0748-7983(16)30890-3. doi: 10.1016/j.ejso.2016.08.023. [Epub ahead of print] PubMed PMID: 27692535.
853. Leyh-Bannurah SR, Gazdovich S, Budäus L, Zaffuto E, Dell'Oglio P, **Briganti A**, Abdollah F, Montorsi F, Schiffmann J, Menon M, Shariat SF, Fisch M, Chun F, Graefen M, Karakiewicz PI. Population-Based External Validation of the Updated 2012 Partin Tables in Contemporary North American Prostate Cancer Patients. *Prostate*. 2017 Jan;77(1):105-113. doi: 10.1002/pros.23253. PubMed PMID: 27683103
854. Zaffuto E, Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, Suardi N, Mirone V, Bandini M, Shariat SF, Karakiewicz PI, Montorsi F, **Briganti A**. Early Postoperative Radiotherapy is Associated with Worse Functional Outcomes in Patients with Prostate Cancer. *J Urol*. 2016 Sep 23. pii: S0022-5347(16)31377-5. doi: 10.1016/j.juro.2016.09.079. PubMed PMID: 27670915
855. Soria F, Moschini M, Haitel A, Wirth GJ, Gust KM, **Briganti A**, Rouprêt M, Klatte T, Hassler MR, Karakiewicz PI, Shariat SF. The effect of HER2 status on oncological outcomes of patients with invasive bladder cancer. *Urol Oncol*. 2016 Dec;34(12):533.e1-533.e10. doi: 10.1016/j.urolonc.2016.07.006. PubMed PMID: 27665356
856. Mbeutcha A, Shariat SF, Rieken M, Rink M, Xylinas E, Seitz C, Lucca I, Mathieu R, Rouprêt M, **Briganti A**, Karakiewicz PI, Klatte T. Prognostic significance of markers of systemic inflammatory response in patients with non-muscle-invasive bladder cancer. *Urol Oncol*. 2016 Nov;34(11):483.e17-483.e24. doi: 10.1016/j.urolonc.2016.05.013. PubMed PMID: 27646875
857. Schiavina R, Bianchi L, Borghesi M, **Briganti A**, Brunocilla E, Carini M, Terrone C, Mottrie A, Dente D, Gacci M, Gontero P, Gurioli A, Imbimbo C, La Manna G, Marchioro G, Milanese G, Mirone V, Montorsi F, Morgia G, Munegato S, Novara G, Panarello D, Porreca A, Russo GI, Serni S, Simonato A, Urzì D, Verze P, Volpe A, Martorana G. Predicting survival in node-positive prostate cancer after open, laparoscopic or robotic radical prostatectomy: A competing risk analysis of a multi-institutional database. *Int J Urol*. 2016 Dec;23(12):1000-1008. doi: 10.1111/iju.13203. PubMed PMID: 27620370
858. Ventimiglia E, Salonia A, **Briganti A**, Montorsi F. Re: Family History and Probability of Prostate Cancer, Differentiated by Risk Category - A Nationwide Population-based Study. *Eur Urol*. 2017 Jan;71(1):143-144. doi: 10.1016/j.eururo.2016.08.063. PubMed PMID: 27609559.
859. Montorsi F, Gandaglia G, Fossati N, Suardi N, Pultrone C, De Groote R, Dovey Z, Umari P, Gallina A, **Briganti A**, Mottrie A. Robot-assisted Salvage Lymph Node Dissection for Clinically

- Recurrent Prostate Cancer. *Eur Urol.* 2016 Sep 3. pii: S0302-2838(16)30524-3. doi: 10.1016/j.eururo.2016.08.051. PubMed PMID: 27600589
860. Moschini M, Luzzago S, Cazzaniga W, Cucchiara V, Bandini M, Damiano R, Soria F, Klatte T, Shariat SF, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Effect of Stage Migration on Bladder Cancer: A Slow but Steady Improvement in Long-Term Survival Rates After Radical Cystectomy in Previous 25 Years. *Clin Genitourin Cancer.* 2016 Aug 8. pii: S1558-7673(16)30227-0. doi: 10.1016/j.clgc.2016.07.024. [Epub ahead of print] PubMed PMID: 27589904
861. Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, **Briganti A**. Radical Prostatectomy in Men with Oligometastatic Prostate Cancer: Results of a Single-institution Series with Long-term Follow-up. *Eur Urol.* 2016 Aug 26. pii: S0302-2838(16)30508-5. doi: 10.1016/j.eururo.2016.08.040. [Epub ahead of print] PubMed PMID: 27574820.
862. Capogrosso P, Salonia A, **Briganti A**, Montorsi F. Postprostatectomy Erectile Dysfunction: A Review. *World J Mens Health.* 2016 Aug;34(2):73-88. doi: 10.5534/wjmh.2016.34.2.73. Review. PubMed PMID: 27574591; PubMed Central PMCID: PMC4999493.
863. Moschini M, Soria F, Klatte T, Wirth GJ, Özsoy M, Gust K, **Briganti A**, Roupret M, Susani M, Haitel A, Shariat SF. Validation of Preoperative Risk Grouping of the Selection of Patients Most Likely to Benefit From Neoadjuvant Chemotherapy Before Radical Cystectomy. *Clin Genitourin Cancer.* 2016 Jul 22. pii: S1558-7673(16)30217-8. doi: 10.1016/j.clgc.2016.07.014. [Epub ahead of print] PubMed PMID: 27530435
864. Castiglione F, Dell'Oglio P, Tosco L, Everaerts W, Albersen M, Hakim L, Van den Broeck T, Moris L, Claessens F, **Briganti A**, Montorsi F, Van Poppel H, Joniau S; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT).. Tumor Volume and Clinical Failure in High-Risk Prostate Cancer Patients Treated With Radical Prostatectomy. *Prostate.* 2017 Jan;77(1):3-9. doi: 10.1002/pros.23242. PubMed PMID: 27527377
865. Fossati N, Cozzarini C, Fiorino C, Gandaglia G, Montorsi F, **Briganti A**. Salvage radiotherapy for patients with rising PSA. *Lancet Oncol.* 2016 Aug;17(8):e314-5. doi: 10.1016/S1470-2045(16)30276-5. PubMed PMID: 27511150.
866. Fossati N, Gandaglia G, Dell'Oglio P, Montorsi F, **Briganti A**. Timing of androgen-deprivation therapy for prostate cancer: still a long way to go. *Lancet Oncol.* 2016 Aug;17(8):e313. doi: 10.1016/S1470-2045(16)30309-6. PubMed PMID: 27511149
867. Fiorino C, Broggi S, Fossati N, Cozzarini C, Goldner G, Wiegel T, Hinkelbein W, Karnes RJ, Boorjian SA, Haustermans K, Joniau S, Palorini F, Shariat S, Montorsi F, Van Poppel H, Di Muzio N, Calandrino R, **Briganti A**. Predicting the 5-Year Risk of Biochemical Relapse After Postprostatectomy Radiation Therapy in \geq PT2, pN0 Patients With a Comprehensive Tumor Control Probability Model. *Int J Radiat Oncol Biol Phys.* 2016 Oct 1;96(2):333-40. doi:10.1016/j.ijrobp.2016.06.014. PubMed PMID: 27497691.
868. Fossati N, Karnes RJ, Boorjian SA, Moschini M, Morlacco A, Bossi A, Seisen T, Cozzarini C, Fiorino C, Chiorda BN, Gandaglia G, Dell'Oglio P, Joniau S, Tosco L, Shariat S, Goldner G, Hinkelbein W, Bartkowiak D, Haustermans K, Tombal B, Montorsi F, Van Poppel H, Wiegel T, **Briganti A**. Long-term Impact of Adjuvant Versus Early Salvage Radiation Therapy in pT3N0 Prostate Cancer Patients Treated with Radical Prostatectomy: Results from a Multi-institutional Series. *Eur Urol.* 2016 Jul 30. pii: S0302-2838(16)30433-X. doi: 10.1016/j.eururo.2016.07.028. [Epub ahead of print] PubMed PMID: 27484843
869. Gandaglia G, Fossati N, Suardi N, Montorsi F, **Briganti A**. STAMPEDE trial and patients with non-metastatic prostate cancer. *Lancet.* 2016 Jul 16;388(10041):234-5. doi: 10.1016/S0140-6736(16)31038-8. PubMed PMID: 27479564.
870. Dell'Oglio P, Boehm K, Trudeau V, Tian Z, Larcher A, Leyh-Bannurah SR, Moschini M, Capitanio U, Shariat SF, **Briganti A**, Montorsi F, Saad F, Karakiewicz PI. Survival After Conservative Management Versus External Beam Radiation Therapy in Elderly Patients With Localized Prostate Cancer. *Int J Radiat Oncol Biol Phys.* 2016 Dec 1;96(5):1037-1045. doi: 10.1016/j.ijrobp.2016.05.004. PubMed PMID: 27478167.
871. Capogrosso P, Ventimiglia E, Ferrari M, Serino A, Boeri L, Capitanio U, **Briganti A**, Damiano R, Montorsi F, Salonia A. Long-term sexual outcomes after holmium laser enucleation of the prostate:

- which patients could benefit the most? *Int J Impot Res.* 2016 Sep;28(5):189-93. doi: 10.1038/ijir.2016.29. PubMed PMID: 27465782.
872. Moschini M, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Luzzago S, Zaffuto E, Suardi N, Damiano R, Shariat SF, Montorsi F, **Briganti A**. Incidence and Predictors of 30-Day Readmission After Robot-Assisted Radical Prostatectomy. *Clin Genitourin Cancer.* 2016 Jun 29. pii: S1558-7673(16)30148-3. doi: 10.1016/j.clgc.2016.06.002. [Epub ahead of print] PubMed PMID: 27452733.
873. Gandaglia G, Dell'Oglio P, Montorsi F, **Briganti A**. Editorial Comment to Perioperative blood transfusion in radical cystectomy: Analysis of the National Surgical Quality Improvement Program database. *Int J Urol.* 2016 Sep;23(9):750-1. doi: 10.1111/iju.13169. PubMed PMID: 27431725.
874. Mathieu R, Lucca I, Rouprêt M, **Briganti A**, Shariat SF. The prognostic role of lymphovascular invasion in urothelial carcinoma of the bladder. *Nat Rev Urol* 2016 Aug;13(8):471-9. doi: 10.1038/nrurol.2016.126. Review. PubMed PMID: 27431340.
875. Moore CM, Giganti F, Albertsen P, Allen C, Bangma C, **Briganti A**, Carroll P, Haider M, Kasivisvanathan V, Kirkham A, Klotz L, Ouzzane A, Padhani AR, Panebianco V, Pinto P, Puech P, Rannikko A, Renard-Penna R, Touijera K, Turkbey B, van Poppel H, Valdagni R, Walz J, Schoots I. Reporting Magnetic Resonance Imaging in Men on Active Surveillance for Prostate Cancer: The PRECISE Recommendations-A Report of a European School of Oncology Task Force. *Eur Urol.* 2016 Jun 24. pii: S0302-2838(16)30281-0. doi: 10.1016/j.eururo.2016.06.011. [Epub ahead of print] PubMed PMID: 27349615
876. Schiffmann J, Sun M, Gandaglia G, Tian Z, Popa I, Larcher A, Meskawi M, **Briganti A**, McCormack M, Shariat SF, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Suboptimal use of neoadjuvant chemotherapy in radical cystectomy patients: A population-based study. *Can Urol Assoc J.* 2016 Mar-Apr;10(3-4):E82-6. doi: 10.5489/cuaj.3292. PubMed PMID: 27330584; PubMed Central PMCID: PMC4907779.
877. Gandaglia G, Fossati N, Dell'Oglio P, Moschini M, Cucchiara V, Suardi N, Mottrie A, Mirone V, Montorsi F, **Briganti A**. Rationale for local treatment in the management of metastatic prostate cancer. *Curr Opin Support Palliat Care.* 2016 Sep;10(3):266-72. doi: 10.1097/SPC.0000000000000218. PubMed PMID: 27328411.
878. Montorsi F, Gandaglia G, Salonia A, **Briganti A**, Mirone V. Effectiveness of a Combination of Cranberries, *Lactobacillus rhamnosus*, and Vitamin C for the Management of Recurrent Urinary Tract Infections in Women: Results of a Pilot Study. *Eur Urol.* 2016 Dec;70(6):912-915. doi: 10.1016/j.eururo.2016.05.042. PubMed PMID: 27283213.
879. Soria F, Moschini M, Haitel A, Wirth GJ, Karam JA, Wood CG, Rouprêt M, Margulis V, Karakiewicz PI, **Briganti A**, Raman JD, Kammerer-Jacquet SF, Mathieu R, Bensalah K, Lotan Y, Özsoy M, Remzi M, Gust KM, Shariat SF. HER2 overexpression is associated with worse outcomes in patients with upper tract urothelial carcinoma (UTUC). *World J Urol.* 2016 Jun 7. [Epub ahead of print] PubMed PMID: 27272502.
880. Trudeau V, Karakiewicz PI, Boehm K, Dell'Oglio P, Tian Z, **Briganti A**, Shariat SF, Valiquette L, Bhojani N. The Effect of Obesity on Perioperative Outcomes Following Percutaneous Nephrolithotomy. *J Endourol.* 2016 Aug;30(8):864-70. doi: 10.1089/end.2015.0789. PubMed PMID: 27257037
881. Larcher A, Capitanio U, Terrone C, Volpe A, De Angelis P, Dehó F, Fossati N, Dell'Oglio P, Antonelli A, Furlan M, Simeone C, Serni S, Carini M, Minervini A, Fiori C, Porpiglia F, **Briganti A**, Montorsi F, Bertini R. Elective Nephron Sparing Surgery Decreases Other Cause Mortality Relative to Radical Nephrectomy Only in Specific Subgroups of Patients with Renal Cell Carcinoma. *J Urol.* 2016 Oct;196(4):1008-13. doi: 10.1016/j.juro.2016.04.093. PubMed PMID: 27235789.
882. Russo A, Capogrosso P, La Croce G, Ventimiglia E, Boeri L, **Briganti A**, Damiano R, Montorsi F, Salonia A. *Serenoa repens*, selenium and lycopene to manage lower urinary tract symptoms suggestive for benign prostatic hyperplasia. *Expert Opin Drug Saf.* 2016 Dec;15(12):1661-1670. PubMed PMID: 27232207.
883. Gandaglia G, De Lorenzis E, Novara G, Fossati N, De Groote R, Dovey Z, Suardi N, Montorsi F, **Briganti A**, Rocco B, Mottrie A. Robot-assisted Radical Prostatectomy and Extended Pelvic Lymph Node Dissection in Patients with Locally-advanced Prostate Cancer. *Eur Urol.* 2016 May 18. pii:

- S0302-2838(16)30172-5. doi: 10.1016/j.eururo.2016.05.008. [Epub ahead of print] PubMed PMID: 27209538.
884. Vartolomei MD, Mathieu R, Margulis V, Karam JA, Rouprêt M, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Wood CG, Weizer AZ, Raman JD, Rioux-Leclercq N, Haitel A, Bensalah K, Rink M, **Briganti A**, Xylinas E, Shariat SF. Promising role of preoperative neutrophil-to-lymphocyte ratio in patients treated with radical nephroureterectomy. *World J Urol.* 2016 May 21. [Epub ahead of print] PubMed PMID: 27209168.
885. **Briganti A**, MacLennan S, Marconi L, Plass K, N'Dow J; EAU Guidelines Office 'IMAGINE' project.. European Association of Urology (EAU) guidelines: do we care? Reflections from the EAU Impact Assessment of Guidelines Implementation and Education group. *BJU Int.* 2016 Jun;117(6):850-1. doi: 10.1111/bju.13383. PubMed PMID: 27173993.
886. Cozzarini C, Chiorda BN, Sini C, Fiorino C, **Briganti A**, Montorsi F, Di Muzio N. Hematologic Toxicity in Patients Treated With Postprostatectomy Whole-Pelvis Irradiation With Different Intensity Modulated Radiation Therapy Techniques Is not Negligible and Is Prolonged: Preliminary Results of a Longitudinal, Observational Study. *Int J Radiat Oncol Biol Phys.* 2016 Jun 1;95(2):690-5. doi: 10.1016/j.ijrobp.2016.01.022. PubMed PMID: 27131081.
887. Favaretto RL, Bahadori A, Mathieu R, Haitel A, Grubmüller B, Margulis V, Karam JA, Rouprêt M, Seitz C, Karakiewicz PI, Cunha IW, Zequi SC, Wood CG, Weizer AZ, Raman JD, Remzi M, Rioux-Leclercq N, Jacquet-Kammerer S, Bensalah K, Lotan Y, Bachmann A, Rink M, **Briganti A**, Shariat SF. Prognostic role of decreased E-cadherin expression in patients with upper tract urothelial carcinoma: a multi-institutional study. *World J Urol.* 2016 Apr 29. [Epub ahead of print] PubMed PMID: 27129576.
888. Mathieu R, Vartolomei MD, Mbeutcha A, Karakiewicz PI, **Briganti A**, Roupret M, Shariat SF. Urothelial cancer of the upper urinary tract: emerging biomarkers and integrative models for risk stratification. *Minerva Urol Nefrol.* 2016 Aug;68(4):381-95. PubMed PMID: 27124417.
889. Rossi MS, Moschini M, Bianchi M, Gandaglia G, Fossati N, Dell'Oglio P, Schiavina R, Brunocilla E, Farina E, Picozzi M, Salonia A, Montorsi F, **Briganti A**. Erectile Function Recovery After Nerve-Sparing Radical Prostatectomy for Prostate Cancer: Is Back to Baseline Status Enough for Patient Satisfaction? *J Sex Med.* 2016 Apr;13(4):669-78. doi: 10.1016/j.jsxm.2016.02.160. PubMed PMID: 27045263
890. Montironi R, Santoni M, Mazzucchelli R, Burattini L, Berardi R, Galosi AB, Cheng L, Lopez-Beltran A, **Briganti A**, Montorsi F, Scarpelli M. Prostate cancer: from Gleason scoring to prognostic grade grouping. *Expert Rev Anticancer Ther.* 2016;16:433-40.
891. Giganti F, Coppola A, Ambrosi A, Ravelli S, Esposito A, Freschi M, **Briganti A**, Scattoni V, Salonia A, Gallina A, Dehò F, Cardone G, Balconi G, Gaboardi F, Montorsi F, Maschio AD, De Cobelli F. Apparent diffusion coefficient in the evaluation of side-specific extracapsular extension in prostate cancer: Development and external validation of a nomogram of clinical use. *Urol Oncol.* 2016 Mar 15. pii: S1078-1439(16)00048-X. doi: 10.1016/j.urolonc.2016.02.015.
892. Fossati N, Gandaglia G, Bossi A, Montorsi F, **Briganti A**. Re: Stephen J. Freedland, Voleak Choeurng, Lauren Howard, et al. Utilization of a Genomic Classifier for Prediction of Metastasis Following Salvage Radiation Therapy after Radical Prostatectomy. *Eur Urol.* In press. <http://dx.doi.org/10.1016/j.eururo.2016.01.008>: Testing the Utility of Genomic Scores in the Setting of Recurrent Prostate Cancer After Radical Prostatectomy: We Can Certainly Do Better. *Eur Urol.* 2016 Mar 15. pii: S0302-2838(16)00269-4. doi: 10.1016/j.eururo.2016.03.012.
893. Fajkovic H, Mathieu R, Lucca I, Hiess M, Hübner N, Al Awamlh BA, Lee R, **Briganti A**, Karakiewicz P, Lotan Y, Roupret M, Rink M, Kluth L, Loidl W, Seitz C, Klatte T, Kramer G, Susani M, Shariat SF. Validation of lymphovascular invasion as an independent prognostic factor for biochemical recurrence after radical prostatectomy. *Urol Oncol.* 2016 Mar 10. pii: S1078-1439(15)00523-2. doi: 10.1016/j.urolonc.2015.10.013.
894. Di Muzio NG, Fodor A, Noris Chiorda B, Broggi S, Mangili P, Valdagni R, Dell'Oca I, Pasetti M, Deantoni CL, Chiara A, Berardi G, **Briganti A**, Calandrino R, Cozzarini C, Fiorino C. Moderate Hypofractionation with Simultaneous Integrated Boost in Prostate Cancer: Long-term Results of a

- Phase I-II Study. *Clin Oncol (R Coll Radiol)*. 2016 Mar 5. pii: S0936-6555(16)00082-0. doi: 10.1016/j.clon.2016.02.005.
895. Dell'Oglio P, Abou-Haidar H, Leyh-Bannurah SR, Tian Z, Larcher A, Gandaglia G, Fossati N, Shariat SF, Capitanio U, **Briganti A**, Montorsi F, Graefen M, Saad F, Karakiewicz PI. Assessment of the Rate of Adherence to International Guidelines for Androgen Deprivation Therapy with External-beam Radiation Therapy: A Population-based Study. *Eur Urol*. 2016 Mar 4. pii: S0302-2838(16)00247-5. doi: 10.1016/j.eururo.2016.02.057
896. Cozzarini C, **Briganti A**, Fossati N, Montorsi F, Di Muzio N, Fiorino C. Dose Escalation in Salvage Radiation Therapy and Urinary Toxicity: A Small Price to Pay for a Significant Prospective Benefit. *J Clin Oncol*. 2016 Mar 7. pii: JCO667139
897. Piva F, Santoni M, Scarpelli M, **Briganti A**, Lopez-Beltran A, Cheng L, Berardi R, Montorsi F, Montironi R. Re: Daniel M. Geynisman. Anti-programmed Cell Death Protein 1 (PD-1) Antibody Nivolumab Leads to a Dramatic and Rapid Response in Papillary Renal Cell Carcinoma with Sarcomatoid and Rhabdoid Features. *Eur Urol* 2015;68:912-4. *Eur Urol*. 2016 Mar 3. pii: S0302-2838(16)00239-6. doi: 10.1016/j.eururo.2016.02.049
898. Mathieu R, Lucca I, Vartolomei MD, MBeutcha A, Klatter T, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Montorsi F, **Briganti A**, Rouprêt M, Margulis V, Rink M, Rieken M, Kenner L, Susani M, Wolfgang L, Shariat SF. Role of Survivin expression in predicting biochemical recurrence after radical prostatectomy: a multi-institutional study. *BJU Int*. 2016 Mar 4. doi: 10.1111/bju.13472.
899. Moschini M, Karnes RJ, Sharma V, Gandaglia G, Fossati N, Dell'Oglio P, Cucchiara V, Capogrosso P, Shariat SF, Damiano R, Salonia A, Montorsi F, **Briganti A**, Gallina A, Colombo R. Patterns and prognostic significance of clinical recurrences after radical cystectomy for bladder cancer: A 20-year single center experience. *Eur J Surg Oncol*. 2016 Feb 18. pii: S0748-7983(16)00105-0. doi: 10.1016/j.ejso.2016.02.011.
900. Gandaglia G, Fossati N, Montorsi F, **Briganti A**. How can we optimize the use of prostate cancer registries? *Future Oncol*. 2016 Mar 1.
901. Blanchard P, **Briganti A**, Bossi A. Re: Christopher J.D. Wallis, Refik Saskin, Richard Choo, et al. Surgery Versus Radiotherapy for Clinically-localized Prostate Cancer: A Systematic Review and Meta-analysis. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2015.11.010>. *Eur Urol*. 2016 Feb 24. pii: S0302-2838(16)00218-9. doi: 10.1016/j.eururo.2016.02.040.
902. Gandaglia G, **Briganti A**, Fossati N, Salonia A, Mottrie A, Catto J, Montorsi F. The Problem Is Not What to Do with Indolent and Harmless Prostate Cancer-The Problem Is How to Avoid Finding These Cancers. *Eur Urol*. 2016 Feb 22. pii: S0302-2838(16)00210-4. doi: 10.1016/j.eururo.2016.02.032.
903. Trudeau V, Larcher A, Sun M, Boehm K, Dell'Oglio P, Sosa J, Tian Z, Fossati N, **Briganti A**, Shariat SF, Karakiewicz PI. Comparison of oncologic outcomes between sarcomatoid and clear cell renal cell carcinoma. *World J Urol*. 2016 Feb 22.
904. Sivaraman A, Ordaz Jurado G, Cathelineau X, Barret E, Dell'Oglio P, Joniau S, Bianchi M, **Briganti A**, Spahn M, Bastian P, Chun J, Chlosta P, Gontero P, Graefen M, Jeffrey Karnes R, Marchioro G, Tombal B, Tosco L, van der Poel HH, Sanchez-Salas R. Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. *World J Urol*. 2016 Feb 20
905. Fajkovic H, Shariat SF, Klatter T, Vartolomei MD, Lucca I, MBeutcha A, Rouprêt M, **Briganti A**, Karakiewicz PI, Margulis V, Rink M, Remzi M, Seitz C, Bensalah K, Mathieu R. Impact of smoking status on survival after cytoreductive nephrectomy for metastatic renal cell carcinoma. *World J Urol*. 2016 Feb 15.
906. Gandaglia G, **Briganti A**, Montorsi P, Mottrie A, Salonia A, Montorsi F. Diagnostic and Therapeutic Implications of Erectile Dysfunction in Patients with Cardiovascular Disease. *Eur Urol*. 2016 Feb 9. pii: S0302-2838(16)00174-3. doi: 10.1016/j.eururo.2016.01.054
907. Abdollah F, Dalela D, Sood A, Sammon J, Jeong W, Beyer B, Fossati N, Rogers CG, Diaz-Insua M, Peabody J, Haese A, Montorsi F, Graefen M, **Briganti A**, Menon M. Intermediate-term cancer control outcomes in prostate cancer patients treated with robotic-assisted laparoscopic radical prostatectomy: a multi-institutional analysis. *World J Urol*. 2016 Feb 12

908. Gandaglia G, Lista G, Fossati N, Suardi N, Gallina A, Moschini M, Bianchi L, Rossi MS, Schiavina R, Shariat SF, Salonia A, Montorsi F, **Briganti A**. Non-surgically related causes of erectile dysfunction after bilateral nerve-sparing radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Feb 9. doi: 10.1038/pcan.2016.1
909. Evangelista L, **Briganti A**, Fanti S, Joniau S, Reske S, Schiavina R, Stief C, Thalmann GN, Picchio M. New Clinical Indications for 18F/11C-choline, New Tracers for Positron Emission Tomography and a Promising Hybrid Device for Prostate Cancer Staging: A Systematic Review of the Literature. *Eur Urol*. 2016 Feb 2. pii: S0302-2838(16)00131-7. doi: 10.1016/j.eururo.2016.01.029
910. Moschini M, Bianchi M, Rossi MS, Dell'Oglio P, Gandaglia G, Fossati N, Mattei A, Damiano R, Shariat SF, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Timing of blood transfusion and not ABO blood type is associated with survival in patients treated with radical cystectomy for nonmetastatic bladder cancer: Results from a single high-volume institution. *Urol Oncol*. 2016 Feb 2. pii: S1078-1439(15)00612-2. doi: 10.1016/j.urolonc.2015.12.016.
911. De Visschere PJ, **Briganti A**, Fütterer JJ, Ghadjar P, Isbarn H, Massard C, Ost P, Sooriakumaran P, Surcel CI, Valerio M, van den Bergh RC, Ploussard G, Giannarini G, Villeirs GM. Role of multiparametric magnetic resonance imaging in early detection of prostate cancer. *Insights Imaging*. 2016;7:205-14.
912. Salonia A, Castagna G, Capogrosso P, Castiglione F, **Briganti A**, Montorsi F. Prevention and management of post prostatectomy erectile dysfunction. *Transl Androl Urol*. 2015;4:421-37
913. Gandaglia G, Suardi N, Cucchiara V, Bianchi M, Shariat SF, Roupret M, Salonia A, Montorsi F, **Briganti A**. Penile rehabilitation after radical prostatectomy: does it work? *Transl Androl Urol*. 2015;4:110-23
914. Sevcenco S, Mathieu R, Baltzer P, Klatte T, Fajkovic H, Seitz C, Karakiewicz PI, Rouprêt M, Rink M, Kluth L, Trinh QD, Loidl W, **Briganti A**, Scherr DS, Shariat SF. The prognostic role of preoperative serum C-reactive protein in predicting the biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2016 Jan 26. doi: 10.1038/pcan.2015.60.
915. Moschini M, Gandaglia G, Dell'Oglio P, Fossati N, Cucchiara V, Burgio G, Mattei A, Damiano R, Shariat SF, Salonia A, Montorsi F, **Briganti A**, Colombo R, Gallina A. Incidence and Predictors of 30-Day Readmission in Patients Treated With Radical Cystectomy: A Single Center European Experience. *Clin Genitourin Cancer*. 2015 Dec 23. pii: S1558-7673(15)00347-X. doi: 10.1016/j.clgc.2015.12.017.
916. Gandaglia G, Montorsi F, **Briganti A**. Editorial Comment to Relationship between androgen deprivation therapy and community-acquired respiratory infections in patients with prostate cancer. *Int J Urol*. 2016 Jan 20. doi: 10.1111/iju.13046.
917. Gandaglia G, **Briganti A**, Montorsi F. Re: Risk Group and Death From Prostate Cancer: Implications for Active Surveillance in Men with Favorable Intermediate-risk Prostate Cancer. *Eur Urol*. 2016;69:370.
918. Bianchi L, Nini A, Bianchi M, Gandaglia G, Fossati N, Suardi N, Moschini M, Dell'Oglio P, Schiavina R, Montorsi F, **Briganti A**. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients DOI: 10.1016/j.eururo.2015.12.010.
919. Dell'Oglio P, Suardi N, Boorjian SA, Fossati N, Gandaglia G, Tian Z, Moschini M, Capitanio U, Karakiewicz PI, Montorsi F, Karnes RJ, **Briganti A**. Predicting survival of men with recurrent prostate cancer after radical prostatectomy. *Eur J Cancer*. 2015 Dec 18;54:27-34
920. Dell'Oglio P, Karnes RJ, Joniau S, Spahn M, Gontero P, Tosco L, Fossati N, Kneitz B, Chlosta P, Graefen M, Marchioro G, Bianchi M, Sanchez-Salas R, Karakiewicz PI, Poppel HV, Montorsi F, **Briganti A**. European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer. *Urol Oncol*. 2015 Dec 16. pii: S1078-1439(15)00570-0. doi: 10.1016/j.urolonc.2015.11.018
921. Sini C, Fiorino C, Perna L, Noris Chiorda B, Deantoni CL, Bianchi M, Sacco V, **Briganti A**, Montorsi F, Calandrino R, Di Muzio N, Cozzarini C. Dose-volume effects for pelvic bone marrow in predicting hematological toxicity in prostate cancer radiotherapy with pelvic node irradiation. *Radiother Oncol*. 2015 Dec 15. pii: S0167-8140(15)00640-4. doi: 10.1016/j.radonc.2015.11.020

922. Conti A, Santoni M, Burattini L, Scarpelli M, Mazzucchelli R, Galosi AB, Cheng L, Lopez-Beltran A, **Briganti A**, Montorsi F, Montironi R. Update on histopathological evaluation of lymphadenectomy specimens from prostate cancer patients. *World J Urol.* 2015 Dec 22.
923. Bianchi L, Gandaglia G, Fossati N, Suardi N, Moschini M, Cucchiara V, Bianchi M, Damiano R, Schiavina R, Shariat SF, Montorsi F, **Briganti A**. Pelvic lymph node dissection in prostate cancer: indications, extent and tailored approaches. *Urologia.* 2015 Dec 16;0(0):0. doi: 10.5301/uro.5000139, in press.
924. Moschini M, Karnes RJ, Gandaglia G, Luzzago S, Dell'Oglio P, Rossi MS, di Trapani E, La Croce G, Damiano R, Salonia A, Shariat SF, Montorsi F, **Briganti A**, Gallina A, Colombo R. Preoperative Favorable Characteristics in Bladder Cancer Patients Cannot Substitute the Necessity of Extended Lymphadenectomy during Radical Cystectomy: a Sensitivity Curve Analysis. *Urology.* 2015 Dec 9. pii: S0090-4295(15)01110-3. doi: 10.1016/j.urology.2015.12.005
925. Capitanio U, Dehò F, Dell'Oglio P, Larcher A, Capogrosso P, Nini A, Carenzi C, Freschi M, **Briganti A**, Salonia A, Montorsi F, Bertini R. Lymphadenopathies in patients with renal cell carcinoma: clinical and pathological predictors of pathologically confirmed lymph node invasion. *World J Urol.* 2015 Dec 15, in press
926. Mbeutcha A, Lucca I, Margulis V, Karam JA, Wood CG, de Martino M, Mathieu R, Haitel A, Xylinas E, Kluth L, Rouprêt M, Karakiewicz PI, **Briganti A**, Rink M, Rieken M, Weizer AZ, Raman JD, Rioux-Leclecq N, Bolenz C, Bensalah K, Lotan Y, Seitz C, Remzi M, Shariat SF, Klatte T. Prognostic role of ERCC1 protein expression in upper tract urothelial carcinoma following radical nephroureterectomy with curative intent. *World J Urol.* 2015 Dec 11,
927. Gandaglia G, **Briganti A**, Salonia A, Montorsi F. Excellent Erectile Function Recovery after Focal Therapy: Is This Enough?. *Eur Urol.* 2015 Nov 26. pii: S0302-2838(15)01164-1. doi: 10.1016/j.eururo.2015.11.014
928. Capogrosso P, Capitanio U, Ventimiglia E, Boeri L, **Briganti A**, Colombo R, Montorsi F, Salonia A. Detrusor Muscle in TUR-Derived Bladder Tumor Specimens – Can We Actually Improve Surgical Quality? *J Endourol.* 2015 Nov 23.
929. Trudeau V, Larcher A, Sun M, Boehm K, Dell'Oglio P, Meskawi M, Sosa J, Tian Z, Fossati N, **Briganti A**, Karakiewicz PI. Sociodemographic Disparities in the Nonoperative Management of Small Renal Masses. *Clin Genitourin Cancer.* 2015 Oct 29. pii: S1558-7673(15)00267-0. doi: 10.1016/j.clgc.2015.10.011
930. Capogrosso P, Ventimiglia E, Serino A, Stabile A, Boeri L, Gandaglia G, Dehò F, **Briganti A**, Montorsi F, Salonia A. Orgasmic Dysfunction After Robot-assisted Versus Open Radical Prostatectomy. *Eur Urol.* 2015 Nov 10. pii: S0302-2838(15)01080-5. doi: 10.1016/j.eururo.2015.10.046
931. Moschini M, Fossati N, Abdollah F, Gandaglia G, Cucchiara V, Dell'Oglio P, Luzzago S, Shariat SF, Dehò F, Salonia A, Montorsi F, **Briganti A**. Determinants of long-term survival of patients with locally advanced prostate cancer: the role of extensive pelvic lymph node dissection. *Prostate Cancer Prostatic Dis.* 2015 Nov 10. doi: 10.1038/pcan.2015.51
932. Trudeau V, Larcher A, Boehm K, Dell'Oglio P, Sun M, Tian Z, **Briganti A**, Shariat SF, Jeldres C, Karakiewicz PI. Comparison of Postoperative Complications and Mortality Between Laparoscopic and Percutaneous Local Tumor Ablation for T1a Renal Cell Carcinoma: a Population-Based Study. *Urology.* 2015 Oct 26. pii: S0090-4295(15)01004-3. doi: 10.1016/j.urology.2015.08.043
933. Mathieu R, Lucca I, Mbeutcha A, Seitz C, Karakiewicz P, Sun M, Montorsi F, **Briganti A**, Rouprêt M, Robinson B, Xylinas E, Shariat S. Valeur pronostique de Caveolin-1 dans le cancer de prostate: une étude multicentrique internationale. *Prog Urol.* 2015 Nov;25(13):741-2
934. Mathieu R, Mbeutcha A, Lucca I, **Briganti A**, Karakiewicz P, Rouprêt M, Seitz C, Klatte T, Shariat S. L'obésité est associée à la récurrence biologique après prostatectomie radicale: une étude multicentrique internationale. *Prog Urol.* 2015 Nov;25(13):740
935. Gontero P, Sylvester R, Pisano F, Joniau S, Oderda M, Serretta V, Larre S, Stasi SD, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Colombo R, **Briganti A**, Babjuk M, Soukup V, Malmstrom PU, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Vakarakis J, Bartoletti R, Dalbagni G, Shariat SF,

- Xylinas E, Karnes RJ, Palou J. The impact of re-TUR on clinical outcomes in a large multi-centre cohort of T1-HG/G3 patients treated with BCG. *BJU Int.* 2015 Oct 15. doi: 10.1111/bju.13354
936. Fossati N, Karnes JR, Cozzarini C, Fiorino C, Gandaglia G, Joniau J, Boorjian SA, Goldner G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T, **Briganti A**. Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. *Eur Urol*, 2015, in press, <http://dx.doi.org/10.1016/j.eururo.2015.10.009>
937. Moschini M, Gallina A, Freschi M, Luzzago S, Fossati N, Gandaglia G, Dell'oglio P, Damiano R, Serretta V, Salonia A, Montorsi F, **Briganti A**, Colombo R. Effect on postoperative survival of the status of distal ureteral margin: The necessity to achieve negative margins at the time of radical cystectomy. *Urol Oncol*, 2015, DOI: <http://dx.doi.org/10.1016/j.urolonc.2015.09.001>
938. Lavorgna G, Chiacchiera F, **Briganti A**, Montorsi F, Pasini D, Salonia A Expression-profiling of apoptosis induced by ablation of the long ncRNA TRPM2-AS in prostate cancer cell. *Genom Data*. 2014 Nov 7;3:4-5.
939. Fossati N, Nguyen DP, Trinh Q-D, Sammon J, Soode a, Larcher A, Guazzoni G, Montorsi F, **Briganti A**, Menon M, Abdollah F. The Impact of Insurance Status on Tumor Characteristics and Treatment Selection in Contemporary Patients with Prostate Cancer, *JNCCN-Journal of the National Comprehensive Cancer Network*, 11: 1-8, 2015,
940. Gandaglia G, Cozzarini C, Mottrie A, Bossi A, Fossati N, Montorsi F, **Briganti A**. The Role of Radiotherapy After Radical Prostatectomy in Patients with Prostate Cancer. *Curr Oncol Rep*. 2015 Dec;17(12):53. doi: 10.1007/s11912-015-0478-5
941. Capogrosso P, Serino A, Ventimiglia E, Boeri L, Dehò F, Damiano R, **Briganti A**, Montorsi F, Salonia A Effects of silodosin on sexual function - realistic picture from the everyday clinical practice. *Andrology*. 2015 Oct 7. doi: 10.1111/andr.12095.
942. Santoni M, Scarpelli M, Lopez-Beltran A, Cheng L, **Briganti A**, Montorsi F, Montironi R, Santini D. Re: Idir Ouzaid and Karim Bensalah. Results of the First Trial Assessing Adjuvant Tyrosine Kinase Inhibitors in Renal Cell Carcinoma Do Not reASSURE. *Eur Urol*. 2015 Sep 29. pii: S0302-2838(15)00930-6. doi: 10.1016/j.eururo.2015.09.022
943. Suardi N, Dell'Oglio P, Gallina A, Gandaglia G, Buffi N, Moschini M, Fossati N, Lughezzani G, Karakiewicz PI, Freschi M, Lucianò R, Shariat SF, Guazzoni G, Gaboardi F, Montorsi F, **Briganti A**. Evaluation of positive surgical margins in patients undergoing robot-assisted and open radical prostatectomy according to preoperative risk groups. *Urol Oncol*. 2015 Sep 28. pii: S1078-1439(15)00442-1. doi: 10.1016/j.urolonc.2015.08.019.
944. Boeri L, Capogrosso P, Ventimiglia E, Serino A, La Croce G, Russo A, Castagna G, Scano R, **Briganti A**, Damiano R, Montorsi F, Salonia A. Lower urinary tract symptoms among Caucasian-European men who have sex with men: findings from a real-life survey. *Prostate Cancer Prostatic Dis*. 2015 Sep 29. doi: 10.1038/pcan.2015.41
945. Abdollah F, Moschini M, Sood A, Sammon J, Dalela D, Hsu L, Beyer B, Haese A, Graefen M, Gandaglia G, Montorsi F, **Briganti A**, Menon M. When should a positive surgical margin ring a bell? An analysis of a multi-institutional robotic-assisted laparoscopic radical prostatectomy database. *J Endourol*. 2015 Sep 28
946. Larcher A, Trudeau V, Sun M, Boehm K, Meskawi M, Tian Z, Fossati N, Dell'Oglio P, Capitanio U, **Briganti A**, Shariat SF, Montorsi F, Karakiewicz PI. Population-based assessment of cancer specific mortality after local tumor ablation or observation for kidney cancer: a competing risks analysis. *BJU Int*. 2015 Sep 19, doi: 10.1111/bju.13326
947. Moschini M, Karnes RJ, Suardi N, Bianchi M, Pellucchi F, Rocchini L, Damiano R, Serretta V, Salonia A, Montorsi F, **Briganti A**, Colombo R. Potential Effect of Antiplatelet and Anticoagulant Therapy on the Timing of the Diagnosis of Bladder Cancer. *Clin Genitourin Cancer*. 2015 July 30, doi: 10.1016/j.clqc.2015.08.003.
948. Grubmueller B, Rouprêt M, **Briganti A**, Shariat SF. The use of biomarkers for bladder cancer diagnosis and surveillance. *Mini Rev Med Chem*. 2015 Sep 9. [Epub ahead of print]
949. Montironi R, Santoni M, Scarpelli M, Piva F, Lopez-Beltran A, Cheng L, **Briganti A**, Montorsi F. Re: Epithelial-to-mesenchymal Transition in Renal Neoplasms. *Eur Urol*. 2015;68:736-7.

950. Moschini M, **Briganti A**, Murphy CR, Bianchi M, Gandaglia G, Montorsi F, Quevedo JF, Carlson R, Kwon E, Karnes RJ. Outcomes for Patients with Clinical Lymphadenopathy Treated with Radical Prostatectomy. *Eur Urol.* 2015 Aug 8. pii: S0302-2838(15)00706-X. doi: 10.1016/j.eururo.2015.011.8557 (
951. Wolff RF, Ryder S, Bossi A, **Briganti A**, Crook J, Henry A, Karnes J, Potters L, de Reijke T, Stone N, Burckhardt M, Duffy S, Worthy G, Kleijnen J. A systematic review of randomised controlled trials of radiotherapy for localised prostate cancer. *Eur J Cancer.* 2015 Aug 5. pii: S0959-8049(15)00699-1. doi: 10.1016/j.ejca.2015.07.019.
952. Gandaglia G, Fossati N, Montorsi F, **Briganti A**. Does Radiotherapy Plus Androgen-Deprivation Therapy Represent the Best Treatment Approach in Elderly Patients With Locally Advanced Prostate Cancer? *J Clin Oncol.* 2015 Sep 1;33(25):2831-2. doi: 10.1200/JCO.2015.61.0964
953. Piva F, Santoni M, Scarpelli M, **Briganti A**, Montorsi F, Montironi R. Re: Johan Lindberg, Anna Kristiansen, Peter Wiklund, Henrik Grönberg, Lars Egevad. Tracking the Origin of Metastatic Prostate Cancer. *Eur Urol* 2015;67:819-22. *Eur Urol.* 2015 Jul 24. pii: S0302-2838(15)00615-6. doi: 10.1016/j.eururo.2015.07.011.
954. **Briganti A**, Gandaglia G, Fossati N, Moschini M, Montorsi F. RE: Androgen Deprivation With or Without Radiation Therapy for Clinically Node-Positive Prostate Cancer. *J Natl Cancer Inst.* 2015 23;107
955. Di Trapani E, Sanchez-Salas R, Gandaglia G, Rocchini L, Moschini M, Lizee D, Carneiro A, Sivaraman A, Barret E, Rozet F, Galiano M, Bennamoun M, Colombo R, Suardi N, **Briganti A**, Montorsi F, Cathelineau X. A nomogram predicting the cancer-specific mortality in patients eligible for radical cystectomy evaluating clinical data and neoadjuvant cisplatinum-based chemotherapy. *World J Urol.* 2015 Jul 22.
956. Mathieu R, Klatte T, Lucca I, Mbeutcha A, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Montorsi F, **Briganti A**, Rouprêt M, Margulis V, Rink M, Kluth LA, Rieken M, Kenner L, Susani M, Robinson BD, Xylinas E, Loidl W, Shariat SF. Prognostic value of Caveolin-1 in patients treated with radical prostatectomy: a multicentric validation study. *BJU Int.* 2015 Jul 18. doi: 10.1111/bju.13224
957. Gandaglia G, Schiffmann J, Schlomm T, Fossati N, Moschini M, Suardi N, Chun FK, Montorsi F, Graefen M, **Briganti A**. Identification of pathologically favorable disease in intermediate-risk prostate cancer patients: Implications for active surveillance candidates selection. *Prostate.* 2015;75:1484-91
958. Ploussard G, Almeras C, **Briganti A**, Giannarini G, Hennequin C, Ost P, Renard-Penna R, Salin A, Leuret T, Villers A, Soulié M, Taille A, Flamand V. Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature. *J Urol.* 2015 May 8. pii: S0022-5347(15)03911-7. doi: 10.1016/j.juro.2015.04.
959. Moschini M, Dell'Oglio P, Capogrosso P, Cucchiara V, Luzzago S, Gandaglia G, Zattoni F, **Briganti A**, Damiano R, Montorsi F, Salonia A, Colombo R. Effect of Allogeneic Intraoperative Blood Transfusion on Survival in Patients Treated With Radical Cystectomy for Nonmetastatic Bladder Cancer: Results From a Single High-Volume Institution. *Clin Genitourin Cancer.* 2015 May 4. pii: S1558-7673(15)00093-2. doi: 10.1016/j.clgc.2015.04.009.
960. Sooriakumaran P, Karnes J, Stief C, Copley B, Montorsi F, Hammerer P, Beyer B, Moschini M, Gratzke C, Steuber T, Suardi N, **Briganti A**, Manka L, Nyberg T, Dutton SJ, Wiklund P, Graefen M. A Multi-institutional Analysis of Perioperative Outcomes in 106 Men Who Underwent Radical Prostatectomy for Distant Metastatic Prostate Cancer at Presentation. *Eur Urol.* 2015 May 30. pii: S0302-2838(15)00425-X. doi: 10.1016/j.eururo.2015.05.023.
961. Rieken M, Shariat SF, Kluth LA, Fajkovic H, Rink M, Karakiewicz PI, Seitz C, **Briganti A**, Rouprêt M, Loidl W, Trinh QD, Bachmann A, Pourmand G. Association of Cigarette Smoking and Smoking Cessation with Biochemical Recurrence of Prostate Cancer in Patients Treated with Radical Prostatectomy. *Eur Urol.* 2015 Jun 3. pii: S0302-2838(15)00440-6. doi: 10.1016/j.eururo.2015.05.038
962. Santoni M, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Cheng L, Epstein JI, Cascinu S, **Briganti A**, Catto JW, Montorsi F, Montironi R. Current Histopathologic and Molecular

- Characterisations of Prostate Cancer: Towards Individualised Prognosis and Therapies. *Eur Urol*. 2015 Jun 9. pii: S0302-2838(15)00443-1. doi: 10.1016/j.eururo.2015.05.041.
963. Giannarini G, **Briganti A**, Crestani A, Rossanese M, Montorsi F, Ficarra V. Dismiss Systematic Transrectal Ultrasound-guided and Embrace Targeted Magnetic Resonance Imaging-informed Prostate Biopsy: Is the Paradigm Ready to Shift?. *Eur Urol*. 2015 Jun 9. pii: S0302-2838(15)00455-8. doi: 10.1016/j.eururo.2015.05.049
964. Capogrosso P, Boeri L, Ferrari M, Ventimiglia E, La Croce G, Capitanio U, **Briganti A**, Damiano R, Montorsi F, Salonia A. Long-term recovery of normal sexual function in testicular cancer survivors. *Asian J Androl*. 2015 Jun 23. doi: 10.4103/1008-682X.149180.
965. Abdollah F, Sood A, Sammon JD, Hsu L, Beyer B, Moschini M, Gandaglia G, Rogers CG, Haese A, Montorsi F, Graefen M, **Briganti A**, Menon M. Long-term Cancer Control Outcomes in Patients with Clinically High-risk Prostate Cancer Treated with Robot-assisted Radical Prostatectomy: Results from a Multi-institutional Study of 1100 Patients. *Eur Urol*. 2015 Jun 25. pii: S0302-2838(15)00523-0. doi: 10.1016/j.eururo.2015.06.020.
966. Hansen J, Becker A, Kluth LA, Rink M, Steuber T, Zacharias M, **Briganti A**, Fisch M, Graefen M, Chun FK. Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation. *Urol Oncol*. 2015 Jun 26. pii: S1078-1439(15)00150-7. doi: 10.1016/j.urolonc.2015.02.01
967. Isbarn H, **Briganti A**, De Visscher e PJ, Futterer J, Ghadjar P, Giannarini G, Ost P, Ploussard G, Sooriakumaran P, Surcel C, Van Oort I, Yossepowitch O, van den Bergh R. Systematic ultrasound-guided saturation and template biopsy of the prostate: Indications and advantages of extended sampling. *Arch Esp Urol*, 68-296-306, 2015
968. Nini A, Gandaglia G, Fossati N, Suardi N, Cucchiara V, Dell'Oglio P, Cazzaniga W, Luzzago S, Montorsi F, **Briganti A**. Patterns of Clinical Recurrence of Node-positive Prostate Cancer and Impact on Long-term Survival. *Eur Urol*, 2015, <http://dx.doi.org/10.1016/j.eururo.2015.04.035>
969. Bourke L, Boorjian SA, **Briganti A**, Klotz L, Mucci L, Resnick MJ, Rosario DJ, Skolarus TA, Penson DF. Survivorship and Improving Quality of Life in Men with Prostate Cancer. *Eur Urol*. 2015 May 1. pii: S0302-2838(15)00325-5. doi: 10.1016/j.eururo.2015.04.023.
970. Moschini M, Sharma V, Dell'Oglio P, Cucchiara V, Gandaglia G, Cantiello F, Zattoni F, Pellucchi F, **Briganti A**, Damiano R, Montorsi F, Salonia A, Colombo R. Comparing long-term outcomes between primary versus progressive muscle invasive bladder cancer after radical cystectomy. *BJU Int*. 2015 Apr 7. doi: 10.1111/bju.13146.
971. Moschini M, Gandaglia G, Suardi N, Fossati N, Cucchiara V, Damiano R, Cantiello F, Shariat SF, Montorsi F, **Briganti A**. Importance of prostate volume in the stratification of patients with intermediate-risk prostate cancer. *Int J Urol*. 2015 Mar 17. doi: 10.1111/iju.12748.
972. Fossati N, Passoni NM, Moschini M, Gandaglia G, Larcher A, Freschi M, Guazzoni G, Sjoberg DD, Vickers AJ, Montorsi F, **Briganti A**. Impact of stage migration and practice changes on high risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades. *BJU Int*. 2015 Mar 17. doi: 10.1111/bju.13125
973. Abdollah F, Montorsi F, **Briganti A**. Reply to Jovo Bogdanović and Vuk Sekulić's Letter to the Editor re: Firas Abdollah, Giorgio Gandaglia, Nazareno Suardi, et al. More Extensive Pelvic Lymph Node Dissection Improves Survival in Patients with Node-positive Prostate Cancer. *Eur Urol* 2015;67:212-9. *Eur Urol*. 2015 Mar 19. pii: S0302-2838(15)00228-6. doi: 10.1016/j.eururo.2015.03.019.
974. Capitanio U, **Briganti A**. Re: surgical outcomes in the management of isolated nodal recurrences: a multicenter, international retrospective cohort. *Eur Urol*. 2015 May;67(5):974-5. doi: 10.1016/j.eururo.2014.12.064.
975. Gallina A, Bianchi M, Cucchiara V, Suardi N, Montorsi F, **Briganti A**. A Detailed Analysis of the Association Between Postoperative Phosphodiesterase Type 5 Inhibitor Use and the Risk of Biochemical Recurrence After Radical Prostatectomy. *Eur Urol* 2015, DOI: 10.1016/j.eururo.2015.02.002
976. Giovacchini G1, Incerti E, Mapelli P, Kirienko M, **Briganti A**, Gandaglia G, Montorsi F, Gianolli L, Picchio M. 11C]Choline PET/CT predicts survival in hormone-naive prostate cancer patients with

- biochemical failure after radical prostatectomy. *Eur J Nucl Med Mol Imaging*. 2015 Feb 20. [Epub ahead of print]
977. Gandaglia G, Karnes RJ, Cozzarini C, Montorsi F, **Briganti A**. Node-positive prostate cancer: a call for level 1 evidence. *Oncology*, (Williston Park), 2015 Feb 15;29(2)
978. **Briganti A**, Karnes RJ, Gandaglia G, Spahn M, Gontero P, Tosco L, Kneitz B, Chun FK, Zaffuto E, Sun M, Graefen M, Marchioro G, Frohneberg D, Giona S, Karakiewicz PI, Van Poppel H, Montorsi F, Joniau S, on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPACT). Natural history of surgically treated high-risk prostate cancer. *Urol Oncol*, 2015, DOI: <http://dx.doi.org/10.1016/j.urolonc.2014.11.018>
979. Fütterer JJ, **Briganti A**, De Visschere P, Emberton M, Giannarini G, Kirkham A, Taneja SS, Thoeny H, Villeirs G, Villers A. Can Clinically Significant Prostate Cancer Be Detected with Multiparametric Magnetic Resonance Imaging? A Systematic Review of the Literature. *Eur Urol*. 2015 Feb 2. pii: S0302-2838(15)00036-6. doi: 10.1016/j.eururo.2015.01.013.
980. Ventimiglia E, Capogrosso P, Colicchia M, Boeri L, Serino A, La Croce G, Russo A, Capitanio U, **Briganti A**, Cantiello F, Mirone V, Damiano R, Montorsi F, Salonia A. Peyronie's Disease and Autoimmunity-A Real-Life Clinical Study and Comprehensive Review. *J Sex Med*. 2015 Jan 29. doi: 10.1111/jsm.12825.
981. Sosnowski R, De Nunzio C, Ahyai S, Autorino R, Bachmann A, **Briganti A**, Novara G, Füllhase C, Thiruchelvam N Surgical management of benign prostatic obstruction: Current practice patterns and attitudes in Europe. *Neurourol Urodyn*. 2015 Jan 24. doi: 10.1002/nau.22727
982. Gandaglia G, Ploussard G, Isbarn H, Suardi N, De Visschere PJ, Fütterer JJ, Ghadjar P, Massard C, Ost P, Sooriakumaran P, Surcel CI, van der Bergh RC, Montorsi F, Ficarra V, Giannarini G, **Briganti A**. Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. What is the optimal definition of misclassification in patients with very low-risk prostate cancer eligible for active surveillance? Results from a multi-institutional series. *Urol Oncol*. 2015 Jan 22. pii: S1078-1439(14)00464-5. doi: 10.1016/j.urolonc.2014.12.011
983. Picchio M, Mapelli P, Panebianco V, Castellucci P, Incerti E, **Briganti A**, Gandaglia G, Kirienko M, Barchetti F, Nanni C, Montorsi F, Gianolli L, Fanti S. Imaging biomarkers in prostate cancer: role of PET/CT and MRI. *Eur J Nucl Med Mol Imaging*. 2015 Jan 17. [Epub ahead of print]
984. Gandaglia G, Sun M, Popa I, Schiffmann J, Trudeau V, Shariat SF, Trinh Q, Graefen M, Widmer H, Saad F, **Briganti A**, Montorsi F, Karakiewicz PI. Cardiovascular Mortality in Patients With Metastatic Prostate Cancer Exposed to Androgen Deprivation Therapy: A Population-Based Study. *Clin Genitourin Cancer*. 2014 Dec 9. pii: S1558-7673(14)00263-8. doi: 10.1016/j.clgc.2014.12.003
985. Moltzahn F, Karnes J, Gontero P, Kneitz B, Tombal B, Bader P, **Briganti A**, Montorsi F, Van Poppel H, Joniau S, Spahn M. Predicting prostate cancer-specific outcome after radical prostatectomy among men with very high-risk cT3b/4 PCa: a multi-institutional outcome study of 266 patients. *Prostate Cancer Prostatic Dis*. 2014 Dec 23. doi: 10.1038/pcan.2014.41
986. De Nunzio C, Autorino R, Bachmann A, **Briganti A**, Carter S, Chun F, Novara G, Sosnowski R, Thiruchelvam N, Tubaro A, Ahyai S; EAU Young Academic Urologists BPH Group Arnhem, The Netherlands. The diagnosis of benign prostatic obstruction: Development of a clinical nomogram. *Neurourol Urodyn*. 2014 Dec 18. doi: 10.1002/nau.22705
987. Oderda M, Audenet F, **Briganti A**, Brown M, De Marco V, Gan M, Janssen M, Navarro R, Sanchez-Salas R, Wit E. Re: Alessandro Volpe, Kamran Ahmed, Prokar Dasgupta, et al. Pilot Validation Study of the European Association of Urology Robotic Training Curriculum. *Eur Urol*. 2014 Dec 5. pii: S0302-2838(14)01241-X. doi: 10.1016/j.eururo.2014.11.047. [Epub ahead of print]
988. Larcher A, Sun M, Schiffmann J, Tian Z, Shariat SF, McCormack M, Saad F, Fossati N, Abdollah F, **Briganti A**, Buffi N, Graefen M, Guazzoni G, Montorsi F, Karakiewicz PI. Differential effect on survival of pelvic lymph node dissection at radical cystectomy for muscle invasive bladder cancer. *Eur J Surg Oncol*. 2014 Nov 21. pii: S0748-7983(14)01204-9. doi: 10.1016/j.ejso.2014.10.061. [Epub ahead of print]
989. Fiorino C, **Briganti A**, Cozzarini C. Re: Mark K. Buyyounouski. Radiobiological Modeling and the Study of Hypofractionated Radiotherapy for Prostate Cancer. *Eur Urol*. 2014 Nov 11. pii: S0302-2838(14)01121-X. doi: 10.1016/j.eururo.2014.10.032. [Epub ahead of print]

990. Loeb S, Bruinsma SM, Nicholson J, **Briganti A**, Pickles T, Kakehi Y, Carlsson SV, Roobol MJ. Active Surveillance for Prostate Cancer: A Systematic Review of Clinicopathologic Variables and Biomarkers for Risk Stratification. *Eur Urol.* 2014 Oct 31. pii: S0302-2838(14)01018-5. doi: 10.1016/j.eururo.2014.10.010. [Epub ahead of print]
991. Lucca I, Shariat SF, **Briganti A**, Lotan Y, Roehrborn CG, Montorsi F, Remzi M, Seitz C, Fajkovic H, Klingler C, Karakiewicz PI, Sun M, Rouprêt M, Loidl W, Pummer K, Klatter T. Validation of tertiary Gleason pattern 5 in Gleason score 7 prostate cancer as an independent predictor of biochemical recurrence and development of a prognostic model. *Urol Oncol.* 2014 Oct 23. pii: S1078-1439(14)00289-0. doi: 10.1016/j.urolonc.2014.08.011.
992. Fiorino C, Cozzarini C, Rancati T, **Briganti A**, Cattaneo GM, Mangili P, Di Muzio NG, Calandrino R. Modelling the Impact of Fractionation on Late Urinary Toxicity After Postprostatectomy Radiation Therapy. *Int J Radiat Oncol Biol Phys.* 2014 Oct 13;90(5):1250-1257.
993. Montorsi F, Gandaglia G, **Briganti A**. Long-Term Outcomes of Robot-Assisted Radical Prostatectomy: Where Do We Stand? *BJU Int.* 2014 Nov 10. doi:10.1111/bju.12981.
994. Cantiello F, Cicione A, Salonia A, Autorino R, De Nunzio C, **Briganti A**, Gandaglia G, Dell'Oglio P, Capogrosso P, Damiano R. Association between metabolic syndrome, obesity, diabetes mellitus and oncological outcomes of bladder cancer: A systematic review. *Int J Urol.* 2014 Oct 23. doi:10.1111/iju.12644.
995. Mathieu R, Shariat SF, Seitz C, Karakiewicz PI, Fajkovic H, Sun M, Lotan Y, Scherr DS, Tewari A, Montorsi F, **Briganti A**, Rouprêt M, Lucca I, Margulis V, Rink M, Kluth LA, Rieken M, Bachman A, Xylinas E, Robinson BD, Bensalah K, Margreiter M. Multi-institutional validation of the prognostic value of Ki-67 labeling index in patients treated with radical prostatectomy. *World J Urol.* 2014 Oct 26.
996. Montironi R, Scarpelli M, Mazzucchelli R, Lopez-Beltran A, Santoni M, **Briganti A**, Montorsi F, Cheng L. Does prostate acinar adenocarcinoma with Gleason Score 3+3=6 have the potential to metastasize? *Diagn Pathol.* 2014 Oct 18;9(1):190.
997. **Briganti A**, Giannarini G, Karnes RJ, Gandaglia G, Ficarra V, Montorsi F. What Evidence Do We Need to Support the Use of Extended Pelvic Lymph Node Dissection in Prostate Cancer? *Eur Urol.* 2014 Sep 30. pii: S0302-2838(14)00962-2. doi: 10.1016/j.eururo.2014.09.025.
998. Suardi N, Cozzarini C, Montorsi F, **Briganti A**. Reply to Bernardino De Bari, Stefano Arcangeli, and Filippo Alongi's Letter to the Editor re: Nazareno Suardi, Andrea Gallina, Giuliana Lista, et al. Impact of Adjuvant Radiation Therapy on Urinary Continence Recovery After Radical Prostatectomy. *Eur Urol* 2014;65:546-51. *Eur Urol.* 2014 Sep 30. pii: S0302-2838(14)00967-1. doi: 10.1016/j.eururo.2014.09.030.
999. Buono R, **Briganti A**, Freschi M, Villa L, La Croce G, Moschini M, Benigni F, Castiglione F, Montorsi F, Hedlund P. Silodosin and tadalafil have synergistic inhibitory effects on nerve-mediated contractions of human and rat isolated prostates. *Eur J Pharmacol.* 2014 Sep 23. pii: S0014-2999(14)00682-7. doi: 10.1016/j.ejphar.2014.09.030. [Epub ahead of print]
1000. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Vizziello D, Sun M, Karakiewicz PI, Menon M, Montorsi F, **Briganti A**. Impact of Adjuvant Radiotherapy on Survival of Patients With Node-Positive Prostate Cancer. *J Clin Oncol.* 2014 Sep 22. pii: JCO.2013.54.7893. [Epub ahead of print]
1001. Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M 3rd, **Briganti A**. Metastasis-directed Therapy of Regional and Distant Recurrences After Curative Treatment of Prostate Cancer: A Systematic Review of the Literature. *Eur Urol.* 2014 Sep 17. pii: S0302-2838(14)00889-6. doi: 10.1016/j.eururo.2014.09.004. Review.
1002. Surcel CI, van Oort IM, Sooriakumaran P, **Briganti A**, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, van den Bergh RC, Yossepowitch O, Giannarini G, Ploussard G; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Prognostic effect of neuroendocrine differentiation in prostate cancer: A critical review. *Urol Oncol.* 2014 Sep 16. pii: S1078-1439(14)00284-1. doi: 10.1016/j.urolonc.2014.08.007. [Epub ahead of print] Review.

1003. Martin NE, Massey L, Stowell C, Bangma C, **Briganti A**, Bill-Axelsson A, Blute M, Catto J, Chen RC, D'Amico AV, Feick G, Fitzpatrick JM, Frank SJ, Froehner M, Frydenberg M, Glaser A, Graefen M, Hamstra D, Kibel A, Mendenhall N, Moretti K, Ramon J, Roos I, Sandler H, Sullivan FJ, Swanson D, Tewari A, Vickers A, Wiegel T, Huland H. Defining a Standard Set of Patient-centered Outcomes for Men with Localized Prostate Cancer. *Eur Urol*. 2014 Sep 15. pii: S0302-2838(14)00845-8. doi: 10.1016/j.eururo.2014.08.075
1004. Fossati N, Trinh QD, Sammon J, Sood A, Larcher A, Sun M, Karakiewicz P, Guazzoni G, Montorsi F, **Briganti A**, Menon M, Abdollah F. Identifying Optimal Candidates for Local Treatment of the Primary Tumor Among Patients Diagnosed with Metastatic Prostate Cancer: A SEER-based Study. *Eur Urol*. 2014 Sep 9. pii: S0302-2838(14)00809-4. doi: 10.1016/j.eururo.2014.08.056.
1005. Gandaglia G, Ravi P, Abdollah F, Abd-El-Barr AE, Becker A, Popa I, **Briganti A**, Karakiewicz PI, Trinh QD, Jewett MA, Sun M. Contemporary incidence and mortality rates of kidney cancer in the United States. *Can Urol Assoc J*. 2014 Jul;8(7-8):247-52. doi: 10.5489/cuaj.1760.
1006. Cozzarini C, Fiorino C, **Briganti A**, Montorsi F, Di Muzio N. Reply to Bernardino De Bari, Filippo Alongi, Stefano Arcangeli's Letter to the Editor re: Cesare Cozzarini, Claudio Fiorino, Chiara Deantoni, et al. Higher-than-expected Severe (Grade 3-4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo>. 2014.06.012. *Eur Urol*. 2014 Sep 5. pii: S0302-2838(14)00803-3. doi: 10.1016/j.eururo.2014.08.050.
1007. Abdollah F, Montorsi F, **Briganti A**. Reply from Authors re: Christian Stief. Mere Extension of the Field of Resection Cannot Be the Answer to Surgery for Metastatic Spread: We Need Individualized Approaches Based on Modern Imaging Techniques. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2014.07.026>: Does Extended Pelvic Lymph Node Dissection Really Improve Survival in Prostate Cancer Patients with Node-positive Disease? Or Is It the Will Rogers Phenomenon Again? *Eur Urol*. 2014 Aug 25. pii: S0302-2838(14)00779-9. doi: 10.1016/j.eururo.2014.08.026.
1008. Fossati N, Sjoberg DD, Capitanio U, Gandaglia G, Larcher A, Nini A, Mirone V, Vickers AJ, Montorsi F, **Briganti A**. Extended Pelvic Lymph Node Dissection in Prostate Cancer Patients Previously Treated With Surgery for Lower Urinary Tract Symptoms. *BJU Int*. 2014 Aug 28. doi: 10.1111/bju.12912.
1009. Gandaglia G, Di Trapani E, **Briganti A**. Extended lymph node dissection in prostate cancer: a procedure with therapeutic utility. *Oncology (Williston Park)*. 2014 Jul;28(7):600, 602.
1010. Gandaglia G, Ghani KR, Sood A, Meyers JR, Sammon JD, Schmid M, Varda B, **Briganti A**, Montorsi F, Sun M, Menon M, Kibel AS, Trinh QD. Effect of Minimally Invasive Surgery on the Risk for Surgical Site Infections: Results From the National Surgical Quality Improvement Program (NSQIP) Database. *JAMA Surg*. 2014 Aug 20. doi: 10.1001/jamasurg.2014.292. [Epub ahead of print]
1011. Gandaglia G, Karakiewicz PI, **Briganti A**, Trudeau V, Trinh QD, Kim SP, Montorsi F, Nguyen PL, Abdollah F, Sun M. Early radiotherapy after radical prostatectomy improves cancer-specific survival only in patients with highly aggressive prostate cancer: Validation of recently released criteria. *Int J Urol*. 2014 Aug 21. doi: 10.1111/iju.12605.
1012. Castiglione F, Montorsi F, **Briganti A**. Tadalafil for erectile dysfunction prevention after radiotherapy for prostate cancer. *JAMA*. 2014 Aug 20;312(7):748.
1013. Giannarini G, Gandaglia G, Montorsi F, **Briganti A**. Reply to M. Valerio et al. *J Clin Oncol*. 2014 Aug 18. pii: JCO.2014.57.7353. [Epub ahead of print]
1014. Ploussard G, Isbarn H, **Briganti A**, Sooriakumaran P, Surcel CI, Salomon L, Freschi M, Mirvald C, van der Poel HG, Jenkins A, Ost P, van Oort IM, Yossepowitch O, Giannarini G, van den Bergh RC; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party of the European Association of Urology. Can we expand active surveillance criteria to include biopsy Gleason 3+4 prostate cancer? A multi-institutional study of 2,323 patients. *Urol Oncol*. 2014 Aug 14. pii: S1078-1439(14)00263-4. doi: 10.1016/j.urolonc.2014.07.007.
1015. Gandaglia G, Karakiewicz PI, **Briganti A**, Passoni NM, Schiffmann J, Trudeau V, Graefen M, Montorsi F, Sun M. Impact of the Site of Metastases on Survival in Patients with Metastatic Prostate

- Cancer. *Eur Urol*. 2014 Aug 6. pii: S0302-2838(14)00672-1. doi: 10.1016/j.eururo.2014.07.020. [Epub ahead of print]
1016. Villa L, Salonia A, Capitanio U, Scattoni V, Abdollah F, Suardi N, Dell'Oglio P, Freschi M, Montorsi F, **Briganti A**. The Number of Cores at First Biopsy May Suggest the Need for a Confirmatory Biopsy in Patients Eligible for Active Surveillance-Implication for Clinical Decision Making in the Real-life Setting. *Urology*. 2014 Sep;84(3):634-41.
1017. Villa L, Salonia A, Capitanio U, Scattoni V, Abdollah F, Suardi N, Dell'Oglio P, Freschi M, Montorsi F, **Briganti A**. Reply. *Urology*. 2014 Sep;84(3):640-1.
1018. Gontero P, Sylvester R, Pisano F, Joniau S, Vander Eeck K, Serretta V, Larré S, Di Stasi S, Van Rhijn B, Witjes AJ, Grotenhuis AJ, Kiemeneij LA, Colombo R, **Briganti A**, Babjuk M, Malmström PU, Oderda M, Irani J, Malats N, Baniel J, Mano R, Cai T, Cha EK, Ardelt P, Varkarakis J, Bartoletti R, Spahn M, Johansson R, Freja B, Soukup V, Xylinas E, Dalbagni G, Karnes RJ, Shariat SF, Palou J. Prognostic Factors and Risk Groups in T1G3 Non-Muscle-invasive Bladder Cancer Patients Initially Treated with Bacillus Calmette-Guérin: Results of a Retrospective Multicenter Study of 2451 Patients. *Eur Urol*. 2014 Jul 16. pii: S0302-2838(14)00614-9. doi: 10.1016/j.eururo.2014.06.040.
1019. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Seitz C, Sun M, Karakiewicz PI, Schramek P, Herman MP, Becker A, Hansen J, Ehdaie B, Loidl W, Pummer K, Lee RK, Lotan Y, Scherr DS, Seiler D, Ahyai SA, Chun FK, Graefen M, Tewari A, Nonis A, Bachmann A, Montorsi F, Gönen M, **Briganti A**, Shariat SF. Clinical nodal staging scores for prostate cancer: a proposal for preoperative risk assessment. *Br J Cancer*. 2014 Jul 15;111(2):213-9.
1020. Ghadjjar P, **Briganti A**, De Visschere PJ, Fütterer JJ, Giannarini G, Isbarn H, Ost P, Sooriakumaran P, Surcel CI, van den Bergh RC, van Oort IM, Yossepowitch O, Ploussard G. The oncologic role of local treatment in primary metastatic prostate cancer. *World J Urol*. 2014 Jul 5.
1021. Cozzarini C, Fiorino C, Deantoni C, **Briganti A**, Fodor A, La Macchia M, Noris Chiorda B, Rancoita PM, Suardi N, Zerbetto F, Calandrino R, Montorsi F, Di Muzio N. Higher-than-expected Severe (Grade 3-4) Late Urinary Toxicity After Postprostatectomy Hypofractionated Radiotherapy: A Single-institution Analysis of 1176 Patients. *Eur Urol*. 2014 Jun 27. pii: S0302-2838(14)00533-8. doi: 10.1016/j.eururo.2014.06.012.
1022. Gandaglia G, **Briganti A**, Montorsi F, Vlachopoulos C. Reply to Christopher Chee Kong Ho, Siew Eng Ho, Srijit Das' Letter to the Editor re: Giorgio Gandaglia, Alberto Briganti, Graham Jackson, et al. A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease. *Eur Urol* 2014;65:968-78. *Eur Urol*. 2014 Jun 17. pii: S0302-2838(14)00525-9. doi: 10.1016/j.eururo.2014.06.004.
1023. Moschini M, Suardi N, Pellucchi F, Rocchini L, La Croce G, Capitanio U, **Briganti A**, Damiano R, Montorsi F, Colombo R. Impact of preoperative thrombocytosis on pathological outcomes and survival in patients treated with radical cystectomy for bladder carcinoma. *Anticancer Res*. 2014 Jun;34(6):3225-30.
1024. Gandaglia G, Karakiewicz PI, Abdollah F, Becker A, Roghmann F, Sammon JD, Kim SP, Perrotte P, **Briganti A**, Montorsi F, Trinh QD, Sun M. The effect of age at diagnosis on prostate cancer mortality: A grade-for-grade and stage-for-stage analysis. *Eur J Surg Oncol*. 2014 May 22. pii: S0748-7983(14)00446-6. doi: 10.1016/j.ejso.2014.05.001. [Epub ahead of print]
1025. Gandaglia G, Karakiewicz PI, **Briganti A**, Menon M, Sun M, Abdollah F. In reply to the letter to the editor 'in Reply to Gandaglia et al.' by De Bari et al. *Ann Oncol*. 2014 Sep;25(9):1862-3
1026. Scattoni V, Maccagnano C, Capitanio U, Gallina A, **Briganti A**, Montorsi F. Random biopsy: when, how many and where to take the cores? *World J Urol*. 2014 Aug;32(4):859-69.
1027. Lucca I, Rouprêt M, Kluth L, Rink M, Tilki D, Fajkovic H, Kassouf W, Hofbauer SL, de Martino M, Karakiewicz PI, **Briganti A**, Trinh QD, Seitz C, Fritsche HM, Burger M, Lotan Y, Kramer G, Shariat SF, Klatte T. Adjuvant cisplatin-based combination chemotherapy for lymph node-positive urothelial carcinoma of the bladder following radical cystectomy: a retrospective international study of more than 1500 patients. *BJU Int*. 2014 Jun 6. doi: 10.1111/bju.12829.
1028. Abdollah F, Gandaglia G, Suardi N, Capitanio U, Salonia A, Nini A, Moschini M, Sun M, Karakiewicz PI, Shariat SF, Montorsi F, **Briganti A**. More Extensive Pelvic Lymph Node Dissection

- Improves Survival in Patients with Node-positive Prostate Cancer. *Eur Urol*. 2014 May 29. pii: S0302-2838(14)00421-7. doi: 10.1016/j.eururo.2014.05.011.
1029. Capitanio U, Suardi N, Matloob R, Roscigno M, Abdollah F, Di Trapani E, Moschini M, Gallina A, Salonia A, **Briganti A**, Montorsi F, Bertini R. Extent of lymph node dissection at nephrectomy affects cancer-specific survival and metastatic progression in specific sub-categories of patients with renal cell carcinoma (RCC). *BJU Int*. 2014 Aug;114(2):210-5
1030. Gandaglia G, Giannarini G, Suardi N, Montorsi F, **Briganti A**. Will Active Surveillance for Clinically Localized Prostate Cancer Survive in the Era of Individualized Medicine? *Eur Urol*. 2014 May 13. pii: S0302-2838(14)00401-1. doi: 10.1016/j.eururo.2014.04.020.
1031. Lucca I, Kassouf W, Kapoor A, Fairey A, Rendon RA, Izawa JI, Black PC, Fajkovic H, Seitz C, Remzi M, Nyirády P, Rouprêt M, Margulis V, Lotan Y, de Martino M, Hofbauer SL, Karakiewicz PI, **Briganti A**, Novara G, Shariat SF, Klatte T. The role of adjuvant chemotherapy for lymph node-positive upper tract urothelial carcinoma following radical nephroureterectomy: a retrospective study. *BJU Int*. 2014 May 13. doi: 10.1111/bju.12801.
1032. Surcel CI, Sooriakumaran P, **Briganti A**, De Visschere PJ, Fütterer JJ, Ghadjar P, Isbarn H, Ost P, Ploussard G, van den Bergh RC, van Oort IM, Yossepowitch O, Sedelaar JP, Giannarini G; Members of the Prostate Cancer Working Group of the Young Academic Urologists Working Party and Members of the Young Urologists Office of the European Association of Urology. Preferences in the management of high-risk prostate cancer among urologists in Europe: results of a web-based survey. *BJU Int*. 2014 May 6. doi: 10.1111/bju.12796.
1033. Gandaglia G, Gallina A, Suardi N, Abdollah F, Passoni N, Bianchi M, Zaffuto E, Nini A, Vizziello D, Salonia A, Montorsi F, **Briganti A**. Preoperative erectile function is the only predictor of the use of a high number of phosphodiesterase type-5 inhibitors after bilateral nerve-sparing radical prostatectomy. *Int J Impot Res*. 2014 May 1. doi: 10.1038/ijir.2014.10. [Epub ahead of print]
1034. Rieken M, Schubert T, Xylinas E, Kluth L, Rouprêt M, Trinh QD, Lee RK, Al Hussein Al Awamlh B, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, **Briganti A**, Bachmann A, Shariat SF; for the UTUC Collaboration. Association of perioperative blood transfusion with oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2014 Apr 13. pii: S0748-7983(14)00380-1. doi: 10.1016/j.ejso.2014.03.018. [Epub ahead of print]
1035. Gandaglia G, Sun M, **Briganti A**, Karakiewicz PI. Reply to E. David Crawford and Bo-Eric Persson's Letter to the Editor re: Giorgio Gandaglia, Maxine Sun, Jim C. Hu, et al. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2014.01.026>. *Eur Urol*. 2014 Apr 13. pii: S0302-2838(14)00309-1. doi: 10.1016/j.eururo.2014.03.043.
1036. Cantiello F, Cicione A, Autorino R, De Nunzio C, Salonia A, **Briganti A**, Aliberti A, Perdonà S, Tubaro A, Damiano R. Metabolic Syndrome, Obesity, and Radical Cystectomy Complications: A Clavien Classification System-Based Analysis. *Clin Genitourin Cancer*. 2014 Mar 14. pii: S1558-7673(14)00050-0. doi: 10.1016/j.clgc.2014.03.001. [Epub ahead of print]
1037. Abdollah F, **Briganti A**, Montorsi F, Stenzl A, Stief C, Tombal B, Van Poppel H, Touijer K. Contemporary Role of Salvage Lymphadenectomy in Patients with Recurrence Following Radical Prostatectomy. *Eur Urol*. 2014 Mar 26. pii: S0302-2838(14)00271-1. doi: 10.1016/j.eururo.2014.03.019.
1038. De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, **Briganti A**, Fonteyne V, Van Vulpen M, Lumen N, Spahn M, Mareel M. Radiotherapy for renal-cell carcinoma. *Lancet Oncol*. 2014 Apr;15(4):e170-7.
1039. Giannarini G, Gandaglia G, Montorsi F, **Briganti A**. Will focal therapy remain only an attractive illusion for the primary treatment of prostate cancer? *J Clin Oncol*. 2014 May 1;32(13):1299-301
1040. Gallina A, Nini A, Montorsi F, **Briganti A**. Metabolic Syndrome as a Marker for Prostate Cancer: Still a Work in Progress. *Eur Urol*. 2014 Mar 25. pii: S0302-2838(14)00270-X. doi: 10.1016/j.eururo.2014.03.018.

1041. Joniau S, Spahn M, **Briganti A**, Gandaglia G, Tombal B, Tosco L, Marchioro G, Hsu CY, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, van Poppel H, Gontero P; for the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Pretreatment Tables Predicting Pathologic Stage of Locally Advanced Prostate Cancer. *Eur Urol*. 2014 Mar 21. pii: S0302-2838(14)00249-8. doi: 10.1016/j.eururo.2014.03.013
1042. Bianchi M, Roghmann F, Becker A, Sukumar S, **Briganti A**, Menon M, Karakiewicz PI, Sun M, Noldus J, Trinh QD. Age-stratified distribution of metastatic sites in bladder cancer: A population-based analysis. *Can Urol Assoc J*. 2014 Mar-Apr;8(3-4):E148-58.
1043. Gandaglia G, Suardi N, Gallina A, Zaffuto E, Cucchiara V, Vizziello D, Shariat S, Cantiello F, Damiano R, Guazzoni G, Montorsi F, **Briganti A**. How to optimize patient selection for robot-assisted radical prostatectomy: functional outcome analyses from a tertiary referral center. *J Endourol*. 2014 Jul;28(7):792-800.
1044. Gandaglia G, Sun M, Popa I, Schiffmann J, Abdollah F, Trinh QD, Saad F, Graefen M, **Briganti A**, Montorsi F, Karakiewicz PI. The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study. *BJU Int*. 2014 Mar 10. doi: 10.1111/bju.12732.
1045. Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, **Briganti A**. Long-term Outcomes of Salvage Lymph Node Dissection for Clinically Recurrent Prostate Cancer: Results of a Single-institution Series with a Minimum Follow-up of 5 Years. *Eur Urol*. 2014 Feb 18. pii: S0302-2838(14)00130-4. doi: 10.1016/j.eururo.2014.02.011.
1046. Gandaglia G, Karakiewicz PI, **Briganti A**, Trinh QD, Schiffmann J, Tian Z, Kim SP, Nguyen PL, Graefen M, Montorsi F, Sun M, Abdollah F. Intensity-modulated radiation therapy leads to survival benefit only in patients with high-risk prostate cancer: a population-based study. *Ann Oncol*. 2014 May;25(5):979-86
1047. Gandaglia G, Abdollah F, Hu J, Kim S, **Briganti A**, Sammon JD, Becker A, Roghmann F, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI, Trinh QD, Sun M. Is robot-assisted radical prostatectomy safe in men with high-risk prostate cancer? Assessment of perioperative outcomes, positive surgical margins, and use of additional cancer treatments. *J Endourol*. 2014 Jul;28(7):784-91
1048. Gandaglia G, Sun M, Hu JC, Novara G, Choueiri TK, Nguyen PL, Schiffmann J, Graefen M, Shariat SF, Abdollah F, **Briganti A**, Montorsi F, Trinh QD, Karakiewicz PI. Gonadotropin-releasing Hormone Agonists and Acute Kidney Injury in Patients with Prostate Cancer. *Eur Urol*. 2014 Jan 28. pii: S0302-2838(14)00095-5. doi: 10.1016/j.eururo.2014.01.026.
1049. Joniau S, **Briganti A**, Gontero P, Gandaglia G, Tosco L, Fieuws S, Tombal B, Marchioro G, Walz J, Kneitz B, Bader P, Frohneberg D, Tizzani A, Graefen M, van Cangh P, Karnes RJ, Montorsi F, Van Poppel H, Spahn M; European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Stratification of High-risk Prostate Cancer into Prognostic Categories: A European Multi-institutional Study. *Eur Urol*. 2014 Jan 25. pii: S0302-2838(14)00071-2.
1050. Gandaglia G, Popa I, Abdollah F, Schiffmann J, Shariat SF, **Briganti A**, Montorsi F, Trinh QD, Karakiewicz PI, Sun M. The Effect of Neoadjuvant Chemotherapy on Perioperative Outcomes in Patients Who Have Bladder Cancer Treated with Radical Cystectomy: A Population-based Study. *Eur Urol*. 2014 Jan 24. pii: S0302-2838(14)00065-7. doi: 10.1016/j.eururo.2014.01.014.
1051. Gandaglia G, Sun M, Trinh QD, Becker A, Schiffmann J, Hu JC, **Briganti A**, Montorsi F, Perrotte P, Karakiewicz PI, Abdollah F. Survival benefit of definitive therapy in patients with clinically advanced prostate cancer: estimations of the number needed to treat based on competing-risks analysis. *BJU Int*. 2014 Jan 27. doi: 10.1111/bju.12645.
1052. Giannarini G, Suardi N, **Briganti A**. Re: Prasanna Sooriakumaran, Abhishek Srivastava, Shahrokh F. Shariat, et al. A multinational, multi-institutional study comparing positive surgical margin rates among 22,393 open, laparoscopic, and robot-assisted radical prostatectomy patients. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2013.11.018>. *Eur Urol*. 2014 Jun;65(6):e89-90.
1053. Suardi N, Larcher A, Haese A, Ficarra V, Govorov A, Buffi NM, Walz J, Rocco B, Borghesi M, Steuber T, Pini G, **Briganti A**, Mottrie AM, Guazzoni G, Montorsi F, Pushkar D, Van Der Poel H; for the

- EAU Young Academic Urologists–Robotic Section. Indication for and Extension of Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: An Analysis of Five European Institutions. *Eur Urol*. 2014 Jan 4. pii: S0302-2838(13)01487-5. doi: 10.1016/j.eururo.2013.12.059.
1054. Gandaglia G, Trinh QD, Hu JC, Schiffmann J, Becker A, Roghmann F, Popa I, Tian Z, Perrotte P, Montorsi F, **Briganti A**, Karakiewicz PI, Sun M, Abdollah F. The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the “post-dissemination” period. *Eur J Surg Oncol*. 2014 Sep;40(9):1080-6.
1055. Giovacchini G, Picchio M, Garcia-Parra R, **Briganti A**, Abdollah F, Gianolli L, Schindler C, Montorsi F, Messa C, Fazio F. 11C-choline PET/CT predicts prostate cancer-specific survival in patients with biochemical failure during androgen-deprivation therapy. *J Nucl Med*. 2014 Feb;55(2):233-41.
1056. Castiglione F, Nini A, **Briganti A**. Penile rehabilitation with phosphodiesterase type 5 inhibitors after nerve-sparing radical prostatectomy: are we targeting the right patients? *Eur Urol*. 2014 Apr;65(4):673-4.
1057. Ost P, **Briganti A**, Giannarini G; Prostate Cancer Working Group of the Young Academic Urologist Working Party of the European Association of Urology. Re: Stephen H. Culp, Paul F. Schellhammer, Michael B. Williams. Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. *Eur Urol* 2014;65:1058-66. *Eur Urol*. 2014 Jun;65(6):e97-8.
1058. **Briganti A**, Joniau S, Gandaglia G, Cozzarini C, Sun M, Tombal B, Haustermans K, Hinkelbein W, Shariat SF, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. *Int J Radiat Oncol Biol Phys*. 2013 Dec 1;87(5):960-7.
1059. **Briganti A**, Karnes RJ, Joniau S, Boorjian SA, Cozzarini C, Gandaglia G, Hinkelbein W, Haustermans K, Tombal B, Shariat S, Sun M, Karakiewicz PI, Montorsi F, Van Poppel H, Wiegel T. Prediction of Outcome Following Early Salvage Radiotherapy Among Patients with Biochemical Recurrence After Radical Prostatectomy. *Eur Urol*. 2013 Dec 12. pii: S0302-2838(13)01309-2. doi: 10.1016/j.eururo.2013.11.045.
1060. Castiglione F, Benigni F, **Briganti A**, Salonia A, Villa L, Nini A, Di Trapani E, Capitanio U, Montorsi F. Naftopidil for the treatment of benign prostate hyperplasia. A systematic review. *Curr Med Res Opin*. 2013 Nov 5. [Epub ahead of print] (I.F.: 2.757).
1061. Dell’Oglio P, Abdollah F, Suardi N, Gallina A, Cucchiara V, Vizziello D, Zaffuto E, Cantiello F, Damiano R, Shariat SF, Montorsi F, **Briganti A**. External validation of the European Association of Urology recommendations for pelvic lymph node dissection in patients treated with robotic-assisted radical prostatectomy. *J Endourol*. 2013 Nov 4. [Epub ahead of print]
1062. Gandaglia G, Abdollah F, Schiffmann J, Trudeau V, Shariat SF, Kim SP, Perrotte P, Montorsi F, **Briganti A**, Trinh QD, Karakiewicz PI, Sun M. Distribution of metastatic sites in patients with prostate cancer: A population-based analysis. *Prostate*. 2013 Oct 16. doi: 10.1002/pros.22742. [Epub ahead of print]
1063. Rieken M, Xylinas E, Kluth L, Trinh QD, Lee RK, Fajkovic H, Novara G, Margulis V, Lotan Y, Martinez-Salamanca JI, Matsumoto K, Seitz C, Remzi M, Karakiewicz PI, Scherr DS, **Briganti A**, Kautzky-Willer A, Bachmann A, Shariat SF; UTUC Collaboration. Diabetes mellitus without metformin intake is associated with worse oncologic outcomes after radical nephroureterectomy for upper tract urothelial carcinoma. *Eur J Surg Oncol*. 2013 Sep 20. doi:pii: S0748-7983(13)00805-6. 10.1016/j.ejso.2013.09.016. [Epub ahead of print]
1064. Gandaglia G, Becker A, Trinh QD, Abdollah F, Schiffmann J, Roghmann F, Tian Z, Montorsi F, **Briganti A**, Karakiewicz PI, Sun M. Long-term survival in patients with germ cell testicular cancer: A population-based competing-risks regression analysis. *Eur J Surg Oncol*. 2013 Sep 25. doi:pii: S0748-7983(13)00812-3. 10.1016/j.ejso.2013.09.019. [Epub ahead of print]
1065. Abdollah F, Karnes RJ, Suardi N, Cozzarini C, Gandaglia G, Fossati N, Bianchi M, Boorjian SA, Sun M, Karakiewicz PI, Montorsi F, **Briganti A**. Predicting Survival of Patients with Node-positive Prostate Cancer Following Multimodal Treatment. *Eur Urol*. 2013 Sep 27. doi:pii: S0302-2838(13)01012-9. 10.1016/j.eururo.2013.09.025.

1066. Kluth LA, Xylinas E, Rieken M, Chun FK, Fajkovic H, Becker A, Karakiewicz PI, Passoni N, Herman M, Lotan Y, Seitz C, Schramek P, Remzi M, Loidl W, Guillonneau B, Rouprêt M, **Briganti A**, Scherr DS, Graefen M, Tewari AK, Shariat SF. Does increasing the nodal yield improve outcomes in contemporary patients without nodal metastasis undergoing radical prostatectomy? *Urol Oncol*. 2013 Sep 18. doi:pii: S1078-1439(13)00283-4. 10.1016/j.urolonc.2013.06.013.
1067. Bianchi M, Gandaglia G, Trinh QD, Hansen J, Becker A, Abdollah F, Tian Z, Lughezzani G, Roghmann F, **Briganti A**, Montorsi F, Karakiewicz PI, Sun M. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma. *Urol Oncol*. 2013 Sep 17. doi:pii: S1078-1439(13)00259-7. 10.1016/j.urolonc.2013.06.010.
1068. Kluth LA, Xylinas E, Rieken M, Ghouayel ME, Sun M, Karakiewicz PI, Lotan Y, Chun FK, Boorjian SA, Lee RK, **Briganti A**, Rouprêt M, Fisch M, Scherr DS, Shariat SF. Impact of Perioperative Blood Transfusion on the Outcome of Patients undergoing Radical Cystectomy for Urothelial Carcinoma of the Bladder. *BJU Int*. 2013 Sep 5. doi: 10.1111/bju.12439.
1069. Passoni NM, Fajkovic H, Xylinas E, Kluth L, Seitz C, Robinson BD, Rouprêt M, Chun FK, Lotan Y, Roehrborn CG, Crivelli JJ, Karakiewicz PI, Scherr DS, Rink M, Graefen M, Schramek P, **Briganti A**, Montorsi F, Tewari A, Shariat SF. Prognosis of patients with pelvic lymph node metastasis following radical prostatectomy: value of extranodal extension and size of the largest lymph node metastasis. *BJU Int*. 2013 Jul 2. doi: 10.1111/bju.12342.
1070. Hansen J, Bianchi M, Sun M, Rink M, Castiglione F, Abdollah F, Steuber T, Ahyai SA, Steurer S, Göbel C, Freschi M, Montorsi F, Shariat SF, Fisch M, Graefen M, Karakiewicz PI, **Briganti A**, Chun FK. Percentage of High-Grade Tumor Volume does not Meaningfully Improve Prediction of Early Biochemical Recurrence after Radical Prostatectomy Compared to Gleason Score. *BJU Int*. 2013 Aug 23. doi: 10.1111/bju.12424.
1071. Gandaglia G, Bianchi M, Trinh QD, Becker A, Larouche A, Abdollah F, Roghmann F, Tian Z, Shariat SF, **Briganti A**, Montorsi F, Karakiewicz PI, Sun M. Survival after nephroureterectomy for upper tract urothelial carcinoma: A population-based competing-risks analysis. *Int J Urol*. 2013 Aug 29. doi: 10.1111/iju.12267.
1072. Gontero P, Spahn M, Marchioro G, Karnes JR, **Briganti A**, Frea B, Ricardi U, van Poppel H, Joniau S. Salvage Radical Prostatectomy in Nonmetastatic Castration-resistant Prostate Cancer Patients Who Received Previous Radiotherapy: A Feasibility Study. *Eur Urol*. 2013 Aug 28. doi:pii: S0302-2838(13)00878-6. 10.1016/j.eururo.2013.08.050.
1073. Gandaglia G, **Briganti A**, Jackson G, Kloner RA, Montorsi F, Montorsi P, Vlachopoulos C. A Systematic Review of the Association Between Erectile Dysfunction and Cardiovascular Disease. *Eur Urol*. 2013 Aug 23. doi:pii: S0302-2838(13)00851-8. 10.1016/j.eururo.2013.08.023.
1074. Ravi P, Bianchi M, Hansen J, Trinh QD, Tian Z, Meskawi M, Abdollah F, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Benefit in regionalisation of care for patients treated with radical cystectomy: a nationwide inpatient sample analysis. *BJU Int*. 2013 Jun 13. doi: 10.1111/bju.12288.
1075. Rieken M, Kluth LA, Xylinas E, Seitz C, Fajkovic H, Karakiewicz PI, Lotan Y, **Briganti A**, Loidl W, Faison T, Crivelli JJ, Scherr DS, Bachmann A, Tewari AK, Kautzky-Willer A, Pummer K, Shariat SF. Impact of statin use on biochemical recurrence in patients treated with radical prostatectomy. *Prostate Cancer Prostatic Dis*. 2013 Sep 3. doi: 10.1038/pcan.2013.31. [Epub ahead of print]
1076. Pfister D, Bolla M, **Briganti A**, Carroll P, Cozzarini C, Joniau S, van Poppel H, Roach M, Stephenson A, Wiegel T, Zelefsky MJ. Early Salvage Radiotherapy Following Radical Prostatectomy. *Eur Urol*. 2013 Aug 15. doi:pii: S0302-2838(13)00834-8. 10.1016/j.eururo.2013.08.013.
1077. Cantiello F, Cicione A, Autorino R, Salonia A, **Briganti A**, Ferro M, De Domenico R, Perdonà S, Damiano R. Visceral obesity predicts adverse pathological features in urothelial bladder cancer patients undergoing radical cystectomy: a retrospective cohort study. *World J Urol*. 2013 Aug 14.
1078. Yossepowitch O, **Briganti A**, Eastham JA, Epstein J, Graefen M, Montironi R, Touijer K. Positive Surgical Margins After Radical Prostatectomy: A Systematic Review and Contemporary Update. *Eur Urol*. 2013 Aug 3. doi:pii: S0302-2838(13)00796-3. 10.1016/j.eururo.2013.07.039.
1079. Bossi A, **Briganti A**. Prostate cancer: AUA-ASTRO guidelines for post-RP radiation fail to go nuclear. *Nat Rev Urol*. 2013 Sep;10(9):498-9. doi: 10.1038/nrurol.2013.163. [Epub ahead of print]

1080. Abdollah F, **Briganti A**. Reply to Chris Parker, Matthew R. Sydes and Howard Kynaston's Letter to the Editor re: Firas Abdollah, Nazareno Suardi, Cesare Cozzarini, et al. Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *Eur Urol* 2013;63:998-1008. *Eur Urol*. 2013 Nov;64(5):e103-4. doi: 10.1016/j.eururo.2013.07.028
1081. Cantiello F, Cicione A, Salonia A, Autorino R, Ucciero G, Tucci L, **Briganti A**, Damiano R. Metabolic syndrome correlates with peri-urethral fibrosis secondary to chronic prostate inflammation: Evidence of a link in a cohort of patients undergoing radical prostatectomy. *Int J Urol*. 2013 Aug 4.
1082. **Briganti A**, Suardi N, Gallina A, Abdollah F, Novara G, Ficarra V, Montorsi F. Predicting the risk of bone metastasis in prostate cancer. *Cancer Treat Rev*. 2013 Jul 26. doi:pil: S0305-7372(13)00132-1. 10.1016/j.ctrv.2013.07.001. [Epub ahead of print]
1083. **Briganti A**, Passoni NM, Abdollah F, Nini A, Montorsi F, Karnes RJ. Treatment of Lymph Node-Positive Prostate Cancer: Teaching Old Dogmas New Tricks. *Eur Urol*. 2013 Jul 10. doi:pil: S0302-2838(13)00718-5. 10.1016/j.eururo.2013.07.003
1084. Kluth LA, Abdollah F, Xylinas E, Rieken M, Fajkovic H, Sun M, Karakiewicz PI, Seitz C, Schramek P, Herman MP, Becker A, Loidl W, Pummer K, Nonis A, Lee RK, Lotan Y, Scherr DS, Seiler D, Chun FK, Graefen M, Tewari A, Gönen M, Montorsi F, Shariat SF, **Briganti A**. Pathologic Nodal Staging Scores in Patients Treated with Radical Prostatectomy: A Postoperative Decision Tool. *Eur Urol*. 2013 Jul 2. doi:pil: S0302-2838(13)00656-8. 10.1016/j.eururo.2013.06.041
1085. Schiavina R, Gacci M, **Briganti A**, Imbimbo C, Simonato A, Borghesi M, Capitanio U, Brunocilla E, Martorana G, Carini M, Montorsi F, Mirone V, Carmignani G. Can side-specific biopsy findings predict the side of nodal metastasis in clinically localized prostate cancer? Results from a multicenter prospective survey. *Eur J Surg Oncol*. 2013 Sep;39(9):1019-24. doi: 10.1016/j.ejso.2013.06.017. [Epub ahead of print]
1086. Abdollah F, Cozzarini C, Sun M, Suardi N, Gallina A, Passoni NM, Bianchi M, Tutolo M, Fossati N, Nini A, Dell'Oglio P, Salonia A, Karakiewicz P, Montorsi F, **Briganti A**. Assessing the most accurate formula to predict the risk of lymph node metastases from prostate cancer in contemporary patients treated with radical prostatectomy and extended pelvic lymph node dissection. *Radiother Oncol*. 2013 Nov;109(2):211-6.
1087. Capitanio U, Abdollah F, Matloob R, Suardi N, Castiglione F, Di Trapani E, Capogrosso P, Gallina A, Dell'Oglio P, **Briganti A**, Salonia A, Montorsi F, Bertini R. When to perform lymph node dissection in patients with renal cell carcinoma: a novel approach to the preoperative assessment of risk of lymph node invasion at surgery and of lymph node progression during follow-up. *BJU Int*. 2013 Jul;112(2):E59-66. doi: 10.1111/bju.12125.
1088. Passoni NM, Suardi N, Abdollah F, Picchio M, Giovacchini G, Messa C, Freschi M, Montorsi F, **Briganti A**. Utility of [(11)C]choline PET/CT in guiding lesion-targeted salvage therapies in patients with prostate cancer recurrence localized to a single lymph node at imaging: Results from a pathologically validated series. *Urol Oncol*. 2013 Jun 12. doi:pil: S1078-1439(13)00171-3. 10.1016/j.urolonc.2013.03.006.
1089. Abdollah F, Suardi N, Capitanio U, Gallina A, Sun M, Villa L, Scattoni V, Bianchi M, Tutolo M, Fossati N, Karakiewicz P, Rigatti P, Montorsi F, **Briganti A**. Spatial distribution of positive cores improves the selection of patients with low-risk prostate cancer as candidates for active surveillance. *BJU Int*. 2013 Aug;112(4):E234-42. doi: 10.1111/bju.12152.
1090. Gakis G, Boorjian SA, **Briganti A**, Joniau S, Karazanashvili G, Karnes RJ, Mattei A, Shariat SF, Stenzl A, Wirth M, Stief CG. The Role of Radical Prostatectomy and Lymph Node Dissection in Lymph Node-Positive Prostate Cancer: A Systematic Review of the Literature. *Eur Urol*. 2013 May 22. doi:pil: S0302-2838(13)00500-9. 10.1016/j.eururo.2013.05.033
1091. Bianchi M, Becker A, Hansen J, Trinh QD, Tian Z, Abdollah F, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Conditional survival after nephrectomy for renal cell carcinoma (RCC): changes in future survival probability over time. *BJU Int*. 2013 Jun;111(8):E283-9.
1092. Joniau S, Tosco L, **Briganti A**, Vanden Broeck T, Gontero P, Karnes RJ, Spahn M, Van Poppel H; European Multicenter Prostate Cancer Clinical and Translational research group. Results of surgery

- for high-risk prostate cancer. *Curr Opin Urol.* 2013 Jul;23(4):342-8. doi: 10.1097/MOU.0b013e3283620f60.
1093. Salonia A, Capogrosso P, Castiglione F, Russo A, Gallina A, Ferrari M, Clementi MC, Castagna G, **Briganti A**, Cantiello F, Damiano R, Montorsi F. Sperm banking is of key importance in patients with prostate cancer. *Fertil Steril.* 2013 Aug;100(2):367-72.e1. doi: 10.1016/j.fertnstert.2013.03.049. [Epub ahead of print]
1094. Capogrosso P, Colicchia M, Ventimiglia E, Castagna G, Clementi MC, Suardi N, Castiglione F, **Briganti A**, Cantiello F, Damiano R, Montorsi F, Salonia A. One patient out of four with newly diagnosed erectile dysfunction is a young man--worrying picture from the everyday clinical practice. *J Sex Med.* 2013 Jul;10(7):1833-41. doi: 10.1111/jsm.12179. Epub 2013 May 7.
1095. Gandaglia G, **Briganti A**, Gontero P, Mondaini N, Novara G, Salonia A, Sciarra A, Montorsi F. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). *BJU Int.* 2013 Aug;112(4):432-41. doi: 10.1111/bju.12118.
1096. Joniau S, Van der Eeckt K, **Briganti A**, Gontero P, Van Bruwaene S, Jeffrey Karnes R, Spahn M, Van Poppel H; European Multicenter Prostate Cancer Clinical and Translational research Group (EMPaCT). Current role of surgery for high risk prostate cancer. *Arch Esp Urol.* 2013 Apr;66(3):259-73, 259-74.
1097. Ploussard G, **Briganti A**, de la Taille A, Haese A, Heidenreich A, Menon M, Sulser T, Tewari AK, Eastham JA. Pelvic Lymph Node Dissection During Robot-assisted Radical Prostatectomy: Efficacy, Limitations, and Complications- A Systematic Review of the Literature. *Eur Urol.* 2013 Apr 6. doi:pii: S0302-2838(13)00351-5. 10.1016/j.eururo.2013.03.057.
1098. Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, Fossati N, Sun M, Dell'Oglio P, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F, **Briganti A**. Extended pelvic lymph node dissection in prostate cancer: a 20-year audit in a single center. *Ann Oncol.* 2013 Jun;24(6):1459-66.
1099. Abdollah F, Boorjian S, Cozzarini C, Suardi N, Sun M, Fiorino C, di Muzio N, Karakiewicz PI, Montorsi F, Karnes RJ, **Briganti A**. Survival following biochemical recurrence after radical prostatectomy and adjuvant radiotherapy in patients with prostate cancer: the impact of competing causes of mortality and patient stratification. *Eur Urol.* 2013 Oct;64(4):557-64. doi: 10.1016/j.eururo.2013.03.006.
1100. Passoni NM, Abdollah F, Suardi N, Gallina A, Bianchi M, Tutolo M, Fossati N, Gandaglia G, Salonia A, Freschi M, Rigatti P, Montorsi F, **Briganti A**. Head-to-head comparison of lymph node density and number of positive lymph nodes in stratifying the outcome of patients with lymph node-positive prostate cancer submitted to radical prostatectomy and extended lymph node dissection. *Urol Oncol.* 2013 Mar 12. doi:pii: S1078-1439(12)00355-9. 10.1016/j.urolonc.2012.10.009.
1101. Abdollah F, Gandaglia G, Thuret R, Schmitges J, Tian Z, Jeldres C, Passoni NM, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI, Sun M. Incidence, survival and mortality rates of stage-specific bladder cancer in United States: a trend analysis. *Cancer Epidemiol.* 2013 Jun;37(3):219-25. doi: 10.1016/j.canep.2013.02.002. [Epub ahead of print]
1102. Suardi N, Gallina A, Lista G, Gandaglia G, Abdollah F, Capitanio U, Dell'Oglio P, Nini A, Salonia A, Montorsi F, **Briganti A**. Impact of adjuvant radiation therapy on urinary continence recovery after radical prostatectomy. *Eur Urol.* 2013, Feb 4, pii: S0302-2838(13)00096-1. doi: 10.1016/j.eururo.2013.01.027.
1103. Capitanio U, Salonia A, **Briganti A**, Montorsi F. Silodosin in the management of lower urinary tract symptoms as a result of benign prostatic hyperplasia: who are the best candidates. *Int J Clin Pract.* 2013 Feb 15. doi: 10.1111/ijcp.12135
1104. Abdollah F, Sun M, Suardi N, Gallina A, Tutolo M, Passoni N, Bianchi M, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, **Briganti A**. A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. *BJU Int.* 2013 Jan 17. doi: 10.1111/j.1464-410X.2012.11560.x.
1105. **Briganti A**. Reply to Emily Vertosick and Andrew Vickers' Letter to the Editor re: Alberto Briganti, Thomas Wiegel, Steven Joniau, et al. Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer after Radical Prostatectomy: Results of a

- Match-Controlled Multi-institutional Analysis. *Eur Urol* 2012;62:472-87. *Eur Urol*. 2013 Apr;63(4):e51-2.
1106. Abdollah F, Sun M, Suardi N, Gallina A, Tutolo M, Passoni N, Bianchi M, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, **Briganti A**. A novel tool to assess the risk of urinary incontinence after nerve-sparing radical prostatectomy. *BJU Int*. 2013 May;111(6):905-13.
1107. **Briganti A**, Abdollah F., Reply from Authors re: Michel Bolla. Adjuvant or Immediate External Irradiation After Radical Prostatectomy with Pelvic Lymph Node Dissection for High-Risk Prostate Cancer: A Multidisciplinary Decision. *Eur Urol*. In press. <http://dx.doi.org/10.1016/j.eururo.2012.12.018>. *Eur Urol*. 2013 Jan 2. doi:pii: S0302-2838(12)01564-3. 10.1016/j.eururo.2012.12.034.
1108. Salonia A, Abdollah F, Capitanio U, Suardi N, Gallina A, Castagna G, Clementi MC, **Briganti A**, Rigatti P, Montorsi F. Circulating sex steroids and prostate cancer: introducing the time-dependency theory. *World J Urol*. 2013 Jan 3.
1109. Abdollah F, **Briganti A**, Montorsi F, Karakiewicz PI, Sun M. Response to Re: Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. *Int J Urol*. 2012 Dec 20. doi: 10.1111/iju.12063.
1110. Abdollah F, **Briganti A**, Montorsi F, Karakiewicz PI, Sun M. Response to Re: Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. *Int J Urol*. 2012 Dec 16. doi: 10.1111/iju.12062.
1111. Tutolo M, **Briganti A**, Suardi N, Gallina A, Abdollah F, Capitanio U, Bianchi M, Passoni N, Nini A, Fossati N, Rigatti P, Montorsi F. Optimizing postoperative sexual function after radical prostatectomy. *Ther Adv Urol*. 2012 Dec;4(6):347-65. doi: 10.1177/1756287212450063.
1112. Giovacchini G, Picchio M, Garcia-Parra R, Mapelli P, **Briganti A**, Montorsi F, Gianolli L, Messa C. [11C]choline positron emission tomography/computerized tomography for early detection of prostate cancer recurrence in patients with low increasing prostate specific antigen. *J Urol*. 2013 Jan;189(1):105-10. doi: 10.1016/j.juro.2012.09.001. Epub 2012 Nov 16.
1113. Capitanio U, **Briganti A**. Editorial Comment to Nodal involvement at nephrectomy is associated with worse survival: A stage-for-stage and grade-for-grade analysis. *Int J Urol*. 2012 Nov 19. doi: 10.1111/j.1442-2042.2012.03187.x.
1114. Capitanio U, Abdollah F, Matloob R, Salonia A, Suardi N, **Briganti A**, Carezzi C, Rigatti P, Montorsi F, Bertini R. Effect of number and location of distant metastases on renal cell carcinoma mortality in candidates for cytoreductive nephrectomy: Implications for multimodal therapy. *Int J Urol*. 2012 Nov 19. doi: 10.1111/iju.12004.
1115. **Briganti A**, Bianchi M, Sun M, Suardi N, Gallina A, Abdollah F, Bertini R, Colombo R, Girolamo VD, Salonia A, Scattoni V, Karakiewicz PI, Guazzoni G, Rigatti P, Montorsi F. Impact of the introduction of a robotic training programme on prostate cancer stage migration at a single tertiary referral centre. *BJU Int*. 2012 Nov 13. doi: 10.1111/j.1464-410X.2012.11464.x.
1116. Abdollah F, Suardi N, Cozzarini C, Gallina A, Capitanio U, Bianchi M, Sun M, Fossati N, Passoni NM, Fiorino C, Di Muzio N, Karakiewicz PI, Rigatti P, Montorsi F, **Briganti A**. Selecting the Optimal Candidate for Adjuvant Radiotherapy After Radical Prostatectomy for Prostate Cancer: A Long-term Survival Analysis. *Eur Urol*. 2012 Oct 26. doi:pii: S0302-2838(12)01267-5. 10.1016/j.eururo.2012.10.036. [Epub ahead of print] PubMed PMID: 23122664.
1117. Bianchi M, Trinh QD, Sun M, Meskawi M, Schmitges J, Shariat SF, **Briganti A**, Tian Z, Jeldres C, Sukumar S, Peabody JO, Graefen M, Perrotte P, Menon M, Montorsi F, Karakiewicz PI. Impact of academic affiliation on radical cystectomy outcomes in North America: A population-based study. *Can Urol Assoc J*. 2012 Aug; 6(4):245-50. doi: 10.5489/cuaj.12032.
1118. Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, **Briganti A**, Salonia A, Rigatti P, Montorsi F. Reply to Manish Garg, Apul Goel and Jai Prakash's letter to the editor re: Renzo Colombo, Lorenzo Rocchini, Nazareno Suardi, et al. Neoadjuvant short-term intensive intravesical mitomycin C regimen compared with weekly schedule for low-grade recurrent non-muscle-invasive bladder cancer: preliminary results of a randomised phase 2 study. *Eur Urol*. 2013 Jan;63(1):e7-8.
- 1119.

1120. Salonia A, Ferrari M, Saccà A, Pellucchi F, Castagna G, Clementi MC, Matloob R, **Briganti A**, Rigatti P, Montorsi F. Delay in seeking medical help in patients with new-onset erectile dysfunction remained high over and despite the PDE5 era--an ecological study. *J Sex Med.* 2012 Dec;9(12):3239-46. doi: 10.1111/j.1743-6109.2012.02953.x. Epub 2012 Oct 11.
1121. Abdollah F, Abdo A, Sun M, Schmitges J, Tian Z, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. Pelvic lymph node dissection for prostate cancer: Adherence and accuracy of the recent guidelines. *Int J Urol.* 2012 Oct 8. doi: 10.1111/j.1442-2042.2012.03171.x.
1122. Villa L, Capitanio U, **Briganti A**, Abdollah F, Suardi N, Salonia A, Gallina A, Freschi M, Russo A, Castiglione F, Bianchi M, Rigatti P, Montorsi F, Scattoni V. The Number of Cores Taken in Patients Diagnosed with a Single Microfocus at Initial Biopsy is a Major Predictor of Insignificant Prostate Cancer. *J Urol.* 2012 Sep 25. doi:pii: S0022-5347(12)04996-8. 10.1016/j.juro.2012.09.100.
1123. Passoni NM, Di Trapani E, Suardi N, Gallina A, Abdollah F, Picchio M, Giovacchini G, Messa C, Rigatti P, Montorsi F, **Briganti A**. Clinical and diagnostic assessment for therapeutic decisions in prostate cancer. *Q J Nucl Med Mol Imaging* 2012;56: 321-330
1124. Gandaglia G, Albersen M, Suardi N, Gallina A, Abdollah F, Castiglione F, Capitanio U, Salonia A, Rigatti P, Hedlund P, Montorsi F, **Briganti A**. Postoperative phosphodiesterase type 5 inhibitor administration increases the rate of urinary continence recovery after bilateral nerve-sparing radical prostatectomy. *Int J Urol.* 2013 Apr;20(4):413-9.
1125. **Briganti A**, Suardi N, Gallina A, Abdollah F, Montorsi F. Pelvic lymph node dissection in prostate cancer. The mystery is taking shape. *Eur Urol.* 2013 Mar;63(3):459-61.
1126. Gandaglia G, Salonia A, Passoni N, Montorsi P, **Briganti A**, Montorsi F. Erectile dysfunction as a cardiovascular risk factor in patients with diabetes. *Endocrine.* 2013 Apr;43(2):285-92.
1127. **Briganti A**, Spahn M, Joniau S, Gontero P, Bianchi M, Kneitz B, Chun FK, Sun M, Graefen M, Abdollah F, Marchioro G, Frohenberg D, Giona S, Frea B, Karakiewicz PI, Montorsi F, Van Poppel H, Jeffrey Karnes R; on behalf of the European Multicenter Prostate Cancer Clinical and Translational Research Group (EMPaCT). Impact of Age and Comorbidities on Long-term Survival of Patients with High-risk Prostate Cancer Treated with Radical Prostatectomy: A Multi-institutional Competing-risks Analysis. *Eur Urol.* 2013 Apr;63(4):693-701.
1128. **Briganti A**, Abdollah F, Montorsi F, Cozzarini C. In reply to Yu. *Int J Radiat Oncol Biol Phys.* 2012, 84:301-2.
1129. Lazzeri M, **Briganti A**, Scattoni V, Lughezzani G, Larcher A, Gadda GM, Lista G, Cestari A, Buffi N, Bini V, Freschi M, Rigatti P, Montorsi F, Guazzoni G. Serum Index Test %[-2]proPSA and Prostate Health Index are More Accurate than Prostate Specific Antigen and %fPSA in Predicting a Positive Repeat Prostate Biopsy. *J Urol.* 2012;188:1137-43
1130. Salonia A, Castagna G, Saccà A, Ferrari M, Capitanio U, Castiglione F, Rocchini L, **Briganti A**, Rigatti P, Montorsi F. Is Erectile Dysfunction a Reliable Proxy of General Male Health Status? The Case for the International Index of Erectile Function-Erectile Function Domain. *J Sex Med.* 2012 Aug 15. doi: 10.1111/j.1743-6109.2012.02869.x.
1131. Sammon J, Trinh QD, Sun M, Bianchi M, Schmitges J, Shariat SF, Ghani KR, Sukumar S, Jeldres C, **Briganti A**, Perrotte P, Rogers CG, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. The effect of gender on nephrectomy perioperative outcomes: a national survey. *Can J Urol.* 2012;19:6337-44.
1132. Hansen J, AuPrich M, Ahyai SA, de la Taille A, van Poppel H, Marberger M, Stenzl A, Mulders PF, Huland H, Fisch M, Abbou CC, Schalken JA, Fradet Y, MarksLS, Ellis W, Partin AW, Pummer K, Graefen M, Haese A, Walz J, **Briganti A**, Shariat SF, Chun FK. Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. *Eur Urol.* 2012 Jul 20. doi: 10.1016/j.eururo.2012.07.030 (
1133. Hansen J, Rink M, Bianchi M, Kluth LA, Tian Z, Ahyai SA, Shariat SF, **Briganti A**, Steuber T, Fisch M, Graefen M, Karakiewicz PI, Chun FK. External validation of the updated Briganti Nomogram to predict lymph node invasion in prostate cancer patients undergoing extended lymph node dissection. *Prostate.* 2012 Jul 20. doi: 10.1002/pros.22559.
1134. Gandaglia G, Suardi N, Gallina A, Abdollah F, Capitanio U, Salonia A, Colombo R, Bianchi M, Chun FK, Hansen J, Rigatti P, Montorsi F, **Briganti A**. ExtendedPelvic Lymph Node Dissection Does Not

- Affect Erectile Function Recovery in Patients Treated with Bilateral Nerve-Sparing Radical Prostatectomy. *J Sex Med.* 2012 Aug;9(8):2187-94.
1135. Suardi N, Moschini M, Gallina A, Gandaglia G, Abdollah F, Capitanio U, Bianchi M, Tutolo M, Passoni N, Salonia A, Hedlund P, Rigatti P, Montorsi F, **Briganti A**. Nerve-sparing approach during radical prostatectomy is strongly associated with the rate of postoperative urinary continence recovery. *BJU Int.* 2013 May;111(5):717-22.
1136. Capitanio U, Suardi N, Matloob R, Abdollah F, Castiglione F, **Briganti A**, Carenzi C, Roscigno M, Montorsi F, Bertini R. Staging lymphadenectomy in renal cell carcinoma must be extended: a sensitivity curve analysis. *BJU Int.* 2013 Mar;111(3):412-8.
1137. Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni N, Karakiewicz PI, Rigatti P, Montorsi F, **Briganti A**. National comprehensive cancer network practice guidelines 2011: need for more accurate recommendations for pelvic lymph node dissection in prostate cancer. *J Urol.* 2012;188:423-8.
1138. Sun M, Abdollah F, Hansen J, Trinh QD, Bianchi M, Tian Z, **Briganti A**, Shariat SF, Montorsi F, Perrotte P, Karakiewicz PI. Is a Treatment Delay in Radical Prostatectomy Safe in Individuals with Low-Risk Prostate Cancer? *J Sex Med.* 2012 Nov;9(11):2961-9.
1139. **Briganti A**, Wiegel T, Joniau S, Cozzarini C, Bianchi M, Sun M, Tombal B, Haustermans K, Budiharto T, Hinkelbein W, Di Muzio N, Karakiewicz PI, Montorsi F, Van Poppel H. Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. *Eur Urol.* 2012;62:472-87.
1140. Colombo R, Rocchini L, Suardi N, Benigni F, Colciago G, Bettiga A, Pellucchi F, Maccagnano C, **Briganti A**, Salonia A, Rigatti P, Montorsi F. Neoadjuvant Short-term Intensive Intravesical Mitomycin C Regimen Compared with Weekly Schedule for Low-grade Recurrent Non-muscle-invasive Bladder Cancer: Preliminary Results of a Randomised Phase 2 Study. *Eur Urol.* 2012 Nov;62(5):797-802.
1141. Capitanio U, Matloob R, Suardi N, Abdollah F, Castiglione F, Di Trapani D, Russo A, **Briganti A**, Carenzi C, Salonia A, Montorsi F, Rigatti P, Bertini R. The extent of lymphadenectomy does affect cancer specific survival in pathologically confirmed T4 renal cell carcinoma. *Urologia.* 2012 Apr-Jun;79:109-15.
1142. Abdollah F, Sun M, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Fossati N, Castiglione F, Freschi M, Karakiewicz P, Rigatti P, Montorsi F, **Briganti A**. Presence of positive surgical margin in patients with organ-confined prostate cancer equals to extracapsular extension negative surgical margin. A plea for TNM staging system reclassification. *Urol Oncol.* 2012 May 14. doi: 10.1016/j.urolonc.2012.04.013.
1143. Salonia A, Abdollah F, Capitanio U, Suardi N, **Briganti A**, Gallina A, Colombo R, Ferrari M, Castagna G, Rigatti P, Montorsi F. Serum sex steroids depict a nonlinear u-shaped association with high-risk prostate cancer at radical prostatectomy. *Clin Cancer Res.* 2012 1;18:3648-57.
1144. Abdollah F, Sun M, Schmitges J, Thuret R, Bianchi M, Shariat SF, **Briganti A**, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. Survival benefit of radical prostatectomy in patients with localized prostate cancer: estimations of the number needed to treat according to tumor and patient characteristics. *J Urol.* 2012;188:73-83.
1145. Spahn M, **Briganti A**, Capitanio U, Kneitz B, Gontero P, Karnes JR, Schubert M, Montorsi F, Scholz CJ, Bader P, van Poppel H, Joniau S. European Multicenter Prostate Cancer Clinical and Translational Research Group. Outcome predictors of radical prostatectomy followed by adjuvant androgen deprivation in patients with clinical high risk prostate cancer and pT3 surgical margin positive disease. *J Urol.* 2012;188:84-90.
1146. **Briganti A**, Tutolo M, Suardi N, Gallina A, Abdollah F, Capitanio U, Freschi M, Bianchi M, Salonia A, Colombo R, Rigatti P, Montorsi F. There is no way to identify patients who will harbor small volume, unilateral prostate cancer at final pathology. implications for focal therapies. *Prostate.* 2012; 72:925-30.
1147. Abdollah F, Schmitges J, Sun M, Jeldres C, Tian Z, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. Comparison of mortality outcomes after radical prostatectomy versus radiotherapy in patients with localized prostate cancer: A population-based analysis. *Int J Urol.* 2012;19:836-44

1148. Lughezzani G, Gallina A, Larcher A, **Briganti A**, Capitanio U, Suardi N, Lista G, Abrate A, Sangalli MN, Buffi N, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Radical prostatectomy represents an effective treatment in patients with specimen-confined high pathological Gleason score prostate cancer. *BJU Int.* 2013 May;111(5):723-30
1149. **Briganti A**, Capitanio U, Abdollah F, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Freschi M, Rigatti P, Montorsi F. Assessing the risk of lymph node invasion in patients with intermediate risk prostate cancer treated with extended pelvic lymph node dissection. A novel prediction tool. *Prostate.* 2012;72:499-506.
1150. Salonia A, Abdollah F, Capitanio U, Gallina A, Suardi N, **Briganti A**, Zanni G, Ferrari M, Castiglione F, Clementi MC, Rigatti P, Montorsi F. Preoperative sex steroids are significant predictors of early biochemical recurrence after radical prostatectomy. *World J Urol.* 2013 Apr;31(2):275-80.
1151. Abdollah F, Sun M, Suardi N, Gallina A, Bianchi M, Tutolo M, Passoni N, Tian Z, Salonia A, Colombo R, Rigatti P, Karakiewicz PI, Montorsi F, **Briganti A**. Prediction of Functional Outcomes After Nerve-Sparing Radical Prostatectomy: Results of Conditional Survival Analyses. *Eur Urol.* 2012;62:42-52
1152. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. Lymph node count threshold for optimal pelvic lymph node staging in prostate cancer. *Int J Urol.* 2012;19:645-51
1153. Schubert M, Joniau S, Gontero P, Kneitz S, Scholz CJ, Kneitz B, **Briganti A**, Karnes RJ, Tombal B, Walz J, Hsu CY, Marchioro G, Bader P, Bangma C, Frohneberg D, Graefen M, Schröder F, van Cangh P, van Poppel H, Spahn M. The role of adjuvant hormonal treatment after surgery for localized high-risk prostate cancer: results of a matched multiinstitutional analysis. *Adv Urol.* 2012;2012:612707.
1154. Giovacchini G, Picchio M, Parra RG, **Briganti A**, Gianolli L, Montorsi F, Messa C. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. *Clin Nucl Med.* 2012;37:325-31.
1155. Bastian PJ, Boorjian SA, Bossi A, **Briganti A**, Heidenreich A, Freedland SJ, Montorsi F, Roach M 3rd, Schröder F, van Poppel H, Stief CG, Stephenson AJ, Zelefsky MJ. High-risk prostate cancer: from definition to contemporary management. *Eur Urol.* 2012;61:1096-106
1156. Bianchi, M., Sun, M., Jeldres, C., Shariat, S.F., Trinh, Q.-D., Briganti, A., Tian, Z., Schmitges, J., Graefen, M., Perrotte, P., Menon, M., Montorsi, F., Karakiewicz, P.I. Distribution of metastatic sites in renal cell carcinoma: A population-based analysis. *Ann Oncol*, 2012, 23: 973-980
1157. Walz J, Bladou F, Rousseau B, Laroche J, Salem N, Gravis G, **Briganti A**, Chun FK, Karakiewicz PI, Fournier G. Head to head comparison of nomograms predicting probability of lymph node invasion of prostate cancer in patients undergoing extended pelvic lymph node dissection. *Urology.* 2012;79:546-51
1158. Bianchi M, Trinh QD, Sun M, Sammon J, Schmitges J, Shariat SF, Sukumar S, Ghani KR, Jeldres C, Perrotte P, Rogers CG, **Briganti A**, Peabody JO, Montorsi F, Menon M, Karakiewicz PI. Discharge patterns after radical cystectomy: contemporary trends in the United States. *J Urol.* 2012;187:1206-9
1159. Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, Shariat SF, **Briganti A**, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI. Competing-risks Mortality After Radiotherapy vs. Observation for Localized Prostate Cancer: A Population-based Study. *Int J Radiat Oncol Biol Phys.* 2012, 84:95-103
1160. Gallina A, Ferrari M, Suardi N, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Saccà A, Salonia A, Rigatti P, Montorsi F, **Briganti A**. Erectile function outcome after bilateral nerve sparing radical prostatectomy: which patients may be left untreated? *J Sex Med.* 2012;9:903-8
1161. **Briganti A**, Suardi N, Capogrosso P, Passoni N, Freschi M, Di Trapani E, Gallina A, Capitanio U, Abdollah F, Tutolo M, Bianchi M, Salonia A, Da Pozzo LF, Montorsi F, Rigatti P. Lymphatic spread of nodal metastases in high-risk prostate cancer: The ascending pathway from the pelvis to the retroperitoneum. *Prostate.* 2012;72:186-92
1162. Van Baelen A, Mottet N, Spahn M, **Briganti A**, Gontero P, Joniau S. Sense and nonsense of an extended pelvic lymph node dissection in prostate cancer. *Adv Urol.* 2012;2012:983058.

1163. Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A, **Briganti A**, Broggi S, Deli A, Guazzoni G, Perna L, Pasetti M, Salvadori G, Montorsi F, Rigatti P, Di Muzio N. Clinical factors predicting late severe urinary toxicity after postoperative radiotherapy for prostate carcinoma: A single-institute analysis of 742 patients. *Int J Radiat Oncol Biol Phys.* 2012; 82:191-9.
1164. Capitanio U, Suardi N, Gallina A, Abdollah F, **Briganti A**. Reply. *BJU Int.* 2012 Jan. doi: 10.1111/j.1464-410X.2011.10831_6.x
1165. Sun M, Abdollah F, Shariat SF, Schmitges J, Trinh Q-D, Tian Z, Jeldres C, Abdo A, Bianchi M, **Briganti A**, Montorsi F, Perrotte P, Karakiewicz PI. Propensity-score matched comparison of complications, blood transfusions, length of stay, and in-hospital mortality between open and laparoscopic partial nephrectomy: A national series. *Eur J Surg Onc.* 2012;38:80-7
1166. **Briganti A**, Di Trapani E, Abdollah F, Gallina A, Suardi N, Capitanio U, Tutolo M, Passoni N, Salonia A, Digirolamo V, Colombo R, Guazzoni G, Rigatti P, Montorsi F. Choosing the Best Candidates for Penile Rehabilitation after Bilateral Nerve-Sparing Radical Prostatectomy. *J Sex Med.* 2012; 9:608-17.
1167. Sun M, Abdollah F, Bianchi M, Trinh Q-D, Shariat SF, Jeldres C, Tian Z, Hansen J, **Briganti A**, Graefen M, Montorsi F, Perrotte P, Karakiewicz PI. Conditional survival of patients with urothelial carcinoma of the urinary bladder treated with radical cystectomy. *Eur J Cancer.* 2012;48:1503-11.
1168. Gandaglia G, Suardi N, Gallina A, Capitanio U, Abdollah F, Salonia A, Nava L, Colombo R, Guazzoni G, Rigatti P, Montorsi F, **Briganti A**. Preoperative Erectile Function Represents a Significant Predictor of Postoperative Urinary Continence Recovery in Patients Treated With Bilateral Nerve Sparing Radical Prostatectomy. *J Urol.* 2012;187:569-74.
1169. Sun M, Trinh Q-D, Bianchi M, Hansen J, Hanna N, Abdollah F, Shariat, SF, **Briganti A**, Montorsi F, Perrotte P, Karakiewicz PI. A Non-Cancer-Related Survival Benefit Is Associated With Partial Nephrectomy. *Eur Urol.* 2012;61:725-31.
1170. Ost P, Cozzarini C, De Meerleer G, Fiorino C, De Potter B, **Briganti A**, Nagler EVT, Montorsi F, Fonteyne V, Di Muzio N. High-Dose Adjuvant Radiotherapy After Radical Prostatectomy with or Without Androgen Deprivation Therapy. *Int J Radiat Oncol Biol Phys.* 2012;83:960-5.
1171. **Briganti A**, Joniau S, Gontero P, Abdollah F, Passoni NM, Tombal B, Marchioro G, Kneitz B, Walz J, Frohneberg D, Bangma CH, Graefen M, Tizzani A, Frea B, Karnes RJ, Montorsi F, Van Poppel H, Spahn M. Identifying the Best Candidate for Radical Prostatectomy Among Patients with High-Risk Prostate Cancer. *Eur Urol.* 2012;61:584-92.
1172. Ficarra V, Sooriakumaran P, Novara G, Schatloff O, **Briganti A**, Van der Poel H, Montorsi F, Patel V, Tewari A, Mottrie A. Systematic Review of Methods for Reporting Combined Outcomes After Radical Prostatectomy and Proposal of a Novel System: The Survival, Continence, and Potency (SCP) Classification. *Eur Urol.* 2012;61:541-8.
1173. De Nunzio C, Ahyai S, Autorino R, Bachmann A, Bialek W, **Briganti A**, Reich O, Sosnowski R, Thiruchelvam N, Novara G. Benign prostatic hyperplasia and lower urinary tract symptoms: Research priorities. *Eur Urol.* 2011;60:1205-6.
1174. Abdollah F, Schmitges J, Sun M, Thuret R, Djahangirian O, Tian Z, Shariat SF, **Briganti A**, Perrotte P, Montorsi F, Karakiewicz PI. Head-to-head comparison of three commonly used preoperative tools for prediction of lymph node invasion at radical prostatectomy. *Urology.* 2011;78:1363-7.
1175. Pellucchi F, Freschi M, Ibrahim B, Rocchini L, Maccagnano C, **Briganti A**, Rigatti P, Montorsi F, Colombo R. Clinical reliability of the 2004 WHO histological classification system compared with the 1973 WHO system for Ta primary bladder tumors. *J Urol.* 2011;186:2194-9.
1176. Gallina A, Maccagnano C, Suardi N, Capitanio U, Abdollah F, Raber M, Salonia A, Scattoni V, Rigatti P, Montorsi F, **Briganti A**. Unilateral positive biopsies in low risk prostate cancer patients diagnosed with extended transrectal ultrasound-guided biopsy schemes do not predict unilateral prostate cancer at radical prostatectomy. *BJU Int.* 2012;110(2 Pt 2):E64-8.
1177. **Briganti A**, Abdollah F, Nini A, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Passoni NM, Salonia A, Colombo R, Freschi M, Rigatti P, Montorsi F. Performance Characteristics of Computed Tomography in Detecting Lymph Node Metastases in Contemporary Patients with Prostate Cancer Treated with Extended Pelvic Lymph Node Dissection. *Eur Urol.* 2012;61:1132-8.

1178. Abdollah F, Cozzarini C, Suardi N, Gallina A, Capitanio U, Bianchi M, Tutolo M, Salonia A, Macchia ML, Muzio ND, Rigatti P, Montorsi F, **Briganti A**. Indications for Pelvic Nodal Treatment in Prostate Cancer should Change. Validation of the Roach Formula in a Large Extended Nodal Dissection Series. *Int J Radiat Oncol Biol Phys*. 2012;83:624-9.
1179. **Briganti A**, Larcher A, Abdollah F, Capitanio U, Gallina A, Suardi N, Bianchi M, Sun M, Freschi M, Salonia A, Karakiewicz PI, Rigatti P, Montorsi F. Updated Nomogram Predicting Lymph Node Invasion in Patients with Prostate Cancer Undergoing Extended Pelvic Lymph Node Dissection: The Essential Importance of Percentage of Positive Cores. *Eur Urol*. 2012;61:480-7.
1180. Crescenti A, Borghi G, Bignami E, Bertarelli G, Landoni G, Casiraghi GM, **Briganti A**, Montorsi F, Rigatti P, Zangrillo A. Intraoperative use of tranexamic acid to reduce transfusion rate in patients undergoing radical retropubic prostatectomy: Double blind, randomised, placebo controlled trial. *BMJ*. 2011; 343:d5701.
1181. Stephenson AJ, Bolla M, **Briganti A**, Cozzarini C, Moul JW, Roach III M, van Poppel H, Zietman A. Postoperative Radiation Therapy for Pathologically Advanced Prostate Cancer After Radical Prostatectomy. 2011. *Eur Urol*. 2012;61:443-51.
1182. Salonia A, Gallina A, Abdollah F, **Briganti A**, Capitanio U, Suardi N, Ferrari M, Raber M, Colombo R, Freschi M, Rigatti P, Montorsi F. Preoperative circulating sex hormones are not predictors of positive surgical margins at open radical prostatectomy. *World J Urol*. 2012;30:533-9.
1183. Capitanio U, Suardi N, Montorsi F, **Briganti A**. Editorial comment to risk factors for pelvic lymphoceles post-radical prostatectomy. *Int J Urol*. 2011;18:644-5
1184. Abdollah F, **Briganti A**, Suardi N, Castiglione F, Gallina A, Capitanio U, Montorsi F. Metabolic syndrome and benign prostatic hyperplasia: Evidence of a potential relationship, hypothesized etiology, and prevention. *Korean J Urol*. 2011;52:507-16.
1185. Rigatti P, Suardi N, **Briganti A**, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F. Pelvic/Retroperitoneal Salvage Lymph Node Dissection for Patients Treated With Radical Prostatectomy With Biochemical Recurrence and Nodal Recurrence Detected by [11C]Choline Positron Emission Tomography/Computed Tomography. *Eur Urol*. 2011;60:935-43.
1186. Gacci M, Carini M, Simonato A, Imbimbo C, Gontero P, **Briganti A**, De Cobelli O, Fulcoli V, Martorana G, Nicita G, Mirone V, Carmignani G. Factors predicting continence recovery 1 month after radical prostatectomy: Results of a multicenter survey. *Int J Urol*. 2011;18:700-8.
1187. Salonia A, D'Addio F, Gremizzi C, **Briganti A**, Dehò F, Caldara R, Orsenigo E, Staudacher C, Succi C, Rigatti P, Secchi A, Montorsi F, Fiorina P. Kidney-Pancreas Transplantation Is Associated With Near-Normal Sexual Function in Uremic Type 1 Diabetic Patients. *Transplantation*. 2011;92:802-8.
1188. Capitanio U, Suardi N, **Briganti A**, Gallina A, Abdollah F, Lughezzani G, Salonia A, Freschi M, Montorsi F. Influence of obesity on tumour volume in patients with prostate cancer. *BJU Int*. 2012;109:678-84
1189. Suardi N, Gallina A, Capitanio U, Salonia A, Lughezzani G, Freschi M, Mottrie A, Rigatti P, Montorsi F, **Briganti A**. Age-adjusted validation of the most stringent criteria for active surveillance in low-risk prostate cancer patients. *Cancer*. 2012;118:973-80
1190. Abdollah F, Sun M, Schmitges J, Tian Z, Jeldres C, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. Cancer-Specific and Other-Cause Mortality After Radical Prostatectomy Versus Observation in Patients with Prostate Cancer: Competing-Risks Analysis of a Large North American Population-Based Cohort. *Eur Urol*. 2011;60:920-30.
1191. Abdollah F, Sun M, **Briganti A**, Thuret R, Schmitges J, Gallina A, Suardi N, Capitanio U, Salonia A, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. Critical assessment of the European Association of Urology guideline indications for pelvic lymph node dissection at radical prostatectomy. *BJU Int*. 2011;108:1769-75
1192. Salonia A, Gallina A, **Briganti A**, Suardi N, Capitanio U, Abdollah F, Bertini R, Freschi M, Rigatti P, Montorsi F. Circulating estradiol, but not testosterone, is a significant predictor of high-grade prostate cancer in patients undergoing radical prostatectomy. *Cancer*, 2011;117:5029-38.

1193. Abdollah F, Schmitges J, Sun M, Tian Z, **Briganti A**, Shariat SF, Perrotte P, Montorsi F, Karakiewicz PI. A critical assessment of the value of lymph node dissection at radical prostatectomy: A population-based study. *Prostate*. 2011; 71: 1587-1594.
1194. Suardi N, **Briganti A**, Salonia A, Rigatti P. Salvage lymphadenectomy in postprostatectomy patients with prostate-specific antigen recurrence. *Curr Opin Urol*. 2011;21:237-40. Review
1195. Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, **Briganti A**, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Dall'Oglio M, Srougi M, Scardino PT, Eastham JA. Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. *Eur Urol*. 2011;60:205-10.
1196. Salonia A, Gallina A, **Briganti A**, Abdollah F, Suardi N, Capitanio U, Colombo R, Freschi M, Rigatti P, Montorsi F. Preoperative hypogonadism is not an independent predictor of high-risk disease in patients undergoing radical prostatectomy. *Cancer*. 2011;117:3953-62.
1197. **Briganti A**, Karnes RJ, Da Pozzo LF, Cozzarini C, Capitanio U, Gallina A, Suardi N, Bianchi M, Tutolo M, Salonia A, Di Muzio N, Rigatti P, Montorsi F, Blute M. Combination of adjuvant hormonal and radiation therapy significantly prolongs survival of patients with pT2-4 pN+ prostate cancer: results of a matched analysis *Eur Urol*. 2011;59:832-40.
1198. Imbimbo C, Creta M, Gacci M, Simonato A, Gontero P, de Cobelli O, **Briganti A**, Fulcoli V, Martorana G, Nicita G, Mirone V, Carmignani G. Patients' desire to preserve sexual activity and final decision for a nerve-sparing approach: results from the MIRROR (Multicenter Italian Report on Radical Prostatectomy Outcomes and Research) Study. *J Sex Med*. 2011;8:1495-502.
1199. **Briganti A**, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, Salonia A, Colombo R, Di Girolamo V, Martinez-Salamanca JI, Guazzoni G, Rigatti P, Montorsi F. What is the definition of a satisfactory erectile function after bilateral nerve sparing radical prostatectomy? *J Sex Med*. 2011;8:1210-7.
1200. Capitanio U, **Briganti A**, Suardi N, Gallina A, Salonia A, Freschi M, Rigatti P, Montorsi F. When should we expect no residual tumor (pT0) once we submit incidental T1a-b prostate cancers to radical prostatectomy? *Int J Urol*. 2011;18:148-53.
1201. Abdollah F, Novara G, **Briganti A**, Scattoni V, Raber M, Roscigno M, Suardi N, Gallina A, Artibani W, Ficarra V, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Trans-rectal versus trans-perineal saturation rebiopsy of the prostate: is there a difference in cancer detection rate? *Urology*. 2011;77:921-5.
1202. Mukenge SM, Catena M, Negrini D, Ratti F, Moriondo A, **Briganti A**, Rigatti P, Cipriani F, Ferla G. Assessment and Follow-Up of Patency After Lymphovenous Microsurgery for Treatment of Secondary Lymphedema in External Male Genital Organs. *Eur Urol*. 2011;60:1114-9.
1203. Cozzarini C, Fiorino C, Da Pozzo LF, Alongi F, Berardi G, Bolognesi A, **Briganti A**, Broggi S, Deli A, Guazzoni G, Perna L, Pasetti M, Salvadori G, Montorsi F, Rigatti P, Di Muzio N. Clinical Factors Predicting Late Severe Urinary Toxicity After Postoperative Radiotherapy for Prostate Carcinoma: A Single-Institute Analysis of 742 Patients. *Int J Radiat Oncol Biol Phys*. 2012;82:191-9.
1204. Abdollah F, Scattoni V, Raber M, Roscigno M, **Briganti A**, Suardi N, Gallina A, Capitanio U, Freschi M, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. The role of transrectal saturation biopsy in tumour localization: pathological correlation after retropubic radical prostatectomy and implication for focal ablative therapy. *BJU Int*. 2011;108:366-71
1205. Gallina A, **Briganti A**, Suardi N, Capitanio U, Abdollah F, Zanni G, Salonia A, Rigatti P, Montorsi F. Surgery and erectile dysfunction. *Arch Esp Urol*. 2010 ;63:640-8.
1206. Abdollah F, Sun M, Thuret R, Jeldres C, Tian Z, **Briganti A**, Shariat SF, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. A Competing-Risks Analysis of Survival After Alternative Treatment Modalities for Prostate Cancer Patients: 1988-2006. *Eur Urol*. 2011;59:88-95
1207. Abdollah F, **Briganti A**, Suardi N, Gallina A, Capitanio U, Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Does diabetes mellitus increase the risk of high-grade prostate cancer in patients undergoing radical prostatectomy? *Prostate Cancer Prostatic Dis*. 2011;14:74-8
1208. Abdollah F, Sun M, Thuret R, Budäus L, Jeldres C, Graefen M, **Briganti A**, Perrotte P, Rigatti P, Montorsi F, Karakiewicz PI. Decreasing Rate and Extent of Lymph Node Staging in Patients

Undergoing Radical Prostatectomy May Undermine the Rate of Diagnosis of Lymph Node Metastases in Prostate Cancer. *Eur Urol.* 2010;58:882-92.

1209. Salonia A, Gallina A, **Briganti A**, Zanni G, Suardi N, Capitanio U, Colombo R, Bertini R, Freschi M, Guazzoni G, Rigatti P, Montorsi F. Sex hormone-binding globulin is a significant predictor of extracapsular extension in men undergoing radical prostatectomy. *BJU Int.* 2011;107:1243-9.
1210. Capitanio U, Pellucchi F, Gallina A, **Briganti A**, Suardi N, Salonia A, Abdollah F, Di Trapani E, Jeldres C, Cestari A, Karakiewicz PI, Montorsi F. How can we predict lymphorrhoea and clinically significant lymphocoeles after radical prostatectomy and pelvic lymphadenectomy? Clinical implications. *BJU Int.* 2011;107:1095-101.
1211. Picchio M, **Briganti A**, Fanti S, Heidenreich A, Krause BJ, Messa C, Montorsi F, Reske SN, Thalmann GN. The Role of Choline Positron Emission Tomography/Computed Tomography in the Management of Patients with Prostate-Specific Antigen Progression After Radical Treatment of Prostate Cancer. *Eur Urol.* 2011;59:51-60.
1212. Lughezzani G, **Briganti A**, Karakiewicz PI, Kattan MW, Montorsi F, Shariat SF, Vickers AJ. Predictive and Prognostic Models in Radical Prostatectomy Candidates: A Critical Analysis of the Literature. *Eur Urol.* 2010;58:687-700.
1213. Giovacchini G, Picchio M, **Briganti A**, Cozzarini C, Scattoni V, Salonia A, Landoni C, Gianolli L, Di Muzio N, Rigatti P, Montorsi F, Messa C. [11C]choline positron emission tomography/computerized tomography to restage prostate cancer cases with biochemical failure after radical prostatectomy and no disease evidence on conventional imaging. *J Urol.* 2010; 184:938-43.
1214. Capitanio U, **Briganti A**, Gallina A, Suardi N, Karakiewicz PI, Montorsi F, Scattoni V. Predictive models before and after radical prostatectomy. *Prostate.* 2010;70:1371-8.
1215. **Briganti A**, Gallina A, Suardi N, Capitanio U, Tutolo M, Bianchi M, Passoni N, Salonia A, Colombo R, Di Girolamo V, Guazzoni G, Rigatti P, Montorsi F. Predicting erectile function recovery after bilateral nerve sparing radical prostatectomy: a proposal of a novel preoperative risk stratification. *J Sex Med.* 2010;7:2521-31.
1216. Mulhall JP, Bella AJ, **Briganti A**, McCullough A, Brock G. Erectile function rehabilitation in the radical prostatectomy patient. *J Sex Med.* 7:1687-98, 2010
1217. Giovacchini G, Picchio M, Scattoni V, Garcia Parra R, **Briganti A**, Gianolli L, Montorsi F, Messa C. PSA doubling time for prediction of [(11)C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy. *Eur J Nucl Med Mol Imaging.* 2010;37:1106-16.
1218. **Briganti A**, Capitanio U, Suardi N, Gallina A, Rigatti P, Montorsi F. Re: Michael W. Kattan. Classification and Regression Trees Versus Nomograms: A Bone Scan Positivity Example. *Eur Urol.* 2010; 57:560-561.
1219. **Briganti A**, Passoni N, Ferrari M, Capitanio U, Suardi N, Gallina A, Pozzo LF, Picchio M, Di Girolamo V, Salonia A, Gianolli L, Messa C, Rigatti P, Montorsi F. When to Perform Bone Scan in Patients with Newly Diagnosed Prostate Cancer: External Validation of the Currently Available Guidelines and Proposal of a Novel Risk Stratification Tool. *Eur Urol.* 2010;57:551-8
1220. Cestari A, Buffi NM, Scapaticci E, Lughezzani G, Salonia A, **Briganti A**, Rigatti P, Montorsi F, Guazzoni G. Simplifying patient positioning and port placement during robotic-assisted laparoscopic prostatectomy. *Eur Urol.* 2010;57:530-3
1221. Suardi N, **Briganti A**, Gallina A, Salonia A, Karakiewicz PI, Capitanio U, Freschi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Testing the most stringent criteria for selection of candidates for active surveillance in patients with low-risk prostate cancer. *BJU Int.* 2010;105:1548-52
1222. Isbarn H, Karakiewicz PI, Vogel S, Jeldres C, Lughezzani G, **Briganti A**, Montorsi F, Perrotte P, Ahyai SA, Budäus L, Eichelberg C, Heuer R, Köllermann J, Sauter G, Schlomm T, Steuber T, Haese A, Zacharias M, Fisch M, Heinzer H, Huland H, Chun FK, Graefen M. Unilateral Prostate Cancer Cannot Be Accurately Predicted in Low-Risk Patients. *Int J Radiat Oncol Biol Phys.* 2010 1;77:784-7
1223. Dehò F, Gallina A, Salonia A, **Briganti A**, Suardi N, Zanni G, Guazzoni G, Rigatti P, Montorsi F. Prophylaxis of erectile function after radical prostatectomy with phosphodiesterase type 5 inhibitors. *Curr Pharm Des.* 2009;15:3496-501.

1224. Salonia A, Gallina A, **Briganti A**, Colombo R, Bertini R, Da Pozzo LF, Zanni G, Saccà A, Rocchini L, Guazzoni G, Rigatti P, Montorsi F. Postoperative orgasmic function increases over time in patients undergoing nerve-sparing radical prostatectomy. *J Sex Med.* 2010;7:149-55
1225. Suardi N, Gallina A, Salonia A, **Briganti A**, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Open prostatectomy and the evolution of HoLEP in the management of benign prostatic hyperplasia. *Minerva Urol Nefrol.* 2009;61:301-8.
1226. Salonia A, Zanni G, Gallina A, **Briganti A**, Saccà A, Suardi N, Matloob R, Da Pozzo LF, Bertini R, Colombo R, Rigatti P, Montorsi F. Unsuccessful Investigation of Preoperative Sexual Health Issues in the Prostate Cancer "Couple": Results of a Real-Life Psychometric Survey at a Major Tertiary Academic Center. *J Sex Med.* 2009;6:3347-55
1227. Salonia A, Gallina A, Matloob R, Rocchini L, Saccà A, Abdollah F, Colombo R, Suardi N, **Briganti A**, Guazzoni G, Rigatti P, Montorsi F. Is sperm banking of interest to patients with nongerm cell urological cancer before potentially fertility damaging treatments? *J Urol.* 2009;182:1101-7
1228. Dehò F, Saccà A, Fabbri F, Gallina A, **Briganti A**, Rokkas K, Salonia A, Rigatti P, Montorsi F. Digital inflection rigidometry and penile dynamic colour doppler ultrasound: Analysis and correlations. 2009. *Journal of Andrological Sciences* 2009;16:108-111.
1229. **Briganti A**, Karakiewicz PI, Chun FK, Suardi N, Gallina A, Abdollah F, Freschi M, Doglioni C, Rigatti P, Montorsi F. Obesity does not increase the risk of lymph node metastases in patients with clinically localized prostate cancer undergoing radical prostatectomy and extended pelvic lymph node dissection. *Int J Urol.* 2009;16:676-81.
1230. **Briganti A**, Capitanio U, Chun FK, Karakiewicz PI, Salonia A, Bianchi M, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Prediction of sexual function after radical prostatectomy. *Cancer.* 2009 Jul 1;115(13 Suppl):3150-9.
1231. Capitanio U, Karakiewicz PI, Jeldres C, **Briganti A**, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F. The probability of Gleason score upgrading between biopsy and radical prostatectomy can be accurately predicted. *Int J Urol.* 2009;16:526-9
1232. Salonia A, Saccà A, **Briganti A**, Del Carro U, Dehò F, Zanni G, Rocchini L, Raber M, Guazzoni G, Rigatti P, Montorsi F. Quantitative sensory testing of peripheral thresholds in patients with lifelong premature ejaculation: a case-controlled study. *J Sex Med.* 2009;6:1755-62
1233. **Briganti A**. Editorial Comment on: Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. *Eur Urol* 2009; 56:667-668.
1234. **Briganti A**, Blute ML, Eastham JH, Graefen M, Heidenreich A, Karnes JR, Montorsi F, Studer UE. Pelvic lymph node dissection in prostate cancer. *Eur Urol.* 2009;55:1251-65
1235. Salonia A, Matloob R, Gallina A, Abdollah F, Saccà A, **Briganti A**, Suardi N, Colombo R, Rocchini L, Guazzoni G, Rigatti P, Montorsi F. Are Infertile Men Less Healthy than Fertile Men? Results of a Prospective Case-Control Survey. *Eur Urol.* 2009;56:1025-31
1236. Dehò F, Salonia A, **Briganti A**, Zanni G, Gallina A, Rokkas K, Guazzoni G, Rigatti P, Montorsi F. Anatomical radical retropubic prostatectomy in patients with a preexisting three-piece inflatable prosthesis: a series of case reports. *J Sex Med.* 2009;6:578-83.
1237. Da Pozzo LF, Cozzarini C, **Briganti A**, Suardi N, Salonia A, Bertini R, Gallina A, Bianchi M, Fantini GV, Bolognesi A, Fazio F, Montorsi F, Rigatti P. Long-term follow-up of patients with prostate cancer and nodal metastases treated by pelvic lymphadenectomy and radical prostatectomy: the positive impact of adjuvant radiotherapy. *Eur Urol.* 2009;55:1003-11
1238. Capitanio U, Karakiewicz PI, Valiquette L, Perrotte P, Jeldres C, **Briganti A**, Gallina A, Suardi N, Cestari A, Guazzoni G, Salonia A, Montorsi F. Biopsy Core Number Represents One of Foremost Predictors of Clinically Significant Gleason Sum Upgrading in Patients With Low-risk Prostate Cancer. *Urology.* 2009;73:1087-91
1239. **Briganti A**. How to Improve the Ability to Detect Pelvic Lymph Node Metastases of Urologic Malignancies. *Eur Urol.* 2009;55:770-2.
1240. Salomon G, Isbarn H, Budaus L, Schlomm T, **Briganti A**, Steuber T, Heinzer H, Haese A, Graefen M, Karakiewicz PI, Huland H, Chun F. Importance of Baseline Potency Rate Assessment of Men Diagnosed with Clinically Localized Prostate Cancer Prior to Radical Prostatectomy. *J Sex Med.* 2009;6:498-504

1241. **Briganti A.** Oestrogens and Prostate Cancer: Novel Concepts about an Old Issue. *Eur Urol.* 2009; 55 543–545.
1242. **Briganti A,** Karakiewicz PI, Joniau S, Van Poppel H. The Motion: Nomograms Should Become a Routine Tool in Determining Prostate Cancer Prognosis. *Eur Urol.* 2009;55 743–747
1243. **Briganti A,** Rigatti P, Montorsi F. The importance of the extent of pelvic-lymph-node dissection in the diagnosis of lymph-node metastases in prostate cancer. *Lancet Oncol.* 2008;9:915-7
1244. Suardi N, Gallina A, Salonia A, **Briganti A,** Dehò F, Zanni G, Abdollah F, Naspro R, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Holmium laser enucleation of the prostate and holmium laser ablation of the prostate: indications and outcome. *Curr Opin Urol.* 2009;19:38-43.
1245. Salonia A, **Briganti A,** Gallina A, Karakiewicz P, Shariat S, Freschi M, Zanni G, Capitanio U, Bosi E, Rigatti P, Montorsi F. Sex Hormone-binding Globulin: A Novel Marker for Nodal Metastases Prediction in Prostate Cancer Patients Undergoing Extended Pelvic Lymph Node Dissection. *Urology.* 2009;73:850-5
1246. **Briganti A.** Rebuttal from Author re: George N. Thalmann. Positive Lymph Nodes at Lymphadenectomy for Prostate Cancer: Where Do We Set the Tiller? *Eur Urol.* 2009; 55: 273-274
1247. Walz J, Haese A, Scattoni V, Steuber T, Chun FK, **Briganti A,** Montorsi F, Graefen M, Huland H, Karakiewicz PI. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower. *Cancer.* 2008;113:2695-703.
1248. **Briganti A,** Karnes JR, Da Pozzo LF, Cozzarini C, Gallina A, Suardi N, Bianchi M, Freschi M, Doglioni C, Fazio F, Rigatti P, Montorsi F, Blute ML Two Positive Nodes Represent a Significant Cut-off Value for Cancer Specific Survival in Patients with Node Positive Prostate Cancer. A New Proposal Based on a Two-Institution Experience on 703 Consecutive N+ Patients Treated with Radical Prostatectomy, Extended Pelvic Lymph Node Dissection and Adjuvant Therapy. *Eur Urol.* 2009; 55: 261-270
1249. **Briganti A,** Gallina A, Salonia A, Zanni G, Cestari A, Guazzoni G, Rigatti P, Montorsi F. The case for postoperative PDE-5 inhibitor drug treatment after radical prostatectomy. *J Endourol.* 2008;22:2025-7
1250. **Briganti A.** Reply to Tommaso Cai, Riccardo Bartoletti and Gabriella Nesi's Letter to the Editor re: Alberto Briganti, Umberto Capitanio, Felix K.-H. Chun et al. Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. *Eur Urol* 2008;54:794-804.
1251. Capitanio U, **Briganti A,** Shariat SF, Karakiewicz PI. The importance of the quantification of the extent of cancer in prostatic biopsies in prediction of biochemical recurrence: a global perspective. *Eur Urol.* 2008;54:717-9
1252. Abdollah F, **Briganti A,** Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Re: Orgasm associated incontinence (climacturia) following radical pelvic surgery: rates of occurrence and predictors. J. M. Choi, C. J. Nelson, J. Stasi and J. P. Mulhall. *J Urol.* 2008 Sep;180:1187
1253. Ahyai SA, Eichelberg C, Isbarn H, Zacharias M, **Briganti A,** Huland H, Chun FK. Editorial Comment on: Prostate Cancer Detection Rate in Patients with Repeated Extended 21-Sample Needle Biopsy. *Eur Urol.* 2009;55:607.
1254. Chun FK, Karakiewicz PI, **Briganti A.** Prostate Cancer Diagnosis: Importance of Individualized Risk Stratification Models over PSA Alone. *Eur Urol.* 2008;54:241-2
1255. **Briganti A,** Capitanio U, Chun FK, Gallina A, Suardi N, Salonia A, Da Pozzo LF, Colombo R, Di Girolamo V, Bertini R, Guazzoni G, Karakiewicz PI, Montorsi F, Rigatti P. Impact of Surgical Volume on the Rate of Lymph Node Metastases in Patients Undergoing Radical Prostatectomy and Extended Pelvic Lymph Node Dissection for Clinically Localized Prostate Cancer. *Eur Urol.* 2008 ;54:794-802.
1256. Capitanio U, Karakiewicz PI, Jeldres C, **Briganti A,** Salonia A, Cestari A, Guazzoni G, Rigatti P, Montorsi F. Suspected Clinical T3 Prostate Cancer Is Associated with a High Rate of Negative Extended Biopsies: Clinical Implications. *Eur Urol* 2009; 55: 253-254
1257. **Briganti A,** Chun FK, Karakiewicz PI, Rigatti P, Montorsi F. Is node-positive prostate cancer always a systemic disease? *Eur Urol.* 2008;54:243-6.

1258. Burnett AL, Teloken PE, **Briganti A**, Whitehurst T, Montorsi F. Intraoperative Assessment of an Implantable Electrode Array for Cavernous Nerve Stimulation. *J Sex Med.* 2008;5:1949-54
1259. Schiavina R, Scattoni V, Castellucci P, Picchio M, Corti B, **Briganti A**, Franceschelli A, Sanguedolce F, Bertaccini A, Farsad M, Giovacchini G, Fanti S, Grigioni WF, Fazio F, Montorsi F, Rigatti P, Martorana G. (11)C-choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. *Eur Urol.* 2008;54:392-401.
1260. **Briganti A**, Salonia A, Cestari A, Montorsi F. Rebuttal. 2008. *J Endourol*
1261. Montorsi F, Naspro R, Salonia A, Suardi N, **Briganti A**, Zanoni M, Valenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center prospective randomized trial in patients with obstructive benign prostatic hyperplasia. *J Urol.* 2008 May;179(5 Suppl):S87-90.
1262. Gallina A, Chun FK, Suardi N, Eastham JA, Perrotte P, Graefen M, Hutterer G, Huland H, Klein EA, Reuther A, Montorsi F, **Briganti A**, Shariat SF, Roehrborn CG, de la Taille A, Salomon L, Karakiewicz PI. Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. *BJU Int.* 2008;101:1513-8.
1263. Chun FK, **Briganti A**. Editorial Comment on: Preliminary Results of a Novel Method to Estimate the Probability of Prostate Cancer in Men with Elevated Serum PSA Values. *Eur Urol.* 2008;54:702.
1264. **Briganti A**. Editorial Comment on: Erectile Dysfunction After External Beam Radiotherapy for Prostate Cancer. *Eur Urol.* 2009; 55:235-6.
1265. Karakiewicz PI, Chun FK, Gallina A, Suardi N, **Briganti A**, Erbersdobler A, Schlomm T, Walz J, Currin E, Michl U, Haese A, Arjane P, Heinzer H, Graefen M, Huland H. Biopsies performed at tertiary care centers are superior to referral biopsies in predicting pathologic Gleason sum. *J Endourol.* 2008;22:533-8
1266. Capitanio U, Scattoni V, Freschi M, **Briganti A**, Salonia A, Gallina A, Colombo R, Karakiewicz PI, Rigatti P, Montorsi F. Radical prostatectomy for incidental (stage t1a-t1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence. *Eur Urol.* 2008;54:118-25.
1267. Roscigno M, Cozzarini C, Bertini R, Scattoni V, Freschi M, Da Pozzo LF, **Briganti A**, Gallina A, Capitanio U, Colombo R, Giorgio G, Montorsi F, Rigatti P. Prognostic value of lymph node dissection in patients with muscle-invasive transitional cell carcinoma of the upper urinary tract. *Eur Urol.* 2008;53:794-802.
1268. Salonia A, Gallina A, **Briganti A**, Zanni G, Saccà A, Dehò F, Karakiewicz P, Guazzoni G, Rigatti P, Montorsi F. Remembered International Index of Erectile Function domain scores are not accurate in assessing preoperative potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. *J Sex Med.* 2008;5:677-83.
1269. **Briganti A**. Words of wisdom. Re: Detection of occult nodal metastases in locally advanced node-negative prostate cancer. *Eur Urol.* 2006;50:1120-1.
1270. **Briganti A**, Gallina A, Suardi N, Chun FK, Walz J, Heuer R, Salonia A, Haese A, Perrotte P, Valiquette L, Graefen M, Rigatti P, Montorsi F, Huland H, Karakiewicz PI. A nomogram is more accurate than a regression tree in predicting lymph node invasion in prostate cancer. *BJU Int.* 2008;101:556-60.
1271. **Briganti A**, Chun FK, Suardi N, Gallina A, Walz J, Graefen M, Shariat S, Ebersdobler A, Rigatti P, Perrotte P, Saad F, Montorsi F, Huland H, Karakiewicz PI. Prostate volume and adverse prostate cancer features: fact not artifact. *Eur J Cancer.* 2007;43:2669-77
1272. Ahyai SA, Graefen M, Steuber T, Haese A, Schlomm T, Walz J, Köllermann J, **Briganti A**, Zacharias M, Friedrich MG, Karakiewicz PI, Montorsi F, Huland H, Chun FK. Contemporary prostate cancer prevalence among T1c biopsy-referred men with a prostate-specific antigen level < or = 4.0 ng per milliliter. *Eur Urol.* 2008;53:750-7.
1273. Raber M, Scattoni V, Roscigno M, Dehò F, **Briganti A**, Salonia A, Gallina A, Di Girolamo V, Montorsi F, Rigatti P. Topical prilocaine-lidocaine cream combined with peripheral nerve block improves pain control in prostatic biopsy: results from a prospective randomized trial. *Eur Urol.* 2008;53:967-73.

1274. Gallina A, **Briganti A**, Chun FK, Walz J, Hutterer GC, Erbersdobler A, Eichelberg C, Schlomm T, Ahyai SA, Perrotte P, Saad F, Montorsi F, Huland H, Graefen M, Karakiewicz PI. Effect of autologous blood transfusion on the rate of biochemical recurrence after radical prostatectomy. *BJU Int.* 2007;100:1249-53.
1275. **Briganti A**. Role of hK2 in predicting clinically insignificant prostate cancer. *Eur Urol.* 2007;52:1297-9.
1276. Salonia A, Gallina A, Zanni G, **Briganti A**, Dehò F, Saccà A, Suardi N, Barbieri L, Guazzoni G, Rigatti P, Montorsi F. Acceptance of and discontinuation rate from erectile dysfunction oral treatment in patients following bilateral nerve-sparing radical prostatectomy. *Eur Urol.* 2008;53:564-70.
1277. Suardi N, Scattoni V, **Briganti A**, Salonia A, Naspro R, Gallina A, Cestari A, Colombo R, Karakiewicz PI, Guazzoni G, Rigatti P, Montorsi F. Nerve-sparing radical retropubic prostatectomy in patients previously submitted to holmium laser enucleation of the prostate for bladder outlet obstruction due to benign prostatic enlargement. *Eur Urol.* 2008;53:1180-5.
1278. **Briganti A**, Shariat SF, Chun FK, Hutterer GC, Roehrborn CG, Gallina A, Rigatti P, Valiquette L, Montorsi F, Karakiewicz PI. Differences in the rate of lymph node invasion in men with clinically localized prostate cancer might be related to the continent of origin. *BJU Int.* 2007;100:528-32.
1279. Salonia A, Gallina A, Zanni G, **Briganti A**, Dehò F, Saccà A, Suardi N, Barbieri L, Guazzoni G, Rigatti P, Montorsi F. Rebuttal from Authors re: Sidney Glina. How Much are Patients Interested in Erectile Dysfunction Treatment after Radical Prostatectomy? *Eur Urol* 2008;53: 462-464
1280. Chun FK, Hutterer GC, Perrotte P, Gallina A, Valiquette L, Benard F, McCormack M, **Briganti A**, Ionescu C, Jeldres C, Guay JP, Saad F, Karakiewicz PI. Distribution of prostate specific antigen (PSA) and percentage free PSA in a contemporary screening cohort with no evidence of prostate cancer. *BJU Int.* 2007;100:37-41.
1281. Gallina A, Karakiewicz PI, Hutterer GC, Chun FK, **Briganti A**, Walz J, Antebi E, Shariat SF, Suardi N, Graefen M, Erbersdobler A, Salonia A, Rigatti P, Huland H, Montorsi F. Obesity does not predispose to more aggressive prostate cancer either at biopsy or radical prostatectomy in European men. *Int J Cancer.* 2007 15;121:791-5.
1282. Gallina A, Karakiewicz PI, Chun FK, **Briganti A**, Graefen M, Montorsi F, Walz J, Jeldres C, Erbersdobler A, Salonia A, Suardi N, Dehò F, Schlomm T, Scattoni V, Haese A, Heinzer H, Valiquette L, Rigatti P, Huland H. Health-insurance status is a determinant of the stage at presentation and of cancer control in European men treated with radical prostatectomy for clinically localized prostate cancer. *BJU Int.* 2007;99:1404-8.
1283. **Briganti A**, Fabbri F, Salonia A, Gallina A, Chun FK, Dehò F, Zanni G, Suardi N, Karakiewicz PI, Rigatti P, Montorsi F. Preserved postoperative penile size correlates well with maintained erectile function after bilateral nerve-sparing radical retropubic prostatectomy. *Eur Urol.* 2007;52:702-7.
1284. Karakiewicz PI, **Briganti A**, Chun FK, Trinh QD, Perrotte P, Ficarra V, Cindolo L, De la Taille A, Tostain J, Mulders PF, Salomon L, Zigeuner R, Prayer-Galetti T, Chautard D, Valeri A, Lechevallier E, Descotes JL, Lang H, Mejean A, Patard JJ. Multi-institutional validation of a new renal cancer-specific survival nomogram. *J Clin Oncol.* 2007;25:1316-22
1285. Chun FK, **Briganti A**, Gallina A, Hutterer GC, Shariat SF, Antebi E, Walz J, Roehrborn CG, Salonia A, Rigatti P, Saad F, Huland H, Montorsi F, Graefen M, Karakiewicz PI. Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. *Eur Urol.* 2007;52:1067-74
1286. Chun FK, Karakiewicz PI, **Briganti A**, Walz J, Kattan MW, Huland H, Graefen M. A critical appraisal of logistic regression-based nomograms, artificial neural networks, classification and regression-tree models, look-up tables and risk-group stratification models for prostate cancer. *BJU Int.* 2007;99:794-800.
1287. **Briganti A**, Chun FK, Hutterer GC, Gallina A, Shariat SF, Salonia A, Scattoni V, Valiquette L, Montorsi F, Rigatti P, Graefen M, Huland H, Karakiewicz PI. Systematic assessment of the ability of the number and percentage of positive biopsy cores to predict pathologic stage and biochemical recurrence after radical prostatectomy. *Eur Urol.* 2007;52:733-43.

1288. **Briganti A**, Salonia A, Gallina A, Chun FK, Karakiewicz PI, Graefen M, Huland H, Rigatti P, Montorsi F. Management of erectile dysfunction after radical prostatectomy in 2007. *World J Urol.* 2007;25:143-8.
1289. **Briganti A**, Montorsi F. Rebuttal from Authors re: John Mulhall. Can Penile Size be Preserved after Radical Prostatectomy? 2007. *Eur Urol*, 2007;52: 628-29
1290. **Briganti A**, Karakiewicz PI, Chun FK, Gallina A, Salonia A, Zanni G, Valiquette L, Graefen M, Huland H, Rigatti P, Montorsi F. Percentage of positive biopsy cores can improve the ability to predict lymph node invasion in patients undergoing radical prostatectomy and extended pelvic lymph node dissection. *Eur Urol.* 2007;51:1573-81.
1291. **Briganti A**, Chun FK, Salonia A, Gallina A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. Critical assessment of ideal nodal yield at pelvic lymphadenectomy to accurately diagnose prostate cancer nodal metastasis in patients undergoing radical retropubic prostatectomy. *Urology* 69:147-51, 2007.
1292. Hutterer GC, **Briganti A**, Chun FK-H, Gallina A, Rigatti P, Montorsi F, Karakiewicz PI. The Evolution of Staging of Lymph Node Metastases in Clinically Localized Prostate Cancer. *EAU-EBU Updated Series*,2007, 5:153-162.
1293. Gallina A, Chun FK, **Briganti A**, Shariat S, Montorsi F, Salonia A, Erbersdobler A, Rigatti P, Valiquette L, Huland H, Graefen M, Karakiewicz PI. Development and Split-Sample Validation of a Nomogram Predicting the Probability of Seminal Vesicle Invasion at Radical Prostatectomy. *Eur Urol* 2007;52:98-105
1294. Chun FK, **Briganti A**, Graefen M, Porter C, Montorsi F, Haese A, Scattoni V, Borden L, Steuber T, Salonia A, Schlomm T, Latchemsetty K, Walz J, Kim J, Eichelberg C, Currlin E, Ahyai SA, Erbersdobler A, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI. Development and external validation of an extended repeat biopsy nomogram. *J Urol* 2007; 177:510-5.
1295. Chun FK, **Briganti A**, Jeldres C, Gallina A, Erbersdobler A, Schlomm T, Walz J, Eichelberg C, Salomon G, Haese A, Currlin E, Ahyai SA, Benard F, Huland H, Graefen M, Karakiewicz PI. Tumour volume and high grade tumour volume are the best predictors of pathologic stage and biochemical recurrence after radical prostatectomy. *Eur J Cancer.*2007; 43:536-43,
1296. Salonia A, **Briganti A**, Gallina A, Zanni G, Dehò F, Rigatti P, Montorsi F. Lower urinary tract symptoms and sexual dysfunction in women. *Current Sexual Health Reports* 4:85-90, 2007.
1297. Gallina A, Jeldres C, Chun FK, Shariat S, **Briganti A**, Walz J, Roehrborn CG, Saad F, Huland H, Graefen M, Montorsi F, Karakiewicz PI. Prediction of Pathological Stage is Inaccurate in Men with PSA Values above 20ng/mL. *Eur Urol* 2007; 52:1374-80
1298. Chun FK, Graefen M, **Briganti A**, Gallina A, Hopp J, Huland H, Karakiewicz PI. Reply to Dr Stephan et al's Letter to the Editor re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial Biopsy Outcome Prediction-Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. *Eur Urol* 51:1448,2007
1299. Steuber T, Chun FK, Erbersdobler A, **Briganti A**, Haese A, Graefen M, Schlomm T, Valiquette L, Huland H, Karakiewicz PI. Development and internal validation of preoperative transition zone prostate cancer nomogram. *Urology.* 2006; 68:1295-300.
1300. Chun FK, **Briganti A**, Graefen M, Erbersdobler A, Walz J, Schlomm T, Meschke M, Haese A, Valiquette L, Huland H, Karakiewicz PI. Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. *Eur J Cancer.* 43:375-82, 2007.
1301. Chun FK, **Briganti A**, Antebi E, Graefen M, Currlin E, Steuber T, Schlomm T, Walz J, Haese A, Friedrich MG, Ahyai SA, Eichelberg C, Salomon G, Gallina A, Erbersdobler A, Perrotte P, Heinzer H, Huland H, Karakiewicz PI. Surgical volume is related to the rate of positive surgical margins at radical prostatectomy in European patients. *BJU Int.* 98:1204-9, 2006.
1302. Chun FK, **Briganti A**, Graefen M, Montorsi F, Porter C, Scattoni V, Gallina A, Walz J, Haese A, Steuber T, Erbersdobler A, Schlomm T, Ahyai SA, Currlin E, Valiquette L, Heinzer H, Rigatti P, Huland H, Karakiewicz PI. Development and External Validation of an Extended 10-Core Biopsy Nomogram. *Eur Urol* 2007 ;52:436-44.

1303. **Briganti A**, Chun FK, Salonia A, Suardi N, Gallina A, Da Pozzo LF, Roscigno M, Zanni G, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. Complications and other surgical outcomes associated with extended pelvic lymphadenectomy in men with localized prostate cancer. *Eur Urol* 50:1006-13, 2006.
1304. Chun FK, Graefen M, **Briganti A**, Gallina A, Hopp J, Kattan MW, Huland H, Karakiewicz PI. Initial Biopsy Outcome Prediction-Head-to-Head Comparison of a Logistic Regression-Based Nomogram versus Artificial Neural Network. *Eur Urol* 2007;51:1236-40
1305. Chun FK, Karakiewicz P, **Briganti A**, Gallina A, Kattan MW, Montorsi F, Huland H, Graefen M. Prostate cancer nomograms: an update. *Eur Urol* 50:914-26, 2006.
1306. Chun FK, **Briganti A**, Jeldres C, Erbersdobler A, Schlomm T, Steuber T, Gallina A, Walz J, Perrotte P, Huland H, Graefen M, Karakiewicz PI. Zonal Origin of Localized Prostate Cancer Does not Affect the Rate of Biochemical Recurrence after Radical Prostatectomy. *Eur Urol* 2007;51:949-55.
1307. Chun FK-H, **Briganti A**, Graefen M, Erbersdobler A, Walz J, Schlomm T, Meschke M, Haese A, Valiquette L, Huland H, Karakiewicz PI. Body mass index does not improve the ability to predict biochemical recurrence after radical prostatectomy. 2007. *Eur J Cancer*.
1308. **Briganti A**, Montorsi F. Penile rehabilitation after radical prostatectomy. *Nat Clin Pract Urol*. 3:400-1, 2006.
1309. *Nat Clin Pract Urol*. 3:400-1, 2006.
1310. Montorsi P, Ravagnani PM, Galli S, Salonia A, **Briganti A**, Werba JP, Montorsi F. Association between erectile dysfunction and coronary artery disease: Matching the right target with the right test in the right patient. *Eur Urol* 50:721-31, 2006.
1311. Chun FK, **Briganti A**, Shariat SF, Graefen M, Montorsi F, Erbersdobler A, Steuber T, Salonia A, Currilin E, Scattoni V, Friedrich MG, Schlomm T, Haese A, Michl U, Colombo R, Heinzer H, Valiquette L, Rigatti P, Roehrborn CG, Huland H, Karakiewicz PI. Significant upgrading affects a third of men diagnosed with prostate cancer: predictive nomogram and internal validation. *BJU Int*. 98:329-34, 2006.
1312. Montorsi P, Ravagnani PM, Galli S, Rotatori F, Veglia F, **Briganti A**, Salonia A, Dehò F, Rigatti P, Montorsi F, Fiorentini C. Association between erectile dysfunction and coronary artery disease. Role of coronary clinical presentation and extent of coronary vessels involvement: the COBRA trial. *Eur Heart J*. 27:2632-9, 2006.
1313. Chun FK, Perrotte P, **Briganti A**, Benayoun S, Lebeau T, Ramirez A, Lewinshtein DJ, Valiquette L, Guay JP, Karakiewicz PI. Prostate specific-antigen distribution in asymptomatic Canadian men with no clinical evidence of prostate cancer. *BJU Int*. 98:50-3, 2006.
1314. **Briganti A**, Chun FK, Salonia A, Zanni G, Gallina A, Dehò F, Suardi N, Da Pozzo LF, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. A nomogram for staging of exclusive nonobturator lymph node metastases in men with localized prostate cancer. *Eur Urol* 51:112-9, 2007.
1315. **Briganti A**, Chun FK, Salonia A, Gallina A, Farina E, Da Pozzo LF, Rigatti P, Montorsi F, Karakiewicz PI. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. *BJU Int*. 98:788-93, 2006.
1316. Karakiewicz P, **Briganti A**, Chun FK, Valiquette L. Outcomes research: a methodologic review. *Eur Urol* 50:218-24, 2006.
1317. Rigatti L, Naspro R, Salonia A, Centemero A, Ghezzi M, Guazzoni G, **Briganti A**, Rigatti P, Montorsi F. Urodynamics after TURP and HoLEP in urodynamically obstructed patients: are there any differences at 1 year of follow-up? *Urology*. 67:1193-8, 2006.
1318. **Briganti A**, Chun FK, Salonia A, Zanni G, Dehò F, Barbieri L, Karakiewicz PI, Rigatti P, Montorsi F. A comparative review of apomorphine formulations for erectile dysfunction: recommendations for use in the elderly. *Drugs and Aging*. 23:309-19, 2006.
1319. Naspro R, Suardi N, Salonia A, Scattoni V, Guazzoni G, Colombo R, Cestari A, **Briganti A**, Mazzoccoli B, Rigatti P, Montorsi F. Holmium laser enucleation of the prostate versus open prostatectomy for prostates >70 g: 24-month follow-up. *Eur Urol* 50:563-8, 2006.
1320. Salonia A, Fabbri F, Zanni G, Scavini M, Fantini GV, **Briganti A**, Naspro R, Parazzini F, Gori E, Rigatti P, Montorsi F. Chocolate and women's sexual health: An intriguing correlation. *J Sex Med*. 3:476-82, 2006.

1321. Karakiewicz PI, Chun FK, **Briganti A**, Perrotte P, McCormack M, Benard F, Valiquette L, Graefen M, Saad F. Prostate cancer nomograms are superior to neural networks. *Can J Urol*.2006;13(2 Supp 1):18-25.
1322. Salonia A, **Briganti A**, Dehò F, Zanni G, Rigatti P, Montorsi F. Women's sexual dysfunction: a review of the "surgical landscape". *Eur Urol* 50:44-52, 2006.
1323. Ramirez A, Benayoun S, **Briganti A**, Chun J, Perrotte P, Kattan MW, Graefen M, McCormack M, Neugut AI, Saad F, Karakiewicz PI. High radical prostatectomy surgical volume is related to lower radical prostatectomy total hospital charges. *Eur Urol* 50:58-62, 2006.
1324. **Briganti A**, Naspro R, Gallina A, Salonia A, Vavassori I, Hurle R, Scattoni E, Rigatti P, Montorsi F. Impact of holmium laser enucleation versus trans-urethral resection of the prostate on sexual function: results of a prospective,two-centre, randomized trial. *J Urol*, 175:1817-21, 2006
1325. **Briganti A**, Karakiewicz PI, Chun F K-H, Montorsi F. Rebuttal from Authors re: Urs E. Studer, Laurence Collette. Morbidity from Pelvic Lymphadenectomy in Men Undergoing Radical Prostatectomy. *Eur Urol* 2006; 50:887-9.
1326. **Briganti A**, Chun FK, Salonia A, Zanni G, Scattoni V, Valiquette L, Rigatti P, Montorsi F, Karakiewicz PI. Validation of a nomogram predicting the probability of lymph node invasion among patients undergoing radical prostatectomy and an extended pelvic lymphadenectomy. *Eur Urol* 49:1019-26, 2006
1327. Karakiewicz P, Lewenstein D, Chun FK, **Briganti A**, Guille F, Perrotte P, Lobel B, Ficarra V, Artibani W, Cindolo L, Tostain J, Abbou CC, Chopin D, De La Taille A, Patard JJ. Tumor size improves the accuracy of TNM predictions in patients with renal cancer. *Eur Urol*. 50:521-8, 2006.
1328. **Briganti A**, Salonia A, Gallina A, Saccà A, Montorsi P, Rigatti P, Montorsi F. Drug insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction. *Nature Clinical Practice Urology*,2:239-247,2005.
1329. Salonia A, Lanzi R, Scavini M, Pontillo M, Gatti E, Petrella G, Licata G, Nappi RE, Bosi E, **Briganti A**, Rigatti P, Montorsi F. Sexual function and endocrine profile in fertile women with type 1 diabetes mellitus: results of a prospective, case-control study. *Diabetes Care*, 29:312-6, 2006.
1330. Montorsi F, **Briganti A**, Salonia A, Rigatti P, Burnett A. Can phosphodiesterase type 5 inhibitors cure erectile dysfunction? *Eur Urol* 49:979-86, 2006
1331. Montorsi P, Ravagnani PM, Galli S, **Briganti A**, Salonia A, Dehò F, Shulman C, Montorsi F. Association between erectile dysfunction and cardiovascular disease: a case report study. *J Sex Med*, 2:575-582,2005
1332. Salonia A, Zanni G, Gallina A, Sacca A, Sangalli M, Naspro R, **Briganti A**, Farina E, Roscigno M, Dapozzo LF, Rigatti P, Montorsi F. Baseline potency in candidates for bilateral nerve-sparing radical retropubic prostatectomy. *Eur Urol* 50:360-5, 2006.
1333. Chun FK, **Briganti A**, Lebeau T, Fradet V, Steuber T, Walz J, Schlomm T, Eichelberg C, Haese A, Erbersdobler A, McCormack M, Perrotte P, Graefen M, Huland H, Karakiewicz PI. The 2002 AJCC pT2 substages confer no prognostic information on the rate of biochemical recurrence after radical prostatectomy. *Eur Urol* 49:273-8,2006.
1334. Montorsi P, Ravagnani PM, Galli S, Rotatori F, **Briganti A**, Salonia A, Rigatti P, Montorsi F. The Artery Size Hypothesis. A "Macro vascular" Link between Erectile Dysfunction and Coronary Artery Disease. *Am J Cardiol*, 96(12 Suppl 2):19-23, 2005.
1335. **Briganti A**, Gallina A, Salonia A, Farina E, Zanni G, Rigatti P, Montorsi F. Reliability of classification of erectile function domain of the international index of erectile function in patients affected by localized prostate cancer candidates to radical prostatectomy. *Urology*, 66:1140, 2005
1336. **Briganti A**, Salonia A, Gallina A, Suardi N, Dehò F, Fabbri F, Zanni G, Scattoni V, Rigatti P, Montorsi F. Potency after Radical Prostatectomy: From New Techniques to Better Results. 2006. *EAU-EBU Update Series* 2006; 4: 33-45.
1337. Scattoni V, Roscigno M, Freschi M, **Briganti A**, Fantini GV, Bertini R, Salonia A, Rigatti P, Montorsi F. Predictors of prostate cancer after initial diagnosis of atypical small acinar proliferation at 10 to 12 core biopsies. *Urology*, 66: 1043-1047, 2005

1338. **Briganti A**, Salonia A, Dehò F, Zanni G, Barbieri L, Rigatti P, Montorsi F. Clinical update on phosphodiesterase type-5 inhibitors for erectile dysfunction. *World Journal of Urology*, 23:374-84, 2005
1339. Montorsi F, Salonia A, Suardi N, Gallina A, Zanni G, **Briganti A**, Dehò F, Naspro R, Farina E, Rigatti P. Improving the preservation of the urethral sphincter and neurovascular bundles during open radical retropubic prostatectomy. *Eur Urol* 48:938-945, 2005
1340. Scattoni V, Roscigno M, Freschi M, Dehò F, Raber M, **Briganti A**, Fantini G, Nava L, Montorsi F, Rigatti P. Atypical small acinar proliferation (ASAP) on extended prostatic biopsies: predictive factors of cancer detection on repeat biopsies. *Arch Ital Urol Androl*. 2005;77:31-6.
1341. Salonia A, **Briganti A**, Montorsi P, Maga T, Dehò F, Zanni G, Mazzoccoli B, Suardi N, Rigatti P, Montorsi F. Safety and tolerability of treatments for erectile dysfunction in the elderly. *Drugs and Aging*, 22:323-38,2005.
1342. Pomara G, Morelli G, Montorsi F, **Briganti A**, Montorsi F, Salonia A, Barbieri L, Zanni G, Surdi N, Cestari A, Montorsi P, Rigatti P. Vardenafil for the treatment of erectile dysfunction: A critical review of the literature based on personal clinical experience. *Eur Urol*. 2005.
1343. Montorsi F, Salonia A, **Briganti A**, Barbieri L, Zanni G, Cestari A, Montorsi P, Rigatti P. A critical analysis of vardenafil in the management of patients with erectile dysfunction: an integration of the literature and collective personal experience. *Eur Urol*, 47:524-529,2005.
1344. Salonia A, Barbieri L, Chen J, **Briganti A**, Dehò F, Naspro R, Carro UD, Rokkas K, Scattoni V, Rigatti P, Montorsi F. Comparison of the Effect of Sildenafil and Apomorphine SL on Nocturnal Erections in Healthy Volunteers: A Placebo-Controlled Study. *Eur Urol* 47:524-9,2005
1345. Salonia A, Nappi RE, Pontillo M, Daverio R, Smeraldi A, **Briganti A**, Fabbri F, Zanni G, Rigatti P, Montorsi F. Menstrual cycle-related changes in plasma oxytocin are relevant to normal sexual function in healthy women. *Horm Behav*. 47:164-9,2005.
1346. Salonia A, Zanni G, **Briganti A**, Fabbri F, Rigatti P, Montorsi F. The role of the urologist in the management of female sexual dysfunctions. *Curr Opin Urol*. 2004;14:389-93.
1347. Montorsi P, Ravagnani PM, Galli S, Rotatori F, **Briganti A**, Salonia A, Dehò F, Montorsi F. Common grounds for erectile dysfunction and coronary artery disease. *Curr Opin Urol*. 14:361-5,2004.
1348. Montorsi F, **Briganti A**, Salonia A, Montorsi P, Rigatti P. The use of phosphodiesterase type 5 inhibitors for erectile dysfunction. *Curr Opin Urol*. 14:357-9,2004.
1349. Montorsi F, Naspro R, Salonia A, Suardi N, **Briganti A**, Zanoni M, Valenti S, Vavassori I, Rigatti P. Holmium laser enucleation versus transurethral resection of the prostate: results from a 2-center, prospective, randomized trial in patients with obstructive benign prostatic hyperplasia. *J Urol* 172:1926-9,2004.
1350. Montorsi P, **Briganti A**, Salonia A, Margonato A, Montorsi F. Impaired vascular reactivity in patients with erectile dysfunction. *Journal American College of Cardiology*, 15:1339-1340, 2004.
1351. Montorsi F, Dehò F, Salonia A, **Briganti A**, Bua L, Fantini GV, Gallina A, Sacca A, Mirone V, Rigatti P. Penile implants in the era of oral drug treatment for erectile dysfunction. *BJU Int*. 94:745-51,2004.
1352. **Briganti A**, Salonia A, Gallina A, Suardi N, Rigatti P, Montorsi F. Emerging oral drugs for erectile dysfunction. *Expert Opin Emerg Drugs*. 2004 ;9:179-89.
1353. Salonia A, Munarriz RM, Naspro R, Nappi RE, **Briganti A**, Chionna R, Federghini F, Mirone V, Rigatti P, Goldstein I, Montorsi F. Women's sexual dysfunction: a pathophysiological review. *BJU Int*.,93:1156-64,2004.
1354. Salonia A, Zanni G, Nappi RE, **Briganti A**, Dehò F, Fabbri F, Colombo R, Guazzoni G, Di Girolamo V, Rigatti P, Montorsi F. Sexual dysfunction is common in women with lower urinary tract symptoms and urinary incontinence: results of a cross-sectional study. *Eur Urol*,45:642-8,2004.
1355. Montorsi F, **Briganti A**, Salonia A, Rigatti P, Burnett AL. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy. *Eur Urol*,45:123-33,2004.

1356. **Briganti A**, Salonia A, Zanni G, Fabbri F, Saccà A, Bertini R, Suardi N, Fantini GV, Rigatti P, Montorsi F. Erectile dysfunction and radical prostatectomy: An update. *EAU Update Series* 2004; 2:84-92.
1357. Montorsi P, Roumeguare T, Montorsi F, Ravagnani PM, Galli S, **Briganti A**, Salonia A, Schulman CC. Is there a link between erectile dysfunction and coronary artery disease? *EAU Update Series*. 2004; 2:43-48.
1358. Montorsi F, **Briganti A**, Salonia A, Rigatti P, Margonato A, Macchi A, Galli S, Ravagnani PM, Montorsi P. Erectile dysfunction prevalence, time of onset and association with risks factors in 300 consecutive patients with acute chest pain and angiographically documented coronary artery disease. *Eur Urol*,44: 360-364,2003
1359. Montorsi F, **Briganti A**, Salonia A, Dehò F, Zanni G, Cestari A, Guazzoni G, Rigatti P, Stief C. The ageing male and erectile dysfunction. *BJU Int*,92:516-520,2003
1360. **Briganti A**, Salonia A, Dehò F, Zanni G, Rokkas K, Rigatti P, Montorsi F. Peyronie's disease: a review. *Curr Opin Urol*,13:417-422,2003
1361. Salonia A, **Briganti A**, Dehò F, Naspro R, Scapaticci E, Scattoni V, Rigatti P, Montorsi F. Pathophysiology of erectile dysfunction. *Int J Andrology*,26:129-136,2003
1362. Salonia A, Maga T, Colombo R, Scattoni V, **Briganti A**, Cestari A, Guazzoni G, Rigatti P, Montorsi F. A prospective study comparing paroxetine alone versus paroxetine plus sildenafil in patients with premature ejaculation. *J Urol*,168: 2486-9, 2002.
1363. Montorsi F, Salonia A, Dehò F, **Briganti A**, Rigatti P. The ageing male and erectile dysfunction. *World J Urol*, 20: 28-35,2002

INTERNATIONAL BOOK CHAPTERS

1. Salonia A, Barbieri L, Naspro R, Zanni G, Dehò F, **Briganti A**, Rigatti P, Montorsi F. Papel do Sildenafil na Disfunção erétil - Sécao II, In: C Teloken, CT Da Ros, M Tannhauser (eds):Disfunção Sexual, Revinter , Rio de Janeiro, 2004.
2. Montorsi F, **Briganti A**, Salonia A, Rigatti P, Burnett A. Current and future strategies for preventing and managing erectile dysfunction following radical prostatectomy, In : Sildenafil, edited by U. Duzendorfer, Birkhauser Verlag, 2004.
3. Montorsi F, **Briganti A**. Rehabilitation of sexual function in Radical Prostatectomy From Open to Robotic Edited By Roger Kirby, Francesco Montorsi, Joseph A Smith, Paolo Gontero, CRC press, 2007.
4. Salonia A, **Briganti A**, Gallina A, Montorsi F. The Utility of PDE5 Inhibitors After Radical Prostatectomy in Sexual Function in the Prostate Cancer Patient. Edited by John P. Mulhall, Springer, 2009.
5. Mulhall J, Bella A, **Briganti A**, McCullough A, Brock G. I Sexual rehabilitation after treatment for prostate cancer in Sexual Medicine: Sexual dysfunctions in men and women. Third International Consultation in Sexual Medicine, ed. 2010 by Montorsi F, R Basson, G Adaikan, E Becher, F Clayton, F Giuliano, S Khoury, I Sharlip.
6. **Briganti A**, Gandaglia G. Epidemiology and Pathophysiology of LUTS/BPO. In Male LUTS/BPH Made Easy edited by Chapple C and Tubaro A, Springer 2013.
7. Gandaglia G, **Briganti A**, Montorsi P, Montorsi F, Vlachopoulos C. Erectile Dysfunction in Coronary Artery Disease and Heart Failure. In Erectile Dysfunction in Hypertension and Cardiovascular Disease edited by Viigimaa et al, Springer 2015.